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1.1 Introduction to the Research Topic: 
Cancer is the leading cause of death in developed countries, with higher incidence and mortality rates 
compared to economically developing countries (Jemal et al., 2011). The latest global estimate from the 
International Agency for Research on Cancer (IARC), showed a total of 12.7 million new cancer cases 
worldwide in 2008, and this number is expected to increase to 21.4 million in 2030 (Ferlay et al., 2010).  
Much effort was taken in the past ten years to fight this global burden. Several developed countries and 
global health institutes have implemented cancer control programs to reduce the incidence- and 
mortality rate and also to improve the quality of life of cancer patients. The World Health Organisation 
(WHO) aims member states to start a systematic implementation of evidence-based interventions for 
prevention, early detection, diagnosis, treatment and palliative care (World Health & Organisation, 
2008). In the long term, prevention and thus raising the awareness of cancer risk factors seem to be the 
most cost-effective and promising strategy in avoiding cancer cases. The primary objective of early 
detection through screening is to detect precancerous changes or early stages of cancers when they can 
be treated most effectively (Jemal et al., 2011). Globally many screening programs (e.g. lung, breast, 
cervical, colon and prostate cancers) are in place, with varying interpretations of the effectiveness of 
specific screening programs (Hugosson et al., 2010).  
Both in early detection and diagnoses of cancer, non-invasive imaging such as radiology (X-Ray), 
Computer Tomography (CT), Magnet Resonance Imaging (MRI), and Ultrasound (US) and nuclear 
medicine procedures (Single-photon emission computed tomography – SPECT; Positron Emission 
Tomography –PET) and their hybrid forms of PET/CT and PET/MRI have gained increasing importance. 
Since the discovery of x-rays by Wilhelm Conrad Roentgen in 1895, new imaging techniques have 
emerged rapidly over the years. X-ray and CT, using ionising radiation, and MRI, using a strong magnetic 
field and radio waves, now enable a precise inspection of on the body’s anatomical structures (Buzug, 
2005). SPECT and PET use short- and ultra-short-lived radionuclides, which are connected to a specific 
biological active substance and therefore accumulate in a region of interest. With a detector, this 
emitting radiation (SPECT) and positrons (PET) can be detected and therefore give a three-dimensional 
picture of the functional processes in the human body (Granov, Tiutin, & Schwarz, 2013).  
Imaging has, therefore, become an indispensable tool in cancer research, clinical trials and medical 
practice (Weissleder & Pittet, 2008). The underlying medical question and the field of investigation 
mainly drives the use of one or the other imaging technique, but imaging specific molecular targets 
should allow earlier diagnosis and better management of oncology patients (Gambhir, 2002). PET/CT is 
seen as a modality with high precision in the identification of early disease, the differentiation between 
benign from malignant lesions, the detection of metastases, and determination of therapeutic 
effectiveness of tumours (Massoud & Gambhir, 2003; Phelps, 2000a). PET is an imaging technique, 
which is thought to be new, the basis for PET was already laid in the 1970s (Granov et al., 2013). 
However, with the evolving knowledge of cancer biology, pharmacology and the clinical implications the 
number of radiolabelled tracers increase steadily and so the field of application in imaging. With the 
fusion of PET with CT (PET/CT Scanner) in 2002, it was then possible to get high-resolution functional 
and morphological images (von Schulthess, Steinert, & Hany, 2006) which considerably changed the 
management of patients with cancer (Fletcher et al., 2008; Juweid et al., 2007; Juweid & Cheson, 2006; 
Lardinois et al., 2003; Rohren, Turkington, & Coleman, 2004; Seam, Juweid, & Cheson, 2007; von 
Schulthess et al., 2006; Weber, 2006).  
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The heart of a PET (PET/CT) and SPECT procedure is its underlying radiopharmaceutical (RP). These drugs 
contain radioactive materials called radioisotopes, which target and accumulate in an affected area and 
are used for diagnosis or therapy. Because of the fractional amount of these substances in imaging 
tracers, these agents, which consist of a radionuclide and pharmaceutical part, do not show any 
pharmacological effect (World Health Organisation, 2008). The amount of activity will be aligned with 
the field of investigation and is expressed in units called Becquerel (Bq) or Curie (Ci). For decades the 
SPECT radionuclides 99 Mo (Molybdenum) and 99m Tc (Technetium) have been the primary source of 
diagnostic RPs, covering approximately 80% of all nuclear medical procedures (Deutsch, Libson, 
Vanderheyden, Ketring, & Maxon, 1986; Liu & Edwards, 1999; Rösch & Baum, 2011). With the step-up 
of PET, more radionuclides are currently used for research and clinical practice: 11C (Carbon), 13N 
(Nitrogen), 15O (Oxygen), 18F (Fluor), 64Cu (Copper), 124I (Iodine) and 68Ga (Gallium) (Schicha & Schober, 
2013). Due to the convenient production of radionuclides via generators the 68Ge/68Ga generator has 
spread quickly and is now a routine source of positron emitting 68Ga for PET/CT imaging (Velikyan, 2014). 
With the rising number of radionuclides and their specifics pharmaceuticals (e.g. monoclonal antibodies, 
peptides) individual diagnoses, treatment planning and control will lead to a patient-based treatment 
of the disease (Rösch, Herzog, & Qaim, 2017).  
1.2 Statement of the Research Problem: 
In the past decade, the term “personalised medicine” (PM) became the magic word for almost every 
player in the healthcare industry. It is the goal: “Provide the right patient with the right drug at the right 
dose at the right time” (Sadee & Dai, 2005). The National Academy of Sciences in the United States (NAS) 
defined personalised medicine as “the use of genomic, epigenomic, exposure and other data to define 
individual patterns of disease, potentially leading to better individual treatment.” (Committee on a 
Framework for Development a New Taxonomy of Disease National Research Council, 2011). 
It is sure that medical diagnostics will play a significant role in PM and the treatment of oncological 
diseases, enabling the identification of the patient´s genetic, anatomical and physiological 
characteristics. Besides molecular diagnostic tests, anatomic imaging and molecular imaging (MI); the 
latter has the advantage to detect and characterises tumours based on their molecular alterations. With 
these new tools, it will be easier to understand the heterogeneity of metastatic diseases, and it can 
examine in-vivo and non-invasively (Kircher, Hricak, & Larson, 2012). 
The current workhorse of PET is 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG), a glucose analogue labelled 
with Fluor- 18, which allows assessing the glucose metabolism levels in tissues and the differentiation 
between healthy and disease levels (Coenen et al., 2010; Fletcher et al., 2008). Because of its non-
patented status, this tracer quickly became a standard in the diagnosis of cancer (Schwaiger & Wester, 
2011). However, 18F-FDG alone cannot serve as a companion diagnostic for the discovery, development, 
and use of new molecular therapeutics. Increasing diversity of tracers beyond 18F-FDG will be needed in 
the clinic to provide useful diagnostics with more specificity over a greater range of disease and injury 
(Coenen et al., 2010). Genome-wide association studies (GWAS) have enabled rapid discovery of genetic 
variants contributing to the pathogenesis of complex genetic diseases (Manolio, 2010). This knowledge 
of molecular biology shifted the way of research towards developing target-specific RPs based on 
receptor binding of a radiolabelled receptor ligand in the diseased tissue. This high receptor binding 
affinity and specificity makes PET and SPECT unique in comparison to any other imaging modality (Liu, 
2004; Phelps, 2000a). 68Ga is, for example, a promising new radioisotope in the field of neuroendocrine 
tumours, which improved the neuroendocrine tumour detection and are now widely applied in Europe 
(Johnbeck, Knigge, & Kjær, 2014; Maecke, Hofmann, & Haberkorn, 2005). 
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Because PET, and the hybrid systems PET/CT and PET/MRI, are such powerful and sophisticated tools, 
research facilities all around the world have established their centralised radiochemistry facilities to 
produce and develop new PET probes independently. At the moment thousands of radiolabelled 
molecules have been researched, several hundred tested in human, but only a few dozen received an 
international market authorisation for a diagnostic and therapeutic purpose (Zimmermann, 2013). 
Since radiopharmaceuticals are approved according to the same rules as pharmaceuticals, public 
universities and research organisations struggle with the high costs of running their research facilities, 
the lengthy process and the high costs associated with the regulatory approval (Schwaiger & Wester, 
2011). Whereas 18F-FDG was very versatile applicable for imaging, newer radiopharmaceuticals used in 
oncology (for imaging and therapy) tend to be more specific and have a narrower field of application. 
A drug´s specialisation subsequently decreases the sales market, the return on investment (ROI) and 
thus the investor´s market attractiveness (Henderson, Alexander, & Smith, 2005; Nunn, 2007a; 
Zimmermann, 2013). A guaranteed profit may not be easily achieved without taking a higher 
commercial risk (Zimmermann, 2013).  
The pharmaceutical industry, as a fundamental investor for RPs, is currently struggling with several 
challenges: less revenue due to expiration of patented blockbusters (≥ 1 billion of annual sales); low 
productivity in new drug development (Khanna, 2012) and pressure on the reimbursement of new 
products (Kaitin & DiMasi, 2011). Thus many of the larger companies adjusted their strategies and risk-
reward ratio and may not be invested in products with lower or moderate market size (< 300 million 
dollars) (Khanna, 2012).  
The decreasing R&D budgets (for products with higher commercial risk) also affect the investor´s 
interest in nuclear medicine products and subsequently prevents the market authorisation of clinically 
useful drugs. Several barriers have been described in literature: 
(1) Economic and Market-related Challenges 
i. The market is very small because imaging agents are undervalued, and current prices will 
not support a new drug unless it is used in high volume (Nunn, 2007b). 
ii. RPs have limited profitability even if they are proprietary (Zimmermann, 2013). 
iii. There is a limited possibility for commercial exploitation of academic discoveries (Mather, 
1998). 
(2) Research and Development 
i. High development costs for radiopharmaceuticals, ranging from 100-200 million dollars 
for an RP imaging agent (Henderson et al., 2005; Nunn, 2006; Zimmermann, 2012a) and 
around 800 million dollars for a new therapeutic drug (e.g. DiMasi, Grabowski, & Hansen, 
2016; DiMasi, Hansen, & Grabowski, 2003; Prasad & Mailankody, 2017)  
ii. Some biological imaging markers are clinically not validated and adopted, because they 
do not measure a relevant biological feature nor enable disease diagnosis or outcome 
prediction (O´Connor et al., 2017). 
iii. Experimental RPs are used in the drug development process to investigate 
pharmacokinetic and to dose but are not developed further (Nunn, 2007a). 
iv. Intellectual property right (IPR) issues between public research groups and potential 
investors. Sharing IPRs may limit exclusive commercial rights and discourage commercial 
development for investors (Schelbert, 2011). 
(3) Regulation and Marketing Authorisation 
i. There are many validation steps necessary to regulatory and safety approval in the 
development and production of RPs by national authorities (Henderson et al., 2005; Nunn, 
2007a; O´Connor et al., 2017; Zimmermann, 2013).  
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ii. At the moment, the requirements by the FDA and EMA for the regulatory approval of 
imaging agents are the same as for therapeutics (Agdeppa & Spilker, 2009).    
(4) Reimbursement and Revenue Planning 
i. Shrinking revenue for investors based on the low or even decreasing reimbursement rates 
for diagnostic imaging tests (Nunn, 2007a; Zimmermann, 2013).  
ii. Health Technology Assessment (HTA) is implemented in many developed countries, 
evaluating the benefit of a medicinal product and the data is used for price/ 
reimbursement negotiations. Imaging biomarkers are evaluated based on the same 
patient-related benefits indicators (mortality, morbidity and health-related quality of life) 
as pharmaceutical drugs (Institute for Quality and Efficiency in Health Care - IQWIG, 
2017a). 
(5) Different goals between the Scientific Community and Investors/Industry 
i. Different goals in the industry- and academic research: The questions asked in academia 
generates data, which may not be helpful in the market authorisation process (Buscombe, 
2015).  
ii. Limited knowledge in the scientific community (outside of the nuclear medicine field) on 
the benefits of radiopharmaceuticals in the diagnosis and therapy of cancer 
(Zimmermann, 2013);  
(6) Special Manufacturing, Distribution and Handling of Radiopharmaceuticals 
i. Special manufacturing and distribution of RPs due to the usage of radioactive components 
(Bundesministerium für Justiz und Verbraucherschutz, 2017; Bundesministerium für 
Erwelt Naturschutz und Reaktorsicherheit, Bundesministerium für Gesundheit, & 
Bundesministerium für Verkehr Bau und Wohnungswesen, 2017; European Commission, 
2017; International Atomic Energy Agency, 2008; Zimmermann, 2013) 
These obstacles lead to fewer RPs receiving market authorisation, even if they could potentially 
significantly contribute to the treatment of specific diseases (Kratochwil et al., 2015). If new, efficient 
and innovative technology does not reach the market, it appears to be a market failure. The same 
phenomenon can also be observed in “neglected diseases” (Trouiller et al., 2002). Initially, Schumpeter 
assumed in his work of Capitalism, Socialism, and Democracy that large firms with industrial research 
laboratories enjoy a static market power and would use their economic profits to finance risky, large-
scale R&D activities whereby the society and the company will profit (Schumpeter, 1975). 
However, on the contrary, one could observe that less and less research-based pharmaceutical 
companies take the financial risk of drug R&D (Comanor & Scherer, 2013). Professional Institutions, such 
as the National Institute of Health (NIH) or the National Cancer Institute (NCI) in the United States 
identified the low investor´s interest and are trying to bring new investors into the market. With the 
success of the concept of public-private partnerships (PPP) in public infrastructure project, it was also 
suggested that this would be a suitable concept for life science and drug development sector (Lazdins-
Helds, 2008; The European Commission, 2013; Vaudano, 2013; Yildirim, Gottwald, Schüler, & Michel, 
2016). The concept pursues the goal to invite different players to participate in clinical trials actively, 
share financial risks and thus overcome the deficiency of authorised products (Aerts, Sunyoto, Tediosi, 
& Sicuri, 2017; Mercanoglu & Ozer, 2015).  
1.3 Statement of the Purpose of this Study 
Several barriers in the development and authorisation of new radiopharmaceuticals have been 
described in literature so far, but little is known about the real weight of each “obstacle” from the view 
of the investors and scientific community. Do stakeholders in Europe experience the same challenges? 
Are challenges seen differently in countries with regulatory approved in-house production? The studies 
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dealing with this topic are mostly written by a member of one stakeholder group such as the 
pharmaceutical industry, the scientific community, and the regulatory authorities. These studies can be 
described as “reviews”, but so far no study could be identified, which surveyed the stakeholder´s 
(industry, scientific community, regulatory organisation) point of view empirically.  
The purpose of the proposed study is to explore and explain the challenges of diagnostic and 
therapeutic radiopharmaceuticals with regards to receiving a marketing authorisation, and 
identifying the underlying disinterest from private investors (“Why”). The study will furthermore 
investigate the challenges and/or success factors for public-private- partnerships and how it could 
resolve some of the critical problems.  
Research questions: 
1. What is the clinical efficacy of Somatostatin Analogues and PSMA ligands in diagnostic and therapy? 
2. What are the main challenges, why diagnostic and therapeutic Radiopharmaceuticals are currently 
mainly developed in public research organisations and don´t reach market authorisation?  
3. What are potential alternatives to the “traditional” pharmaceutical drug development process and 
how could these address/solve the above problems? Can the concept of public-private partnerships 
(PPP) serve as an alternative to improve the number of diagnostic and therapeutic 
radiopharmaceuticals? 
1.4 Methodology 
For this research purpose, a quantitative and a qualitative research method will be used to triangle the 
problem from different perspectives and test the consistency of findings from one method to another. 
This research approach has its roots in the pragmatic worldview: “Instead of focusing on methods, 
researchers emphasise the research problem and use all approaches available to understand the 
problem” (Rossman & Wilson, 1985). Methodological pluralism can increase the scope and the level of 
possible analysis (Johnson & Onwuegbuzie, 2004). 
The first theoretical framework of the mixed research method by Rossmann & Wilson in 1985 initially 
described three purposes: corroboration, elaboration and initiation. Soon this concept was extended by 
another purpose: development (Greene, Caracelli, & Graham, 1989; Rossmann & Wilson, 1991).  
 Corroboration: A classical triangulation where different methods are employed to test the 
consistency of findings from one method to another (Rossman & Wilson, 1985).  
“Pinpoint the values of a phenomenon more accurately by sighting in on it from different 
methodological viewpoints” (Brewer & Hunter, 1989) 
 Elaboration: Is a concept of complementarity and provides additional richness and detail if just 
one method is used. It “enhances, illustrates, clarifies the results from one method with the 
results from the other” (Greene et al., 1989; Rossman & Wilson, 1985; Rossmann & Wilson, 
1991) 
 Development: “The results from one method shape the instrumentation, sampling and analysis 
strategies of the other method” (Greene et al., 1989).  
 Initiation: This purpose intends to uncover “paradox and contradiction”, reframe the research 
question to challenge the original conceptual framework (Greene et al., 1989; Rossman & 
Wilson, 1985). 
Dickson, C. and Wilson, B. significantly demonstrated the efficacy of the mixed research model in two 
social studies (Dickson, 1991; Wilson, Rossman, & Adduci, 1991).  
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The reason we analyse the efficiency of two of the most widely studied radiopharmaceuticals 
(neuroendocrine tumours and prostate cancer) in the first step: we need to make sure that the 
technology is efficient and does not fall short due to inferiority. Otherwise, the assessment of 
challenges/ barriers, and the reasons for the low investor interest is not reasonable.  
1.4.1 Quantitative Research – Focused Literature Review 
The aim of conducting a literature review is often to enable the researcher both to map and to assess 
the current intellectual territory, and to specify a research question to develop the existing body of 
knowledge further (Tranfield, Denyer, & Smart, 2003). It is nowadays well known that a good literature 
review is the basis of both theoretical and methodological detailing, and improves the quality and 
usefulness of the following research (Boote & Beile, 2005). Especially in medicine, where 
recommendations are based on solid clinical research, it is essential to achieve a certain level of 
evidence. Systematic reviews and meta-analyses are a crucial element of evidence-based healthcare, 
ensuring that clinical decisions are made by the most up-to-date, trustworthy, reliable scientific 
evidence (Khan, Kunz, Kleijnen, & Antes, 2003; Sackett, Rosenberg, Gray, Hynes, & Richardson, 1996). 
We were guided by the requirements of the systematic literature review, but it was not the goal to 
create a systematic review of the cases NET and PSMA. Nevertheless, we tried to carry out a scientifically 
transparent process, to eliminate bias by extensive literature search and to refer to currently available, 
scientifically high-quality reviews.   
The primary databases for both literature reviews were: PubMed, Science Direct, EMBASE and Google 
Scholar.  
Search Terms used for the identification of relevant literature: 
I. Search terms to identify studies dealing with Radiopharmaceuticals and Neuroendocrine Tumours: 
 Diagnostic: “PET” OR “PET/CT” AND “neuroendocrine tumour” OR “carcinoid”  
 Therapeutic: “peptide receptor radiotherapy” OR “PRRT” OR “radiotherapy” OR “lutetium” OR 
“yttrium” AND “neuroendocrine” OR “neuroendocrine tumour”  
II. Search terms to identify studies dealing with Radiopharmaceuticals and Prostate Cancer: 
 Diagnostic: “PET” OR “PET/CT” AND “prostate” OR “prostate cancer” OR “PSMA” 
 Therapeutic: “peptide receptor radiotherapy” OR “PRRT” OR “radiotherapy” OR “lutetium” OR 
“yttrium” AND “prostate” OR “prostate cancer” OR “PSMA” 
III. Search terms to identify studies dealing with the challenges and barriers to get Radiopharmaceuticals approved: 
 “molecular imaging” OR “radiopharmaceutical” OR “imaging biomarker” OR “radiotracer” AND 
“constraints” OR “challenge” OR “uncertain” OR “economic”  
Inclusion Criteria for Search Term I and II: 
 Only full publications  
 Only studies with the species “human” 
 Studies in the field of oncology 
 Studies needed to have a prospective, retrospective design. Case reports have been excluded. 
Inclusion Criteria for Search Term III: 
 Only full publications  
 Studies in the field of oncology 
 Studies discussing challenges, problems, opportunities or topics related to regulation and market authorization of 
radiopharmaceuticals 
 Studies after 2001 (In 2001 the European Union introduced a new directive (EU 2001/83) on the use of medicinal 
products in human use, which affected the marketing authorization of radiopharmaceuticals (Decristoforo & 
Peñuelas, 2005) 
Exclusion criteria: 
 Studies with focus on medical efficacy, technical implementation, and health efficacy assessments, paediatric, 
nanoparticles, animal studies, ultrasound, Magnet Resonance Imaging and all studies not related to the above 
research question and the field of oncology. 
All included studies were screened for additional relevant references. 
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1.4.2 Qualitative Research – Expert Interviews 
While quantitative research tools identify the causal mechanism with statistical methods, qualitative 
research looks into the causal mechanism and identify the scope´s determination (Gläser & Laufel, 
2009). For decades there is an ongoing methodological debate, whether scientific conclusions can be 
made based on qualitative research methods or quantitative research, such as the gold standard 
Randomised Controlled Trials (RCTs), are the only valid scientific procedure in health studies, education, 
social work and social sciences (Cochrane Collaboration & Campbell Collaboration, 2017). There is a long 
history of criticism that qualitative research does not adequately justify its assertions and that the 
creation of theory is based on rather thin evidence (Gioia, Corley, & Hamilton, 2013). 
The different views are hieratic, and so in the last decades, a mixed methods research approach has 
emerged as an alternative in social and behavioural science (Creswell, Klassen, Plano, & Smith, 2011). 
This new methodical approach should improve the quality and scientific power of data, by investigating 
complicated health problems with a multi-level approach (Creswell et al., 2011). In this context multi-
level means that investigators, with knowledge of the social and health word, gather evidence via 
various sources and levels that influence a given problem. The opportunity to integrate a variety of 
theoretical perspectives (Creswell et al., 2011).  
Quantitative methods are used to measure the depressiveness of a known phenomenon, whereas 
qualitative research methods build on the gathered evidence. One can identify previously unknown 
processes and explanations of why and how phenomena occur, and the range of their effects (Creswell 
et al., 2011; Pasick et al., 2009). The strength is the focus on the context, the intentional collection of 
both quantitative and qualitative data and the interpretation of qualitative data to understand 
processes. 
“It is a systematic and rigorous form of inquiry that uses methods of data collection such as in-
depth interviews, ethnographic observation, and review of documents. Qualitative data help 
researchers understand processes, especially those that emerge over time, provide detailed 
information about setting or context, and emphasise the voices of participants through quotes. 
Qualitative methods facilitate the collection of data when measures do not exist and provide a 
depth of understanding of concepts.” (Creswell et al., 2011) 
We used the qualitative research tool “interview”, what we find to be a suitable method for collecting 
data and answering the research questions. Interviews, in general, are useful to generate valued 
scientific knowledge, also because it has become one of the most widespread knowledge-producing 
practices across the human and social sciences in general (Brinkmann, 2014). Knowledge is generated 
through the interaction between the interviewer and an interviewee, with the purpose of obtaining 
descriptions of the living world and describing the phenomena (Brinkmann & Kvale, 2017). Interviews 
techniques have been extensively described in literature, ranging from focused-, biographic-, narrative, 
qualitative-, problem- centred-, standardised-, partly standardised interviews and many more (Gläser & 
Laufel, 2009).  
In this thesis, we have opted for a semi-structured expert interview approach. The idea is that the 
researcher provides some structure to the interviewee, based on the research interest, but allows for 
more spontaneous descriptions and narratives (Brinkmann, 2014). The rationale to interview 
“experts” is that those persons should be better informed, have a unique source of inside information 
and are more motivated compared to mass surveys (Dorussen, Lenz, & Blavoukos, 2005). Experts are 
seen as individuals, who are part of the sphere of activity and are responsible for the development, 
implementation or control of solutions, strategies or policies (Audenhove, 2007; Meuser & Nagel, 
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1991). Furthermore, interviews with experts allow the researcher to have control over the dimensions 
that are central to the related research topic (David, 1996; Dorussen et al., 2005).  
Even this approach is commonplace in medicine, management and marketing, communication, political 
science and education studies (Dorussen et al., 2005), there is some debate on whether qualitative 
research data is reliable. For example, there is criticism that the results rely upon few data points, that 
experts do not have the same knowledge, interviewees may report on their thoughts or actions which 
could be incomplete or even deceitful, and the interpretation of the data is affected by the researcher´s 
subjectivity (Brinkmann, 2014; Brinkmann & Kvale, 2017). Indeed, an interviewee can provide a 
convincing narrative of a situation, but also other things could be said about the topic. Therefore, it is 
necessary to be suspicious, as these narratives could be constructed. The argument about the 
researcher’s subjectivity could be countered by the argument that all research involves interpretation, 
even data from statistical tests need to be interpreted based on pre-existing theories, personal 
preferences and contextual understanding (Brinkmann, 2014). 
“Qualitative research procedures are explicitly interpretive in their approach, striving to make 
sense of data and often expressing great caution about generalizability.” (Brinkmann, 2014) 
Dorussen et al. (2005) used the Condorcet Jury Theorem to evaluate the quality and reliability of the 
expert-opinion data. In the most basic form of the Condorcet Jury Theorem, a group of individuals 
independently make a binary decision that is either “right” or “wrong”, with each has a fixed probability 
of being right. The asymptotic part of the theorem states that “it becomes extremely likely that the 
majority is right when the number of individuals increases”, and the non-asymptotic part assumes that 
“the majority is more reliable than each citizen” (Dorussen et al., 2005). And as a result this research 
group has revealed that expert interviews are an attractive data collection method, but the validity of 
the information depends on the quality of the experts. They also clarified that: 
“Any theoretical link between the reliability and validity of data cannot simply be assumed. 
However, the Condorcet Jury Theorem can be used to argue for the existence of such a link. More 
coherent, i.e. reliable, experts are also more likely to be right, i.e. provide valid information, 
under some quite general and reasonable assumptions. The Condorcet Jury Theorem does not 
require all experts to be equally knowledgeable, and they may be better informed on some issues 
rather than others.” (Dorussen et al., 2005) 
The limitations are apparent: Only with high-quality data sophisticated assumptions can be made, and 
the experts need to be willing to participate (Dorussen et al., 2005).  
1.4.2.1 Qualitative Content Analysis 
The starting point of the Qualitative Content Analysis is the Quantitative Content Analysis. In this case, 
the quantitative content analysis is our focused literature review, which was our basis to systematically 
draft the qualitative research questions. The generated dataset is subject to the analysis of the 
researcher, with the main purpose to reach for statements about the subject matter. “Because without 
a specific line of inquiry or established direction of analysis any content analysis would be unthinkable” 
(Mayring, 2014). Based on the nature of the research question we have selected the qualitative content 
analysis approach based on the methodology of Bryman & Bell (2011) and Philipp Mayring (2000). 
Because qualitative data is related to concepts, values, opinions and behaviours of people, the data 
cannot be reduced to numbers but is processed in some form of explanation and understanding (Lewins, 
Taylor, & Gibbs, 2010). Different methods are described in the literature, associated with specific 
approaches or traditions such as grounded theory (Strauss & Corbin, 1998), narrative analysis (Andrews, 
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Squire, & Tamboukou, 2013), phenomenology (e.g. Sokolowski, 2000), and discourse analysis (e.g. 
Brown & Yule, 1983). The basis for Strauss, Corbin´s ground theory is recognised as the inductive analysis 
approach, a systematic procedure for analysing data guided by specific evaluation objectives (Thomas, 
2006). “The researcher begins with an area of study and allows the theory to emerge from the data” 
(Strauss & Corbin, 1998). The analysis is “goal-free”, the extensive and varied raw data is condensed 
into a brief, summary format. Clear links are established between research objectives and the raw data´s 
findings to show transparency and defensibility, and to develop a model or a theory about the 
underlying structure (Thomas, 2006).  
The second approach is called deductive analysis used to test whether data is consistent with prior 
assumptions, theories, or hypotheses. Researchers very often use both methods to analyse their data. 
A central element in the analysis is the “category system”, which can be either deductive or inductive. 
The latter emerge out of the analysis itself, whereas in the deductive approach the theoretical 
considerations are the basis for the categories (Mayring, 2000). 
1.4.2.1.1 Category System and Coding: 
For the analysis of the semi-structured interview qualitative data set, we have chosen to use the 
deductive as well as the inductive method. The benefit of the inductive approach: frequent, dominant, 
or significant themes can emerge from the raw data, without being restrained by structured 
methodology (Thomas, 2006). In the concept of content analytical procedures, the text is not 
interpreted as a whole but split into segments, which are defined (in advance) into categories. This 
segmentation is also called “coding into units”, it is distinctive and offers a second reviewer the 
possibility to come to similar results (Mayring, 2014). The author has used the approach by Gioia et al. 
(2013), stepwise identifying informant terms and categories via the 1st-order analysis, looking for 
similarities and differences among the many different categories and label them. In the 2nd –order 
analysis one is looking for emerging themes, which may help to describe and explain phenomena. 
1.4.2.1.2 Unit level data and Coding unit: 
In some cases, it made sense to classify responses in whether they “agree”, “disagree” or were “neutral/ 
undecided”. It is worth mentioning that due to the structure of the interview, the majority of questions 
was not towards receiving a “Yes” or “No” answer, but in some instances interposed questions led to 
answer such as “agree”, “disagree” or “neutral/undecided”. 
The coding unit (Baxter, 1991) is a constellation of words or statements that relate to the same central 
meaning, also known as a keyword and phrase, a unit of analysis, and a theme (Graneheim & Lundman, 
2004). So a coding unit can be words, sentences or paragraphs, and should be defined in advanced. In 
this thesis the coding unit is at least a sentence, more often we used paragraphs. These coding units had 
to contain a statement or a causal statement relevant to the research questions. After transcription of 
all interviews, those were reviewed several times to identify significant themes and categories.  
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1.4.2.2 Characteristics of the Study Population 
The primary research interest of this study is to explore and explain the economically, regulatory, and 
developmentally challenges of diagnostic and therapeutic radiopharmaceuticals with regards to 
receiving marketing authorisation, and the future role of 
molecular imaging in patients with cancer disease. Typically, 
several stakeholders take part in the development of new 
drugs/ imaging biomarkers as outlined in Figure 1. Especially in 
nuclear medicine, new products have often been developed 
within a unique collaboration between national laboratories, 
academia, different research communities and the industry 
(National Research Council (US), Institute of Medicine (US), & 
Committee on State of the Science of Nuclear Medicine, 2007). 
The academic community was and still is the foundation for 
basic research, the translation from basic research to applied 
clinical research and has been driving many new pharmaceutical , 
radiopharmaceutical and biopharmaceutical innovations (Kaitin, 
2010).  
Experts from the following fields were identified in advance to be most valuable to answer the research 
question:  
1. Experts in nuclear medicine and/or molecular imaging 
2. Experts in the treatment of patients with prostate and/or neuroendocrine cancer 
3. Experts from the pharmaceutical industry with knowledge in imaging and/or companion 
diagnostics 
4. Experts from the Radiopharmaceutical business with knowledge in Research & Development 
and/or General Management 
5. Experts from the Molecular Imaging Equipment industry with knowledge in the nuclear 
medicine/ molecular imaging area 
6. Experts from a national and/or cross-country regulatory authority responsible for the 
authorisation imaging biomarkers and/or implementation of new regulations. 
1.4.2.2.1 Identification of Experts 
For our study, we identify several experts from the stakeholder groups, who would be willing to take 
part in this study. In advance, we have defined the expert to be “a leading physician, leading manager, 
leading researcher, who is qualified because of his skill, knowledge, education, experience, or training. 
He/she knows the medical and healthcare professional field, beyond that of an average person.”  
i. Identification of Medical Experts (Nuclear medicine physicist, medical specialist, and 
oncologist):  
“Must” criterion: high knowledge and experience in their field of specialisation; knowledge 
evaluated by the number of relevant publications in peer-reviewed, high-impact journals; 
currently high ranked job position in well-respected (mainly university) hospitals;  
“May” criterion: Personal recommendation of a previously selected interview partner, if he/she 
is prevented. 
ii. Identification of experts in the industry:  
“Must” criterion: general knowledge and experience in the pharmaceutical, 
radiopharmaceutical and medical technology field; very sound knowledge in molecular imaging 
and/or the application of companion diagnostics; Perennial experience in the relevant industry; 
Patients
Researchers 
& Doctors
Industry
Public 
Research 
Organisations
Advocate 
Groups
Funders
Regulatory 
Agencies
Figure 1 shows the main stakeholders 
involved in the approval, development and 
research of new radiopharmaceuticals. 
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high ranked position in the company, preferred in Research & Development or General 
Management; 
“May” criterion: relevant publications in journals or speeches in relevant scientific congresses 
or engagement in industrial- or scientific associations related to the research topic;  
Among other things, the academic research platform “research gate” and the professional job 
platform “LinkedIn” was used to identify these individuals. 
iii. Identification of experts in the regulatory field:  
The selection of interview partners has proofed to be provoking. Employees generally do not 
show their expertise on public platforms but could be identified through an indirect way based 
on official government documents such as code of practices, regulations and public Q&A 
sessions. Primary contact demonstrated to be not helpful, for example due to in-house 
allowance rules. We, therefore, had to use the proper contact path and experts, if even 
available, have been selected by the regulatory agencies by themselves. Nevertheless, the two 
interview partners seemed to have profound knowledge in the field of radiopharmaceuticals 
and/or companion diagnostics. 
“Must” criterion: existing permanent employment with a regulatory authority involved in the 
approval/evaluation of marketing authorisation and/or other regulatory issues related to 
radiopharmaceuticals; Several years of experience in radiopharmaceuticals, molecular imaging 
or companion diagnostics;  
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1.4.2.3 Details on the Qualitative Interviews 
The interviews have mainly been conducted by telephone (23/25), two interviews have been performed 
face to face. The average length of the interviews was around ~ 36 minutes, with a range from 16 
minutes to 57 minutes. The distribution of interview partners from the specific segments is highlighted 
in Table 1. 
Table 1 shows the distribution of interviews within the speciality, the number of interviews performed, the number of interview 
inquiries sent to specialists in this field, as well as the mean duration of the talk 
All interviewees were asked to give their consent to the recording of the interview at the written 
invitation. At the beginning of the interview, the interviewees have been asked again if they agree that 
the interview will be recorded if no written consent was available in advance of the interview. Written 
or oral consent is available from twenty-two (22) interviewees, disagreement by three (3) interviewees. 
If there was no consent, the participants were asked to give permission to take notes. This was 
confirmed by the three interviewees. In two cases, the quality of the recording was low, which meant 
that some parts of the conversation (not relevant to the analysis) were incomprehensible. 
1.4.2.3.1 Transcription: 
The interviews were transcribed word-for-word using the online software tool http://otranscribe.com/. 
The interviews were put down in writing promptly after the interviews were finished, allowing the 
researcher to get familiar with the data and also prepare for upcoming interviews.  
All transcripts have been checked for mistakes. 
1.4.2.3.2 Categories and Coding: 
Since up to five different stakeholder groups, with different perceptions and views, answered analogical 
questions, there was a wide range of responses, terms and categories in the 1st-order analysis. 
Therefore, the data was first arranged in preliminary sub-categories (for each stakeholder group) using 
the program MS Excel. Specific text segments related to the objective have been identified and labelled, 
and subsequently, the essential categories have been incorporated in the program FreeMind. The 
original coding has been performed by the author; subsamples were independently read by MR, a well-
experienced university staff member in qualitative research. MR also agreed with the author on the 
coding frame and together they conceptualise broad themes.  
After a final critical re-reading, no new themes emerged suggesting that the major themes have been 
identified (Marshall & Rossman, 1999). Ineluctably, the findings are influenced by the questions outlined 
Segment 
Total  number/ 
% of total 
interviews 
Number of 
interview 
inquiries sent 
The average 
duration of the 
interviews (min) 
Senior Academics in the Nuclear Medicine Segment 7/35 9 ~37 
Specialist Physicians in Cancer Treatment 4/ 16 8 ~29 
Senior Managers from the Pharmaceutical Industry  3/12 12 ~44 
Senior Managers in the Radiopharmaceutical Industry 5/20 6 ~35 
Senior Managers from the Molecular Imaging Equipment 
Industry 
2/8 6 ~42 
Specialists Regulatory Authority  3/10 7 ~27 
International Agency promoting the safe, secure and peaceful 
use of nuclear technology in Healthcare 
1/ 4 5 ~34 
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by the researcher, as well as shaped and ranked according to their importance by the assumptions of 
the researcher 
1.4.2.3.3 Remarks and Limitations:  
The identification of the right interview partner in the pharmaceutical, radiopharmaceutical, molecular 
imaging technology, and regulatory group proved to be difficult, and time-consuming. We sent several 
interview inquiries, some had not been answered at all, and few had a negative answer (details in Table 
1). In one case an interviewee had to refuse due to internal company restrictions (in the molecular 
imaging technology group) but has referred to a company brochure. The mobilisation of interview 
partners in the group of national/international regulatory agencies was particularly tricky. Here, the rate 
of refusals was the highest. During the research period, we identified another stakeholder group (Health 
insurance companies/ Health insurance policymakers), which could have eventually contributed to 
answering the research questions. Unfortunately, no interview was conducted since the interview 
inquiries were rejected or not answered (healthcare insurance companies: four interviews inquiries 
sent, two rejections, two pending requests; healthcare insurance policy makers: three interviews 
inquiries sent, one rejection, two pending requests). 
Due to the inexperience of the interviewer, it sometimes happened that questions were skipped or 
evasively answered by the interview partners. In this case, the interviewees were contacted again and 
asked to answer the question. Unfortunately, this works only in two cases, in two other cases, we 
received no answer to our written request. 
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THEORETICAL PART 
2 Role of Nuclear Medicine in Oncology 
Early diagnoses may be a fundamental contributor to the reduction of morbidity and mortality by early 
identification of functional abnormalities (Higgins & Pomper, 2011b). When speaking about malignant 
diseases, nuclear medicine is an essential contributor to the detection, staging, therapy selection and 
planning stage (Velikyan, 2014). Diagnostic nuclear medicine procedures add value to standard 
diagnostic methods, by identifying essential and vital tissue segments (Bartenstein & Haug, 2011). 
Compared to contrast agents, which are non-specific and accumulate in the bloodstream and or in 
organs, many RPs are highly specific, have a high affinity to a specific receptor molecule (Figure 2) and 
thus only bind to specific molecules (Möllmann, 2006). Ideally, the target receptor is only found on 
diseased tissue, or the receptor is overexpressed in the region of interest relative to other tissues 
(Möllmann, 2006; Srinivasarao, Galliford, & Low, 2015). Newer anticancer drugs use a similar approach 
(Figure 3) substituting the radionuclide with a therapeutic agent and adding a spacer and a cleavable 
bridge to permit the drug release in the target cell. A variety of targeting therapy- ligands have been 
used so far: antibodies, aptamers, small protein scaffolds, peptides and low-molecular-weight non-
peptidic ligands (Srinivasarao et al., 2015). The ongoing findings in proteomics and genomics further 
expand the knowledge about the function of receptors, enzymes, antigens and substrates (Velikyan, 
2014). So newer RPs used in molecular imaging make it quite easy to adequately assess and understand 
the primary process of metabolism of elements and the more complicated metabolic system in organs 
(Müller in Schwiegk & Turba, 1961). 
 
 
 
 
 
 
Nuclear medicine therapy has successfully started with the use of radioiodine to treat thyroid disease 
disorders. In more than 50 years, millions of people have been treated with radioiodine to treat benign 
and malignant thyroid diseases (Oyen et al., 2007). In this approach primarily β emitting radionuclides 
are used since they are characterised by a small range, high linear energy transfer and subsequently a 
high biological efficacy (Bartenstein & Haug, 2011).  
Two different types of nuclide therapy are available: 
Systematic Nuclide Therapy: 
The radionuclide is being administered oral or intravenous. It either follows a physiological uptake and 
accumulates in the target organ via metabolism or is coupled with receptors (receptor-ligand 
therapy/receptor peptide therapy) to reach the target region. The second way is used with RP such as 
somatostatin-analogue or marked antibodies (radioimmunotherapy). The efficacy of PRRT will be 
highlighted in the case study of 177Lu- DOTATATE and 90Y-PSMA. 
Various clinical studies have confirmed the high value of Peptide receptor radionuclide therapy (PRRT) 
in patients with cancer and multiple inoperable metastases (see chapter 2.2 & 2.3). The success story of 
Bioactive 
Molecule 
Receptor 
Ta
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e
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Figure 2 shows the components of a radiopharmaceutical 
complex using a bioactive molecule to bind to a receptor 
(Source: Möllmann, 2006)  
Figure 3 shows a new generation therapeutic agent 
using a target ligand to permit the drug release in 
the target cell (Source: Möllmann, 2006) 
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PRRT started with the use of somatostatin analogues with the radionuclides Indium, Yttrium and 
Lutetium, especially 90Y-DOTATOC and 177Lu- DOTATATE (Bergsma et al., 2013; Teunissen, Kwekkeboom, 
Valkema, & Krenning, 2011). The new era of highly specific drugs (imatinib, trastuzumab, and epidermal 
growth factor–receptor inhibitors) it is increasingly important to select the right patients for the right 
drug as maybe just a few patients have the right target and the drug is effective (Tofilon, Saxman, & 
Coleman, 2003). The efficacy of PRRT will be highlighted in the case study of 177Lu- DOTATATE and 90Y-
PSMA. 
Local nuclide therapy:   
The radionuclide is placed in the place of interest and is taking effect on the surrounding tissue. Effective 
therapy is radiosynoviorthesis, which is successfully used for local treatment of painful inflammatory 
joint disease for many decades. Also important is the “Selective internal radiation therapy” (SIRT) used 
to treat/ control inoperable cancer in the liver. Tiny microspheres, which contain a radioactive substance 
block small blood vessels and restrict the blood flow to the tumour.  
2.1 Theranostics – combining diagnostics and therapy 
Since a decade theranostics is thought to be a promising tool for drug - and diagnostic test developers. 
The idea of theranostics: administrating a specific targeted therapy based on a previously performed 
specific targeted diagnostic tests. The diagnostic test stratifies those patients, who are most likely to be 
helped or harmed by new targeted drug therapy using e.g. specific genomic expression profiles, semi-
quantitative immunohistochemical (IHC) assays and molecular imaging tests. (Warner, 2004).  
Probably the most well-known example in this field is trastuzumab (registered trade name: Herceptin). 
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 
(HER2, c-erbB2). This receptor type is overexpressed in 25% to 30% of breast cancers. It inhibits the 
tumour cell proliferation by targeting the extracellular domain of the protein encoded by the HER2/neu 
gene (Boku, 2014; Dawood, Broglio, Buzdar, Hortobagyi, & Giordano, 2010). Patients are selected by 
HeceptTest and/or Path-Vysion, and so far several studies confirmed the clinical benefit of this approach 
showing a significantly prolonged overall survival and progression-free survival (Boku, 2014; Dawood et 
al., 2010). HER2 is also overexpressed in other forms of cancer, such as gastric cancer and seems to be 
effective, additionally to chemotherapy, in patients with advanced gastric or gastro-oesophageal 
junction cancer (Bang et al., 2010). 
Theranostics/Theragnostic in Nuclear Medicine 
While the term “theragnostics” is used to explain a treatment strategy that specifically combines 
therapeutics with diagnostics, the term “theranostics” explains more in general the ongoing efforts to 
develop more specific, individualized therapies for various diseases (Dobson, 2010; Pene, Courtine, 
Cariou, & Mira, 2009). In the case of nuclear medicine the targeting vectors (e.g. peptides) can be either 
labelled with a diagnostic radionuclide for PET or SPECT or with a therapeutic radionuclide. Some 
molecular targeting vectors allow a quantitative diagnosis of a disease, (personalised) treatment with 
the same vector but different radionuclides, with the option to consider patient-individual dosimetry 
(Rösch & Baum, 2011). This thesis will focus on two exemplary cases, which highlight the concept of 
Theranostics/ theragnostics and the contribution of nuclear medicine procedures in imaging and 
therapy.   
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2.2 Case 1 - Somatostatin Receptor Scintigraphy in Neuroendocrine 
Tumours (NETs) 
Probably the best example of the successful implementation of a peptide-based radiopharmaceutical 
for diagnoses (and much later the use of a very similar vector for therapy) was in the field of 
neuroendocrine tumours.  
Neuroendocrine tumours (NETs) are rare but a broad family of neoplasms, which mainly occur in the 
lungs, intestine and the pancreas. The originate in neural and diffuse endocrine structures of the 
gastrointestinal tract and pancreases and present many clinical challenges (Modlin et al., 2008; Öberg, 
2015; Rindi & Wiedenmann, 2011). NETs are frequently sporadic, unpredictable, have an unusual 
biological behaviour and have a delayed diagnosis with poor outcome (Modlin et al., 2008; Öberg, 2015; 
Ramage et al., 2005). In earlier stages of the disease, patients often have non-functioning tumours or 
exhibit nonspecific symptoms, and once these tumours start to metastasize they often feature 
hypersecretory syndromes and release peptide hormones and bioactive substances such as gastrin, 
insulin into the bloodstream (Modlin et al., 2008; Vinik & Moattari, 1989). The tumours originate from 
pancreatic islet cells, gastroenteric tissue, neuroendocrine cells within the respiratory epithelium, and 
parafollicular cells within the thyroid (Öberg, 2015; Ramage et al., 2005).  
“About 72 % of NETs arise in gastrointestinal structures, 25 % are bronchopulmonary in origin, 
and less than 5 % arise at other sites (e.g. thymus, breast and genitourinary system). Frequently, 
these tumours are discovered when metastatic or locally advanced and therefore inoperable.” 
(Zaknun et al., 2013) 
In the past, these tumours have also been called “carcinoids”, named by Oberndorfer in 1907 to 
distinguish a tumour of the small intestine which is less aggressive than most carcinomas (Williams & 
Sandler, 1963). Until 2010 these tumours were classified based on their primary localisation (foregut 
tumours, midgut tumours, and hindgut tumours), but this classification system has been updated and 
is now based on the localisation and the eventual hormone production: NET G1 (Ki-67 <2%), NET G2 (Ki-
67, 2-20%) and NEC (G3) with Ki-67 > 20% (Bosman & Carneiro, 2010). 
The neoplasm varies from being well-differentiated endocrine tumours (WDET) and poorly 
differentiated endocrine carcinoma/small cell carcinoma (PDEC) (Barbieri et al., 2014; Bosman & 
Carneiro, 2010). PDEC generally show a poorer outcome as the tumours are biologically more aggressive 
compared to WDET, which can be cured entirely or allow a long-term survival even in the presence of 
relapse or metastasis (Barbieri et al., 2014).  
Some criticism came up on the existing WHO 2010 classification/staging systems by the European 
Neuroendocrine Tumour Society (ENETS) and the American Joint Committee on Cancer (AJCC). But a 
current study by Kim et al. 2016 evaluated the 2010 WHO, ENETS and AJCC grading system to predict 
survival after gastric neuroendocrine tumour (NET) resection. They retrospectively evaluated 175 gastric 
Table 2 ENETS classification of pancreatic neoplasms (Falconi et al. 2012) 
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NET patients and showed an overall low prognostic value of the ENETS and WHO classification, a low 
prognostic value for well-differentiated NETs (G1 or G2) but a high prognostic value for G3 or mixed 
tumours by the AJCC classification system.  
2.2.1 Epidemiological data 
Based on the Surveillance, Epidemiology, 
and End Results (SEER) Program registries 
in the USA the annual incidence of NETs 
have been rising from 1.09/100,000 to 
5.25/100,000 over the past 30 years (Yao et 
al., 2008). An increase which may also be 
due to an increase in incidentally identified 
lesions (benign and malign) due to more 
performed diagnostic imaging tests 
(endoscopy and radiological procedures) 
(Modlin et al., 2008) The SEER data 
demonstrated that ~ 40% of the 
patients had a localised disease, 17% 
had regional disease and 20% had already distant metastases (Yao et al., 2008). The age-adjusted 
incidence of NETs of the small intestine therefore increase by 460% over 30 years, NETs in digestive 
system increase by 720% in the same period (Modlin et al., 2008). One has to keep in mind that SEER 
data only counts malignant tumours without having a standardised histopathological protocol. 
Consequently, the numbers from the SEER database could be underestimated.   
A study from Austria identified 1.49% of all malignant digestive 
tumours being classified as NETs. Based on the WHO 2010 
classification, 46% of NETs had been classified as benign, 15% 
have been showing uncertain biological behaviour, and 39% 
marked as malignant (Niederle, Hackl, Kaserum, & Niederle, 
2010). Studies from Switzerland and the Netherlands in 2000 
and 2001 also estimated the incidence with approximately 1–
2/100,000 patients (Levi, Te, Randimbison, Rindi, & La Vecchia, 
2000; Quaedvlieg, Visser, Lamers, Janssen-Heijen, & Taal, 2001). 
Nevertheless, in a 30 year period, the incidence rate has 
annually increased by ~ 5.8% (Modlin et al., 2008; Yao et al., 
2008).  
One has to keep in mind that NET- incidence data are mainly 
based on national cancers registries. Thus there could be 
substantial limitations in the accuracy of this analysis. Firstly benign or NETs with the uncertain clinical 
course may not be fully incorporated in these registries because of registries’ specifications. Secondly, 
the definitions of these tumours have evolved over time, resulting in a change in the classification 
standards (Niederle et al., 2010). 
Figure 5 Incidence rates of GEP NET (n/100.000 
per year); age-adjusted using the 2000 US 
standard population comparing the recent 
data with Norway, USA and Austria (Niederle 
et al. 2010; Hauso et al. 2008). 
Figure 4 Incidence of all malignant neoplasms and neuroendocrine tumours from 
1973 t0 2003 (Source: SEER database). 
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2.2.2 Diagnostic workup of NETs –Biochemical Markers 
Despite broad access to modern imaging methods, NETs still have a delayed diagnosis of several years 
(Modlin et al., 2008). There is a clear need for sensitive and specific biomarkers, which allow earlier 
diagnosis, identification of residual disease, minimal disease detection and demonstration of 
failure/efficacy of therapy. (Modlin et al., 2014) 
NETs show a vast divergent biological behaviour and can be classified into non-functioning (e.g. 
besides local obstruction and bleeding) and function tumours. Tumours which are classified into 
functioning tumours release specific peptides and amines via the involved neuroendocrine cell types 
(e.g. beta cells, enterochromaffin-like cells, G-cells) and therefore cause special symptoms (Duque, 
Modlin, Gupta, & Wasif Saif, 2013; Modlin et al., 2008; Ramage et al., 2012).  
The functional status of a tumour, the clinical symptoms and histological features can be assessed during 
the biochemical workup analysing specific substances, such as insulin, proinsulin, glucagon, calcitonin, 
gastrin, pancreatic polypeptide and VIP (vasoactive intestinal peptide) (K Öberg, 2012). Other 
biomarkers used in the work-up are chromogranin A (CgA), urinary 5-HIAA (Duque et al., 2013; Modlin 
et al., 2008), KI-67, and Placental growth factor (PGF) (Hilfenhaus et al., 2013). 
2.2.2.1 Diagnostic workup of NETs -Imaging 
The selection of the appropriate imaging method and therapeutic intervention is particularly dependant 
on the location of the primary tumour, the degree of differentiation and dissemination, the functional 
status and the tumour’s grade (Modlin et al., 2008). The European Neuroendocrine Tumour Society 
(ENETS) extends these characteristics to the evaluation of tumour somatostatin receptor density, 
therapy monitoring and detection of recurrent disease (Sundin et al., 2009).  
Based on the high diversity of NETs, also the imaging workup consists of a variety of different imaging 
modalities in the detection, characterisation and staging of NETs (Leung & Schwartz, 2013). Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) is the widely used imaging techniques in 
establishing the diagnosis and location of NETs. Modern CT systems reach a high spatial resolution of 
the whole abdomen and thorax, with hundreds or more of 1-mm or sub-millimetre transaxial images 
per second (Leung & Schwartz, 2013; Sundin et al., 2009). Imaging with a rapid bolus injection of 
intravenous (i.v.) contrast media can be beneficial in many NETs, as the tumours are visualised as 
enhancing or hypervascular lesion on the early and later arterial phase images (Leung & Schwartz, 2013).  
Figure 6 shows graphs of the incidence of NETs over time based on data from SEER database. Graph (B) shows a time- trend 
analyses of the incidence of NETs by primary tumour site (1973-2004) and (C) the incidence by disease stage at diagnosis 
(Yao et al. 2008) 
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CT is still the most commonly used modality with a low sensitivity ranging from 50% – 85% (see Table 
3), and specificity from 25% - 99% (Sundin et al., 2009). Multidetector CT increased the detection of 
insulinomas to 94%, in combination with Endoscopic ultrasonography (EUS) the sensitivity reached 
100% (Gouya et al., 2003) 
Also, MRI is an essential tool in the visualisation of NETs, using mainly 1.5 or 3.0 Tesla systems. Currently 
the number of meaningful studies is limited, but generally supports the use of MRI in NET diagnosis with 
high sensitivity and specificity (see Table 5) (Sundin et al., 2009). Early studies showed a lower sensitivity 
for the detection of the primary tumour and their metastases compared to CT, however, newer studies 
evaluate MRI to be equal or superior to CT, especially in the visualisation of liver metastases (Ichikawa 
et al., 2000; Owen et al., 2001; Schraml et al., 2013; Semelka, Custodio, Balci, & Woosley, 2000). Larger 
lesions show a higher enhancement than smaller lesions but could be heterogeneous in hyperintensity 
on T2- weighted sequences (Leung & Schwartz, 2013). Liver metastases show a better lesion 
visualisation compared to CT scans (Rockall & Reznek, 2007). 
Type of NET Sensitivity 
mean 
(range) 
Specificity 
mean 
(range) 
Detection 
rate mean 
(range) 
Number of 
patients/ 
studies 
Reference 
Endocrine pancreatic 
tumour 
93% (85–
100) 
88% (75–
100) 
73%  
(50-94) 
54/2 
192/5 
(Carlson, Johnson, Stephens, Ward, & Kvols, 1993; 
Ichikawa et al., 2000; Owen et al., 2001; Semelka et al., 
2000; Shi, Johnston, et al., 1998; Termanini et al., 1997; 
Thoeni, Mueller-Lisse, Chan, Do, & Shyn, 2000) 
Liver metastases n.a. 
 
n.a. 
 
82%  
(80-85) 
95% 
74/3 
64/1 
(Carlson et al., 1993; Cwikla et al., 2004; Dromain et al., 
2005; Seemann, Meisetschlaeger, Gaa, & Rummeny, 
2006; Shi, Buchanan, et al., 1998) 
Extrahepatic 
abdominal soft tissue 
metastases 
89% 100%  
68%  
(55-81) 
34/1 
58/2 
(Carlson et al., 1993; Cwikla et al., 2004; Seemann et al., 
2006; Shi, Johnston, et al., 1998) 
Table 4 Sensitivity, Specificity and Detection Rate of NET diagnosis with Magnet Resonance Imaging (MRI) 
Ultrasound is a helpful tool in the detection of the tiny NETs. Especially insulinomas, which are primarily 
located in the pancreas, could be easily missed with conventional imaging methods if their diameter is 
smaller than 2 cm, and located in the gastrointestinal wall (Zimmer et al., 1994). For example, 
transabdominal ultrasonography (US) shows a much lower sensitivity and specificity compared to 
Endoscopic ultrasonography (EUS) in the detection of insulinomas and gastrinomas (Zimmer et al., 2000; 
Zimmer, Stölzel, et al., 1996). Also, intraoperative ultrasonography/ultrasound (IOUS) is a sensitive 
method for the identification of tumours with a low density of somatostatin receptors (e.g. 
insulinomas). Contrast-enhanced ultrasonography (CEUS) has been shown to be more sensitive in 
Type of NET Sensitivity 
mean 
(range) 
Specificity 
mean 
(range) 
Detection 
rate mean 
(range) 
Number of 
patients/ 
studies 
Reference 
Endocrine pancreatic 
tumour 
 
73% (63-82) 
 
96% (83-
100) 
 
73% (39-94) 
162/5 
178/6 
(Ferlay et al., 2013; Fidler et al., 2003; Procacci et al., 
2001; Rossi et al., 1985; Stark, Moss, & Tumors, 1984; 
Van Hoe, Gryspeerdt, Marchal, Baert, & Mertens, 
1995) 
Liver metastases  
82% (78-
100) 
 
92% (83-
100) 
 
81% 
135/4 
21/1 
(Chiti, Fanti, Savelli, Romeo, Bellanova, Rodari, 
Graafeiland, & Bombardieri, 1998; Cwikla et al., 2004; 
Hubalewska-Dydejczyk et al., 2006; Kumbasar et al., 
2004; Shi, Johnston, et al., 1998) 
Extrahepatic 
abdominal soft 
tissue metastases 
 
75% (63-90) 
 
99% (98-
100) 
81% 77/4 
21/1 
(Chiti, Fanti, Savelli, Romeo, Bellanova, Rodari, 
Graafeiland, & Bombardieri, 1998; Cwikla et al., 2004; 
Hubalewska-Dydejczyk et al., 2006; Kumbasar et al., 
2004) 
Various NET lesions 
in abdomen and 
thorax 
 
83% (61-
100) 
 
76% (71-80) 
76% 164/3 
25/1 
(Cwikla et al., 2004; Gabriel et al., 2007; Koopmans et 
al., 2006; Shi, Buchanan, et al., 1998) 
Small bowel NET at 
CT enteroclysis 
50% 
85% 
25% 
97% 
n.a. 
 
8/1 
219a/1 
(Johanssen, Boivin, Lochs, & Voderholzer, 2006; 
Pilleul et al., 2006) 
a. Out of 219 patients included in the study, there were 19 subjects with carcinoids 
Table 3 Sensitivity, Specificity and Detection Rate of NETs with Computed Tomography 
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neuroendocrine metastases and liver lesions, compared to US (Mörk, Ignee, Schuessler, Ott, & Dietrich, 
2007). 
However, as US, EUS, IOUS and CEUS seem to miss or misdiagnosed some tumours/metastases, a 
combination of SRS, CT or MRI shows the best outcome during surgery or if no metastases have been 
detected by the first line diagnostic procedures (SRS, CT or MRI) (Hiramoto, Feldstein, LaBerge, & 
Norton, 2001; Zimmer et al., 1994, 2000; Zimmer, Stölzel, et al., 1996). It should be mentioned that EUS 
is an invasive and operator-dependent procedure, thus results vary from centre to centre (Ramage et 
al., 2012).  
Type of NET 
Sensitivity 
mean 
(range) 
Specificity 
mean 
(range) 
Detection 
rate mean 
(range) 
Number 
of 
patients/ 
studies 
Reference: 
Endocrine pancreatic tumour: 
US (Transabdominal 
Ultrasonography) 
n.a. n.a. 39%  
(17-79) 
153/6 Angeli et al., 1997; De Angelis, Carucci, Repici, & Rizzetto, 1999; 
Galiber et al., 1988; Pitre, Soubrane, Palazzo, & Chapuis, 1996; 
Zimmer et al., 1994; Zimmer, Stolzel, et al., 1996 
EUS (Endoscopic 
ultrasonography) 
 
93% 
 
95% 
90%  
(77-100) 
261/10 
75/1 
Ariyama, Suyama, Satoh, & Wakabayashi, 1998; Celso Ardengh, 
Andrade De Paulo, & Paulo Ferrari, 2004; De Angelis et al., 
1999; Gouya et al., 2003; Pitre et al., 1996; Proye, Malvaux, 
Pattou, Filoche, Godchaux, Maunoury, Palazzo, Huglo, 
Lefebvre, Paris, et al., 1998; T. Rösch et al., 1992; Zimmer et al., 
1994, 2000; Zimmer, Stolzel, et al., 1996 
IOUS (Intraoperative 
Ultrasonography/ 
ultrasound) 
n.a. n.a. 92% 
(74-96) 
127/4 Galiber et al., 1988; Hiramoto et al., 2001; Huai et al., 1998; 
Pitre et al., 1996 
Insulinoma: 
EUS n.a. n.a. 92%  
(88-94) 
86/4 M. A. Anderson et al., 2000; Gouya et al., 2003; Zimmer et al., 
2000; Zimmer, Stölzel, et al., 1996 
IOUS n.a. n.a. 92%  
(84-96) 
109/3 Galiber et al., 1988; Hiramoto et al., 2001; Huai et al., 1998 
Duodenal tumours and lymph node metastases: 
US n.a. n.a. 18% 25/1 De Angelis et al., 1999 
EUS n.a. n.a. 63% 59/2 De Angelis et al., 1999; Proye, Malvaux, Pattou, Filoche, 
Godchaux, Maunoury, Palazzo, Huglo, Lefebvre, & Paris, 1998 
Liver metastases US: 
US 88% 95% n.a. 131/1 (rturo Chiti et al., 1998 
CEUS 82% n.a. n.a. 48/1 Mörk et al., 2007 
US, Ultrasound; EUS, Endoscopic Ultrasound; IOUS, Intraoperative ultrasound; 
Table 5: Sensitivity, Specificity and Detection Rate for NET diagnosis by US, EUS, IOUS and CEUS 
2.2.3 Therapy Options in the Treatment of NETs 
There is a variety of therapy options available, but surgery is the foundation for curative treatment in 
various NET cancers types (Falconi et al., 2016). Due to the high prevalence of already metastatic disease 
stage at the time of diagnosis (Kianmanesh, O’Toole, Sauvanet, Ruszniewski, & Belghiti, 2005), surgical 
approaches for locally advanced or metastatic tumours (with or without new molecular targeted 
therapies) are generally more aggressive but seem to be safe and may offer long-term survival (Basuroy, 
Srirajaskanthan, & Ramage, 2012; Birnbaum et al., 2015). An analysis from the German NET registry 
showed that around 77% of patients with NET had surgery as first treatment,18.6% medical therapy, 
2.7% radiotherapy and around 1.1% ablative therapy  (Ploeckinger, Kloeppel, Wiedenmann, & Lohmann, 
2009).  
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Since it is not the intention of this thesis to explain the surgical options for the treatment of NETs, we 
refer to the literature/ guidelines of M. S. Khan & Caplin, 2011 and Falconi et al., 2016, 2012 and the 
corresponding literature in the papers.  
2.2.4 Specific Targeting via Somatostatin Analogues - Imaging 
The groundwork for the successful use of somatostatin analogues was to a certain extent laid by Jean  
Claude Reubi, a pathologist emeritus from the University of Berne (Switzerland). In 1987 Reubi 
published a study showing the somatostatin receptor density in 
NETs and suggested that the chronically applied somatostatin 
receptors analogues, used to treat the symptoms in NET disease, 
are likely to bind to a tumour itself (Reubi, 1987). 
Before, Krulich mentioned the inhibiting effect on the release of 
growth hormone from the hypothalamus by a small 
tetradecapeptide (somatostatin) in 1968 (Krulich, Dhariwal, & 
McCann, 1968). The group identified an inhibitor, which reduced 
the release of growth hormone in the pituitary in-vitro but may not 
have been aware of the significance. Brazeau (1973) later 
extracted a synthetic somatotropin release inhibiting factor (SRFI), 
which was biologically active in-vivo (Brazeau et al., 1973). Today, 
it is clear that SRIF, later named Somatostatin, acts though six G-
protein coupled receptors (SSTR1, SSTR2a, SSTR2b, SSTR3, SSTR4 
and SSTR5) acts on the biological activity on neurotransmission, 
inhibits cell proliferation & endocrine secretion, and affects 
smooth muscle contractility (Bronstein-Sitton, 2006).  
Somatostatin is produced by neurons and secretory cells in various 
organs such as the central and peripheral nervous system, 
placenta, kidney, retina and cells of the immune system 
(Bronstein-Sitton, 2006). The distribution of the six different SSTRs differs depending on the tissue, but 
receptors can be found in varying degrees of intensity in almost all tissues (Table 6). In cases of a benign 
 Tissue distribution Antibodies 
SSTR1 
Brain 
Pancreas (ß cells) 
GI tract 
several human tumours 
Anti-SSTR1  
(extracellular) 
SSTR2a Brain 
Pituitary gland 
GI tract 
Adrenal gland 
Immune cells 
Several human tumours 
Anti-SSTR2 
(extracellular) SSTR2b 
SSTR3 
Brain 
GI tract 
Liver 
Spleen 
Several human tumours 
Anti-SSTR3 
(Intracellular) 
SSTR4 
Brain (less than other 
subtypes) 
GI tract 
Lung 
Heart 
Placenta 
Several human tumours 
Anti-SSTR4  
(Extracellular) 
SSTR5 
Brain (mainly 
hypothalamus) 
Pituitary gland 
Pancreas (ß and Ŏ cells) 
GI tract 
Several human tumours 
Anti- SSTR5 
(extracellular) 
SSSTR – Somatostatin Receptor 
SST – Somatostatin 
GI tract – gastrointestinal tract 
Table 6 Distribution of Somatostatin 
Receptors in different tissues 
5-HIAA: 5-hydrixyindole acetic acid; SSRS: somatostatin receptor scintigraphy; CgA: chromogranin A; STZ: streptozocin; MIBG: 
metaiodobenenzylguanidine; chemoT: chemotherapy; 68-Ga-oct PET; 68-Ga-DOTA-octretotate positron emission tomography 
 
Figure 7 Algorithm for the management of patients with NETs (Khan & Caplin, 2011); adapted from (Ramage et al., 2005) 
33 
 
and malignant disease, the expression of SSTR´s is considerably upregulated in the majority of tumour 
cell lines (Bronstein-Sitton, 2006; Krenning et al., 1993; Reubi, Maurer, & Von Werder, 1987). Table 7 
represents an early study evaluating the incidence of SSTRs in tumours and comparing the results from 
the in-vivo scintigraphy with 111In-DTPA-D-Phe1-Octreotide and in-vitro SSTR autoradiography. 
Nowadays we know that SSTR2 is the most widely expressed subtype in tumours, in particular in 
neuroblastomas, medulloblastomas, breast carcinomas, meningiomas, paragangliomas, lymphomas 
and renal cell carcinomas (Bronstein-Sitton, 2006; Reubi, Waser, Schaer, & Laissue, 2001). GEP NETs 
show a mixture of various SSTRs, but having a preference for SSTR2 or SSTR1. SSTR2 is omnipresent in 
breast cancer with a powerful expression of SSTR5 (around 30% of tumours) (Evans et al., 1997). The 
evidence that many neuroendocrine tumours have an overexpression of at least one somatostatin 
receptor subtype was strong enough to test the target for imaging- and therapeutic applications. 
At the beginning, the synthetic somatostatin analogue was used for the treatment of symptoms in 
patients with NETs, but soon after the Iodine-123 marked analogue (123I-Tyr3-Octreotide) was used as 
an imaging agent (Lamberts, Bakker, Reubi, & Krenning, 1990). The radioiodinated synthetic derivate of 
somatostatin could visualise the primary tumour and metastases in endocrine pancreatic tumours very 
well (Krenning et al., 1989). The results from imaging were compared to 123I-Tyr3-Octreotide receptor 
autoradiography, a quantitatively, morphological technique with high (pharmacologically) specificity 
(Reubi, 2015). The in-vivo imaging results in detection were quite promising, but the use of the 
radioligand 123-I had several drawbacks at that time:  
 the labelling with 123-I was exhausting, and special labelling skills were needed, 
 123I in specific activity is expensive and rarely available, 
 the production and distribution of Na- 123-I possessed a challenge, and 
 123-I Tyr3- Octreotide accumulated in the intestine and made the interpretation of planar and 
single-photon emission tomography difficult (Krenning et al., 1993). 
Subsequently, Iodine-123 was replaced by Indium-111 and some of the obstacles have been solved. For 
an efficient binding of 111-In, a diethylenetriaminopentaacetic acid (DTPA) conjugated derivative of 
octreotide was produced, which could bind around 95% of Indium in an easy and single step process, 
without further purification (Bakker et al., 1991). In animal studies of the rat, it was then suggested that 
the compound might show a lower affinity to SSTRs compared to the 123I complex (Bakker et al., 1991). 
The first larger clinical study with this new radiopharmaceutical was conducted by Eric Krenning and his 
 
In-vivo Scintigraphy1 
 
In-vitro Receptor Status2 
GH producing pituitary tumour 7/10 70% 
 
45/46 98% 
TSH producing pituitary tumour 2/2 100% 
 
- - 
Non- functioning pituitary tumour 12/16 75% 
 
12/22 55% 
Gastrinoma 12/12 100% 
 
6/6 100% 
Insulinoma 14/23 62% 
 
8/11 72% 
Glucagonoma 3/3 200% 
 
2/2 100% 
Unclassified APUDoma 18/18 89% 
 
4/4 100% 
Paraganglioma 33/33 200% 
 
11/12 92% 
Medullary thyroid carcinoma 20/28 72% 
 
10/26 38% 
Neuroblastoma 8/9 89% 
 
15/23 65% 
Phaeochromocytoma 12/14 86% 
 
38/52 73% 
Carcinoid 69/72 96% 
 
54/62 88% 
Small cell lung cancer 34/34 100% 
 
4/7 57% 
GH- Growth hormone 
     
TSH - Thyroid stimulating hormone 
     
APU- Amine Precursor Uptake  
     
Table 7 Incidence of Somatostatin Receptors in Neuroendocrine Tumours: Results of in-vivo 111In-DTPA-D-Phe3 – Octreotide 
Scintigraphy (1), and in-vitro Somatostatin Receptor Autoradiography (2). Data from different patient groups  
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colleagues from the University Hospital in Rotterdam, by the time the probably most advanced users 
and developers. They published the findings from 735 patients undergoing an 111In- DTPA-o-Phel1-
octreotide (111In-pentetreotide) scan, implying at least an unequivocal diagnosis and optimal anatomical 
information, whether provided by the common imaging modalities by histology and by autopsy 
(Krenning et al., 1993). The scan showed a high sensitivity for various somatostatin receptor positive 
tumours (NETs), granulomas and (autoimmune) diseases but less for insulinomas, as these tumours 
express more than one SST subtype with a different affinity of octreotide (Krenning et al., 1993). 
Especially in endocrine pancreatic tumours (gastrinomas, insulinomas, and glucagonomas) where 
surgery remains the best treatment choice, 111In-pentetreotide scintigraphy showed to be very 
beneficial. Before SRS, the detection of a primary tumour and its metastases with conventional imaging 
methods was difficult or even impossible (Moertel, 1987). CT and MRI are well suited for sites where a 
tumour is clinically expected but aren´t that sensitive in the detection of distant metastases (Krenning 
et al., 1993). In endocrine pancreatic tumours ultrasonography and CT are usually limited to the 
pancreas and liver region, thereby missing possible metastases, e.g. in the chest, especially in the left 
supraclavicular region. Inconclusive results with US and CT, particularly with tumours less than 2 cm in 
diameter, are usually followed sequentially by invasive localisation methods, e.g. transhepatic selective 
portal venous sampling and selective visceral arteriography. These usual methods may fail to localise a 
tumour in 40%-60% of patients (Sloan, Schwartz, & Kenady, 1993)  
2.2.4.1 111In-DTPA0- Octreotide (Octreoscan) 
Up to now, 111In- DTPA-o-Phel1-octreotide (111In- pentetreotide) is the most commonly used agent for 
SRS, using two-dimensional planar images and three-dimensional SPECT at 4, 24 and optionally 48hours 
after injection (Bodei, Sundin, Kidd, Prasad, & Modlin, 2014). Other forms of synthetic somatostatin 
analogues vary in the peptide sequences, chelators and chelator-peptide conjugate and consequently 
have different affinity profiles to the somatostatin receptor subtypes (Reubi et al., 2000). Reubi et al. 
identified that even small structural changes could have a significant impact on the affinity profile, e.g. 
marking DOTA-[Tyr3]-octreotate with the radioligand gallium improved the binding affinity by eight 
times (Reubi et al., 2000)  
Table 8 Affinity profiles (IC50) for human SST1-SST5 receptors with a series of somatostatin receptors (Source: J. C. Reubi et 
al., 2000) 
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111In-DTPA0-Octreotide (trade name: Octreoscan) is registered for SSTR scintigraphy since June 1994 in 
the USA (FDA approval) and December 1994 in Europe (EMA approval).  
At the time of registration 111In-DTPA0-Octreotide has been clinically tested in nine unblended studies 
in a total of 365 patients, suspected of a neuroendocrine tumour. The results of the scan were consistent 
with the final diagnosis in 86.4% of patients, with lower success rates in insulinomas, neuroblastomas, 
pituitary adenomas and medullary thyroid carcinomas (Mallinckrodt Inc., 1994). A review of 1,200 
patients with gastrointestinal NETs showed a median detection rate of 89% (67%-100%) and a sensitivity 
of 84% (57%- 93%) (Modlin, Kidd, Latich, Zikusoka, & Shapiro, 2005). Koopmans et al., 2009 further 
reviewed the use of 111In-DTPA0-Octreotide in abdominal carcinoid, pheochromocytoma, gastric 
carcinoid, Merkel cell tumour, medullary thyroid carcinoma, neuroblastoma, pancreatic islet cell 
tumour, paraganglioma, small cell lung cancer and bronchial carcinoid (see Table 9 Sensitivity with a 
calculated confidence interval for 111In-DTPA0- Octreotide in different neuroendocrine tumour 
subtypes (Koopmans et al., 2009). 
Abdominal Carcinoids Sensitivity 
Calculated confidence 
interval 
Number of 
patients 
Hoffman et al., 1992 58% 44% - 71% 57 
Arturo Chiti et al., 1998 95% 82% - 100% 17 
Krausz et al., 1998 86% 81% - 91% 87 
Hoegerle et al., 2001 57% 46% - 67% 17 
Shikano et al., 2003 100% 97% - 100% 22 
Klaas P. Koopmans et al., 2006 46% 43% - 50% 53 
Klaas P. Koopmans et al., 2008 49% 44% - 54% 23 
Montravers et al., 2006 93% 78% - 99% 23 
Orlefors et al., 2005 52% 42% - 62% 13 
Raderer et al., 2000 92% 89% - 95% 133 
W. Shi, Johnston, et al., 1998 87% 72% - 96% 25 
Virgolini et al., 2001 87% 72% - 96% 38 
    
Pheochromocytoma    
Tenenbaum et al., 1995 63% 51% - 73% 14 
    
Gastric Carcinoids    
Gibril et al., 2000 75% 68% - 82% 162 
V. Briganti et al., 2001 100% 68% - 100% 10 
Orazio Schillaci et al., 2003 90% 84% - 95% 40 
    
Merkel-cell-tumour    
Durani, Klein, Henze, Haberkorn, & Hartschuh, 2003 78% 39% - 98% 11 
Guitera-Rovel et al., 2001 78% 40% - 95% 9 
    
Medullary thyroid carcinoma    
S. Adams et al., 1998 29% 17% - 42% 18 
Arslan et al., 2001 44% 29% - 60% 14 
Bernà et al., 1998 75% 51% - 92% 20 
de Groot, Links, Jager, Kahraman, & Plukker, 2004 41% 23% - 61% 26 
Diehl et al., 2001 25% 16% - 35% 46 
Belhocine et al., 2002 52% 32% - 71% 11 
Kurtaran et al., 1998 71% 41% - 92% 14 
    
Neuroblastoma    
Kropp, Hofmann, & Bihl, 1997 61% 35% - 83% 18 
Schilling et al., 2000 64% 53% - 74% 88 
    
Pancreatic Islet cell tumours    
V. Briganti et al., 2001 83% 34% - 100% 6 
Corleto et al., 1996 93% 73% - 99% 24 
Krausz et al., 1998 77% 56% - 91% 18 
Rickes, Unkrodt, Ocran, Neye, & Wermke, 2003 54% 32% - 71% 29 
Klaas P. Koopmans et al., 2008 46% 40% - 52% 22 
    
Paraganglioma    
Duet et al., 2003 100% 91% - 100% 42 
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Muros et al., 1998 83% 74% - 91% 8 
K. P. Koopmans et al., 2008 89% 75% - 97% 27 
    
Small cell lung cancer    
Bohuslavizki et al., 1996 26% 15% - 39% 20 
Bombardieri et al., 1995 86% 74% - 94% 20 
    
Bronchial carcinoid    
Fanti et al., 2003 71% 52% - 86% 31 
Table 9 Sensitivity with a calculated confidence interval for 111In-DTPA0- Octreotide in different neuroendocrine tumour subtypes 
(Koopmans et al., 2009) 
111In-DTPA0-Octreotide´s sensitivity was good in most forms of the neuroendocrine tumours, additional 
information to morphological imaging was added and that SRS clearly influenced the patient e.g. surgical 
approaches in GEP-NETs (Briganti et al., 2001; Chiti, Fanti, Savelli, Romeo, Bellanova, Rodari, 
Graafeiland, & Bombardieri, 1998; Frilling et al., 1998; Gotthardt et al., 2003; Jamar, Fiasse, Leners, & 
Pauwels, 1995; Lebtahi et al., 1997; Termanini et al., 1997). Lebtahi et al., 1997 demonstrated that SRS 
massively changed the patient/tumour classification (in 24% of cases) and the surgical strategy (in 25% 
of cases) by identifying new primary tumour sites and metastases.  Chiti et al., 1998 reported a change 
of the therapeutic schedule in 21% of patients, which means an exclusion of surgical procedures or the 
starting of palliative treatment with somatostatin analogues. However, SRS, as well as all other 
diagnostic methods alone, had an inferior sensitivity in patients with metastases but unknown primary 
tumour (Chiti, Fanti, Savelli, Romeo, Bellanova, Rodari, Graafeiland, Monetti, et al., 1998). Therefore 
actual guidelines for the management of GEP NETs (including carcinoids) recommend, with a level of 
evidence 3 and a grade of recommendation A/B, the use of a multimodality approach to detect the 
primary tumour with CT, MRI and somatostatin receptor scintigraphy (SRS) (Ramage et al., 2012). All 
imaging techniques can change the therapeutic management to a comparable extent, which is 
especially true in patients with advanced disease (Gotthardt et al., 2003).  
The question remains if SRS is an efficient imaging technology under ideal conditions or effective in 
ordinary (not ideal) conditions in the sense of a change of outcome for the patient (Brook & Lohr, 1985). 
Fryback and Thornbury created a six-tiered model of efficacy to identify the usefulness of a diagnostic 
imaging procedure, even though diagnostic imaging is a step in an extensive process (Fryback & 
Thornbury, 1991). Based on this model a breakdown of the published studies of SRS in GEP NETs showed 
that every study (Briganti et al., 2001; G Cadiot et al., 1997; Guillaume Cadiot et al., 1996; Chiti, Fanti, 
Savelli, Romeo, Bellanova, Rodari, Graafeiland, & Bombardieri, 1998; De Kerviler et al., 1994; Frilling et 
al., 1998; Gibril et al., 1996; Gotthardt et al., 2003; Hammond, Arka, Peters, Bloom, & Gilbey, 1994; 
Jamar et al., 1995; Krausz et al., 1998; Lebtahi et al., 1997; Meko, Doherty, Siegel, & Norton, 1996; Proye 
et al., 1998; Raderer et al., 2000; Scherubl et al., 1993; O. Schillaci, Massa, & Scopinaro, 2000; O Schillaci 
et al., 1996; Schirmer et al., 1995; Termanini et al., 1997; Vezzosi et al., 2005; Weinel et al., 1993; Westlin 
et al., 1993; Zimmer et al., 1994; Zimmer, Stölzel, et al., 1996) contributed either to the level 1 (technical 
efficacy), level 2 (diagnostic accuracy efficacy), level 3 (diagnostic thinking efficacy) and level 4 
(therapeutic efficacy) efficacy, but no study was designed to achieve level 5 (patient outcome efficacy) 
and level 6 (societal efficacy). It is therefore difficult to judge, how SRS influenced the disease outcome 
also because it took time for new treatment options to be available. Over the years some specialised 
centres reported increased survival over the time in GEP NETs; the SEER database could (for example) 
not show a better 5-year survival rate for carcinoids tumours of the small intestine since 1973 (Modlin 
et al., 2008). With the newly available therapy option this figure may change. A recently published 
randomized controlled Phase-3 registration trial showed a markedly increased progression –free 
survival with 177-Lu-DOTATATE compared to octreotide LAR in patients with well-differentiated, 
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metastatic midgut neuroendocrine tumours. CT, MRI were used for diagnosis and SRS to assess the 
somatostatin receptor status before therapy planning (Strosberg et al., 2017).  
2.2.4.2 Gallium-68 PET/CT- advancement in Somatostatin Receptor Scintigraphy (SRS) 
With the increased availability of PET and PET/CT system, it was just a matter of time until somatostatin 
analogues were labelled with positron emitting isotopes and further increased the sensitivity. Today 
most of the SRS scans in western European countries are PET-based, as this technique allows for higher 
spatial resolution, better visualization of small lesions (< 10mm), and thus increases the sensitivity 
(Ambrosini, Campana, Tomassetti, & Fanti, 2012).  
Gallium- 68 became the preferred nuclide, mainly for technical reasons. The synthesis process is 
relatively easy and economical, no cyclotron is necessary as the nuclide is skimmed from a generator 
(Ambrosini et al., 2012), and it is possible to measure the standardised uptake value (SUV), a semi-
quantitative measurement of the activity in a given region of interest, which correlates with the clinical 
and pathologic features and may be an accurate prognostic index (Ambrosini et al., 2012; Campana et 
al., 2010; Haug, Assmann, et al., 2010). In 1994 a preclinical study already used Ga67 and Ga68 octreotide 
(DFO-B-succinyl-(D)phe1-octreotide) but experienced a low tumour-to-background ratio (Smith-Jones et 
al., 1994). In 1997 another research group labelled octreotide with 18F (2-[‘8F]fluoropropionyl-(D)phe1)-
octreotide) but detected an unfavourable fast tumour washout and a high hepatobiliary excretion which 
limited the use of this tracer in abdominal located tumours (Wester et al., 1997). 
Finally, a research group from the University Hospital of Basel conjugated three new somatostatin 
analogues with the metal chelator DOTA (see Figure 8) and labelled those with 111In, 90Y and 67Ga 
(Froidevaux et al., 1998). The preclinical results: 67Ga- DOTATOC, 67Ga- DOTATATE and, to a lesser extent 
67Ga- DOTAOC had an excellent tumour selectivity, with 67Ga-DOTATOC being superior in the affinity to 
SSTR2, tumour uptake and the lower kidney uptake (Froidevaux et al., 1998). Up to now several studies 
engaged in biokinetics, clinical performance, SUV analyses and comparison to other 
radiopharmaceuticals and imaging modalities:  
2.2.4.2.1 68Ga-DOTATOC (Gallium- 68-Edotreotide):  
Even 68Ga-DOTATATE showed a 10-fold higher in-vitro 
affinity to SSTR2 (0.2 ± 0.04 nM), compared to 68Ga-
DOTATOC (2.5 ± 0.5 nM), the difference may not seem to be 
clinically relevant in the visualisation of NETs mainly 
expressing SSTR2 (Pöppel et al., 2011; Reubi et al., 2000). 
68Ga – DOTATOC seems to have a higher affinity to SSTR5 
compared to 68Ga- DOTATATE, which may explain the higher 
tumour uptake of DOTATOC in some NET types (Pöppel et 
al., 2011; Reubi et al., 2000). Mentionable is the 
considerable discrepancy in SSTR expression in individual 
patients and between different tumour manifestations 
(Forrer et al., 2004; Pöppel et al., 2011). Further studies are 
analysing the biokinetics, SUVmax and compared 68Ga- 
DOTATOC to 111In-Octreoscan, 18F-FDG, 18F-DOPA, 68Ga-
DOTATATE, EUS, CT, MRI and histopathology (see Table 10). 
In all studies 68Ga- DOTATOC showed a higher sensitivity in the 
detection of NET lesions compared to 111In-Octreotide 
Figure 8: Four different somatostatin 
analogues conjugated with the metal chelator 
DOTA: DOTAOC, DOTAtransTOC, DOTATATE, 
DOTASATATE (Froidevaux et al., 1998) 
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(Buchmann et al., 2007; Hofmann et al., 2001; Kowalski, 2003; Müssig et al., 2010). Since December 
2016 (SomKit TOC®) and November 2017 (TOCscan®) Gallium (68Ga)-Edotreotide have received official 
marketing authorisation by the European Medicines Agency (EMA) with a 10-year orphan market 
exclusivity in the European territory.  
Author Topic Year 
Hofmann et al., 2001 Biokinetics and Comparison to 111In- Octreoscan 2001 
Buchmann et al., 2007 Comparison to 111In- Octreoscan 2007 
Kowalski, 2003 Comparison to 111In- Octreoscan 2003 
Koukouraki et al., 2006 Pharmacokinetics of 68Ga-DOTATOC 2006 
Miederer et al., 2009 SUVmax and SSTR correlation 2009 
Poeppel et al., 2011 Comparison to 68Ga DOTATATE 2011 
Boy et al., 2011 SUVmax and SSTR correlation 2011 
Poeppel et al., 2013 Comparison to 68Ga-DOTATATE 2013 
Müssig et al., 2010 Comparison to 111In-Octreoscan 2010 
Daniel Putzer et al., 2009 Comparison to CT 2009 
Versari et al., 2010 Comparison to EUS and surgery 2010 
Ruf et al., 2010 Comparison to CT and histopathology 2010 
D Putzer et al., 2010 Comparison 18F-DOPA 2010 
Ruf et al., 2011 Comparison to CT and histopathology 2011 
Alexander Kroiss et al., 2013 SUVmax Uptake  2013 
Koukouraki et al., 2006 Comparison 18F-FDG 2006 
Van Binnebeek et al., 2016 Comparison to 111In-Octreoscan 2016 
Velikyan et al., 2014 Comparison to 68Ga-DOTATATE 2014 
Giesel et al., 2012 Comparison to CT and MRI 2012 
Table 10: Further studies analysing Biokinetics, SUVmax, sensitivity, specificity of 68Ga- DOTATOC 
  
2.2.4.2.2 68Ga-DOTATATE (Gallium (68Ga) DOTA-(Tyr3)-Octreotate):  
A recent systematic review and meta-analyses, comparing 68Ga-DOTATATE with 111In-DTPA-Octreotide 
and conventional imaging for pulmonary and gastroenteropancreatic NETs, showed a higher 
sensitivity of 68Ga-DOTATATE compared to 111In-DTPA- Octreotide and high sensitivity (90.9%) and 
specificity (90.6) compared to conventional imaging (Deppen, Blume, et al., 2016).  
Besides the substantiated meta-analyses, many other studies have been conducted with 68Ga- 
DOTATATE (see Table 11 shows a literature overview of imaging studies using Gallium- 68 in neuroendocrine tumours with a 
comparison to SRS, PET and conventional imaging.) comparing its performance to other PET radiopharmaceuticals, 
SPECT and conventional imaging.  
68 Ga- DOTATATE 
  
Author Topic Year 
Haug et al., 2012 a 68Ga-DOTATATE compared to histopathology 2012 
Haug et al., 2014 a 68Ga-DOTATATE compared to histopathology 2014 
Goel et al., 2014 68Ga-DOTATATE compared to CT 2014 
Armbruster et al., 2014 68Ga-DOTATATE compared to DCE-MRI, 18F-FDG 2014 
Schmid-Tannwald et al., 2013 68Ga-DOTATATE compared to DW-MRI 2013 
Maurice et al., 2012 68Ga-DOTATATE compared to 123I-MIBG SPECT 2012 
Hofman et al., 2012 a 68Ga-DOTATATE compared to conventional imaging and 111In-Octreotide 2012 
Łapińska et al., 2011 68Ga-DOTATATE compared to conventional imaging and histopathology  2011 
Naji et al., 2011 68Ga-DOTATATE compared to 123I-MIBG SPECT 2011 
Srirajaskanthan et al., 2010  a 68Ga-DOTATATE compared to CT, MRI, 111In-Octreotide and histopathology 2010 
Conry et al., 2010 68Ga-DOTATATE compared to 18F-FDG 2010 
Kayani et al., 2009 68Ga-DOTATATE compared to 18F-FDG 2009 
Kayani et al., 2008 a 68Ga-DOTATATE compared to 18F-FDG 2008 
Win et al., 2007 68Ga-DOTATATE compared to CT and 123I-MIBG SPECT 2007 
Nickel et al., 2016 
68Ga-DOTATATE compared to CT, MRI, US, IOUS and selective arterial secretagogue 
injection (SASI) 
2016 
Panagiotidis et al., 2016 68Ga-DOTATATE compared to 18F-FDG 2016 
Kazmierczak et al., 2016 68Ga-DOTATATE compared to CT 2016 
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The 
study by Haug et al. (2012) from the Ludwig-Maximilians-University of Munich compared 68Ga-
DOTATATE to the gold standard pathology and should therefore be highlighted. The results showed that 
68Ga- DOTATATE had an overall sensitivity of 81%, correct identification of NETs in 29 of 36 cases, and a 
specificity of 90% with a correct exclusion of NET in 61 of 68. In a follow-up study in patients with 
metastatic NET, 68Ga-DOTATATE identified a recurrence of disease in 26 of 29 patients (sensitivity 90%) 
and excluded the presence of recurrence in 28 of 34 patients (specificity 82%). The sensitivity (94%), 
specificity (89%) and accuracy (91%) were higher in patients with gastroenteropancreatic NETs (Haug et 
al., 2014a).  
Hofman et al. (2012) suggested a high management (inter-modality change) impact of 68Ga-DOTATATE, 
compared to 111In-Octreotide in 28 (47%) of patients, moderate impact (intra-modality change) in 6 
(10%) of patients, low impact in 24 (41%) of patients and the impact was not rateable in one patient 
(2%). Deppen et al. (2016) showed that 68Ga-DOTATATE lead to an overall change of treatment in 36% 
(27 patients) of cases, in which 19 patients (24%) the significant change resulted in the cancellation of a 
surgery, a radical change in type of surgery or referring the patients for PRRT. Similarly Ilhan et al., 2015 
demonstrated a change in surgical management in 20% of patients and provided additional information 
for surgical planning in more than 95% of cases.  
Panagiotidis et al.(2016) demonstrated that 68Ga-DOTATATE, as well as 18F-FDG, affected the original 
treatment plan in 40 patients (38.4%). In 14 (27.4%) patients, the finding led to the initiation of PRRT 
and the commencement of somatostatin analogues in 12 (23.5%) of patients (Panagiotidis et al., 2016). 
One of the first papers, stating the impact of DOTATATE on the management of patients, was published 
in 2010 showing a change in 70.6% of patients, already undergoing 111In-Octreotide imaging 
(Srirajaskanthan et al., 2010). After DOTATATE PET almost 39% of patients were considered for 90Y- 
DOTATATE PRRT, in 13.7 patients with positive uptake, but without functional symptoms, an ant 
proliferative treatment with somatostatin analogues was conducted. In four patients (7.8%) a surgical 
approach was proposed (Srirajaskanthan et al., 2010).  
With regard to the efficacy of 68Ga-DOTATATE, based on the six-tiered model by Frynback & Thornbury, 
the results are comparable to study quality seen in the 111In-Octreotide studies: the studies (refer to 
Table 11) were able to show diagnostic accuracy efficacy (level 1) and diagnostic thinking efficacy (level 
2) in 96% of cases. Six studies (23%) focused on showing therapeutically efficacy (level 3), and succeeded 
in identifying an impact on patient management (Deppen, Liu, et al., 2016; Goel et al., 2014; M.S. 
Hofman et al., 2012; Kayani et al., 2008; Panagiotidis et al., 2016; Srirajaskanthan et al., 2010). Level 4 
(improvement of patient outcome) and level 5 (improvement of societal efficacy) outcome was not 
shown in any study.  
From the previously mentioned studies, it becomes evident that imaging plays an essential role in 
diagnosis, staging, treatment selection and follow-up of NETs. Currently, the clinically relevant 
Janssen et al., 2016 
68Ga-DOTATATE compared to CT, MRI, 18F-FDG (and partially 18F-FDOPA and 18F-
FDA) 
2016 
Deppen et al., 2016  a 68Ga-DOTATATE compared 111In Octreotide 2016 
Alonso et al., 2014 a 68Ga-DOTATATE compared to conventional imaging (CT) 2014 
Etchebehere et al., 2014 a 68Ga-DOTATATE compared to SSRS SPECT and Whole Body MRI 2014 
Haug et al., 2009 a 68Ga-DOTATATE compared to 18F-DOPA 2009 
Lastoria et al., 2016 a 68Ga-DOTATATE compared to conventional imaging (CT, MRI, US, EUS) 2016 
Poeppel et al., 2011 a Comparison to 68-Ga DOTATOC 2011 
Wild et al., 2013 a 
Comparison to 68-Ga DOTANOC, conventional imaging (CT, partially MRI), partially 
18F-FDG and histology 
2013 
a) Studies included in the meta-analyses by (Deppen, Blume, et al., 2016) 
Table 11 shows a literature overview of imaging studies using Gallium- 68 in neuroendocrine tumours with a comparison to 
SRS, PET and conventional imaging. 
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information is gathered in a multimodality approach: clinical manifestations, general anatomical- 
(radiological) and specialised functional (nuclear medicine) imaging techniques. In addition to the 
routine measurement of secretory products, imaging is indicated in different stages in the patient´s care 
such as screening, primary lesion detection, assessment of the disease extent and the follow-up/ 
treatment response (Modlin et al., 2008; Ramage et al., 2012). Imaging has essential influence on 
patient´s management and support the right therapy selection with cold or radiolabelled somatostatin 
analogues (PRRT) based in additional functional information (Bodei, Sundin, et al., 2014). Especially the 
positive results from the NETTER trial had substantial influence on current guidelines such as the 
practice guideline neuroendocrine tumours in Germany. Created under the leadership of the German 
Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and with participation of 
neighbouring scientific societies there is a strong recommendation and strong consensus among the 
societies that an initial PET/CT imaging procedure is recommended for every NET G1 or NET G2 besides 
stomach NET type I, rectum NET G1 (each <1 cm and no risk factors), and the incidental finding of an 
appendix NET (<1 cm) with no risk factors (Rinke et al., 2018).  
2.2.5 Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues  
With the ability to identify somatostatin receptor positive tumours with radiolabelled somatostatin 
analogues in the 1990s, it was the next logical step to use these analogues for therapy (especially) in 
patients with well-differentiated neuroendocrine tumours in stage IV disease, because chemotherapy 
does not seem to be so beneficial (Öberg, 2001; Rougier & Mitry, 2000). Already in 1987, Mörtel et al. 
evaluated the usefulness of different chemotherapeutical agents [Doxorubicin, 5-Fluorouracil (5FU), 
Dacarbazine (DTIC), Dactinomycin, Cisplatin, Streptozotocin, Mitomycin, Melphalan,  Fluorometholone] 
in patients with advanced carcinoid tumours (significant symptoms; disabilities of malignant disease; 
poor prognostic signs) and concluded: 
“The 33% response rate with the 5-FU combination has been our best experience, and this was 
duplicated by an ECOG study. Even with this, our most active regimen, the frequency of usually 
partial responses is too low, duration of response is too transient, and the price in often 
miserable toxicity is too high. We do not feel that any chemotherapy regimen for carcinoid 
tumours is of sufficient value to justify use in routine clinical practice (Mörtel, 1987).” 
The 2012 guidelines for GEP NETs (including carcinoids) considered a platinum-based regimen in poorly 
differentiated NETs (Level of evidence 2; grade of recommendation B), and a streptozotocin (STZ) based 
combination for moderately and well-differentiated tumours (Level of evidence 1; grade of 
recommendation A) (Ramage et al., 2012). A recently published meta-analysis by Wong et al., (2016) 
reviewed chemotherapies/systematic therapies in patients with advanced or metastatic NETs. Despite 
the poor quality of the studies they concluded that there is no difference between STZ/5-fluorouracil 
(5FU) to other chemotherapies in response rate (RR), progression-free survival (PFS) and overall survival 
(OS). Interferon (IF) may show a little higher response rate, but survival rates do not change (M. H. Wong 
et al., 2016).  
Peptide Receptor Radionuclide Therapy (PRRT) was, therefore, a good alternative for patients with 
unrespectable NETs. Early radionuclide therapy used 111In-DTPA-pentetreotide to treat patients with 
advanced disease stage, mainly with a high progressive tumour load. Symptoms decreased, but no 
consistent biochemical response could be shown (Valkema et al., 2002). Somatostatin analogues 
predominately had antisecretory (~70-80%) and ant proliferative (~50%) effects, but little cytoreductive 
capacity (Eriksson et al., 2007; Sabet, Biersack, & Ezziddin, 2016). In the next step radioisotopes with a 
wider particle range have been used to overcome the low tissue penetration such as Yttrium 90 
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(maximum energy Eβmax = 2.27 MeV, penetration range Rβmax=11 mm, half-life T1/2 = 64 h) and 
Lutetium 177 (Eβmax = 0.49 MeV, Rβmax = 2 mm, T1/2 = 6-7 days) (Bergsma et al., 2013; Bodei, 
Kwekkeboom, Kidd, Modlin, & Krenning, 2016). At the moment nuclear medicine procedures such as 
PRRT are not recommended (recommendation with consensus among the societies) as first line therapy 
in patients with metastasised neuroendocrine tumours in the German practical guidelines (Rinke et al., 
2018). But the guidelines states that PRRT may be considered in patients with exceptional high tumour 
burden of a small bowel tumour (Rinke et al., 2018). 
2.2.5.1 Requirements 
Prerequisite for a successful PRRT is a sufficient overexpression of somatostatin receptors on the 
tumour´s cell membrane surface, so the substance can sufficiently interacting with the tumour. 
Following the binding of the complex on the cell membrane, the radiolabelled somatostatin agonist 
complex is internalised and can subsequently release the radioactivity in the cell (Bodei et al., 2016). In 
a recent development a new SST analogue with receptor antagonistic properties showed a 5-times 
higher uptake of 177Lu DOTA- JR11 (88% ± 1% membrane-bound) than of 177Lu DOTA- octreotate (74% ± 
3% internalised) and a higher DNA double-strand break in preclinical models (Dalm et al., 2016). The 
significant difference: contrary to the mechanism of action of agonists, the substance is not internalized, 
but recognises more binding sites and thus receives greater tumour irradiation (Wild et al., 2014). 
Haug et al. (2010) from the University of Munich were first to assess the predictability of clinical 
outcome and progression-free survival after the first cycle of PRRT in NET patients using 68Ga- DOTATATE 
PET/CT. Their findings suggest that the standardised uptake value maximum (SUVmax) is not a significant 
predictor of time-to-progression, because of the fluctuation of the value after several PRRT cycles 
(Gabriel et al., 2009; Haug, Auernhammer, et al., 2010). The standardised uptake value tumour-to-
spleen ratio (SUV T/S) was seen to be superior to baseline SUVmax ΔSUVmax in this study (Haug, 
Auernhammer, et al., 2010). Contrarily  Kratochwil et al. (2014) suggested that a SUVmax cut-off > 16.4 
(sensitivity 95 %) is a valid marker (95 % of the responding lesion being detected), but having a lower 
specificity of 60%. The research group concluded that tumour-to-lesion ratios are less robust, but may 
overcome the problem of comparability between different PET scanner hardware and reconstruction 
algorithm. A tumour-to-liver (T/L) ratio may be more reliable than a tumour-to-spleen (T/S) ratio 
(Kratochwil et al., 2014). The newest data from a multicentre trial with 141 patients undergoing 
radionuclide therapy suggests that the survival prediction is best estimated by eight independent 
heterogeneity parameters such as: entropy, skewness, correlation, short zone emphasis and 
homogeneity. Those textural characteristics have demonstrated superior diagnostic capability than 
standard PET parameters such as mean and maximum standardised uptake value (SUVmax/SUVmean) 
(Werner et al., 2017).  
2.2.5.2 Dosimetry  
PRRT can be seen as a serious personalised therapy procedure by quantifying and delivering the 
necessary therapeutically dose based on the patient’s individual disease status. The goal is to administer 
the maximal harmful radiation dose to a tumour and spare (healthy) organs and cells (Bodei, Cremonesi, 
& Paganelli, 2014). Due to the significant differences in patient´s individual organ dose limits, an 
individual patient dosimetry (IPD) before PRRT is suggested (Delker et al., 2015; Förster et al., 2001; 
Guerriero, Ferrari, & Botta, 2013; Helisch et al., 2004). Different dosimetry simulations (2D and 3D 
methods) (e.g.: Garkavij et al., 2010; Larsson et al., 2012; Sandström, Garske, Granberg, Sundin, & 
Lundqvist, 2010) are available and allow a more accurate estimation on the distribution and 
accumulation of the injected RP in different tissues (Celler, Grimes, Shcherbinin, Piwowarska-Bilska, & 
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Birkenfeld, 2013). IDP furthermore tries to establish a dose-response relation to predicting tumour 
response and organ toxicity by pre-therapy dosimetry, which in effect allows a comparison of the results 
of different radionuclide therapies and radiopharmaceuticals (Flux et al., 2006). IPD complies with the 
EU council directive 97/43/EURATOM (Rat der Europäischen Union, 1997), which tries to overcome the 
differences in patient treatment response by establishing a minimum effective and maximum tolerated 
absorbed dose per patient (Brans et al., 2007; Flux et al., 2006).  
2.2.5.3 Administration  
In the systemic administration protocol several cycles (usually four to five) every 6-10 weeks are 
scheduled until the cumulative activity has been reached (Bodei et al., 2016; Ramage et al., 2012). The 
recommended dose protocol based on the current guidelines (Ramage et al., 2012):  
 90Y- DOTATATE and DOTATOC activity per interval is in the range of 3-6 GBq; 6-8 week cycles 
with a total cumulative dose of 12-18 GBq. 
 177Lu- DOTATATE the activity ranges from 3.7- 7.4 GBq per cycle with intervals of 6-10 weeks 
and a total of 22-29.6 GBq  
Intra-arterial administration of 90Y and 177Lu has been tested in NETs with mainly hepatic metastases, to 
overcome the first-pass effect and increase the radioligand concentration and binding in hepatic 
tumours (Bodei et al., 2016; Kratochwil et al., 2010; McStay et al., 2005). The results present a several-
fold higher SUV and a partial and complete response in 60% of patients with G1/G2 GEP NETs 
(Kratochwil et al., 2010, 2011). 
2.2.5.4 Side Effects 
Generally PRRT with 90Y and 177Lu is well tolerated, acute side effects are usually mild and are related to 
the co-administration of nephron-protecting drugs, with nausea and occasional vomiting, or the 
radiopeptide itself with symptoms such as fatigue, weight loss, hematologic or renal toxicity, slight loss 
of hair, impairment of male fertility or, more rarely, an aggravation of a clinical syndrome (Bodei, 
Cremonesi, et al., 2014; Bodei et al., 2016; Geisler et al., 2012; Paganelli et al., 2014; Sabet et al., 2016; 
van der Zwan et al., 2015). Severe long-term adverse events such as kidney - and haematotoxicity have 
been reported, but are generally mild if precautions (amino acids, dosage fractioning, consider risk 
factors) are undertaken (Bodei et al., 2011, 2015; Hörsch et al., 2016; Imhof et al., 2011; Iten et al., 2007; 
Kwekkeboom et al., 2008; Sabet et al., 2013, 2014; Valkema et al., 2006). Kidney renal- protective 
agents, such as lysine and arginine or amifostine, are commonly used to reduce toxicity to the kidney 
through inhibition the proximal tubular reabsorption (Bodei et al., 2016; van Essen et al., 2009). The 
reabsorption can be inhibited by saturating the apical membrane megalin, which reduces the 
radioactivity in the kidney by 9-53% (Bernard et al., 1997). A reduction of renal function was more often 
associated with 90Y peptides, likely to be based on the much larger particle penetration into the kidney 
and very high radioactivity doses (Bodei et al., 2016). One study detected the presence of two kidney 
clearance phases, which could hamper accurate dose estimation when using a single-phase dosimetry 
model (Delker et al., 2015). 
Long-standing hypertension or poorly controlled diabetes or both have also been associated with a 
reduction of renal function (Bodei et al., 2003; Valkema et al., 2005). The latest multicentre study in 
Germany showed a meagre rate of nephrotoxicity (0.65%), which may be attributed to a high number 
of patients treated with both radiopeptides (90Y and 177Lu) and a short follow-up (Hörsch et al., 2016). 
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2.2.5.5 Results and Efficacy of Yttrium-90 
After the insignificant success of [111In-DTPA0], -octreotide as a therapeutic agent, a new somatostatin 
analogue ([Tyr3]-octreotide) and chelator (DOTA) were developed to safely bind the β- emitting 
radionuclide Yttrium- 90. This new stable β- emitting radionuclide compound (90Y-DOTA-tyr3-octreotide 
= 90Y-DOTATOC) showed a higher affinity to somatostatin receptors 2 (and 3) and could deliver a 
cytotoxic dose of radiation to somatostatin receptor–positive tumour cells (de Jong, Breeman, Bernard, 
Bakker, Visser, et al., 2001).  
Several studies (Table 13) have investigated the usefulness of 90Y- DOTATOC and indicated great safety 
and tolerability (De Jong et al., 2002; Paganelli et al., 2001; Valkema et al., 2002; Waldherr, Pless, 
Maecke, Haldemann, & Mueller-Brand, 2001) as well as clinical efficiency in the sense of morphological, 
biochemical and clinically response in progressive metastasized neuroendocrine tumours (Iten et al., 
2007; Waldherr, Pless, et al., 2002; Waldherr et al., 2001). The objective response ranges from four to 
thirty-three per cent, however, a direct comparison is not valid as the studies included different cycle 
doses, tumour subtypes and patient characteristics. Nevertheless, the results were encouraging, 
especially as there are few alternatives for patients at this stage of the disease. For this reasin 90Y 
became the most widely used radiopeptide in the first decade of PRRT (Bodei et al., 2016).  
In some subtypes of NETs the response rate to 90Y was remarkable, such as gastrinomas with a high rate 
of complete remission. This may be mainly based on the high somatostatin receptor status and 
radiosensitivity of these tumours (Imhof et al., 2011). In the same large phase II study with 1,109 
patients with a broad spectrum of neuroendocrine tumours, 34.1% of patients experienced a 
morphologic response, 15.5% a biochemical response and 29.7% a clinical response with a significant 
correlation to longer survival (Imhof et al., 2011). Another single-arm, multicentre study investigated 
the effect of 90Y-DOTA-tyr3-octreotide in 90 patients with biopsy-proven malignant carcinoid tumours. 
A total of 74.4% patients were objectively stable or responded (0% complete remission, 4.4% partial 
remission and 70% stable disease). The number of adverse events (nausea, vomiting, and abdominal 
pain) was high (87.6%), but severe adverse events with induced nephrotoxicity of grade 3/4 were only 
observed in 3.3% of patients (Bushnell et al., 2010).  
“The overall median survival of 26.9 months was better than historical controls (12.0 and 18.0 
months) (Anthony et al., 2002; Perez et al., 2007) and then to the most promising combination 
chemotherapy results for metastatic carcinoid (11.9, 15.7, 24.3 months) (Sun, Lipsitz, Catalano, 
Mailliard, & Haller, 2005).”(Bushnell et al., 2010) 
Study Ligand n 
Nr. 
SAEs 
(% of 
pat.) 
% of patients with … toxicities 
Renal Hematologic 
Myelo-
proliferative 
diseases 
Liver 
Iten et al., 2007 90Yr- DOTATOC 31 11 (35.4) 19.4 Grade 3/4 12.9   
Imhof et al., 2011 90Yr- DOTATOC 1109 142 
(22.1) 
9.3 Grade 4/5 12.8 0.2  
Kwekkeboom et al., 
2008 
[177Lu-DOTA0,Tyr3]octreotate 504 9 (1.8) 0.4 Grade 4a  0.8 0.6 
Lisa Bodei et al., 2011 [177Lu-DOTA0,Tyr3]octreotate 
n 
51 11 (21.7) 21.7 Grade I 0 0 0 
Hörsch et al., 2016 90Yr & 177Lu with DOTATATE 
and DOTATOCb 
450 13 
(2.89)c 
0.22 Grade III 
(no data for 
Grade I-II) c 
2.67 c   
Lisa Bodei et al., 2015 90Yr- octreotide (44.4%) & 
177Lu - ocetreotate (34.4%); 
90Yr & 177Lu combined (19.5%) 
807 88 (9.17) 33.1 Grade I/II 
1.5 Grade III/IV 
82.2 Grade I/II 
9.5 Grade III/IV 
2.35 0 
Valkema et al., 2006 [90Y- DOTA0, Tyr3]Octreotide 58 5 (8.62) 3.45 Grade IV 1.7 1.7 1.7 
Sabet et al., 2013, 2014 177Lu- DOTATATE 74/203 27 (13.3) 1.3 Grade III/IV 11.3 Grade III/IV 1.4  
Nr. SAEs, Number of severe adverse events in per cent of patients 
Table 12 Long-term toxicity in patients treated with Yttrium-90 and Lutetium-177 somatostatin analogues. 
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Data on efficacy in specific tumour subtypes such as paraganglioma, pheochromocytoma and 
meningioma are rare.  
2.2.5.6 Results and Efficacy of Lutetium- 177 
Compared to Yttrium-90, Lutetium-177 is a medium energy β- emitter with a maximum tissue 
penetration of 2mm and also emits low energy γ- rays, which can be used for imaging purpose. The 
replacement of threoninol with threonine in the C-terminal of the Somatostatin complex also induced 
in a six- to nine-fold higher affinity with SSTR 2 compared to [DOTA0, Tyr3] octreotide (Kwekkeboom et 
al., 2001; Reubi et al., 2000). This new radioligand ([177Lu-DOTA0, Tyr3]- octreotate (177Lu DOTATATE)) 
indicated an objective response rate ranging from 7 to 60 per cent, with a favourable low radioactive 
burden to the kidney (Table 13). 
Study Ligand N 
CR 
(%) 
PR 
(%) 
SD 
(%) 
PD 
(%) 
CR+PR 
(%) 
90Yr- labelled somatostatin analogues       
Bodei et al., 2003 ³ [90Yr-DOTA0,Tyr3]- octreotide 21 0 29 52 19 29 
Waldherr, Pless, et al., 2002; Waldherr, 
Schumacher, et al., 2002; Waldherr et al., 
2001,³ 
[90Yr-DOTA0,Tyr3]- octreotide 74 4 20 65 11 24 
Valkema et al., 2006 ¹ [90Yr-DOTA0,Tyr3]- octreotide 58 0 9 61 19 9 
Bushnell et al., 2010 ¹ [90Yr-DOTA0,Tyr3]- octreotide 90 0 4.4 70 12 4.4 
Pfeifer et al., 2011 ² [90Yr-DOTA0,Tyr3]- octreotide 53 4 19 64 13 23 
Forrer, Waldherr, Maecke, & Mueller-Brand, 
2006 ³ 
[90Yr-DOTA0,Tyr3]- octreotide 58 4 22 62 11 26 
Imhof et al., 2011 ² [90Yr-DOTA0,Tyr3]- octreotide 1109 0.6 33.5 5.2 60.7 34.1 
Cwikla et al., 2010 ² [90Yr-DOTA0,Tyr3]- octreotate 58 0 23 73 5 23 
        
177Lu- labelled somatostatin analogues       
Kwekkeboom et al., 2003 4 [177Lu-DOTA0,Tyr3] -octreotate 35 3 35 41 21 38 
Kwekkeboom et al., 2008 ¹ [177Lu-DOTA0,Tyr3] -octreotate 310 2 28 35 20 30 
Garkavij et al., 2010 ² [177Lu-DOTA0,Tyr3] -octreotate 12 0 17 40 17 17 
Swärd et al., 2010 ² [177Lu-DOTA0,Tyr3] -octreotate 26 0 38 50 13 38 
Bodei et al., 2011 ² [177Lu-DOTA0,Tyr3] -octreotate 42 2 29 26 21 31 
Sansovini et al., 2013 ¹ [177Lu-DOTA0,Tyr3] -octreotate 52 8 21 52 19 29 
van Vliet et al., 2013 ¹ [177Lu-DOTA0,Tyr3] -octreotate 268 1 24 49 26 25 
Ezziddin et al., 2014 ¹ [177Lu-DOTA0,Tyr3] -octreotate 68 0 60 12 15 60 
Paganelli et al., 2014 ¹ [177Lu-DOTA0,Tyr3] -octreotate 43 7 0 77 16 7 
Delpassand et al., 2014 ² [177Lu-DOTA0,Tyr3] -octreotate 32 0 31 41 28 31 
Sabet et al., 2015 ¹ [177Lu-DOTA0,Tyr3] -octreotate 61 0 13.1 47.5 8.2 13.1 
Ianniello et al., 2016 ¹ [177Lu-DOTA0,Tyr3] -octreotate 34 3 12 16 69 15 
Baum et al., 2016 ² [177Lu-DOTA0,Tyr3] -octreotide 56 16.1 17.9 32.1 33.9 34 
        
Combination therapy with 90Y & 177Lu SSA       
Kunikowska et al., 2011 ²,A 90Y/177Lu-DOTATATE 25 0 0 62 8 0 
Pfeifer et al., 2011 ² 90Y/177Lu-DOTATOC 69 7.4 16.2 61.8 14.7 23 
Villard et al., 2012 ² 90Y/177Lu-DOTATOC 249 Na Na Na Na Na 
Seregni et al., 2014 ² 90Y/177Lu-DOTATATE 26 7.7 34.6 42.3 15.4 42.3 
Hörsch et al., 2016 ² 90Y and 177Lu-DOTATOC & 90Y and 
177Lu DOTATATE5  
357 7 28 59 5 35 
Kong et al., 2016 ² 90Y/177Lu-DOTATATE 26 0 21 5 0 21 
CR, complete remission; MR, minor remission; PD, progressive disease; PR, partial response; SD, stable disease; NA, not available; 
¹ SWOG, Southwest Oncology Group: PR ≥ 30% reduction of tumour size; MR, 30% reduction or an increase of SD, ˂ 30% reduction or an increase of ˂ 20% of 
tumour size; PD, ≥ 20% increase of tumour size or new lesion(s), measurement bi-dimensional;  
² RECIST, Response Criteria in Solid Tumours: PR, ≥ 50% reduction of tumour size; SD, <25% reduction or an increase of tumour size; PD, >50% increase of tumour 
size. Unidimensional. 
³ WHO, World Health Organisation: PR, ≥ 50% reduction of tumour size; SD, <50% reduction or an increase of <25% of tumour size; PD, ≥ 25% increase of tumour 
size or new lesion(s). measurement bi-dimensional 
Four not mentioned 
5 Patients treated with 90-Y only: 76; 177Lu only: 243; combined: 130; 
A.) Data from 36 months’ follow-up 
Table 13 Efficacy of somatostatin analogues labelled with Yttrium-90 and Lutetium-177 for the therapeutically purpose. Studies 
using different criteria to evaluate the therapy response such as SWOG, RECIST or WHO. 
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The first study reporting the efficacy of 177Lu- DOTATATE was published by the research group from 
Rotterdam, showing an objective response in 38% of patients treated with three fixed cycles of 177Lu-
DOTATAE (1st cycle 100mCi, 2nd cycle 150mCi, 3rd cycle 200mCI with intervals of 6-9 weeks) 
(Kwekkeboom et al., 2003). The same group published a follow-up study with 310 patients (504 patients 
included, but at the time of the study data on objective response and survival was only available for 310 
patients) showing a reduction in tumours size in 46% of patients, a median overall survival of > 48 
months and a PFS of 33 months (Kwekkeboom et al., 2008). The quality of life (mainly fatigue, insomnia 
and pain) also improved significantly in patients with objective response, but interestingly also in those 
with progressive disease (Khan et al., 2011; Teunissen, Kwekkeboom, & Krenning, 2004).  
A recent meta-analyses by Kim, S. J. et al. (2015) analysed six studies (Bodei et al., 2011; Delpassand et 
al., 2014; Ezziddin et al., 2014; Paganelli et al., 2014; Romer et al., 2014; van Vliet et al., 2013) with a 
total of 473 patients with inoperable or metastatic NETs. All patients have been treated with 177Lu- 
labelled somatostatin analogues. The disease response rate, defined as the percentages of patients with 
CR and PR, in the RECIST group (four studies with 256 patients) showed a pooled effect of 29% and a 
disease control rate, defined as CR, PR and SD, of 81%. In the SWOG group (three studies with 374 
patients) the disease response rate was 23% and the disease control rate 82% (Kim et al., 2015). 
With high expectation, the nuclear medicine community was looking for the first results from the Phase 
III multicentre, stratified, open, randomised, controlled trial evaluating 177Lu-DOTATATE (Lutathera®) in 
patients with inoperable, progressive, somatostatin receptor positive midgut NETs (Strosberg et al., 
2016).  
“230 patients with Grade 1-2 metastatic midgut NETs were randomised to receive Lutathera 7.4 
GBq every eight weeks (x4 administrations) with renal protection (amino acid solution infusion) 
versus Octreotide LAR 60 mg every 4-weeks. The primary endpoint was PFS per RECIST 1.1 
criteria, with objective tumour assessment performed by an independent reading centre every 
12 weeks until tumour progression. Secondary objectives included objective response rate, 
overall survival, TTP, safety, tolerability and health-related quality of life. An independent Data 
Safety Monitoring Board regularly assessed the safety outcome.” (Strosberg et al., 2017) 
The results confirmed previous academic clinical studies and showed a superiority of 177Lu- DOTATATE 
and 30mg Sandostatin –LAR compared to 30mg Sandostatin-LAR alone. Estimated PFS at month 20 was 
65.2% in the 177Lu- Dotatate group and 10.8% in the control group. The response rate was 18% in the 
177Lu-Dotatate group versus 3% in the control group (P<0.001). The overall survival in the planned 
interim analysis revealed 14 deaths in the 177Lu-Dotatate group and 26 in the control group (P = 0.004) 
(Strosberg et al., 2017). 
2.2.5.7 Combination Therapy with Yttrium-90 and Lutetium-177 Somatostatin Analogues 
Theoretically, simultaneous treatment of large- (high energy and penetration range of 90Y) and small 
lesions such as metastases (low energy and penetration range of 177Lu) should be beneficial due to the 
different physical properties of both radionuclides (Bodei et al., 2016). In 2005 the research group from 
Rotterdam conducted an animal tumour model, investigating the antitumor effect of a combination of 
50 percent 177Lu and 50 percent 90Y- analogues. The results suggested a superiority of the combinational 
treatment compared to 90Y- or 177Lu analogue alone (de Jong, Breeman, Valkema, Bernard, & Krenning, 
2005). 
In humans, Villard et al. (2012) showed a significantly longer median survival (66.1 vs. 47.5 months) and 
median survival from diagnoses (123.6 vs. 82.6 months) in 86 patients treated with a combination of 
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90Y-DOTATOC and 177Lu-DOTATOC compared to the group which has only been treated with 90Y- 
DOTATOC. Similar results have been shown in a study with 50 patients with disseminated NETs being 
randomised to either 90Y-DOTATATE (n=25) or 90Y/177Lu-DOTATATE (n=25). The patients in the 90Yr/177Lu-
DOTATATE group showed a longer overall survival with a calculated probability of 24-month survival of 
89% vs 62% in the 90Y- group (Kunikowska et al., 2011). In another phase II clinical study by Seregni et 
al. (2014) 26 patients with NETs have been treated with 90Y- and 177Lu- DOTATATE and showed an 
objective response of 42.3% and a median PFS longer than 24 months.  
In a sizeable multi-institutional registry study in Germany the data from 450 patients with progressive, 
locally advanced or metastatic low to intermediate grade neuroendocrine neoplasms with 
overexpression of somatostatin receptors had been evaluated (Hörsch et al., 2016). These results 
suggest that patients exclusively treated with 90Y had a significant decreased OS and PFS compared to 
patients treated with 177Lu alone or in combination with 90Y (median OS and PFS shown in Table 14) 
(Hörsch et al., 2016). 
 
 
 
  
Radionuclide Patients median OS median PFS 
Lutetium-177 241 Not reached 40 
Yttrium-90 76 38 27 
Combined 130 58 50 
Table 14 Median Overall survival (OS) and progression-free survival (PFS) in a multi-institutional registry 
study in Germany. The study population included 450 patients with progressive, locally advanced or 
metastatic low to intermediate grade NETs (Hörsch et al., 2016) 
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2.3 Case II- Radionuclide Imaging and Therapy in Prostate carcinoma  
Prostate cancer (PC) is the fourth most common cancer in both sexes combined and the most common 
malignancy in men worldwide, with a death rate of ~ 1-2% in men (Attard et al., 2016; Ferlay et al., 
2014). The incidence rate varies worldwide more than 25- fold, mainly due to the implementation of 
the screening programs (prostate-specific antigen –PSA) and routinely biopsies (Ferlay et al., 2014). 
The risk factors for PC can be classified as endogenous and exogenous. In the group of endogenous risk 
factors age, race and family history are the most established. During ageing, cellular oxidants (free 
radicals and reactive oxygen species) are continuously produced in the metabolic process and lead to 
damage of macromolecules and organelle functions in the cells (Minelli, Bellezza, Conte, & Culig, 2009). 
The race-related differences in risk may reflect multiple factors, including differences in genetic factors, 
exposures, dietary and detection. African- American men have the highest incidence rates for PC in the 
world (Bostwick et al., 2004). Family history also seems to play an important role: the risk for first- 
degree relatives of men with PC is about twice that for men in the general population (Schaid, 2004), 
and about four times higher in first- degree relatives of men with cancer diagnosed younger than 60 
years (Johns & Houlston, 2003). Genetic predisposition seems to have a high impact on PC: around 77 
single nucleotide polymorphisms (SNPs) have been identified to be associated with PC (Attard et al., 
2016). Diet and nutrition may be an exogenous risk factor contributing to PC, but the overall 
inhomogeneity of prospective epidemiological studies showed considerable inconsistency 
(Markozannes et al., 2016). An umbrella review of existing meta-analyses indicates that the associations 
between food, body size, physical activity and PC remain uncertain (without substantial evidence), 
except the factor “height” which seems to have a positive correlation to PC risk (Markozannes et al., 
2016).  
2.3.1.1 Pathology of the Prostate: 
The healthy prostate is composed of glands and stroma, and with normal ageing of the prostate, small 
clotting within the glandular lumina happens. Benign prostatic hyperplasia is a progressive enlargement 
from a non-malignant proliferative process of epithelial and stromal elements of the prostate gland and 
is present in more than 50% of men aged over 60 years (Bushman, 2009; Thorpe & Neal, 2003). In up to 
25% of cases, the benign prostatic hyperplasia needs surgical and medical therapy because of lower 
urinary tract symptoms, which can have serious medical complications (Thorpe & Neal, 2003). Prostatic 
Intraepithelial Neoplasia (PIN) is described as a deformity of the epithelium lining of the prostate glands 
with the high-grade PIN being a precursor lesion to prostate cancer (Singh et al., 2009).  
Nearly all prostate cancers are prostatic adenocarcinoma, very common in aged men, but often small 
and clinically insignificant (Mercer University School of Medicine, 2016). The use of a serum prostate-
specific antigen (PSA) test has improved the percentage of pathologically organ-confined PC (Catalona, 
Smith, Ratliff, & Basler, 1993), but many false positive results remain, if only PSA measurement was 
used (Partin et al., 1997). PSA is a glycoprotein, which is almost exclusively produced in the epithelium 
of the prostate gland with subtypes of a complexed PSA (cPSA) or free PSA (fPSA). The total PSA (cPSA 
+ fPSA) level usually does not exceed 4 ng/ml; a level less than 10.0 ng/ml indicates early-stage disease, 
whereas a PSA level greater 10.0 ng/ml is a reference of advanced disease in more than 50% of the 
patients (Catalona et al., 1994). Unfortunately, the PSA level in the range of 4.0 – 10.0 ng/ml shows a 
lack of specificity and thus leads to many unnecessary biopsies (Catalona et al., 1998). The measurement 
of the specific PSA types and their ratios (fPSA, cPSA, fPSA/tPSA, cPSA/tPSA, fPSA/cPSA) has shown 
promise to discriminate between prostate cancer and benign prostatic disease, especially in the grey 
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zone of 4.0 – 10.0 ng/ml total PSA (Brawer et al., 1998; Catalona et al., 1998; Jung et al., 2000; Luderer 
et al., 1995; Polascik, Oesterling, & Partin, 1999) 
2.3.1.2 Staging: 
Autopsy studies have shown that in men over 50 the prevalence of prostate cancer is about 30% (Dhom, 
1983; Mcneal et al., 1986; Montie, Wood, Pontes, Boyett, & Levin, 1989; Scardino, Weaver, & Hudson, 
1992), although not every cancer is clinically relevant. PC shows a wide range of biological behaviour 
with around 80% being clinically unimportant and 20% possessing a threat to the patient’s life or well-
being (Scardino et al., 1992). PC are usually graded according to the Gleason grading system, developed 
by Dr Donald F Gleason, a pathologist in Minnesota, and members of the Veterans Administration 
Cooperative Urological Research Group (VACURG). The score differentiates between five grades (see 
Figure 9), which are based upon the architectural patterns of the carcinoma.  
 
 
 
 
 
 
 
 
 
 
 
 
The challenge in adenocarcinoma is that roughly half of the tumours could not be fitted in one grade 
and typically showed more than one histologic grade. For this reason, two grades are added together 
Figure 9 Prostatic adenocarcinoma (histologic 
patterns). Standardized drawing for grading 
system on the left (Gleason, 1992) 
Table 15 Original Gleason scoring system and the 2005 modified system 
(defined by the International Society of Urological Pathology) (Ahmed, 
Arya, Freeman, & Emberton, 2012) 
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to a final grade of 2 to 10, in which the first grade represents the most common- and the second grade 
the second most common architectural patterns. The stage is determined by the size and location of 
cancer, whether it has invaded the prostatic capsule or seminal vesicle, and whether it has metastasised 
(Gleason, 1992). Adenocarcinomas with a Gleason grade of four and five typically show adverse 
pathologic findings and disease progression. Gleason score two to four describe well- differentiated, 
five to seven moderately differentiated, and a score of eight to ten as poorly differentiated (Epstein, 
Partin, Sauvageot, & Walsh, 1996; Humphrey, 2004). 
In the current guidelines from the European Association of Urology (EAU), European Society for 
Radiotherapy & Oncology (ESTRO) and the International Society of Geriatric Oncology (SIOG) the 2009 
TNM classification for staging, and the EAU risk group classification was recommended for patients with 
curative prostate cancer (Mottet et al., 2016). Currently, the recommended PCa grading system is the 
modified Gleason score (GS) introduced from the International Society of Urological Pathology (ISUP) in 
2005 the (see Table 15).  
2.3.1.3 Diagnosis 
Prostate cancer may be diagnosed either by digital rectal examination (DRE), transrectal ultrasound 
(TRUS) or screening for rising PSA levels. The current EAU, ESTRO and SIOG Guidelines for patients with 
curative intent value PSA as a better predictor of cancer than DRE and TRUS. However, definitive 
diagnosis is still based on histopathologic verification via TRUS- guided biopsy (Mottet et al., 2016).  
Epidemiological data from the SEER database show a dramatically decrease of patients with PC and 
distant metastases at the time of diagnosis from around 20% (1975-1984) to 5% (1995-2000), as well as 
a significant increase in five-year survival rates in all races in the period from 1980-2000 (1980: 83%; 
1990: 93% and 99% since 2000) (Jemal et al., 2005; Siegel, Miller, & Jemal, 2016). These data also 
highlight a spike in incidence rates of PC in the late 1980s and early 1990s, which reflects the increased 
use of PSA testing and prostate needle biopsy to detect asymptomatic PC forms (Potosky, Miller, 
Albertsen, & Kramer, 1995). However, absolute PSA serum levels must be interpreted with care as there 
is a high proportion of cancers, which may not develop symptoms during their lifetime (Bangma, 
Roemeling, & Schröder, 2007). The right treatment selection requires a more profound characterisation 
of a tumour, to maximise cancer control and to minimise the risk of complications (Hricak, Choyke, 
Eberhardt, Leibel, & Scardino, 2007).  
Moreover, while imaging plays a significant role in many malignant cancer diseases, the value of 
prostate cancer imaging is controversially discussed. It is often argued that the majority of men are 
diagnosed with the low-risk disease (T1c or T2a; Gleason score ≤ 6; and a PSA serum level < 10 ng/m) 
and a low risk of metastasis (D’Amico et al., 1997). Nonetheless, this patient group has a high use of 
imaging for staging purpose, whereby this is not indicated and recommended (Choi et al., 2011; 
Cooperberg, Broering, Kantoff, & Carroll, 2007; Mottet et al., 2016). In the period from 1995 to 2002 a 
shift towards fewer staging imaging studies before treatment in patients with low-risk (63%), 
intermediate-risk (25.9%) and high-risk patients (11.4%) has been observed (Cooperberg, Lubeck, 
Grossfeld, Mehta, & Carroll, 2002). But an overuse in low- risk patients still seems to persist (Choi et al., 
2011; Dinan et al., 2010; Lavery et al., 2011; Palvolgyi, Daskivich, Chamie, Kwan, & Litwin, 2011; Porten 
et al., 2014; Prasad, Gu, Lipsitz, Nguyen, & Hu, 2012). A Swedish national registry study confirmed the 
more appropriated use of imaging in Europe with a dramatic decrease in low-risk patients in the period 
from 1998 to 2009, and a small but still significant reduction of imaging procedures in high-risk patients 
(Makarov et al., 2013). With the ongoing debate about the usefulness of imaging the following question 
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remains: “What is the optimal role of imaging in prostate cancer detection, staging, treatment planning 
and follow- up?” 
The current interdisciplinary German S3- guideline for early diagnosis, diagnosis and therapy of the 
prostate carcinoma recommends the use of DRE and TRUS for primary staging, and in cases of a negative 
biopsy MRI (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, 2016). For patients with low-risk (cT1) no 
imaging test is recommended, for patients with intermediate-risk a recommendation is not possible 
because of lacking evidence and for patients with Gleason score ≥ 8 or cT3/4 tumours a CT or MRI study 
of the pelvis is recommended. PET/CT is not recommended in staging, scintigraphy in patients with 
histologically confirmed prostate carcinoma and a serum PSA level > 10 ng/ml or a Gleason score ≥ 8  
(Deutsche Krebsgesellschaft, Deutsche Krebshilfe, 2016).  
Also the current EAU, ESTRO, SIOG guidelines (see Figure 
10) do not recommend imaging for patients with low risk 
of localised PC, but suggest at least cross-sectional 
abdominopelvic imaging and a bone scan for patients with 
intermediate- and high risk PC (Mottet et al., 2016).  
In case of relapsing, metastatic, and castration-resistant 
prostate cancer the early diagnosis of local recurrence is 
necessary, but imaging was said to be poor in 
asymptomatic patients (Rouviére, Vitry, & Lyonnet, 2010). 
A recurrence after treatment with curative intent is 
defined as a rising PSA level after a specific post-treatment 
nadir and is called a biochemical failure or biochemical recurrence.  
“Following radical prostatectomy (RP), biochemical recurrence (BCR) is defined by two 
consecutive rising PSA values > 0.2 ng/ml (Amling, Bergstralh, Blute, Slezak, & Zincke, 2001). 
After primary radiation therapy (RT), the Radiation Therapy Oncology Group (RTOG) and 
American Society for Radiation Oncology Phoenix Consensus Conference definition of PSA failure 
is any PSA increase > 2 ng/ml higher than the PSA nadir value, regardless of the serum 
concentration of the nadir (M. Roach et al., 2006)” (Cornford et al., 2016). 
Not every rise in PSA is due to a recurrence of prostate cancer. Hence it is crucial to accurately detect 
the possible local or distant recurrence to continue with the right treatment choice (Rouviére et al., 
2010). The standard imaging modality for detection of distant metastases usually includes 
abdominopelvic CT and skeletal scintigraphy, but in this case especially PET/CT using the 
radiopharmaceutical PSMA shows promising results.  
In the following pages, we briefly review essential imaging modalities and their benefit in local and 
distant tumour staging and monitoring.  
2.3.1.3.1 Transrectal ultrasound (TRUS) 
Transrectal ultrasound (TRUS) is currently the most widely used imaging modality in the staging process 
of PC. TRUS enables a good measurement of the volume of the prostate gland and the tumour, predicts 
nomograms, and helps to calculate the PSA density (PSAD) (Benson et al., 1992; Terris & Stamey, 1991). 
Secondly, TRUS is essential for the ultrasound-guided needle biopsy to systemically sample (usually from 
six areas of the prostate peripheral zone). A TRUS examination without a biopsy is considered to be of 
little value in the detection of cancer and is as useful as a DRE (Hricak et al., 2007).  
Figure 10: EAU, ESTRO and SOIG Guidelines for 
staging of prostate cancer (Mottet et al., 2016). 
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In general, TRUS has significant higher sensitivity (77.2% vs 57.9%) and a similar specificity (96.3% vs 
89.4%) compared to DRE (Mettlin, Lee, Drago, & Murphy, 1991).  
Today, with the better awareness and the use of PSA testing, the tumours tend to be smaller, and TRUS 
alone does not seem to be sufficient for PCs detection alone (Kuru et al., 2015). Also, the use of Doppler 
sonography with and without contrast does not significantly change the detection rate (Taverna et al., 
2011). Nevertheless, ultrasound will remain an essential instrument for therapeutically applications 
such as the guidance for the placement of brachytherapy seeds, cryotherapy, and high-intensity focused 
ultrasound (HIFU)  
2.3.1.3.2 Computer Tomography (CT) 
CT is not the first choice in PC detection or staging, because of a low resolution of the prostate anatomy 
and poor delimitation to surrounding tissue (Hricak et al., 2007). It is still used to detect or rule out 
lymph-node metastases, but with low sensitivity and specificity (Heesakkers et al., 2008; Hoevels et al., 
2008; Wolf et al., 1995). With the rise in PSA testing, the majority of patients with newly diagnosed 
localised prostate cancer have a low risk of metastases, and thus the diagnostic yield of CT is low 
(Albertsen et al., 2000). The current EAU/ESTRO/SIOG guidelines recommend the use of at least a cross-
sectional abdominopelvic imaging with CT or MRI, and a bone scan for metastatic screening (staging in 
curative intent) in patients with predominantly Gleason pattern 4 (Mottet et al., 2016) 
2.3.1.3.3 Magnetic Resonance Imaging (MRI) 
MRI is said to be the best available imaging technique for the identification of PC to date. It is especially 
recommended in cases of a suspected cancer but with negative TRUS and biopsy (Barentsz et al., 2012; 
Mottet et al., 2016). However, signals in MRI can also be associated with prostatitis, scarring, or 
hyperplasia (Schuster, Nanni, & Fanti, 2016) and there is a considerable variation in sensitivity in 
unenhanced MRI ranging from 37% to 96%, depending on the observer and study’s inclusion and 
exclusion criteria (Kirkham, Emberton, & Allen, 2006; Rifkin et al., 1990). Additionally, the sensitivity for 
tumours smaller than 5mm is low (5%), but increases up to 89% detection rate in tumours with a size 
greater than 10mm (Ikonen et al., 1998; Nakashima et al., 2004).  
To overcome the shortcomings of one or the other single MRI technique, a multiparametric MRI (mp-
MRI) protocol was developed to improve accuracy (Hoeks et al., 2011). The mp- MRI includes the 
anatomic T2 weighted MR imaging protocol (T2WI) and at least two functional MRI techniques such as 
a dynamic contrast–enhanced (DCE-MRI) protocol, diffusion-weighted imaging (DWI) or MR 
spectroscopic imaging (MRSI) (Barentsz et al., 2012). The ESUR guideline recommends a fast mp-MRI 
protocol without an endorectal coil and a pelvic phased array coil. The entire prostate should be 
covered, and T2WI, DWI and DCE-MRI should be included. For staging purpose, the use of an endorectal 
coil is recommended (Barentsz et al., 2012). 
Many single- centre studies suggest a negative predictive value of 63% to 98% and positive predictive 
value of 34% to 68% in the detection of aggressive tumours with mpMRI (Fuetterer et al., 2015). In 
tumours with Gleason score > 7 several studies acknowledged a high sensitivity for the mp-MRI protocol 
(Bratan et al., 2013; Selnæs et al., 2012; Turkbey et al., 2010, 2011), and the identification of anterior 
tumours missed in the systematic biopsy (Hoeks et al., 2011; Kim et al., 2016; Lemaitre et al., 2009). 
Furthermore, MRI can better evaluate the aggressiveness of the tumour based on biopsies targeted on 
MR abnormalities (Hambrock et al., 2012; Komai et al., 2013).  
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However, the variance of accuracy data (54% to 93%) of staging prostate cancer with MRI raised 
questions on inter-observer variability and the heterogeneity of definition of NPV and PPV (Hricak et al., 
2007; Mottet et al., 2015, 2016).  
2.3.1.3.4 Positron Emission Tomography (PET)  
Current guidelines do not recommend PET as the first choice in the detection and staging of localised 
prostate cancer. The guidelines recommend DRE and PSA evaluation, and a histological verification. CT 
or MRI of the lower abdomen. Bone scintigraphy is recommended in patients with intermediate- to 
high-risk prostate cancer, and patients with recurrence disease to detect new sites and evaluate 
treatment response (European Association of Urology, 2016). However, the current results suggest that 
some lesions, especially in advanced disease status, might still be missed with these diagnostic 
modalities (Dianat, Carter, & Macura, 2014; Hoeks et al., 2013; Reisæter et al., 2014; Schimmöller et al., 
2014). 
The efficacy of PET in diagnosis and staging of PC was initially evaluated in connection to the 
radiopharmaceuticals [11C]- and [18F]-labelled choline derivate and fluorodeoxyglucose (FDG). 
Unfortunately these specific tracers showed some limitations in the reliable identification of local 
recurrence, lymph node involvement, or visceral metastases and PET as a complete method was 
consequently evaluated to be not beneficial (Bangma et al., 2007; Beresford, Gillatt, Benson, & 
Ajithkumar, 2010; Brogsitter, Zöphel, & Kotzerke, 2013; Evangelista, Guttilla, Zattoni, Muzzio, & Zattoni, 
2013; Graute et al., 2012; Krause et al., 2008; Souvatzoglou et al., 2011; Tilki et al., 2013; Yu, Desai, Ji, 
Groshen, & Jadvar, 2014). The main restriction of 11C- or 18F- choline tracers was the low sensitivity (10 
to 73%) in the detection of lymph node metastases (Brogsitter et al., 2013; Poulsen et al., 2012). Also, 
the relatively high rate of false negative results of 11C-choline narrowed the use of intraprostatic tumour 
identification (Farsad et al., 2005).  
More recently, a promising tracer selectively binds to the type II transmembrane protein “PSMA”, which 
is also known as glutamate carboxypeptidase 2. It consists of a small intracellular segment, a 
transmembrane domain, and an extracellular domain (Afshar-Oromieh, Avtzi, et al., 2015). PSMA is a 
cell surface protein which is expressed with a thousand-fold greater level on the prostate compared to 
other tissues such as kidney, small intestine, salivary gland (Ghosh & Heston, 2004). PSMA expressions 
were also reported in blood vessels of some other solid tumours such as breast, renal- and subtypes of 
bladder cancer and colon (Chang, 2001; Chang et al., 1999; Samplaski, Heston, Elson, Magi-Galluzzi, & 
Hansel, 2011) and in astrocytes of the central nervous system (Marmiroli, Slusher, & Cavaletti, 2012). In 
the past there have been several reports of a high uptake of the tracer in several non-prostatic lesions, 
which may have been considered pathological, but have in fact been physiological (Krohn et al., 2014; 
St. P Rowe et al., 2016; Verburg, Krohn, Heinzel, Mottaghy, & Behrendt, 2015). 
Very quickly it became clear that PSMA is an ideal target for molecular imaging in prostate cancer. The 
protein is overexpressed in 90-100% of local PC lesions, cancerous lymph node metastases and bone 
lesions with higher expressions in high-grade, metastatic and castration resistant PCs (Bostwick, Pacelli, 
Blute, Roche, & Murphy, 1998; Chang, 2004; Silver, Pellicer, Fair, Heston, & Cordon-Cardo, 1997; Wright, 
Haley, Beckett, & Schellhammer, 1995). In addition to the large binding properties of PSMA, the ligand 
is also rapidly internalised via clathrin-coated pits and prolonged retained in lysosomal compartments 
or the cytoplasm (Ghosh & Heston, 2004; Kratochwil, Giesel, et al., 2016b).  
Up to now numerous studies have shown the benefit of radiolabelled PSMA targeted agents in 
identifying local PCa lesions and metastases (Afshar-Oromieh, Avtzi, et al., 2015; Babich et al., 2013; 
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Budäus et al., 2015; Milowsky et al., 2004; Pandit-Taskar et al., 2015). One of the first RPs targeting 
PSMA was 111Indium capromab pendetide (Prostacint®), which consists of a monoclonal antibody 
targeting the cytoplasmic domain (Kahn et al., 1998). The second generation had an improved tumour 
uptake by binding to the extracellular domain such as the antibody J591 (Chang et al., 1999). This 
monoclonal anti- PSMA antibody has also been labelled with 131I, 177Lu and 90Y and has shown proper 
tumour targeting, acceptable toxicity and therapeutically efficiency (Milowsky et al., 2004, 2007; 
Tagawa et al., 2013). 
However, antibodies have some disadvantages: increased size of the protein and consequently a longer 
plasma half-life and limited diagnostic value (Warram et al., 2014). Small- molecule RPs such as PSMA 
inhibitors are advantageous because they are typically cleared quickly from the bloodstream and have 
a low background activity. 68Ga-PSMA-11 (Glu-NH-CO-NH-Lys-(Ahx)) also known as 68Ga- PSMA-HBED-
CC is an already clinically investigated urea-based inhibitor (Afshar-Oromieh, Avtzi, et al., 2015; Budäus 
et al., 2015). The high affinity to PSMA, the favourable biodistribution and half-life, as well as excellent 
contrast as early as one hour after injection makes 68Ga- PSMA-11 an excellent imaging ligand, even in 
PCs with low PSA levels (Afshar-Oromieh et al., 2013; M. Eder et al., 2012; Matthias Eder et al., 2014). 
Unfortunately, 68Ga- PSMA-11 cannot be labelled with 177Lu or 90Y, so it cannot be used for PRRT 
(Weineisen, Simecek, Schottelius, Schwaiger, & Wester, 2014). Consequently, some modifications have 
been made to PSMA-11 resulting in a new ligand called PSMA-617. This ligand even shows a significantly 
higher affinity to PSMA, a better internalisation into the PCa cells compared to PSMA-11 and can be 
labelled to 68Ga, 177Lu, 111In and 90Y (Afshar-Oromieh, Hetzheim, et al., 2015; Benešová et al., 2015).  
Another chelator is DOTAGA-FFK (Sub-KuE), a radiometalated 
analogue with natural labelling properties, quick internalisation 
and a favourable pharmacokinetic profile (Weineisen et al., 
2014). The same research group further optimised DOTAGA-FFK 
by increasing the lipophilic interaction of the tracer with the 
PSMA enzyme, creating the new ligand called PSMA I&T (for 
imaging and therapy) (Weineisen et al., 2015). This ligand showed 
favourable dosimetry, comparable to other PET RPs, a good bio 
distribution and desirable image quality (see Table 16) (Herrmann 
et al., 2015). A direct comparison to 68Ga PSMA HBED-CC showed comparable results in the detection 
of recurrent prostate cancer, and increased sensitivity in patients with rising PSA levels (Berliner et al., 
2016). Another benefit for the PSMA I&T tracer is the easy labelling with 111In, thus an option for centres 
currently relying on SPECT imaging.  
Table 16 Doses for each target organ using different prostate specific compounds. Table adapted from (Herrmann et al., 2015) 
Target organ Unit PSMA-IT(1) DOTATOC(2) DOTATATE(2) 18F-FDG(3) 
123I-MIP-
1072(4) 
123I-MIP-
1095(4) 
124I-PSMA(7) 
Kidneys 
mSv/ 
MBq 
2.20E-01 8.20E-02 9.30E-02 1.70E-02 5.4E-02 1.10E-2 1.39E+00 
Liver 
mSv/ 
MBq 
4.31E-02 4.10E-02 5.00E-02 2.10E-02 2.4E-02 5.8E-2 1.66E-00 
Spleen 
mSv/ 
MBq 
6.34E-02 1.08E-01 1.09E-01 1.10E-02 2.3E-2 4.7E-2 7.7E-01 
Urinary bladder wall 
mSv/ 
MBq 
6.74E-02 1.19E01 9.80E-02 1.30E-01 9.2E-2 2.1E-2 5.7E-01 
Effective dose 
coefficient 
mSv/ 
MBq 
1.99E-02 2.10E-02 2.10E-02 1.90E-02 2.5E-2 3.2E-2 5.9E-01 
Typical injected 
activity 
MBq 150 185 150 370 370 370 67 
Effective dose mSv 3.0 3.9 3.2 7.0 9.3 11.8 38.9 
Data source: (1) Herrmann et al., 2015; (2) Sandstroem et al., 2013; (3) International Commission on Radiological Protection (ICRP), 2013 (4) Barrett et al., 
2013; (5) Zechmann et al., 2014 
Figure 11 Chemical structures of DOTAGA-
FFK (Sub-KuE) (top) and PSMA I&T (below) 
(Weineisen et al., 2015). 
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Recently a PMSA inhibitor (DCFPyL) has also been labelled with 18F for imaging purpose. In comparison 
to 68Ga-PSMA-HBED-CC, 18F-DCFPyL showed an excellent image quality and detected the same 
suspicious lesions in patients with biochemical relapsed PCa as 68Ga-PSMA-HBED-CC. The mean SUVmax 
of 18F-DCFPyL (14.5 vs 12.2; p=0.028) and the tumour to background ratios (referring to kidney, spleen 
and parotid) were significantly higher compared to 68Ga-PMSA-HBED-CC (Dietlein et al., 2015). The 
advantage of 18F labelled RPs would be the better spatial resolution, higher positron yield, shorter 
positron range in tissues and a longer half-life (Sanchez-Crespo, 2013).  
2.3.1.3.4.1 PSMA PET in Staging: 
Morphological imaging (CT and MRI) alone missed almost 80% of metastatic lymph nodes since the 
threshold size of 8mm is mostly not reached (Heesakkers et al., 2008; Hoevels et al., 2008). DWI MRI 
improved sensitivity and specificity, but CT and MRI may still not reliably identify lymphatic spread 
(Maurer et al., 2015). However, current guidelines recommend the use of mpMRI in patients with 
suspected PCa, but negative biopsy findings, as well as for clarification of capsule penetration and 
seminal vesicle involvement.  
Lately, several study groups compared the sensitivity and specificity of 68Ga- PSMA PET/CT (or PET/MRI) 
to mpMRI (see table 18) in primary and secondary staging. Equal or even superiority results for PET/CT 
has been demonstrated (Fendler et al., 2016; Rhee et al., 2016).  
Author N 
Desi
gn 
Purpose Ligand Inclusion criteria 
Compariso
n modality 
The result of 
Comparison 
Imaging 
Modality 
PET/CT or PET/MRI results 
Giesel et al., 
2016 
10 RS Primary staging 
(Tumour size/ 
Origin) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa, 
high risk, before 
radiotherapy 
mp-MRI 96.8% of 
PET/CT lesions 
detected 
89.4% of mp-MRI lesions 
detected 
Zamboglou et 
al., 2016  
22 RS Primary staging 
(Tumour size/ 
Origin) 
68Ga PSMA-
11 PET/CT 
Confirmed Pca mp-MRI Gross tumour 
volume in 
accordance in 
47 % of 
patients (40%– 
54%of lesions) 
Gross tumour volume 
significantly larger in PET/CT 
Budäus et al., 
2015 
30 RS Primary staging  
(lymph node 
assess.) 
68Ga PSMA Confirmed PCa w 
intermediate/ 
high risk, before 
RP 
Histopatho
logy 
n.a. Sensitivity 33.3% , Specificity 
100%, PPV 100%, NPV 69.2%, 
S. P. Rowe et 
al., 2015 
12 RS Primary staging 
(Tumour 
size/Origin) 
18F-DCFBC  Confirmed PCa 
with high risk, 
before RP 
mp-MRI/ 
histopatho
logy 
Sensitivity 39%, 
Specificity 89%; 
PPV 73%, NPV 
58% 
Sensitivity 17%, Specificity 
96%; PPV 81%, NPV 53% 
Rhee et al., 
2016 
20 PS Primary staging 
(Tumour size/ 
Origin) 
68Ga PSMA-
11 PET/CT 
Suspected Pca, 
before RP 
mp-MRI/ 
histopatho
logy 
Sensitivity 44%, 
Specificity 94%; 
PPV 81%, NPV 
76% 
Sensitivity 49%, Specificity 
95%; PPV 85%, NPV 78% 
W. P. Fendler 
et al., 2016 
21 PS Primary staging 
(Tumour size/ 
Origin) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa 
with high risk, 
before RP 
Histopatho
logy 
n.a. Sensitivity 67%, Specificity 
92%; PPV 97%, NPV 42% 
Sahlmann et 
al., 2016 
35 RS Primary & 
Secondary 
staging 
(lymph node 
staging) 
68Ga PSMA-
11 PET/CT 
Confirmed Pca, 
high risk; for 
staging and BCR 
CT and 
histopatho
logy 
n.a. Sensitivity 94%, Specificity 
99%; PPV 89%, NPV 99.5% 
Sterzing et al., 
2016  
57 RS Primary & 
Secondary 
staging 
68Ga PSMA-
11 PET/CT 
Confirmed Pca, 
high risk; for 
staging and BCR 
Conv.l 
Imaging 
(MRI, CT, 
bone scan) 
CT: In 21.1 % 
patients at least 
1 lesion 
detected 
85 lesions detected in 34 
patients 
Matthias 
Eiber et al., 
2016 
53 RS Primary staging 
(Tumour size/ 
Origin) 
68Ga PSMA-
11 PET/MRI 
Confirmed Pca, 
intermediate and 
high risk 
PET & MRI 
only 
Sensitivity 43%, 
Specificity 98% 
Sensitivity 76%, Specificity 
97% 
Maurer et al., 
2015 
13
0 
RS Primary staging 
(lymph node 
involv.) 
68Ga PSMA-
11 PET/CT & 
PET/MRI 
Confirmed Pca, 
high risk, before 
RP + LND 
CT/MRI 
and 
histopatho
logy 
Sensitivity 44%, 
Specificity 85%, 
PPV 58%, NPV 
77% 
Sensitivity 66%, Specificity 
99%, PPV 96%, NPV 86% 
Herlemann et 
al., 2016 
34 PS Primary & 
Secondary 
staging 
68Ga PSMA-
11 PET/CT 
Confirmed PCa 
with high risk, 
before RP + LND 
CT and 
histopatho
logy 
Sensitivity 65%, 
Specificity 76%, 
Sensitivity 84%, Specificity 
84%, PPV 82%, NPV 84% 
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(lymph node 
staging) 
PPV 75%, NPV 
67% 
van Leeuwen 
et al., 2016 
30 PS Primary staging 
(lymph node 
involv.) 
68Ga PSMA-
11 PET/CT 
Confirmed Pca, 
intermediate and 
high risk, before 
RP 
Histopatho
logy 
n.a. Sensitivity 64%, Specificity 
95%, PPV 88%, NPV 82% 
Steven P 
Rowe et al., 
2016 
17 PS Primary staging 
(metastases) 
18F-DCFBC 
PET/CT 
Confirmed PCa, 
intermediate and 
high risk 
CT and 
bone scan 
73% 83% 
Levent 
Kabasakal et 
al., 2015 
28 RS Primary & 
Secondary 
staging 
(metastases) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa, 
intermediate and 
high risk 
Bone scan, 
CT, MRI 
n.a. primary tumour 77%; lymph 
nodes 36%, Bone lesions 25% 
(per patient) 
Pyka et al., 
2016 
12
6 
RS Primary & 
Secondary 
staging 
(metastases) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa, 
high risk 
Bone scan Sensitivity 87%, 
Specificity 61% 
Sensitivity 99%, Specificity 
88% 
A. Afshar-
Oromieh et 
al., 2015 
31
9 
RS Mainly 
Secondary 
staging, but 
also primary 
staging (27) 
68Ga PSMA-
11 PET/CT 
Mixed: 292 with 
BCR, 27 primary 
staging 
n.a. n.a. Sensitivity 76.6%, Specificity 
100%, PPV 100%, NPV 91.4% 
(all lesion based)  
Van Leeuwen 
et al., 2016 
70 PS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa, 
BCR after RP; 
scheduled RT 
CT n.a. positive lesions in 54% of 
patients 
Verburg et al., 
2016 
15
5 
RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
n.a. CT n.a. 68Ga PSMA positive in 44 % 
(PSA level ≤1 ng/ml), 79 % 
(PSA 1-2 ng/ml), 89 % (PSA ≥2 
ng/ml) 
Eiber et al., 
2015 
24
8 
RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
BCR after RP CT n.a. PSA 0.2 - 0.5 ng/mL (57.9%), 
PSA 0.5 - 1 ng/mL (72.7%), 
PSA 1 -2 ng/mL (93%) and 
PSA ≥ 2 ng/mL (96.8%)  
Ceci et al., 
2015 
70 RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
BCR after 
definitive primary 
treatment 
MR/CT 
and 
partially 
histopatho
logy, 18F-
choline 
n.a. 74.4% positive findings with 
low PSA value 
Morigi et al., 
2015 
38 PS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
Disease 
progression 
before salvage 
LND 
18F-
fluoromet
hylcholine 
PET/CT; 
diagnostic 
CT; 
histopatho
logy 
n.a. 54% positive with 68Ga 
PSMA; 68% with 18F-
fluoromethylcholine and 
68Ga-PSMA; 4% with 18F-
fluoromethylcholine alone 
Ali Afshar-
Oromieh et 
al., 2014 
37 RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
Confirmed PCa, 
progressive 
disease; prior 
treatment (RP, RT) 
18F-
fluoromet
hylcholine 
PET/CT. 
n.a. SUVmax higher in 79.1 % of 
lesions,  Tumour to 
background ratio higher in 
94.9 % of lesions (compare to 
18F choline) 
David Pfister 
et al., 2016 
28 RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
Disease 
progression 
before salvage 
LND 
18FEC 
PET/CT 
Sensitivity 
71.2%, 
Specificity 
86.9%; PPV 
67.3%, NPV 
88.8%  
Sensitivity 86.9%, Specificity 
93.1%; PPV 75.7%, NPV 
96.6%  
Dietlein et al., 
2015 
14 RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
BCR after primary 
treatment 
18F-
DCFPyL 
PET/CT 
mean SUVmax 
= 14.5 (PSMA-
positive lesions) 
- 18F 
mean SUVmax = 12.2 (PSMA-
positive lesions) - 68Ga 
Sachpekidis et 
al., 2016 
31 RS Secondary 
staging 
(BCR) 
68Ga PSMA-
11 PET/CT 
BCR after primary 
treatment 
dynamic 
PET 
SUVaverage = 
12.6 
SUVmax = 20.2 
SUVaverage = 16.3 
SUVmax = 23.5 
Overall detection rate 71% 
Zang et al., 
2017 
40 PS Primary & 
Secondary 
staging 
68Ga PSMA-
11 PET/CT 
Consecutive 
patients; staging 
and risk 
stratification Pca 
and mCRPC 
MRI, bone 
scan 
n.a. Sensitivity 97.3%, Specificity 
100%, Accuracy 97.5%, 
RS, Retrospective study design; PS, Prospective study design; SUV, Standard Uptake Value; SUVmax, maximum standard uptake value; PCa, Prostate 
carcinoma; PET, Positron Emission Tomography; BCR, Biochemical Recurrence; MRI, Magnetic Resonance Imaging; mp-MRI, multiparametric Magnet 
Resonance Imaging; CT, Computer Tomography 
Table 17: Study overview for PSMA ligands being used in imaging studies of prostate cancer in primary and secondary staging. 
Data includes PET/CT results and those from the comparisons modality 
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A study group from the Ludwig Maximilian University in Munich investigated the 68Ga- PSMA-11 
accuracy in localising primary tumour lesions in patients with proven histopathological PCa. The results 
showed a significant higher SUVmax in histopathological affirmative than in negative regions, a high 
accuracy (72%), sensitivity (67%) and specificity (92%). Furthermore, PET/CT correctly detected invasion 
of seminal vesicles (86% accuracy) and tumour spread through the capsule (71% accuracy) (Fendler, 
Schmidt, et al., 2016). The same research group also evaluated the accuracy of 68Ga-PMSA-11 PET/CT 
for nodal staging before lymph node dissection (LND) in PCa patients. The results showed a higher 
accuracy of 68Ga PSMA -11 PET/CT for primary LND (88% vs 75%) and secondary LND (77% vs 65%) 
detection compared to conventional imaging with CT. A possible explanation: around 40% of lymph 
nodes metastases were smaller than 5mm and thus undetectable by size criteria in conventional CT 
(Herlemann et al., 2016). Other studies confirmed the high accuracy in lymph node staging (see Table 
17) (Maurer et al., 2015; van Leeuwen et al., 2016). However, it should also be mentioned that PSMA-
PET missed tumour-positive lymph nodes in PSMA negative primary tumours and cases of micro 
metastases (Maurer, Eiber, Schwaiger, & Gschwend, 2016). 
PSMA PET Imaging is also more accurate in the detection of bone and visceral metastases compared to 
conventional imaging such as CT or bone scan (Chakraborty, Kumar, Tripathi, Das, & Bal, 2015; Levent 
Kabasakal et al., 2015; Pyka et al., 2016; Steven P Rowe et al., 2016). The reason: 99mTc-MDP has a low 
specificity and the uptake in many benign bone lesions could lead to false-positive results. Additional 
imaging with CT or MRI is very often requested. In a retrospective comparison between PSMA PET/CT 
and bone scan in 126 patients, PSMA PET/CT showed a higher sensitivity (98.7%- 100%) and specificity 
(88.2%-100%) compared to bone scan (sensitivity: 86.7-89.3%; specificity: 60.6%-96.1%) (Pyka et al., 
2016).  
2.3.1.3.4.2 PSMA PET in Biochemical Recurrence 
Biochemical recurrence (BCR) is quite frequent in patients with prostate cancer following radical 
prostatectomy and occurs in approximately 35% of patients within a ten year period (Han, Partin, Pound, 
Epstein, & Walsh, 2001; Ward, Blute, Slezak, Bergstralh, & Zincke, 2003). Other studies suggest an even 
higher number of biochemical recurrence with 26-68% of patients within five to six years after 
treatment (Bolla et al., 2012; Stephenson et al., 2007; Wiegel et al., 2014) 
Salvage radiotherapy is known to be most effective in patients with PSA values > 0.2ng/ml and < 
0.5ng/ml and should therefore be started as early as possible (Briganti et al., 2012; D Pfister et al., 2014; 
Taguchi et al., 2016). Especially in patients with low PSA values, a differentiation between localised 
disease and metastatic spread is essential for further therapeutically strategies. For this reason it is very 
important to have an accurate marker that helps to identify candidates for early salvage therapy before 
the clinical progression begins (Cookson et al., 2007).  
The 2016 EAU–ESTRO–SIOG Guidelines on Prostate Cancer recommend a bone scan, abdominal CT, 
mpMRI, or choline PET/CT for patients suspicions for biochemical recurrence (Cornford et al., 2016). 
Unfortunately the probability of a positive bone scan is <5% if the PSA level is < 7ng/ml, thus bone scan 
and abdominal-pelvic CT are recommended to be used in patients with BCR after RP and a high baseline 
PSA > 10ng/ml, high PSA kinetics (PSA DT < 6mo) or in patients with symptoms of bone disease 
(Beresford et al., 2010). Also, CT may have a significant disadvantage in the detection of small-sized 
metastasis, as it was proven to miss almost 2/3 of nodal size metastases since they fall below the 
detectable size criteria (F. L. Giesel, Fiedler, Stefanova, Sterzing, & Rius, 2015) 
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Recently, several studies have been published investigating the clinical relevance of PSMA PET/CT and 
PET/MRI in patients with biochemical recurrence (see Table 17). Afshar-Oromieh, Avtzi et al. (2015), 
members from a research group at the University Hospital in Heidelberg, retrospectively analysed 
results from 319 patients, of whom 292 patients showed progression after local therapy. The lesion 
based sensitivity was 76.6%, specificity 100%, PPV 91.4% and an NPV of 100%. On a patient based 
breakdown the detection rate increase to 88.1%, independent from the PSA value. However, it became 
apparent that the detection rate increased with rising PSA levels, showing the lowest rate (50%) 
between 0.2 – 0.5ng/ml and the highest (86%) in PSA levels > 2 ng/ml (Afshar-Oromieh, Avtzi, et al., 
2015). These detections rates have also been confirmed in two additional retrospective studies by Eiber 
et al. (2015) and Verburg et al. (2016).  
Van Leeuwen et al. (2016) published results from a prospective study with 70 patients, which had a 
prostatectomy but a BCR and where therefore planned to receive salvage radiotherapy. The study 
population had a median PSA of 0.2 ng/ml and were inconspicuous in conventional imaging. After the 
68Ga-PSMA-11 PET/CT scan 38 patients (54%) had a pathological uptake of the tracer, with 24 patients 
(34%) having verified positive lesions. This high detection rate in patients with low PSA levels (0.2– 0.29 
ng/mL) is especially beneficial as this patient- group benefits the most from early salvage treatment 
(Cornford et al., 2016). Consequently a significant change in patient management in 35% of patients due 
to the results of the 68Ga-PSMA PET/CT (Van Leeuwen et al., 2016). Another prospective study compared 
the detection rate of 18F-fluoromethylcholine and 68Ga-PSMA-11 in thirty-eight (83) PC patients with a 
rising PSA level after radical prostatectomy, radiotherapy (external beam or other), or both (Morigi et 
al., 2015). The results indicate a rising detection rate with rising PSA levels as suggested by other studies 
(Afshar-Oromieh, Avtzi, et al., 2015; Eiber et al., 2015; Morigi et al., 2015), but also a significant higher 
detection rate for 68Ga-PSMA-11 compared to 18F- fluoromethylcholine (Morigi et al., 2015). The habit 
between detection rate and PSA levels was also established with other tracers such as 11C-Acetate 
PET/CT: In a retrospective study with 721 men with histologically proven PCa and PSA biochemical 
recurrence the detection rate in patients with PSA levels <1 ng/ml was 74%, and the optimal PSA cut-
off was 1.09 ng/ml (Almeida et al., 2017). The dependency of the PSA value was in accordance with 
other studies (27-74%) using 18F-fluorocholine (Graute et al., 2012; Kwee, Coel, & Lim, 2012; Morigi et 
al., 2015; Tilki et al., 2013; Vees et al., 2007) and 11C- choline PET/CT (Krause et al., 2008; Mitchell et al., 
2013). 
2.3.1.3.4.2.1 68Ga PSMA versus choline PET/CT 
In a direct comparison between 68Ga-PSMA PET/CT and choline PET/CT, the Gallium-PSMA tracer is way 
ahead in staging of recurrent disease in patients with PCa (Table 17). This is true for accuracy and tumour 
to background ratios on a patient and lesion based analyses (Afshar-Oromieh, Avtzi, et al., 2015; Bluemel 
et al., 2016; Giesel et al., 2016; Morigi et al., 2015; David Pfister et al., 2016). In a study by Morigi et al. 
(2015) 38 patients with BCR suspicious findings were detected in 26 patients (68%) using 68Ga-PSMA 
PET/CT and 18F- Fluorethylcholine. Of these 26 positive scans, 14 (54%) were positive with 68Ga-PSMA 
alone and 11 (42%) with both 18F-fluoromethylcholine and 68Ga-PSMA. Only one (4%) scan was positive 
using 18F fluoromethyl- choline alone (Morigi et al., 2015). Bluemel et al. (2016) showed that 68Ga- PSMA 
I&T identified lesions in 43.8% of the choline-negative patients and improved the overall recurrence 
detection rate from 74.4% to 86.6%.  
2.3.1.3.4.3 PSMA PET/CT Impact on Patient Management 
An early detection of lesions at low PSA values (< 1.0 ng/ml) is of particular clinical interest, as salvage 
radiotherapy, especially for cancers with aggressive features, is most effective at this stage (D’Amico, 
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Chen, Roehl, & Catalona, 2005; Fossati et al., 2016; Karlin et al., 2013; Pfister et al., 2014; Valicenti et 
al., 2013). Findings suggest that patients with salvage therapies and a PSA level smaller 2.0ng/ml have 
a significantly improved disease-free survival (Briganti et al., 2014; Stephenson et al., 2004) 
Currently there is excellent scientific evidence that 68Ga-PSMA PET/CT has a clinical impact, but 
unfortunately, the proof in prospective randomised clinical studies is limited. Two retrospective studies 
demonstrated a change in management after 68Ga PSMA PET/CT in patients with biochemically 
recurrent prostate cancer in 50.8% and 29% of patients (Sterzing et al., 2016; Van Leeuwen et al., 2016). 
In the first study, the PMSA scan changed the management of 29 patients (50.8%), compared to the 
initial plan based upon conventional staging. In 89.6% (26 patients) the radiation dose and field was 
adjusted, and four patients (10.4%) moved from radiotherapy to systemic therapy (Sterzing et al., 2016). 
The second study demonstrated a significant management change in 20 patients (28.9%), which were 
also directly attributed to the 68Ga-PSMA findings (Van Leeuwen et al., 2016). In a further study, 
examining a sequential imaging approach with 18F-choline (initial imaging approach) and 68Ga-PSMA-
PET/CT (secondary approach, if 18F-choline PET/CT was negative), 14 (43.8%) additional lesions have 
been detected in patients with a previously negative 18F-choline scan. These results are highly likely to 
impact patient management, but have not been further investigated (Bluemel et al., 2016). But other 
retrospective (Albisinni et al., 2017; Eiber et al., 2015; Giesel et al., 2015) and some prospective studies 
(Roach et al., 2018) have looked into the influence of Ga-PSMA PET/CT on the clinical management and 
have a very positive view. 
2.3.1.3.4.4 The conclusion of PSMA imaging 
PSMA- based imaging has the potential to influence the future management of patients with prostate 
cancer, whether for primary staging or staging recurrent disease. Currently, there are some limitations 
in the use of PSMA- based tracers, especially about regulatory approval (Maurer et al., 2016). Several 
clinical trials still evaluate PSMA imaging in patients with the prostatic disease, no agent has reached 
phase III stage so far (clinicaltrials.gov). Because of national regulations, some countries in Europe, 
South American and Asia are also allowed to use these novel tracers other than clinical trials and expand 
knowledge on efficacy and safe usage. However a widespread of this new imaging technique may not 
be observed shortly, seeing obstacles with regulatory approval, reimbursement and the limiting number 
of prospective trials (Maurer et al., 2016). 
2.3.1.3.5 Theranostics Approach with PSMA 
The therapeutic management of prostate cancer has become extremely complex, depending on the 
patient's characteristics, actual TNM staging level and available treatment options. Current treatment 
ranges from active surveillance and watchful waiting for men patients with very low-risk PCa, 
prostatectomy for localised PCa and more radical therapies for intermediate to high-risk PCa patients 
(Mottet et al., 2016).  
Improvements in radical prostatectomy and radiation therapy have led to decreasing morbidity and 
improved outcome in localised PCa (Metcalfe, Smaldone, Lin, Aparicio, & Chapin, 2017), but the overall 
survival and cancer-specific survival with metastatic PCa has not significantly changed in the past 20 
years (Mohler, 2014). Especially patients with metastatic castration-resistant prostate cancer (mCRPC) 
represent a significant clinical hurdle with poor prognosis and a predicted survival rate of less than two 
years (Frieling, Basanta, & Lynch, 2015; Huang, Chau, & Figg, 2012). Salvage Radiotherapy (SRT) is usually 
introduced in patients with BCR after RP and can cure patients with an increasing PSA after RP (Cornford 
et al., 2016). Androgen deprivation therapy (ADT) with or without chemotherapy is added to SRT and 
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has shown to increase the PFS after five years in retrospective series (Goenka et al., 2012) and in high-
risk tumours (Soto, Passarelli, Daignault, & Sandler, 2012).  
For mCRPC, the first line therapy is the use of life-prolonging agents such as docetaxel and cabazitaxel 
or using the immunotherapeutic pathway with sipuleucel-T or newer antihormonal drugs such as 
abiraterone and enzalutamide (Cornford et al., 2016). The EAU-ESTRO-SIOG Guidelines also recommend 
treating painful metastases early on with external beam therapy, RT, radionuclides (SM-153 EDTMP, 
Strontium, Alpharadin, Lu-177 labelled bisphosphonates), and adequate use of analgesics (Cornford et 
al., 2016). Radium-223 is a bone-seeking radiopharmaceutical based on the alpha- (𝛼-) particle emitter 
Radium-223 dichloride and can relief pain, but also showed a significant increase in survival in a phase- 
III study (Parker et al., 2013). 
Current chemotherapeutical drugs such as Abiraterone and Enzalutamide, which provide an average 
survival benefit of 3.9 and 4.9 months, tend to prolong overall survival (Morris et al., 2015; Ramadan, 
Kabbara, & Al Bassiouni Al Masri, 2015), 223 Radium chloride increases average survival by 3.6 months in 
patients with skeletal metastases (Parker et al., 2013) and immunotherapy with Sipuleucel-T also adds 
a few months but shows some immunological side effects (Kantoff et al., 2010). The real challenge for 
clinicians is to determine the optimum treatment pathway by combining different strategies (Asselah & 
Sperlich, 2013). 
Another option for patients with mCRPC has emerged with the alternative to label the PSMA ligand with 
Lutetium- 177 or Yttrium- 90. The first PSMA ligand used in humans for mCRPC treatment was a small 
molecule inhibitor of PSMA (MIP-1095) labelled with Iodine -131. A second generation inhibitor was 
J591, which has been labelled with 90Yr and 177Lu and tested in several preclinical trials focusing on 
toxicity and dosimetry. In a trial with 90Yr- J591 the patients (2) experienced thrombocytopenia in the 
highest dose of 20mCi/m², but also an 85% and 70% decline in PSA and objective, measurable disease 
response (Milowsky et al., 2004). Using the radionuclide Lutetium-177 allowed a much higher maximum 
tolerated dose (MTD) of 70mCi/m² compared to Yttrium-90, and even multi-dose with 30mCI/m² are 
well tolerated (Bander et al., 2005).  
Actually, Lutetium seems to be better suited for this Theranostic approach because of its preferred 
physical properties: (1) The longer half-life allows  the delivery of high activity to the tumour cell, (2) the 
shorter ß -range (< 2mm) fits best for small tumours and protects healthy tissue around and (3) allows 
a higher proportion of its energy to a tumour/metastases (O’Donoghue, Bardies, & Wheldon, 1995). 
Indeed the most significant advantage for Lutetium is the dual usage for imaging and therapeutically 
use, and the lower share of gamma radiation, which reduces the mandatory hospital stay.  
2.3.1.3.5.1 Regulatory Requirements 
To date, no PSMA ligand has received an official market authorisation for therapeutically use from any 
regulatory agency worldwide. Several clinical trials currently test the radioligand, some centres 
administered the ligands outside of clinical trials based on current legal exceptions. For example in 
Germany, the Medicinal Products Act (Arzneimittelgesetz- AMG) explicitly deals with RPs and prohibits 
the placement of RPs on the market unless the authorisation has been given by ordinance. There are 
some exemptions, which are very strict, but allow the in-house production of some RPs under strict 
rules and guidance (AMRadV; §13 (2) AMG; §§ 7 and 8 ApBetrO).  
For the application of an RP in an investigational trial, the rules in Germany are in line with the Directive 
2001/20/EC by the European Union and require a manufacturing license according to Good 
manufacturing practice (GMP), approval by the local ethics committee, the BfArM and the Federal Office 
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for Radiation Protection). Thus studies being currently performed are very restrictive and focusing on a 
very narrow patient population. For example, several characteristics need to be fulfilled when the 
patient applies via an individual treatment attempt (“Heilversuch”- GER). Histologically proven 
adenocarcinoma of the prostate, already treated with hormone deprivation therapy, asymptomatic or 
mildly symptomatic progression course; unsuitable for taxane-based chemotherapy (age, not tolerated 
because of comorbidity et cetera) and/or alpharadin therapy, tumour progression and current 
treatment options are exploited (§ 41 AMG). 
From a medical point of view, the radioligand therapy can be successful, if there is adequate binding of 
the PSMA- ligand to the tumour cells and its metastases. Currently, 177Lu- PSMA therapy is mainly 
offered to patients with advanced mCRPC and verifiable progressions such as a PSA level rise or tumour 
expansion based on a radiology scan. The therapy is contraindicated in patients with high renal 
insufficiency, bone marrow depression, and haematological changes. Treatment schedules are 
ordinarily 4-6 cycles at intervals of 6-8 weeks with average 5– 7 Giga Becquerel (GBq) dose per cycle 
(Heck et al., 2017). The number of cycles depends on the tumour burden, tolerance, and therapy 
response.  
2.3.1.3.5.2 Dosimetry  
Patient-specific dosimetry does not only improve the efficacy of the therapy, but also the safety in 
already profoundly ill persons. The goal is to deliver the highest possible tumour dose and spare normal 
organs (such as the kidneys). This individual dosimetry can be very challenging since there is 
considerable tumour and organ uptake variability in individuals and an in-depth knowledge on 
biodistribution and biokinetics is necessary (Thierens, Monsieurs, & Bacher, 2005).  
The pre-therapy biodistribution tests, the dosimetry study and overall therapy cycles became simpler 
when the ß- and γ emitting radionuclide Lutetium-177 had been used. Furthermore, the linear quadratic 
model, made it easier to assess dose rates and organ-dose delivery, as well as the repair potential (Erbas 
& Tuncel, 2016). A comparison between different models (MIRDOSE3, MIRD Pamphlet 19 and BED) 
showed that the effective biologic dose (BED) model was the most accurate reliable predictor of renal 
toxicity, being based on the linear quadratic model (Barone et al., 2005). At the Ludwig-Maximilian 
University Munich the dosimetry is based on quantitative SPECT images and a quantitative 3D SPECT 
OSEM reconstruction. The data from the images is used to calculate the absorbed dose for various 
organs using a combination of linear approximation, exponential fit, and target-specific S-values, 
according to MIRD (Delker et al., 2016). This quantitative SPECT dosimetry calculation enables a 
reduction of 20 to 30% of radiation to the salivary gland compared to planar scintigraphy; and 
approximately a six to twelve-fold higher radiation to a tumour than to critical organs (Delker et al., 
2016; L. Kabasakal et al., 2015; Kratochwil, Giesel, et al., 2016a). 
The kidneys are the main dose-limiting organ because of the effective glomerular filtration, tubular 
reabsorption by the proximal tubules, and interstitial retention of the tracers (Erbas & Tuncel, 2016). 
The recommended dose limit should not exceed 27 Gy (Kwekkeboom et al., 2005), a valued which 
derives from conventionally fractionated external beam therapy and was associated with a 5% 
probability of developing severe late kidney damage within five years (Cassady, 1995). Current studies 
show that with exact dosimetry tests the dose to the kidney is well below the 23Gy dose limit and that 
the parotid gland receives higher doses than the kidney (Baum, Kulkarni, et al., 2016; Delker et al., 2016). 
61 
 
2.3.1.3.5.3 Side Effects 
The side effects of PRRT with PSMA are generally low (see Table 18). Some grade 3 and 4 toxicities 
(mainly haemoglobin toxicities) have been mentioned, but are mostly limited to individual cases. A third 
(30%) of all patients reported xerostomia, 25% felt fatigue and 10% reported nausea up to 48 hours 
after injections (Emmett et al., 2017). Whereas a dry mouth is mostly reversible using the beta-emitting 
radionuclide Lutetium-177, it seems to be persistent with Actinium-225 (Ahmadzadehfar, Eppard, 
Kurpig, et al., 2016; Fendler, Reinhardt, et al., 2016; Heck et al., 2016; Kratochwil, Bruchertseifer, et al., 
2016; Rahbar et al., 2017).  
Due to the currently mainly retrospective study designs, the side effects can hardly be assigned to 
effects caused by the therapy and those due to the progression of the disease. Especially haematological 
toxicity may predominantly occur because of advanced skeletal metastases and borderline marrow 
function, rather than radiation effect on the bone marrow (Emmett et al., 2017). To date, the most 
significant retrospective study was initiated in multiple centres in Germany and analysed the data from 
145 patients. Overall the toxicity profile was favourable, with some of the reported adverse events may 
also be connected to prior therapies and/or advanced disease (Rahbar et al., 2017).  
“In the current study grade, 3-4 hematologic adverse events occurred in 12% of the patients: 
thrombocytopenia and anaemia occurred in 4% and 10%, respectively. The reported rate of 
adverse events is slightly lower or comparable to the rate in other mCRPC cohorts. Patients 
undergoing placebo or 223Ra within the ALSYMPCA trial (Parker et al., 2013) demonstrated grade 
≥3 anaemia in 13 to 14% and grade ≥3 thrombocytopenia in 3% to 7%. The present study shows 
significantly lower haematotoxicity when compared to results of second-line chemotherapy or 
radiolabelled antibody therapy: The TROPIC study (De Bono et al., 2010) revealed a grade ≥ three 
leukopenia in 68% of patients receiving cabazitaxel and in 42% of patients receiving 
mitoxantrone vs 3% in our study. Application of 177Lu labelled J591 monoclonal antibody was 
associated with grade 4 thrombocytopenia in 47% of patients (Tagawa et al., 2013). In the 
present study, only 4% of the patients experienced a grade ≥ three thrombocytopenia.” (Rahbar 
et al., 2017)  
   Adverse Events 
Author Ligand Number of 
Patients 
Grade 3  Grade 4 
Ahmadzadehfar et al., 2015 177Lu-DKFZ-617 PSMA 10 10% Haematotoxicity 
Ahmadzadehfar, Eppard, Kürpig, et al., 2016 177Lu-DKFZ-617 PSMA 24 8% Anaemia - 
Kambiz Rahbar et al., 2016 177Lu-DKFZ-617 PSMA 74 1.4% haemoglobin 
1.4% platelets 
- 
C. Kratochwil, Giesel, et al., 2016a 177Lu-DKFZ-617 PSMA 30 3.3% Anaemia 
3.3% Thrombocytopenia 
- 
Ferdinandus et al., 2016 177Lu-DKFZ-617 PSMA 40 Toxicity data published in (Kambiz Rahbar et al., 2016) 
W.P. Fendler et al., 2016 177Lu-DKFZ-617 PSMA 15 7% Leukocytes 
7% Nausea 
- 
K. Rahbar et al., 2017 177Lu-DKFZ-PSMA-617 145/121 
(Toxicity)  
99 (BCR) 
3% Leukopenia (n=121) 
10% Anaemia (n=145) 
4% Thrombocytopenia (n=121) 
1% Biliary obstruction (n=145) 
1% Fatigue (n=145) 
2% Lung embolism (n=145) 
1% Stroke (n=145) 
2% Bone fracture (n=145)  
Yadav et al., 2016 177Lu-DKFZ-PSMA-617 31 3.2% haemoglobin toxicities - 
M. Weineisen et al., 2015 177Lu- PSMA I&T 2 - - 
Richard P Baum et al., 2016 177Lu-PSMA I&T 56 - - 
Matthias M. Heck et al., 2016 177Lu-PSMA I&T 19 - - 
Tagawa et al., 2013 177Lu-J591 47 10.6% Haemoglobin 
46.8% Leukocytes  
36.2% Neutrophils  
2.1% Febrile neutropenia  
21.3% Thrombocytopenia 
46.8% Thrombocytopenia 
25.5% Febrile 
neutropenia 
8.5% Leukocytes 
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C. Kratochwil, Bruchertseifer, et al., 2016 225Ac-PSMA-617 2 50% Xerostomia - 
Table 18 Overview of Grade 3 and Grade 4 adverse events after several cycles of 177Lu- PSMA PRRT  
2.3.1.3.5.4 Response and Efficacy  
Up to date, few randomised controlled trial investigated the efficacy of 177Lu-PSMA in patients with 
mCRPC in a controlled manner. Recently, a single arm, single centre Phase II study investigated the 
response and efficacy in men with mCRPC with progressive disease and after standard treatment regime 
with chemotherapy. Their results indicate a high response rate in this population, with 17 patients (57%) 
experiencing a PSA decline of 50% or more, an objective response in nodal or visceral disease in 14 (82%) 
of 17 patients and 11 patients (37%) experienced a ten point or more improvement in global health 
score by the second cycle of treatment. (Hofman et al., 2018).  
The bulk of knowledge, however, relies on retrospective studies, mostly single- arm with a high variance 
in the treatment regime (dose and number of cycles). Nevertheless, these studies showed a clear benefit 
for most patients, who have already completed every treatment option available and are running out 
of alternatives. In these studies, around 30-100% of patients experienced a more than 50% reduction in 
serum PSA, and > 58% of patients experienced any PSA decline (see Table 19). Compared to currently 
available chemotherapy agents (Mitoxantrone and Cabazitaxel) the change in PSA (>50%) is similar to 
the therapy with Lutetium-177 PSMA (Mitoxantrone: 17.8%; Cabazitaxel: 39.2%), but having a 
significantly lower rate of adverse events (Rahbar et al., 2017).  
Germany is taking the lead in the research and clinical testing with radiolabelled therapeutic agents, 
mainly because of favourable regulations and intense university research. In 2014 Zechmann et al., from 
the research group of Haberkorn from the University Hospital of Heidelberg, reported about their 
experience with one cycle (dose 4.8 GBq) of 131I-MIP-1095 in 28 mCRPC patients. 61% of patients showed 
a decrease of PSA serum level of >50% and 85% reported a reduction in pain, but also an intense 
accumulation in the salivary and parotid glands with some adverse events (Zechmann et al., 2014).  
Soon after the research group from the University Hospital of Bonn published first results of the novel 
agent 177Lu-DKFZ-617 PSMA in ten hormone- and/or chemo-refractory patients with distant metastases 
(seven patients with serious metastatic disease in bone and lymph nodes) and progressive disease. A 
mean dose of 5.6 GBq was administrated and eight weeks after the therapy 50% of patients had a PSA 
decline >50% and three had progressive disease (Ahmadzadehfar et al., 2015). In a follow-up study, 30 
patients with mCRPC resistant to or with contraindications to other conventional therapies received up 
to three cycles repeated every second month. The initial dose was 3.7 – 4.0 GBq but was increased to 
6GBq after the first ligand-specific dosimetry data was available. 21 patients (70%) showed any PSA 
response and 13 (43.3%) a decrease >50%. After three cycles, 8 of 11 patients had an ongoing PSA 
response of >50% for over 24 weeks, which was also verified via radiologic imaging (Kratochwil, Giesel, 
et al., 2016a). 
The research group at the Ludwig Maximilian University in Munich investigated 15 patients with mCRPC, 
who received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n =10) 177Lu-PSMA-617 at an eight to ten weeks’ 
interval. Their primary endpoint was radiological response rate based on RECIST (PR 27%; SD 40%; PD 
33%), and secondary endpoints were PSA change (80% any PSA decline; 60% PSA decline >50%), quality 
of life (improvement in 60%) and pain- relief (70% significant improvement) (Fendler, Reinhardt, et al., 
2016). 
Results from a second generation Lutetium analogue (177Lu- PSMA I&T), with higher affinity to PSMA 
and better internalisation into the cells, showed high absorbed tumour doses and a PSA decrease in 
80.4% of patients. These 56 patients with progressive mCRPC (median Gleason score 8) had a rising PSA 
level and received several cycles of 177Lu-PSMA (1 cycle for 16 patients, 2 cycles for 15 patients, 3 cycles 
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for 17 patients, 4 cycles for 6 patients, and 5 cycles for 2 patients) with a dose/ cycle of 5.76GBq. 
Remarkable also in this study that 45% of patients already had systemic chemotherapy (Docetaxel), 
bone metastases were present in 77%, liver metastases in 9% and lung metastases in 13% of patients. 
This study suggested a possible survival benefit with a survival rate after 28 months of 78.6%, median 
progression-free survival of 13.7 months and median overall survival was not reached. Imaging results 
from 15 patients minimum after six months showed partial remission in 20%, stable disease in 52% and 
progressive disease in 28% of patients (Baum, Kulkarni, et al., 2016). 
In the currently most significant retrospective multicentre study worldwide, 12 centres in Germany 
analysed results from 145 patients (median age 73 years, range: 43-88) with mCRPC treated with 248 
cycles of 177Lu-PSMA-617 between February 2014 and end of July 2015. The patients had an advanced 
mCRPC stage with 87% having bone -, 77% lymph node- and 36% either liver-, lung- or other metastases. 
All patients had previous androgen deprivation therapy, 64% received Abiraterone, 54% chemotherapy 
and some Enzalutamide (52%), 223Ra (17%) and EBRT to bone (35%).  
Results from 99 patients with PSA levels over the whole treatment cycle were available: After the first 
cycle 40% of patients showed a PSA decline > 50%; after the second therapy cycle 57% had PSA decline 
> 50%; after the third (65%) and the fourth (100%) of patients had a PSA decline > 50%. Visceral 
metastases and alkaline phosphatase ≥ 220 U/L hurt biochemical response, whereas more therapy 
cycles had a positive effect on the biochemical response (Rahbar et al., 2017).  
In general therapy with 177-Lu PSMA seems to be promising, but the different retrospective results and 
treatment regimens need to be verified with prospective trials in future. In Germany, the treatment 
with Lutetium PSMA expanded rapidly but is still categorised as a treatment attempt (“Heilversuch”) 
with the palliative purpose to treat patients with mCRPC.  
Author Ligand 
Number 
of 
Patients 
Median 
Serum PSA 
level 
(ng/ml) 
PSA 
declin
e 
PSA 
decline 
>50% 
Respons
e CT 
(RECIST) 
Response 
PSMA 
PETa/ PSA 
riseb 
Symptomatic 
Response 
 
PFS 
 
OS 
Ahmadzadehfar et 
al., 2015 
177Lu-DKFZ-
617 PSMA 
10 298.5 70% 50%  PD 30%b  - - - 
Ahmadzadehfar, 
Eppard, Kürpig, et 
al., 2016 
177Lu-DKFZ-
617 PSMA 
24 522 79.1% 41.6% PR 40% 
SD 55% 
PD 5% 
PR 80%  
SD 0% 
PD 20% 
- - - 
Kambiz Rahbar et 
al., 2016 
177Lu-DKFZ-
617 PSMA 
74 342 64% 31% - PD 23% b  - - - 
C. Kratochwil, Giesel, 
et al., 2016a 
177Lu-DKFZ-
617 PSMA 
30 n.a. 70% 43.3% - PD 27% b  -  - 
Ferdinandus et al., 
2016 
177Lu-DKFZ-
617 PSMA 
40 325.5 67.5% 32.5% - PD 32.5% b  -  - 
Fendler et al., 2016 177Lu-DKFZ-
617 PSMA 
15 388 80% 60% PR 27% 
SD 40% 
PD 33% 
- Pain: CR 20%; 
PR 27%; PD 
20% 
QoL: 53% 
improvement; 
20% a 30% 
Improvement 
 - 
Rahbar et al., 2017 177Lu-DKFZ-
PSMA-617 
145/121 
(Toxicity
)  
99 (BCR) 
214 60% 45% CR 2%1 
PR 45%1 
SD 28%1 
PD 25%1 
- -  - 
Yadav et al., 2016 177Lu-DKFZ-
PSMA-617 
31 275 
(mean) 
Pre- and post 
275/141 (mean) 
- CR 6.4%  
PR 9.6% 
SD 3.2% 
PD 0% 
CR 6.4%2  
PR 64.5%2 
SD 9.6%2 
PD 19.3%2 
12 
mo 
16 
mo 
Weineisen et al., 
2015 
177Lu- PSMA 
I&T 
2 47.2  100% (1 
patient) 
- PR 50% symptomatic 
pain relief 
- - 
Baum et al., 2016  177Lu-PSMA 
I&T 
56 43.2 58.3% 58.9% PR 20% 
SD 52% 
PD 28% 
PR 56% 
SD 8% 
PD 36% 
33% PR 13.7 
mo 
(medi
an) 
medi
an 
not 
reac
hed 
Heck et al., 2016 177Lu-PSMA 
I&T 
19 349 89.4% 26.3% PR 11% 
SD 56% 
CR 5% 
SD 63% 
CR 14% 
PR 42% 
175 
days 
- 
64 
 
PD 33% PD 32% (medi
an) 
Tagawa et al., 2013 177Lu-J591 47 74.4 59.6% 10.6% PR 
8.3%3 
SD 66%3 
PD 
16.6%3 
- - - 17.6 
mo 
(me
dian) 
Kratochwil, 
Bruchertseifer, et 
al., 2016 
225Ac-
PSMA-617 
2 >3000 & 
294 
100% 100% - CR 100% 
 
- - - 
1 data from 47 patients; 2 Data based on PSA values; 3 Data from 12 patients 
OS, Overall Survival; PFS, Progression Free Survival; mo, months; 
Table 19 Currently published trials showing the efficacy of PSMA ligands in the treatment of patients with metastatic 
castration-resistant prostate carcinoma (mCRPC) 
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3 Current Challenges in the Radiopharmaceutical Industry – A 
Case Story of DOTATATE 
Probably the best example of successful clinical implementation of a peptide-based 
radiopharmaceutical for diagnoses and therapy was in the field of neuroendocrine tumours.  
The case started with the discovery of an extract from the rat´s hypothalamus in 1968, which stimulated 
or inhibited the release of pituitary growth hormone and was thus named growth hormone- inhibiting 
factor (GIF) (Krulich et al., 1968). In further research Roger C L Guillemin and colleagues isolated, 
sequenced and synthesised the 14- amino-acid peptide structure and confirmed the inhibiting 
properties in in-vivo and in-vitro experiments (Brazeau et al., 1973). This discovery led to the patent 
application (US 3904594 A) and was described as a “novel peptide compositions having an inhibitory 
influence on the growth-promoting function of the pituitary gland in humans and animals. More 
particularly the present invention is directed to novel peptide compositions which influence the release 
of growth hormone by the pituitary gland.” (Guillemin et al., 1975). Roger Guillemin and Andrew Schally 
were honoured with the Nobel Prize in Medicine 1977 for their work with somatostatin and other 
hormones.  
Early on it has already been suggested that this novel peptide could have pathological and potential 
therapeutic use. Based on the preliminary work of Rivier, Vale and Veber (Rivier, Brazeau, Vale, & 
Guillemin, 1975; Veber et al., 1979, 1981) the preclinical research group from Sandoz Ltd. developed a 
highly potent and active somatostatin analogue that would also be therapeutically effective. The 
compound was well tolerated in laboratory animals and in human and active by several routes of 
administration (Bauer et al., 1982). The substance was named Sandostatin LAR (octreotide acetate, EQ 
0.05 mg base/ml injection, Sandoz AG) and was the first therapeutically somatostatin analogue granted 
marketing authorisation by the US Food and Drug Administration (FDA) in October 1988 and registered 
in Germany under the tradename Octreotide s.c.D in 1990. The authorisation granted the indications 
acromegaly, severe diarrhoea/flushing episodes associated with metastatic carcinoid tumours and 
profuse watery diarrhoea associated with VIP- secreting tumours (Novartis Pharmaceuticals 
Corporation, 2002).  
Parallel to the therapeutic use of somatostatin, J.C. Reubi, a professor of pathology and cell biology at 
the University of Bern, researched with his team the affinity binding sites of the somatostatin complex 
(Reubi, Perrin, Rivier, & Vale, 1981). Their discovery of the over-expression of these somatostatin 
receptors on some tumour cell´s surface led to the development of the first diagnostic compound 
labelled with Iodine-125 (Krenning et al., 1989; Reubi, Häckl, & Lamberts, 1987), which was later 
replaced by the radionuclide Indium-111 and Technetium-99m. The preclinical research group from 
Sandoz Ag published first preclinical imaging studies with the 111In-labelled SRIF analogue SDZ 215-811 
in 1993 and showed a high affinity to somatostatin receptors (Bruns, Stolz, Albert, Marbach, & Pless, 
1993). A final product (Indium-111 Pentetreotide kit, tradename: “Octreoscan”) was submitted to the 
FDA in October 1992 by Mallinckrodt and was approved as a medicinal product to be used in the 
diagnosis of gastroenteropancreatic neuroendocrine (GEP) tumours and carcinoid tumours in February 
1994. Octreoscan was developed by Mallinckrodt and Sandoz, with Sandoz providing the synthetic 
somatostatin analogue octreotide known as Pentetreotide (Sandostatin).  
In connection with the successful development of Octreoscan, several other patents had been filled by 
Mallinckrodt Medical, Inc. including US 5,382,654 registered in February 1992 for a “radiolabelled 
peptide compound, methods of preparing these compounds, pharmaceutical compositions comprising 
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these compounds and use of these compounds in kits for therapeutic treatment of tumours and for 
diagnostic imaging of tumours” (Lyle, Rajagopalan, & Deutsch, 1995) and WO 1993004702 A1 a 
stabilizer for radiolabelled peptides and proteins (Deutsch, Goedemans, Maria De, Miller, & Brodack, 
1993).  
In the 1990s also the research of Gallium- 68 radiochemistry improved and led to the development of 
new chelate conjugates, suitable for PET imaging. PET is said to be a method with higher diagnostic 
yield, compared to SPECT, due to higher sensitivity, absolute quantification, shorter scanning time and 
a reduction in radiation absorbed dose by the patient (Rahmim & Zaidi, 2008). Also from a 
radiochemistry point of view, RPs labelled with Gallium-68 have some desirable features like the general 
availability, the inexpensiveness of the nuclide and the easy access via an in-house generator (Ambrosini 
et al., 2012). 
In 1993, Mäcke et al. synthesised a new modification to octreotide designed to be linked to Gallium 67 
and Gallium 68 and showed a high binding affinity and fast tumour localisation in rats. The trivalent 
metal radionuclides had to be conjugated to a suitable chelator to complex with Indium, Yttrium, 
Gallium, and Lutetium in order to get a stable radiolabelled somatostatin analogue. Two chelators have 
been widely used: DTPA (diethylenetriameinepentaacetic acid) and DOTA (1,4,7,10-
tetraazacyclododecanetetraacetic acid), at which DOTA complexes have a higher thermodynamic and 
kinetic stability compared to DTPA complexes (Sosabowski & Mather, 2006). The DOTA complex is also 
tetra acid and thus has four sites for conjugation, which makes it the preferred application for peptide 
conjugation. 
DOTATATE 
DOTA – [Tyr3] octreotate also known as DOTATATE proved to be a diagnostically and therapeutically 
very useful compound (see Chapter 2.2.4 and 2.2.5) and is currently the clinically most widely used 
analogue for diagnosis and therapy in neuroendocrine tumours. The substance has been used without 
marketing authorisation for a long time (Leugs, 2013) and just recently granted official approval by the 
FDA and EMA as a diagnostic (68Ga- DOTATATE) and therapeutic (177Lu-DOTATATE) compound (European 
Medicines Agency, 2017c; U.S. Food and Drug Administration, 2018b). 
This was preceded by extensive researched of academic research facilities in Europe, in cooperation 
with employees from Mallinckrodt Medical Inc. in the late 90s and beginning of 2000. The preclinical 
and clinical investigational work was mainly focused on toxicity and dosimetry (Lewis et al., 2001; Lewis, 
Laforest, Lewis, & Anderson, 2000; Lewis et al., 1999), the use of the substance as an PET imaging 
biomarker (De Jong et al., 1998), and labelled with Lutetium-177 and Yttrium-90 to be used in the PRRT 
approach (Bernard et al., 2004; de Jong, Breeman, Bernard, Bakker, Schaar, et al., 2001; Kwekkeboom 
et al., 2001). On the basis of the published literature one can assume that the support from Mallinckrodt, 
acquired by Tyco International in 2000, decreased in the years after 2003 and academic research 
institutions (notably the Erasmus Medical Centre in Rotterdam) resume research efforts. 
Mallinckrodt Medical Inc. filled the intellectual property rights (later Covidien- Mallinckrodt and later 
sold to IBA Molecular) in June 1996, and the patent expired in June 2016. Even the compound could not 
be used in daily routine, Mallinckrodt allowed some licensed manufacturers to supply the product to 
research groups, who conducted registered clinical trials approved by health authorities (Leugs, 2013). 
Two of these licensed manufactures where ABX GmbH, a German company manufacturing chemicals 
for nuclear medicine based in Leipzig, and the Swiss-based biochemical and pharmaceutical drug 
products producer Bachem AG with its affiliates in Europe and the US. Those were able to provide 
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DOTATATE for clinical trials registered in the EudraCT registry for diagnostic use with Gallium-68 or 
therapeutic use with Yttrium-90. Currently, Advanced Accelerator Applications (AAA) exclusively holds 
the rights for a special labelling method for DOTATATE (in context to Lutetium-177 and Gallium-68) and 
has presented encouraging results from a randomised, controlled phase III trial in 2017 (Chiti, 2013; 
Strosberg et al., 2017).  
DOTATOC 
The other compound used for the diagnostic purpose in NETs is DOTATOC, a somatostatin peptide 
analogue (Tyr3-octreotide) coupled with (DOTA). Even 68Ga-DOTATATE showed a 10-fold higher in-vitro 
affinity to SSTR2 compared to 68Ga-DOTATOC, the difference may not seem to be clinically relevant in 
the visualisation of NETs mainly expressing SSTR2 (Pöppel et al., 2011; Reubi et al., 2000). Until 2007, 
Novartis held the intellectual property rights to DOTATOC (commercial name OctreoTher) and 
conducted Phase I and Phase II trials to demonstrate the safety and therapeutic effectiveness 
(disappearance or significant shrinkage) of somatostatin receptor positive solid tumours (e.g. 
neuroendocrine, breast or small cell lung tumours) (Smith et al., 2000). Phase II multicentre clinical trials 
have were performed in cooperation with Mallinckrodt Medical Inc. in Australia, Europe and the United 
States. It was also announced that the compound’s efficacy should be tested in breast and small cell 
lung cancer. In 2007 also a phase II study tested the therapeutic compound [90-Yttrium-DOTA]-TOC in 
metastasised medullary thyroid cancer with grant support by the Swiss National Science Foundation.  
Also in 2007, Novartis Pharma AG licensed Onalta (previously OctreoTher, Y-90 SMT 487) to Molecular 
Insight Pharmaceuticals Inc., which sublicensed the intellectual property rights and know-how to 
BioMedica Life Sciences in September 2009. Novartis still allowed the distribution of the diagnostic 
compound by licensed manufactures, if producers could state that the peptide is going to be used under 
the local radiopharmaceutical rules. The patent has already expired, and the compound is available at 
ABX, piCHEM, Bachem, JPT, IBD and BioMedica.  
DOTANOC 
DOTANOC is the third compound used for neuroendocrine tumours and is somewhat different to 
DOTATATE and DOTATOC due to its higher affinity to the somatostatin receptors subtypes 2 and 5 (Wild 
et al., 2003). The patent (US7122622 B2) for DOTANOC was filled in 2002 by Biosynthema Inc. with the 
inventors Helmut Robert Mäcke, Jean-Claude Reubi, Jörg Simon Schmitt, Mihaela Ginj and was 
transferred to Advanced Accelerator Applications (AAA) on May 1st 2015. The patent will expire in April 
2022 in the United States.  
3.1 The long Way to Market Authorisation 
At the moment thousands of radiolabelled molecules have been researched, several hundred tested in 
human, but only a few dozen received an international market authorisation for a diagnostic and 
therapeutic purpose (Zimmermann, 2013). Over the years, 122 new molecular entities for all imaging 
modalities have been approved by the FDA till the end of 2015: Thirty-three were approved for anatomic 
imaging and sixty-seven for functional or molecular based imaging. This clearly shows that 
cardiovascular, oncology and neurology applications now lead the way of imaging, whereas the area of 
urology decreased over the century (Kinch & Woodard, 2017). 
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Historically, the private sector has been responsible for research and development of these imaging 
agents, mainly driven by five companies: Mallinckrodt, Squibb (now in Bristol-Myers Squibb), Roche 
Medic Physics (now in GE Healthcare), DuPont (now in Lantheus) and Schering AG (now in Bayer AG). 
However, their investment decreased substantially and R&D efforts have been replaced by public sector 
organisations (Kinch & Woodard, 2017). In the case of somatostatin analogues, it is well shown that 
several companies still registered new compounds suitable for imaging and therapy, but very few tried 
to receive a marketing authorisation. There are many reasons for this low approval rate, ranging from 
economic-, scientific-, regulatory-, manufacturing, and other non-medical related issues. The 
development process, including the approval of new RPs, is very complex and linked to a sustainable 
development period and high costs, also because RPs are regulated under the same rules as therapeutic 
drugs (Schwaiger & Wester, 2011). Newer radiopharmaceuticals in oncology (for imaging and therapy 
purpose) also tend to be more specific, which has a negative effect on the sales volume, the return on 
investment (ROI) and thus the investor´s market attractiveness (Henderson et al., 2005; Nunn, 2007a; 
Zimmermann, 2013). Also, the reimbursement values for diagnostic RPs have dropped in the past, which 
has brought significant uncertainty to the market (Zimmermann, 2013).  
The pharmaceutical industry, as a fundamental investor for RPs, is currently struggling with several 
challenges: less revenue due to expiration of patented blockbusters (≥ 1 billion of annual sales); low 
productivity in new drug development (Khanna, 2012) and pressure on the reimbursement of new 
products (Kaitin & DiMasi, 2011). Several of the larger pharmaceutical companies adjusted their 
business strategies, their risk-reward ratios and may as a result not invest in products with low or 
moderate market size (< 300 million dollars) (Khanna, 2012). Furthermore, especially in the imaging 
sector there was a substantial decline in private companies involved in imaging R&D, mainly because of 
industry consolidation (Kinch & Woodard, 2017). The declining R&D budgets (for products with higher 
commercial risk) are also leading to falling investor´s interest in nuclear medicine products and, as a 
result, subsequently prevents the market authorisation of new RPs.  
Several barriers, connected with the development of RPs, have been described in literature and can be 
summarised in five subordinated topics: 
I. Economic and Market-related Challenges 
i. The market is small because imaging agents are undervalued and current prices will not 
support an investment in a new drug unless the agent is used in high volume (Nunn, 
2007b). 
ii. RPs have limited profitability even if they are proprietary (Zimmermann, 2013). 
iii. There is a limited possibility for commercial exploitation of academic discoveries (Mather, 
Figure 12 Overview of imaging new molecular entities (NMEs) 
approved from (before) 1940 to 2017 (Kinch & Woodard, 2017; 
U.S. Food and Drug Administration, 2017b).  
Figure 13 Approved indications of the 124 NME imaging 
agents until September 2017 (Kinch & Woodard, 2017; U.S. 
Food and Drug Administration, 2017b) 
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1998). 
II. Research and Development Challenges 
i. High development costs for radiopharmaceuticals, ranging from 100-200 million dollars 
for an RP imaging agent and around 800 million dollars for a new therapeutic drug (e.g. 
Dimasi, Grabowski, & Hansen, 2016; DiMasi, Hansen, & Grabowski, 2003; Henderson et 
al., 2005; Nunn, 2006)  
ii. Some biological imaging markers are clinically not validated and adopted, because they 
do not measure a relevant biological feature nor enable disease diagnosis or outcome 
prediction (O´Connor et al., 2017). 
iii. Experimental RPs are used in the drug development process to investigate 
pharmacokinetic and dosing, but are not intended to be developed further (Nunn, 2007a). 
iv. Intellectual property right (IPR) issues between public research groups and potential 
investors. Sharing IPRs may limit exclusive commercial rights and discourage commercial 
development for investors (Schelbert, 2011). 
III. Regulation and Marketing Authorisation Challenges 
i. National authorities request several validation steps to receive regulatory and safety 
approval either in the development but also in production (Henderson et al., 2005; Nunn, 
2007a; O´Connor et al., 2017; Zimmermann, 2013).  
ii. Regulatory approval requirements by FDA and EMA are the same for imaging agents as 
for therapeutic drugs (Agdeppa & Spilker, 2009). 
iii. Imaging biomarkers are evaluated based on the same patient-related benefits indicators 
(mortality, morbidity and health-related quality of life) as pharmaceutical drugs (Institute 
for Quality and Efficiency in Health Care - IQWIG, 2017a). 
IV. Reimbursement and Revenue Planning Challenges 
i. Shrinking revenue for investors based on the low or even decreasing reimbursement rates 
for diagnostic imaging tests (Nunn, 2007a; Zimmermann, 2013).  
ii. Health Technology is often assessed in advance by government-related organisations 
demanding evidence of the value of the technology (Ciani & Jommi, 2014). The results of 
this assessment will subsequently affect reimbursement negotiations between the 
industry and healthcare provider.  
V. Different goals between the Scientific Community and Investors/Industry  
i. There is a fundamental difference in industrial- and academic research: The questions 
asked in academia most of the time generates data, which may not be helpful in the 
market authorisation process (Buscombe, 2015).  
ii. Limited knowledge in the scientific community (outside of the nuclear medicine field) on 
the benefits of radiopharmaceuticals in diagnosis and therapy of cancer (Zimmermann, 
2013);  
VI. Special Manufacturing, Distribution and Handling of Radiopharmaceuticals  
i. Special manufacturing and distribution of RPs due to the utilization of radioactive 
components (Bundesministerium für Justiz und Verbraucherschutz, 2017; 
Bundesministerium für Erwelt Naturschutz und Reaktorsicherheit, Bundesministerium für 
Gesundheit, & Bundesministerium für Verkehr Bau und Wohnungswesen, 2017; European 
Commission, 2017; International Atomic Energy Agency, 2008; Zimmermann, 2013). 
To date, just a handful of imaging biomarkers received market authorisation in the US and Europe, and 
many of these biological imaging agents are still under evaluation and tested in clinical trials (European 
Medicines Agency, 2017b; U.S. National Institute of Health, 2017). The history of DOTATATE, DOTATOC 
and DOTANOC indicates that the interest from potential investors is low and that big pharmaceutical 
companies have intentionally avoided the nuclear medicine business. To overcome the issue of lacking 
marketing approval for many new RPs the U.S. National Institute of Health (NIH) and the U.S. National 
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Cancer Institute (NCI) for example try to promote the entry of new investors into the segment. Lately, 
several small and medium-sized enterprises (SME) have entered the market and facilitated the 
translation of clinically successful markers into final products. However, SMEs may lack the structure 
and experience in performing the tasks of identification, validation, translation and qualification of 
biomarkers. Understanding the biology of biomarkers, the relevance to the disease, the technological 
features and of course the regulatory requirements is demanding (Asadullah, Busch, Gottwald, Reinke, 
& Landeck, 2015). Especially the regulatory requirements, to provide the same level of empirical 
evidence for an imaging marker as for a therapeutic drug, are a significant cost and time contributor 
and a real obstacle for SME (Gazelle, McMahon, Siebert, & Beinfeld, 2005). This statement is confirmed 
by an evaluation by the FDA, which highlighted that SMEs ask more questions during the approval 
process than large companies and that quality documentation seems to be a particular bottleneck in 
SMEs (Putzeist, Mantel-teeuwisse, & Leufkens, 2011). 
Furthermore, SMEs have a substantially longer preclinical phase, which higher stage related out-of-
pocket cost and therefore overall costs (DiMasi, Grabowski, & Vernon, 1995). In Europe, EMA also 
addressed these challenges and started an initiative to support SMEs in the fields of administration, 
regulatory and offer them a financial incentive (European Medicines Agency, 2017d). Also, the concept 
of public-private partnerships (PPP) was promoted, to invite different players to actively participate in 
clinical trials and share the financial risk (Mercanoglu & Ozer, 2015).  
With the further push towards personalised therapy, including the measurement of early therapy- and 
drug response, the use of specific biomarkers in the drug development process and clinical routine will 
become increasingly more important (Asadullah et al., 2015). Thus, it will be crucial to identify the 
barriers and challenges in the current authorisation process of RPs, determine the success factors in 
new R&D processes (e.g. public-private partnerships) and clear the way for new biological imaging 
markers to enter clinical routine. In the following, we will analyse the challenges described in the 
literature, and then put them in context with our empirical results.  
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3.2 Market Size and Potential 
In the current economic environment, privately held companies follow the path of maximising the value 
of the company. They have to make decisions based on investment, financing and dividends with the 
objective to generate revenue for themselves or shareholders. This is of course also true for the 
pharmaceutical industry, which focuses on attrition rates to balance costs of R&D, explore cost 
containment and thus generate shareholder value (Kola & Landis, 2004). Moreover, when it comes to 
investment decisions the principles states, that the return must be higher than the minimum acceptable 
hurdle rate (Damodaran, 2012). The hurdle rate is the personal riskiness indicator and reflects the mix 
of debt and equity financing the investment, with the return to defined as the magnitude and timing of 
the cash flows and all side effects (Damodaran, 2012). The return, therefore, can be a gain or a loss 
relative on investment, with greater potential of wins and losses the more risk is associated with the 
investment. These opportunity costs are by a magnitude higher in the pharmaceutical industry than 
interest rates on other safe investments and compensates the funders’ higher risks and attract them to 
further invest into the business (Chit et al., 2015). 
Consequently, new discoveries in the medicinal product market are often not solely shaped by the 
autonomous progress of scientific breakthroughs, but rather by the extent of the market (Schmookler, 
1966). This market is often influenced by three factors: (1) demographic and socioeconomic changes; 
(2) degree of competition and (3) public policies (Dubois, de Mouzon, Scott-Morton, & Seabright, 2015). 
Substantial literature investigates the external and internal factors influencing investment decisions in 
new drug development, and how the size of the market affects R&D decisions. One study showed that 
a 10% increase in real drug prices increases the future R&D spending by approximately six per cent 
(Giaccotto, Santerre, & Vernon, 2005). An increase in the U.S. pharmaceutical market size by one per 
cent increases the total market of new drugs by six per cent (Acemoglu & Linn, 2004). Also, several 
studies showed a dramatic change in private-sector R&D investment after federal policies changed, 
which substantially affected the market size (Blere-Kohout & Sood, 2013; Finkelstein, 2004; Yin, 2008). 
It is the task of economic models to assess the elasticity of innovation and thus to show how R&D 
investments react to a change in market size. Dubois et al. (2015) calculated an elasticity of innovation 
of 23.1%, which means that a company needs to have another $ 2.5 billion in revenue growth to support 
one new drug development.  
With the shareholders in mind, the pharmaceutical industry prioritise 
projects with high net present value, adjusted for the future risk (risk-
adjusted net present value -rNPV) (Stewart, Allison, & Johnson, 2001). 
This rNPV describes the current value of a drug by summarising all future 
cash flows (discounted to today’s money), integrate the risk and costs 
associated with the development, and the time it takes to go to market. 
The intimate goal is to choose those projects, which “maximise expected 
financial returns at an acceptable level of risk for a given level of 
corporate resources” (Blau, Pekny, Varma, & Bunch, 2004). Moreover, a 
minimum expected financial return is more than $ 600 million per year 
in peak sales (Tollman, Morieux, Murphy, & Schulze, 2011). However, a 
report indicates a 11.4 percent year-on-year decline in average peak 
sales per asset since 2010 and a lower return on the R&D investment 
(Deloitte Centre for Health Solutions, 2016). It seems that companies with a clear focus on a specific 
therapy areas outperform those, who are changing the focus of their R&D program. Thus, any R&D 
Project therapeutic 
class 
Risk adjusted NPV x 
$1,000,000 
Musculoskeletal 1,150 
Neuroscience 720 
Oncology 300 
Vaccines 160 
Injectable Antibiotic 
(Gm+) 
100 
MS- Psoriasis 60 
Liver Transplant 20 
Oral Contraceptive 10 
Table 20 shows the risk-adjusted 
Present Net Value (rNPV) of drugs 
in different therapeutic classes. 
Data from 2003. (Projan, 2003) 
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investment decision is never seen as a singular event but always in connection to other competing R&D 
investment decisions. Mcgrath & Nerkar (2004) analysed more than 7.000 patent filings from 
pharmaceutical companies between 1979 and 1995 and assessed the factors influencing decision 
making in the R&D process. It seems that the scope of opportunity, prior experience, and competitive 
effects are the main drivers. Investments, which relate to the same scope of previous research, seem to 
be more positive valued because they also do not increase investor´s risk premiers (Mcgrath & Nerkar, 
2004). Companies with distinctive focus and expertise on specific therapy areas built a robust target 
product profile and target the population with maximised value. They appear to be more successful and 
achieve a higher commercial value (Deloitte Centre for Health Solutions, 2016). 
Strategic focus on therapy areas seems to be of high value for every pharmaceutical company. It is said 
that they can make better decisions, leverage existing relationships to critical stakeholders (opinion 
leaders, researchers, clinical investigators, et cetera), have more focused portfolio and business 
development efforts, efficiently use internal and external resources, and can further improve research 
execution based on prior development expertise (Deloitte Centre for Health Solutions, 2016). With the 
pressure from shareholders, and their preference to have lower R&D investments and greater dividends 
(Scannell, Blanckley, Boldon, & Warrington, 2012), pharmaceutical companies seem to become more 
focused and efficient in their area of expertise. Excursions in new therapy areas, such as orphan 
diseases, show a higher average gross margin (85.9%) compared to non-orphan drug companies (74.8%) 
but also need a double R&D investment (as a percentage of sales; 33.9% vs 17.3% of sales) (Morel, Popa, 
& Simoens, 2013). So profitability for an investor, measured in return on equity (ROE), is 33% lower in 
the field of orphan drug companies, compared to non-orphan drug companies (Morel et al., 2013). In 
the last century a lower profit may not have stopped pharmaceutical companies from investing, because 
“[…] that the mission of Merck and other pharmaceutical companies at the time was to take care of 
patients and profits would follow” reported by Prof. J. Hay from the University of Southern California 
(Bobkoff, 2016). However, today many shareholders are capable of putting pressure on the company´s 
management and influence the strategic orientation. It is in the shareholder´s interest since wrong 
decisions in new product development efforts strongly influence the market valuations and news about 
a candidate’s failure can create high financial losses on the market (Sharma & Lacey, 2004). 
3.2.1 The Radiopharmaceutical Market Potential and Investors Interest 
Market research institutes estimate the global nuclear/radiopharmaceutical market to be around $ 4.67 
billion, rising to $ 7.27 billion in 2021 with a share gain for the therapeutic radioisotopes (Markets and 
Markets, 2016). Others see the market to rise to $ 8.2 billion in 2022 (Allied Market Research, 2014) or 
$ 8.5 billion in 2026 (Future Market Insights, 2017). Outstanding are the expectations by the 
Radiopharmaceutical company Advanced Accelerator Applications (AAA), which expects a global 
radiopharmaceutical market of $ 25 billion by 2030, with an annual growth rate of 7% for diagnostic RPs 
and 27% for therapeutic RPs. Their main argument: therapeutic products, now 10% of the global nuclear 
medicine market, will represent 60% of the total market in 2030 and have a much higher reimbursement 
rate of up to 100 times the costs of diagnostic products (Advanced Accelerator Applications SA, 2016). 
However, the market is very fragmented: SPECT (SPECT/CT) procedures still lead in the cardiology 
segment, PET (PET/CT) procedure dominate the oncology segment. The growth of the market is 
expected to be driven by increased use of SPECT (SPECT/CT), PET (PET/CT), advances in radiotracers and 
targeted cancer treatment (Markets and Markets, 2016). So the market could to be attractive for 
newcomers, but new companies may not be able to enter the market quickly since the development, 
handling and production of RPs is somewhat special and challenging. 
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The Case of Somatostatin Analogues Imaging and Therapy: 
Since newer RPs tend to have a more specific targeting, the markets may be significantly smaller than 
products in the conventional pharmaceutical market. A good example are the imaging somatostatin 
analogues Octreotide (OctreoScan, Mallinckrodt) and DOTA- TOC/NOC/TATE (NETSPOT® (U.S.A) or 
SomaKit TOC™ (European Union)), which are currently labelled with Indium-111, Gallium-68 or Fluor-
18. But the same compounds can also be used in a theranostic approach and linked to β– 
radionuclides (e.g. Lutetium-177, Yttrium-90) to treat patients (DOTA- TOC/NOC/TATE (Lutathera®)) 
(see Chapter 2.2.5).  
The evaluation of the imaging market showed that the return on investment of 111In-Octreotide is 
very low compared to an average product in the conventional pharmaceutical market. Mallinckrodt 
Inc. introduced 111In Octreotide in 1994 with the indication to use the imaging agent for an adjunct 
in the diagnosis and management of receptor-bearing gastroenteropancreatic neuroendocrine (GEP) 
tumours and carcinoid tumours (Mallinckrodt Inc., 1994). The very straightforward market potential 
calculation for 111In- Octreotide (without taking into account the costs of the radionuclide and in-
house preparation costs) at the time of market entry was approximately $ 18.8 to 37.6 million 
(depending on the incidence rate) in the U.S.A and Western Europe1. With a participated price drop 
of ~ 50% since the introduction of the product in 1994 (Schreiter et al., 2012), the market has shrunk 
even further. For the new product DOTATATE the current mean pharmaceutical price for NETSPOT® 
in the U.S. is around $ 3.550, without taking into account any discounts. The same product is 
registered in the EU under the name SomaKit TOC™, but no retail prices are available and due to the 
different market structure a much lower price can be anticipated. The cost for Lutathera® 
intravenous solution (370 MBq/mL) is around $49,598 for the supply of 1 solution in the U.S., prices 
in Europe are commercial in confidence (National Institute for Health and Care Excellence, 2017). 
The indication for NETSPOT®/ SomaKit TOC™ is very similar to OctreoScan but since the incidence of 
NET has risen over the years and the diagnostic agent is also more often used in the tandem 
theranostic approach we can anticipate a higher sales volume. A current limitation is the low number 
of PET scanners in Europe and the U.S.A. (Europe: SPECT 3,309 vs PET 724; U.S.A.: SPECT 14,825 vs 
PET ~2,380) (Eurostat, 2014; Imaging Technology News, 2013; IMV, 2015). Troublesome could also 
be that many countries already have fixed reimbursement rates for the scintigraphy with 111In-
Octreotide or even radio-targeted therapy, which could limit pricing negotiations. With the currently 
approved indication Lutathera® will apply to a very narrow patient population, but with an expected 
higher price compared to diagnostic DOTATATE products.  
Due to the low market potential, compared to other drugs in the oncological business, big 
pharmaceutical companies have decreasing interest in their molecular imaging portfolio. Merck 
discontinued their joint venture with DuPont on their radiopharmaceuticals division in 1997, since it 
was not a significant contributor to their earnings growth objectives (Diagnostig Imaging, 1998). Bristol-
Myers Squibb bought DuPont in 2001, but sold the business to a New York City investment firm already 
in 2008. The investment firm founded Lantheus Medical Imaging in March 2018. Another smaller 
radiopharmaceutical company Avid Radiopharmaceutical founded in 2004 as a spinoff from the 
University of Philadelphia, received venture capital from Pfizer and Lilly in 2006 and was fully acquired 
                                                          
1 Calculation Input: Incidence rate of GEP-NETs as stated in the literature 2.5 to 5/100,000 population p.a. (Massironi et al., 
2008)); Estimated average price for the U.S.A and Western Europe of $ 1,600/ dose OctreoScan ($ 1,850 for 6.6 mCi; $ 1,500 
for 3.3 mCi ) (The Medicare Services Advisory Committee, 1999); Population (1996): 269 million in the USA, 181 million in 
Western Europe; Assumption that every patient just needs one scan as SPECT has higher radiation doses and a PRRT 
approach was not often used in 90s; Higher Values in case OctreoScan is used for differential diagnosis outside of indication. 
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by Eli Lilly in 2010. Bayer Healthcare AG sold their PET tracer assets to Piramal Imaging SA in April 2012, 
focusing solely on RPs with therapeutic applications such as Xofgio (Radium 223 Dichloride). Today, 
several SMEs are participating in the development of diagnostic and therapeutic RPs and even some 
bigger pharmaceutical companies have shown interest in the development of new therapeutic RPs such 
as PSMA (U.S. National Library of Medicine, 2018). 
3.3 Barriers and Challenges associated with Research and Development 
(R&D): 
3.3.1 High Development Costs and Low Chances of Success – Conventional Drugs 
When talking about market potential we also have to take the costs of development into account, which 
are said to be very high in the pharmaceutical industry. R&D expenses are all costs associated with 
research, development and final regulatory approval (Mestre-Ferrandiz, Sussex, & Towse, 2012). There 
have been several publications on the costs of drug development (see Table 21), systematic reviews, 
publications by pharmaceutical associations, and calculations by consultancies. Notable is the 
differentiation between the actual R&D costs directly spent for a successful candidate  – “cash or out-
of-pocket costs” and “capitalised costs”, which are the full out-of-pocket costs capitalised over a specific 
period (mostly until the date of marketing approval) (DiMasi et al., 2016; S. Morgan, Grootendorst, 
Lexchin, Cunningham, & Greyson, 2011). Studies estimate R&D costs for the successful registration of a 
new molecular entity (NME) from $ 965 million ($ 860 million in 2000 USD) to $ 2.2 billion (C. P. Adams 
& Brantner, 2006; DiMasi et al., 2016, 2003; Gilbert, 2003; Mestre-Ferrandiz et al., 2012; O´Hagan & 
Farkas, 2009; Paul et al., 2010). However, these numbers should be evaluated with caution since there 
are significant differences in the study designs, the quantity of analysed drug candidates, the area of 
indication and the limited access to private databases. Furthermore, the R&D process is susceptible to 
changes in science, technology and regulatory requirements (U.S. Congress, 1993) and thus it is tough 
to compare the available data.  
The most active research group is from the Tufts Center for the study of drug development at the Tufts 
University in Boston, USA. Joseph DiMasi and colleagues have continuously published the latest R&D 
expenditures and the change of costs and success rates in the development process of a new molecular 
drug. Their calculation of the overall clinical approval rate, estimated distribution of failures and total 
costs in each phase is based on data from the top fifty pharmaceutical companies (DiMasi et al., 2016). 
Since their methodological approach has not changed over the years, they believe that the data is 
comparable and this data indicates that costs are rising and the success rate is decreasing. In the 1991 
publication (data from new drugs between 1970 and 1982) mean R&D out-of-pocket costs per 
successful NME were $ 114 million in 1987 USD ($ 245 million in 2017 USD). In 2003 (data from new 
drugs between 1983 to 1994) these costs already increased to $ 403 million in 2000 Dollars ($ 572 million 
in 2017 Dollars), and in the latest publication from 2016 (data from new drugs between 1990–2010) the 
mean R&D out-of-pocket costs have risen to $ 1.395 million in 2013 Dollars ($ 1.464 million in 2017 USD) 
(DiMasi et al., 2016, 2003). 
Other researchers (see Table 21) estimate different out-of-pocket costs, ranging from $ 235 million to $ 
1.395 million (both in 2017 USD) and a success rate of 9.0% to 21.5%. The wide variety of costs results 
from different indications, different economic analyses and - models (C. P. Adams & Brantner, 2010; 
DiMasi et al., 2016; Young & Surrusco, 2001). Mestre- Ferrandiz and colleagues from the Office of Health 
Economics in London analysed unpublished data (via confidential surveys) for new drugs in any phase 
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of clinical development from 1997 to 2002 and calculated out-of-pocket costs of $ 977 million (in 2017 
USD) (Mestre-Ferrandiz et al., 2012). 
 
It is liable to assume that capitalised costs are higher than out-of-pocket costs, ranging from $ 458 
million (Young & Surrusco, 2001) to more than $ 2 billion, depending on the indication area and the data 
used (C. P. Adams & Brantner, 2006; DiMasi et al., 2016; Mayerhoefer et al., 2013; Paul et al., 2010). 
Not all studies calculated the out-of-pocket costs (Gilbert, 2003; O´Hagan & Farkas, 2009), some just 
focused on capitalised costs. Gilbert (2003) for example identified declining productivity and increased 
phase III costs an estimated total cost of $ 2.259 billion, including launch costs of $ 250 million. The 
study from O´Hagan & Farkas (2009) estimated total costs of $ 2.2 billion, but it is difficult to validate 
their results since they have not specified their methodological approach or given access to their data 
set. Another research group created a specific model with industry-appropriate R&D assumptions for 
success rate, cycle time and costs. They calculated capitalised costs of $ 1.778 billion per NME, excluding 
costs for exploratory discovery research, post-launch expenses and overhead (Paul et al., 2010). Finally, 
Dimasi et al. (2016) calculated capitalised costs of $ 2.558 billion. 
A very new study from Prasad & Mailankody (2017) has a slightly different approach. They have used 
the publicly accessible data from SEK-10 fillings from pharmaceutical manufacturers which had, at the 
time of the FDA approval, no other drugs on the market. The reported R&D costs are therefore directly 
linked to the single successful drug candidate, plus the failing “sibling- candidates”. The results show 
median costs of development of $ 648 million (in 2017 USD) and $ 757.4 million in capitalised costs 
(discount rate of 7% p.a.). A few interesting details within this study: drugs being authorised via the 
“accelerated approval process” cost less than those in the regular approval process (median $ 328.1 
million vs $ 817.6 million; p = .08). Drugs being classified as novel drugs (New Molecular Entity; not 
previously approved by the FDA) were higher than next-in-class drugs (variation of previously existing 
product) (median, $899.2 million vs $473.3 million; p = .047). Drugs being developed by the company 
itself had a significantly higher R&D spending than drugs acquired by a third party (median $899.2million 
vs $ 328.1million; p= .02) (Prasad & Mailankody, 2017). 
Unfortunately, all published studies have a retrospective study design and almost all data cannot be 
validated due to confidentiality (C. P. Adams & Brantner, 2006, 2010; DiMasi & Grabowski, 2007; DiMasi 
 
 
    
Out-of-pocket costs (in million 
Dollar 2017 $) 
 
Study Period Primary data Study Design 
Out-of-
pocket 
Costs* 
Pre-clinical Clinical Total 
Success rate 
estimate 
(in %) 
(Young & Surrusco, 2001) 1990-2000 published data Retrospective 166 n.a. n.a. 235 9.0 % 
(DiMasi et al., 2003) 1983-1994 Confidential surveys Retrospective 224 169 397 567 21.5 % 
(C. P. Adams & Brantner, 
2006) 
1989-2002 private database Retrospective 459 186 436 624 11.0 % 
(DiMasi & Grabowski, 2007) 1990-2003 Confidential surveys Retrospective 525 247 451 698 21.5 % 
(C. P. Adams & Brantner, 
2010) 
1989-2001 private database Retrospective n.a. n.a. 577 n.a. 11.0 % 
(Paul et al., 2010) 1995-2010 Confidential surveys Retrospective 897 323 682 1.006 11.7 % 
(Mestre-Ferrandiz et al., 
2012) 
1997-2002 Confidential surveys Retrospective 899 82 897 977 10.7 % 
(DiMasi et al., 2016) 1995-2013 Confidential surveys Retrospective 1.395 430 965 1,395 11.83 % 
(Prasad & Mailankody, 
2017) 
2006-2015 SEC10-K filings Retrospective 648 n.a. n.a. n.a. n.a. 
*average, no capitalised costs        
Table 21. Overview of published literature analysing costs associated with the development of new pharmaceutical drugs (New 
Molecular Entities -NMEs).  
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et al., 2016, 2003; Gilbert, 2003; Mestre-Ferrandiz et al., 2012; O´Hagan & Farkas, 2009; Paul et al., 
2010; Prasad & Mailankody, 2017).  
In line with the rising costs and challenging success 
rate is the reduction of R&D returns over time, which 
were reduced from 10.1% in 2010 to 3.7% in 2016 
(Deloitte Centre for Health Solutions, 2016). A 
consulting group linked the R&D spending in the 
period of 1998 to 2004 of the 25 leading 
pharmaceutical companies to the successfully 
launched NMEs (peak sales per year exceeded $ 600 
million) in the year 2002-2008 (see Figure 3). The figure 
shows big differences in total R&D expenditures and 
the number of successful introduced drugs (Tollman et 
al., 2011).  
In Europe, we can look at the numbers published by the 
European Federation of Pharmaceutical Industries and Associations (EFPIA). They have reported that 
their member´s annual R&D expenditures increased from 7.766 million in 1990 to 31.500 million in 2015 
(European Federation of Pharmaceutical Industries and Associates, 2017). The US counterpart PhRMA 
published a likely rise in R&D spending from $ 8,420 million in 1990 to $ 58,820 million in 2015 (PhRMA, 
2016). One has to bear in mind that under the US and European law investments are deductible from 
tax, and that research is often supported by government/ taxpayer-funded research institutions or 
grants (Young & Surrusco, 2001). Nevertheless, the data from these lobby groups indicate an increase 
in R&D spending and a constant decline in R&D efficiency. Also Munos (2009) reported that the annual 
number of drugs approved in the USA per billion USD dropped from around ten drugs per one billion 
USD in the 1960s to less than one drug in the years after 2000. The reasons for the decrease in efficiency 
are manifold: the FDA believe that applied sciences have not kept pace with advances in basic science 
and that the current development process works with tools from the last century and have failed to 
introduce new tools for safety and effectiveness measurement (U.S. Department of Health and Human 
Services - Food and Drug Administration, 2004). Others blame regulatory and organisational obstacles 
(Ruffolo, 2006; Weatherall, 1982), organisational challenges (Gassmann & Reepmeyer, 2005), the 
“cautions regulator” problem (Scannell et al., 2012), overestimation of basic research in genomics and 
molecular biology in general (Scannell et al., 2012), and many more. 
3.3.2 High Development Costs and Low Chances of Success – RP Imaging Markers 
The number of studies investigating the R&D expenses in the field of radiopharmaceuticals is very low. 
As there are no publicly available figures, Adrian D. Nunn, an employee of Bracco Research USA Ltd., 
estimated costs for the development for an imaging agent to be around $100 to $150 million in 2006 
Dollar ($ 121- $ 181 million in 2017 USD). This number is not specifically for RPs, but an evaluation for 
any imaging agent used in CT, MRI, Ultrasound or molecular imaging. His assumption was accurate in 
the context of a new magnetic resonance imaging agent developed by the company Epix 
Pharmaceuticals in the U.S.A (Epix Pharmaceuticals Inc., 2004; Nunn, 2006). For radiopharmaceuticals 
there is no in-depth study or calculation available, except for some estimations by Zimmermann (2008, 
2012). In the 2008 paper he guessed that total R&D costs (in a ten year research period) should be 
around 22 to 30 million € ($ 26 to 35 million in 2017 USD) for a diagnostic - and 44 to 69 million € ($ 52 
to 82 million in 2017 USD) for a therapeutic compound. He specified that for the therapeutic compound 
Figure 14 compares the R&D expenditures of the leading 
25 pharmaceutical companies from 1998 to 2004 and the 
number of successful new molecular entities (NME) in the 
year 2002 to 2008. Visible is that some companies achieve 
a high number of NMEs with substantial less R&D 
investment (Tollman et al., 2011). 
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an existing vector has been used and thus substantial costs for preclinical and Phase III R&D could be 
saved. The expenses break down: 500 k€ ($ 595.000 in 2017 US) for formulation and manufacturing 
(without equipment), 900k€ ($ 1.07 million in 2017 US) for Regulatory Affairs and the rest for clinical 
testing (Zimmermann, 2008). In the 2012 publication, he focused on therapeutic RPs and estimated total 
development costs of less than € 100 million ($ 119 million in 2017 USD) for a new therapeutic RP being 
registered worldwide (Zimmermann, 2012a). Unfortunately, he did not specify whether these expenses 
are out-of-pocket- or capitalise costs. 
The Case of DOTATATE - R&D Costs and Timeline for Lutathera: 
Lutathera is a somatostatin analogue which is linked to Lutetium-177 and is used for therapy of 
patients with inoperable progressive midgut carcinoid. The vector is octreotate, a synthetic 
somatostatin analogue initially developed to treat symptoms in patients with neuroendocrine 
tumours, linked to a DOTA complex to allow dynamic marking with a radioisotope (DOTA-
octreotate also known as DOTATATE). In 2012 Advanced Accelerator Applications (AAA) started 
their commercial development process on the existing preclinical results and Phase II studies 
from Sandoz and other, mainly academic institutions. A phase III study was initiated in 
September 2012 and lasted until mid-January 2016, enrolling 229 patients in 41 sites (27 sites in 
Europe and 14 in the United States). Based on the public available company reports and SEK-10 
documents the expenses for R&D were rising from 7.2 million € ($ 8.5 million in 2017 USD) in 
2013, to 10.4 million € ($ 12.4 million in 2017 USD) in 2014, 14.7 million € ($ 17.4 million in 2017 
USD) in 2015 and 13.8 million € ($ 16.4 million in 2017 USD) in 2016. In total € 46.1 million ($ 
54.7 million in 2017 USD), which have been predominantly related to the Phase III trial of 
Lutathera as stated by AAA in their 2016 report (Advanced Accelerator Applications S.A., 2016). 
Some of the 2013-2016 R&D expenses may also be related to the development of the imaging 
agent NETSPOT, and the new therapeutic and diagnostic candidates such as 177Lu-PSMA-R2 and 
68Ga-PSMA-R2, and 177Lu-NeoBOMB1 and 68Ga-NeoBOMB1. From a time perspective, one can 
see that a single Phase III study already needed five years till final publication. 
As already mentioned in the chapter market 
potential (chapter 3.2), R&D costs are very 
much dependant on the success rate of new 
molecule entities in the development 
process. In the conventional drug discovery 
process the success rate, defined as the 
cumulative probability of success from 
preclinical to phase III, ranges from 12.9% 
(Paul et al., 2010) to 34% (C. P. Adams & 
Brantner, 2006). Since RPs are commonly 
considered to be less toxic than conventional drugs, the success rates are somewhat higher (see Table 
22). Only ~ 20% of the molecules drop out in the toxicological phase, and chances of success in the first 
human trial are about 30% (Zimmermann, 2008).  
When the diagnostic compounds show enough sensitivity and specificity in Phase I/II, “Phase III is 
usually only a confirmation of the potential of the drug and has a very high level of success.” 
(Zimmermann, 2008).  
Preclinical Phase 
(Proof of Concept)
Toxicology Clinical Phase I/II Clinical Phase III
Estimated chances of 
success
40% 80% 33% 80%
Number of molecules
1 12 5 4 1
Estimated chances of 
success
33% 80% 33%2 50%2
Number of molecules1 24 8 6 2
D
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(1) Number of molecules investigated to reach a minimum number of molecules for the next phase
(2) Assumption that imaging biomarker is developed in parallel. 
Table 22: Estimated minimum  number of molecules investigated to 
achieve marketing authorization for at least one diagnostic or one 
therapeutic radiopharmaceutical (Zimmermann, 2008) 
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3.4 Intellectual Property Right Issues  
Another hurdle that complicates the introduction of new RPs according to the literature is the issue of 
Intellectual Property Rights (IPRs). The pharmaceutical- and chemical industry is highly dependent on 
IPRs and patent applications since the production of their products does not rely on complex and 
expensive manufacturing infrastructure like in other industries. Their products can easily be replicated 
by a 3rd party, without investing much in the production facilities (Lehman, 2003). Pharmaceutical 
companies therefore secure the investment and block potential competitors via IPRs on potential new 
chemical entities (NMEs) years ahead of the final product. However, this early application has a negative 
effect by significantly shortening the period of market exclusivity since the development of these 
products is time consuming (Lehman, 2003). 
Protecting the product and thus the investment via patents is a definite advantage for the company. On 
the one hand, competitors are blocked for a specific period to introduce a generic product and patent 
holders can also set a higher-than-competitive price over the patent period. However, even IPRs and 
other incentives such as direct R&D tax incentives, non-profit tax exemptions for research institutions, 
public financing of R&D activity are in place (Lichtenberg & Philipson, 2002), R&D efforts in medicines 
for tropical diseases (in developing countries) and for rare diseases (also known as orphan disease) are 
minor (H. Grabowski, 2002). From an industry perspective, the investment may not be economically 
feasible since R&D expenditures on rare diseases are also very high (see Chapter 3.3.1) and return of 
investment is low. The FDA in the U.S.A. and EMA in Europe have therefore, among other things, 
introduced another incentive: additional time of market exclusivity for the drug´s market application 
holder (The Congress of the United States of America, 1997; The European Parliament and the Council 
of the European Union, 2000). In the USA these exclusivity is granted for drugs treating diseases or 
conditions affecting fewer than 200,000 people (or more than 200,000 and no hope of recovering costs) 
over a period of seven years (CDER Small Business and Industry Assistance & Issues, 2015). In Europe, 
the European Commission grants market exclusivity for orphan drugs for maximum ten years (reduction 
to six years under certain conditions) for diseases or conditions with a prevalence of fewer than five in 
10,000 people. The European Commission (EC) and the member states declare that they will not accept, 
grant and approve a marketing application for the same therapeutic indication, in respect of a similar 
medicinal product (The European Parliament and the Council of the European Union, 2000).  
In the US the Orphan Drug Act is regarded as a domestic success story (M. E. Haffner, 1998) and also in 
Europe the positive tenor predominate: “The response in the EU has far exceeded initial expectations, 
more than 450 applications for orphan designation have been submitted in the period between April 
2000 and April 2005. Of those, more than 260 have been designated (April 2005), and 22 have gone on 
to receive a marketing authorisation” (European Medicines Agency, 2006). Of course, this exclusivity 
also has some disadvantages: high drug prices and subsequently a burden for health insurances with 
Definition of a patent:  
“A patent is an exclusive right to exploit (make, use, sell, or import) an invention over a limited 
period (20 years from filing) within the country where the application is made. Patents are granted 
for inventions which are novel, inventive (non-obvious) and have an industrial application (useful). 
There are other types of exclusive rights over intangible assets, notably copyright, design protection 
and trademarks, but patents provide broader protection that extends beyond the specific expression 
of an invention to the invention itself. [..].” (Organisation for Economic Cooperation and 
Development (OECD), 2004). 
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the consequences that the access for patients gets restricted. This is not satisfactory for all parties, and 
so it was suggested that incentives go beyond market exclusivity and also integrate patient access and 
reimbursement (Drermond, Wilson, Kanavos, Ubel, & Rovira, 2007). 
3.4.1 Academic Institutions and Intellectual Property Rights  
A look at the history of Nuclear Medicine shows that especially universities- and other public (and few 
private) research centres all over the world have set the groundwork for new imaging products, tests 
and radiopharmaceuticals. In the past there was also a strong link between governmental investment 
and the development of nuclear medicine technology, with public investments exceeding the financial 
support of the industry (Committee on State of the Science of Nuclear Medicine, 2007). In the onset of 
nuclear medicine activities in the 1950s to 1960s mainly long-lived radiopharmaceuticals have been 
produced in primarily state-controlled facilities, further products were then supported by big enterprise 
companies (Feld, de Roo, & Schicha, 2003). Especially medical imaging instrument companies knew that 
the RP is as important as the equipment technology itself. As a result, big medical technology companies 
have acquired or partnered with RP producing companies and invested in R&D of new RPs, until 
recently. Now the big medical imaging equipment companies (such as GE Healthcare or Siemens) and 
some well-known companies in the radiopharmaceutical business (e.g. Mallinckrodt) downsized, 
outsourced, sold or discontinued their R&D projects for radiopharmaceuticals.  
One could say that the nuclear medicine business was kept alive by the academic sector, who continued 
their research in the oncology and neurology area and extended their knowledge in the development 
and testing of RPs. However, when it comes to setting the research objectives, the goals of academics 
and industry are very different. Academic, medical scientists are encouraged to research new scientific 
findings, conduct experiments, analyse their results and timely publish those in peer-reviewed scientific 
or medical journals. The value for the scientist is manifold and desirable: 
“For individual investigators, the publication is a way of receiving intellectual credit and 
recognition from one’s peers (and perhaps the broader public) for the genesis of new knowledge 
and the prospect of its conversion into beneficial goods and services. The publication also 
enhances a researcher’s job prospects, ability to be promoted or gain tenure, and prospects for 
research support.” (Committee on Responsibilities of Authorship in the Biological Sciences, 
2003). 
However, even if a quick publication of research findings may be advantageous in some cases (e.g. 
growth in interest from investors, the effect on share prices, recognition, et cetera) the private “for-
profit” investors generally do not have the desire to quickly publish research findings since the 
publication of these valuable data may negatively affect the development and IPRs (Committee on 
Responsibilities of Authorship in the Biological Sciences, 2003). Current evidence already indicates a 
decrease in unrestricted sharing of publication-related data, which could be based on a rise in research 
collaborations between the pharmaceutical industry, academia and other third-party research 
institutes. (Committee on Responsibilities of Authorship in the Biological Sciences, 2003). For many big 
pharmaceutical companies (GSK, Merck, Pfizer, Bayer et cetera), as well as companies in the imaging 
sector (Philips, Siemens, GE Healthcare, etc.), these partnerships are great to get access to new ideas, 
skills, technologies (Schuhmacher, Gassmann, & Hinder, 2016). In detail, the industry gains access to 
new research, new product development, obtain new patents, solve technical problems and can 
additionally tighten the relationship with the Universities (Lee, 1996). From an university perspective 
this partnership can also be beneficial as they can obtain further funds for research assistance, lab 
equipment and test their theory empirically (Lee, 1996). Moreover, universities recognised that they 
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could benefit by securing their innovations through patents and licensing, especially in the Anglo-Saxon 
region (Mowery & Sampat, 2005). In the USA the government introduced the Bayh-Dole Act of 1980 
and encouraged universities and other public funded non-commercial research institutions to protect 
their inventions, and get economic returns in case it was federally funded (Committee on 
Responsibilities of Authorship in the Biological Sciences, 2003).  
The Case of Somatostatin Imaging and DOTATATE: 
The groundwork for the successful use of somatostatin analogues in imaging was to a certain extent 
laid by Jean Claude Reubi, a pathologist emeritus from the University of Berne (Switzerland). In 1987 
Reubi published a study showing the somatostatin receptor density in neuroendocrine tumours and 
suggested that the chronically applied somatostatin receptors analogues, used to treat the 
symptoms in NET disease, are likely to bind to the tumour itself (Reubi, 1987). At the time of the 
discovery, J.C. Reubi was employed at the Sandoz Research Institute in Berne and the IPRs thus 
belonged to Sandoz Ltd. 
Today, many of the interesting RPs or at least molecular pathways have been developed or co-
developed by academic institutions or other non-for-profit research institution, which thereby gain 
rights on intellectual property and royalties for the cession of exclusive commercial rights (Schelbert, 
2011). An excellent example is Pittsburgh Compound B, an RP developed by the University of 
Pittsburgh to image amyloid plaques in the brain of Alzheimer patients. Pittsburgh Compound B 
never got marketed, but it was the basis of a new Fluor based Amyloid tracer receiving marketing 
authorisation in 2014.  
 
Academic scientists need to decide in an early stage, if they want to share the findings with the 
scientific community, which may stop further industrial supported development. Or decide whether 
they want to find a potential investor to continue development with the intention to receive a 
marketing authorisation in the end. The second strategy would lead to broad use within the nuclear 
medicine community and access of patients (Zimmermann, 2008).  
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3.5 Experimental RPs are not Evolving  
The pharmaceutical industry is challenged by a very complex, costly and time-consuming R&D process 
(DiMasi, Seibring, & Lasagna, 1994; Hughes, Rees, Kalindjian, & Philpott, 2011; Janero, 2012). Overall 
costs are rising substantially with every drug failure that´s why the industry is feverish looking for new 
tools to separate the possible failure candidates from the best drug targets in early stage (DiMasi, 2001; 
Hughes et al., 2011). It has been mentioned that 72% of overall spending is attributed to failing 
candidates, mainly because there is poor predictability of preclinical models and insufficient learning 
before entering Phase III (Bergström, Grahnén, & Langström, 2003). 
With vigorous exploration of new biological processes and the influence of gene modification on the 
molecular level (Phelps, 2000b) molecular imaging (PET and SPECT) has the potential to visualize the 
distribution of potential drugs and evaluate their effectiveness on disease tissue and organ systems in 
early phases (Bergström et al., 2003). PET or SPECT radionuclides linked to a potential biological target 
in very low levels (100 μg) enable the exploration of in-vivo pharmacokinetic (PK) and 
pharmacodynamics (PD) properties in Phase O and at the same time a very small chance of adverse 
events (Bergström et al., 2003; Burt et al., 2016). These studies are commonly called micro-dosing trails 
(also named Phase- O trails) and there is an excellent hope that promising drug candidates can be 
detected before the expensive, time- consuming pre-clinical trials start (U.S. Department of Health and 
Human Services - Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2006).  
Regulatory authorities in Europe and the USA have supported this initiative and drafted clear regulations 
for such exploratory clinical trials (European Medicines Agency, 2009; U.S. Department of Health and 
Human Services - Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2006). 
For example, EMA has described two different approaches to micro-dosing studies: 
“The first approach would involve not more than a total dose of 100 μg that can be divided 
among up to five doses in any subject. This could be useful to investigate target receptor binding 
or tissue distribution in a PET study. A second use could be to assess pharmacokinetics with or 
without the use of an isotopically labelled agent. These uses could be supported by an extended 
single dose toxicity study in one species, usually rodent, by the clinical route of administration, 
together with the appropriate characterisation of pharmacology.  
The second microdose approach is one that involves < five administrations of a maximum of 100 
μg per administration (a total of 500 μg per subject). This can be useful for similar applications 
as for the first microdose approach described above, but with less active PET ligands. This 
approach could be supported by a seven-day toxicity study in one species, usually rodent, by the 
clinical route of administration, together with SAR assessment of the genotoxic potential of the 
unlabelled compound and appropriate characterisation of pharmacology.” (European Medicines 
Agency, 2009) 
There are commonly three main techniques to assess PD and PK in (pre-) clinical trials: liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), positron emission tomography (PET), and 
accelerator mass spectrometry (AMS) (see Table 23).  
 
 
 
AMS PET LC-MS/MS 
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Sensitivity    
Sample Types 
Mostly plasma but any sample 
may be used (e.g. biopsies, 
bronchial lavage, VSF, urine, 
faeces, blister samples 
Real-time imaging, dynamic, 
contemporaneous 
information from multiple 
tissues/ targets 
Mostly plasma but any sample may 
be used (e.g. biopsies, bronchial 
lavage, VSF, urine, faeces, blister 
samples 
Sample frequency/ 
duration 6-10h duration limited 
Continuous/ dynamic; 
duration limited by 
radioisotope half-life 
6-10h duration limited 
Plasma sample volume Typically 50 μl, but as little as 
two μl 
n/a; continuous/ dynamic 
"counting" of drug molecules 
per unit space 
Typically 100 μl- 2ml, but as little 
as 25 μl 
Radiolabelling 14C 11C, 13N, 15O, 18F, and 124I None 
Radiation exposure Very low low none 
Parent compound and 
metabolites 
Discriminating parent compound 
from metabolites possible 
No discrimination 
Discriminating parent compound 
from metabolites possible 
Administration PO and IV IV PO and IV 
Site of analysis Can be outsourced On-site only Can be outsourced 
Costs per Study ~ $ 400-600k ~ $ 500-700k $ 80-140k  
Availability 
Limited availability; ~six facilities 
dedicated to biomedical 
research worldwide 
Available in specialised 
centres (e.g., tertiary- care 
facilities) 
Commonly available 
AMS, accelerator mass spectrometry; PET, positron emission tomography, LC-MS/MS, liquid chromatography-tandem mass 
spectrometry; CSF, cerebrospinal fluid; N/A, not applicable 
Table 23 Comparison of the three most commonly used techniques for pharmacodynamics and pharmacokinetic assessment 
(original table from M. Bauer et al., 2008; adapted by Burt et al., 2016) 
All methods have some advantages and disadvantages in terms of their sensitivity, sample frequency, 
availability and costs per study (Bauer et al., 2008; Svendsen et al., 2015; Yamane et al., 2013). AMS is 
seen to be the most sensitive method, compared to PET; but cannot sample the distribution and PK in 
all organs over time (Bauer et al., 2008). PET has the ability to identify very important drug properties 
at an early stage such as: (1) exposure at the target site to measure the pharmacological effect over a 
certain period, (2) efficient binding to the pharmacological target (binding kinetics- desirable and 
unwanted binding) and (3) expression of primary pharmacology at the site of action (sufficient levels) 
(Morgan et al., 2012). 
To date, many of the newer biomedical drugs already have a fitting companion diagnostic assay or 
imaging diagnostic agent co-developed with success (Naylor & Cole, 2010; Van Heerter, Scarimbolo, 
Ford, Berdougo, & Neal, 2015), which reduced the clinical trial costs due to picking the right patients 
(fewer, but the right patients) for Phase III trials and speed up the development process (Agarwal, 
Ressler, & Snyder, 2015). Unfortunately, 97% of all FDA approved companion diagnostics (counting 40 
in September 2017) are in-vitro diagnostic devices/assays (total 39) with currently only one imaging 
companion diagnostic (Ferriscan) registered (U.S. Food and Drug Administration, 2017c). Those in-vitro 
assays typically have some limitations in terms of locating the drug target, showing overall distribution, 
which in the end narrows the scope and sensitivity (Van Heerter et al., 2015). In contrast, PET is able to 
provide a more objective assessment, but so far micro-dosing studies with RPs are infrequently used by 
the pharmaceutical industry. Svendsen et al. (2015) showed in his recent review that only 33 studies 
have used RP micro-dosing in the drug development process. PET was generally used less often in 
pharmacokinetic -, never in biodistribution -, but most often in distribution studies and some occasions 
in combination with other methods. Even if imaging biomarkers are potentially better suited to assess 
the phenotype of the disease and to offer continuous structural and functional assessment of the 
therapy (planning and monitoring), their clinical evaluation, in regard to primary effectiveness 
measurement, is extensive (M. Bauer et al., 2008; Burt et al., 2016; Katz, 2004; Pien, Fischman, Thrall, 
Sorensen, et al., 2005; Willmann, Bruggen, & Dinkelborg, 2008). This assessment (the correlation 
between the imaging biomarker and the clinical outcome) requires large, costly and time-consuming 
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trials, which are currently rarely performed by the pharmaceutical industry (Willmann et al., 2008). 
Consequently, RPs used in the development process have no clinical role after drug approval (Nunn, 
2007a). However, this could change quickly if the imaging- and biomarker community can verify that 
their data is robust, quantitative and easy to implement across multiple centres (Willmann et al., 2008). 
This is achieved by having the imaging biomarkers validated. 
3.5.1 Imaging Markers are not Validated  
In the past, especially academic curiosity was a driver for academic and other non-profit research 
organisations research purposes. That is why we have some beneficial radiolabelled compounds for 
diagnostic and therapeutic today, but few of them have been developed due to a clear clinical need 
(Mather, 1998).   
“A good example is the use of radiolabelled monoclonal antibodies for tumour imaging. Over the 
last fifteen years, an enormous amount of work has gone into development programmes based 
on these materials, and this has resulted in radiopharmaceuticals which can effectively image 
cancer with sensitivities and specificities comparable or superior to other imaging modalities. 
But, however successful the particular imaging technique developed, unless it influences the 
management of a particular group of patients, it will not find routine application in clinical 
practice, and so far at least, this seems to be the situation for these new 
radiopharmaceuticals.”(Mather, 1998). 
Molecular imaging biomarkers, as well as therapeutic RPs, need to be extensively validated on their 
pathophysiological effects and clinical endpoints, otherwise they will not be successfully implemented 
in clinical routine and/ or the personalised medicine approach. So far, regulatory agencies have 
demanded evidence that shows benefits in “hard endpoints”, which has been a big challenge for the 
applicants. But their perspective has changed partially and the FDA now permits applicants to use 
surrogate endpoints for the approval of a new drug product, “if well-controlled clinical trials establish 
that the surrogate endpoint is reasonably likely to predict a clinical benefit” (U.S. Food and Drug 
Administration, 2017a). Also EMA, in their adaptive pathways approach, allows drug applicants to use 
surrogate endpoints for risk assessment in their marketing authorisation, if they can predict important 
clinical outcomes (European Medicines Agency, 2017a). This move also reflects the industry´s pipeline 
problem and authorities, as well as the industry, hope that this adaption can cut development times for 
new therapeutic drugs and make the R&D process more efficient. 
Before the introduction of this regulation, some drugs had already been approved based on their effects 
on surrogate markers such as blood pressure, tumour size, serum cholesterol, and intra-ocular pressure 
(Katz, 2004). However, so far the FDA and EMA have hardly accepted any imaging biomarker to be used 
as validated imaging-based surrogate endpoint (Willmann et al., 2008). Many biomarkers quantitatively 
correlate with disease progression but have no clinically meaningful endpoint. They are not validated in 
showing a change in mortality, morbidity, quality of life and/or predicting the effect of the therapy (Katz, 
2004; Temple, 1999). For regulatory agencies, surrogate endpoints can only be accepted if the clinical 
outcome (symptomatic or structural effects) cannot be practically achieved in “conventional” clinical 
trials (Katz, 2004). Moreover, correlating the surrogate marker with the clinical benefit requires large 
trials, time and capital (Willmann et al., 2008).  
Imaging biomarkers are currently extensively used in oncology for screening, diagnosis and staging; 
treatment targeting; patient stratification, prediction and monitoring of disease progression 
(Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials Board 
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on Health Care Services et al., 2012; O´Connor et al., 2017). An outstanding number of 10,000 studies 
were published between 2004 and 2014 investigating new or established imaging biomarkers, but very 
few of these biomarkers guide clinical decisions (Hayes et al., 2013; Macleod et al., 2014; O´Connor et 
al., 2017; Poste, 2011). This lack of validation reflects, on the one hand, technical barriers such as 
questions regarding accuracy and availability, and secondly difficulties in the biological and clinical 
performance addressing the aspects of clinical outcome measurement (O´Connor et al., 2017).  
Excursus: A Roadmap for the Qualification and Validation of Imaging Biomarkers  
In a recent expert meeting, organised by the Cancer Research UK (CRUK) and the European Organisation for 
Research and Treatment of Cancer (EORTC), many of the top global organisations in cancer research discussed the 
ongoing challenges of imaging biomarker validation/ qualification. They called it “The imaging biomarker 
roadmap” and reviewed the challenges in the validation process for each domain and introduced 
recommendations for accelerating the clinical translation of imaging biomarkers (O´Connor et al., 2017): 
Domain 1 – Discovery: 
The expert panel recommends linking the funding of new imaging biomarker´s studies to a clear statement of how 
to achieve validation and qualification. Extended data on study design, protocols, quality assurance processes and 
standard operating procedures, as well as specifications on used software should be published. This should pave 
the way for the integration of an increased number of studies in meta-analysis, which can support the qualification 
and validation of imaging biomarkers (O´Connor et al., 2017). 
Domain 2 and 3 – Technical validation: 
Guarantee of repeatability (same equipment, software and operators over a short timeframe in in-vivo and/or in-
vitro studies) and reproducibility (different equipment, different software or operators, or at different sites and 
times in in-vivo and/or in-vitro studies) in any geographic region will enhance the qualification process using these 
imaging biomarkers in large multicentre trials. These imaging biomarkers also need to have regulatory and ethical 
approval, be available, feasible, safe and well-tolerated (O´Connor et al., 2017). 
For a quicker technical validation the experts, therefore, recommend having accredited imaging laboratories with 
standardised approaches. The imaging biomarkers precision should be validated in the early phase to guarantee 
technical and biological validity before the start of multicentre reproducibility (O´Connor et al., 2017). 
Domain 2 – Biological and Clinical Validation:  
 “The terms ‘biological validation’, ‘clinical validation’ and ‘clinical utility’ describe the stepwise linking   of 
biomarkers to tumour biology, outcome variables and value in guiding decision-making, respectively.”(O´Connor 
et al., 2017) 
Whereas biological validation only links the imaging biomarker with biological process (European Society of 
Radiology (ESR), 2013), clinical validation and clinical utility can already demonstrate influence on clinical end-
points and shows a net improvement of health outcomes. The generated information is useful for diagnosis, 
treatment, management, or prevention of a disease (Hayes et al., 2013; McShane & Hayes, 2012; O´Connor et al., 
2017). 
Since the validation of an imaging biomarker is normally relatively late in the development phase (Waterton, 
2013), the panel recommends to gather extensive preclinical studies to examine the relationship between the 
imaging biomarkers to pathology and effects of interventions. Pivotal is also the correct choice of the experimental 
model, with early-stage in-vitro models, suitable tumour models and in-vivo studies in the end. All data should be 
stored and essential data should be published to avoid selective reporting and publication bias. (O´Connor et al., 
2017). 
Domains 2 and 3 – Cost Effectiveness: 
Successful translation into clinical routine is only possible if cost-effectiveness is confirmed by demonstrating an 
advantage regarding QALY (Waterton, 2013). This qualification evidence is costly and time- consuming (Gazelle et 
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al., 2005) and thus creates a barrier for investors to fund such research. Consortia of commercial and not-for-profit 
sponsors could possibly overcome this issue, but other challenges such as IPR and business related questions need 
to be addressed explicitly. A simultaneous development of the drug compound and the fitting companion 
diagnostic could be beneficial for healthcare payers and the pharmaceutical industry in the first place, but a failure 
in the translation of the therapy can diminish the market for the companion diagnostic and lead to an even higher 
business risk (O´Connor et al., 2017). 
Consequently, the panel recommends finding new models for funding and regulation, and new imaging biomarker 
should be integrated into studies using existing and validated radiological tests. Larger trials should also evaluate 
the cost-effectiveness of the imaging biomarker versus the other tests (O´Connor et al., 2017) 
Domain 3 – Qualification: 
After steps in domain 2, the imaging biomarker are already validated to a biological process and clinical endpoints. 
But they may have not reach the “clinical utility” level since data from large clinical trials are missing. Qualification 
means that the imaging biomarker is able to show prognostic value in the selecting of patients with specific 
attributes who are likely to benefit most from this therapeutic approach. Generally, the biomarkers are qualified 
for multiple settings such as for specific tumour types, different therapies or different research questions 
(O´Connor et al., 2017; Shankar et al., 2009) 
The panel recommends large multicentre clinical trials, a robust study design with adequate statistical methods 
(Sensitivity, Specificity, Receiver Operating Characteristic (ROC), Negative Predictive Value (NPV), Positive 
Predictive Value (PPV), Hazard Ratios, et cetera). These studies need enough power to demonstrate clinical 
influence on prognostic quality of life, progression-free survival and overall survival (Mcshane et al., 2005; 
O´Connor et al., 2017). 
In order for the pharmaceutical industry to continue to engage on the results of academic research on biomarker 
development, the data obtained must already be very robust and quantifiable. Furthermore, imaging biomarkers 
should also be easy to use and already in the exploratory clinical development or post-development phase 
(Willmann et al., 2008). The drug industry is very interested in using surrogate end-points for their clinical trials, 
since this would have a significant effect on cost-savings in the R&D process (N Lassume et al., 2007; Paul et al., 
2010; Pien et al., 2005; Richter, 2006; Shi & Sargent, 2009; Van Bröcklin, 2008; Van Heerter et al., 2015; Willmann 
et al., 2008). Especially PET could be very beneficial as it enables the validation of biodistribution, 
pharmacokinetics and pharmacodynamics from a cell culture setting to preclinical animal models to clinical 
applications (Massoud & Gambhir, 2003).  
3.6 Regulation and Marketing Authorisation 
3.6.1 Challenges in the Regulatory and Safety Approval Process 
With the increased discussion around the topic of personalised medicine, the number of biomarkers 
used in practice was continually rising even to date only a small number of these markers really affect 
clinical decision making (O´Connor et al., 2017). In the period from 2004 to 2014, approximately 10,000 
publications have dealt with new or established imaging biomarkers, coming from new modalities, new 
techniques or new analytic approaches (O´Connor et al., 2017). 
There are two main groups of biomarkers: disease-related and interventional- related. Disease-related 
biomarkers are helpful in the identification, staging, monitoring and outcome-prediction in cancer 
patients (Ludwig & Weinstein, 2005; Richmond & Dunn, 2012) whereas interventional-related markers 
serve as predictors or surrogates of therapy response and may also predict or indicate drug toxicity 
(Richmond & Dunn, 2012).   
However, regardless of the group, many of these biomarkers have not been translated into a clinical 
routine because they simply do not measure the relevant biological feature, improve diagnosis or 
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outcome prediction (O´Connor et al., 2017). Many fail in one of the “Translation gaps” such as the step 
from in-vitro evaluation in humans/ animals to the reliable use in clinical cancer research; and secondly 
the step from being a research tool to become a validated biomarker in routine patient care (O´Connor 
et al., 2017). Another group experience the challenges of regulatory and safety approval by the 
regulatory agencies in Europe and the United States of America. Especially since the implementation of 
specific pharmaceutical laws in the USA in 1962 and, e.g. 1976 in Germany, the drug approval process 
became more comprehensive over the decades. Authorities requested more clinical data, more 
randomised controlled trials and more data on safety and efficacy such as dose-response information, 
gender-specific data, long-term tolerability data, subgroup evaluation, et cetera (Woodcock & Woosley, 
2008). At some point it was criticised that regulatory bodies are solely focusing on avoiding risk and 
safety issues, rather than finding the best balance of benefit and risk (Scannell et al., 2012). 
Notwithstanding the above, the higher regulatory requirements, among other things, reduced the 
approval rate of NMEs from the peak in end of the 1990s until the beginning of the 21st century (U.S. 
Department of Health and Human Services - Food and Drug Administration, 2004).  
The stagnation of newly approved NMEs and rising R&D budgets was also recognised by the FDA, which 
published a white paper in 2004 dealing with the critical path in the development process. The paper 
proposed efforts for improvement, the need for new tools to evaluate safety/ effectiveness and offered 
help to the industry to identify critical burdens upfront in the review process. The agency was 
committed to make internal changes to better respond to crucial issues, support high-priority research 
efforts and to improve the cooperation with all stakeholders (U.S. Department of Health and Human 
Services - Food and Drug Administration, 2004). EMA was even first to implement a scientific advice in 
1996 with the goal to improve the communication between the industry and the agency, advise 
sponsors on adequate risk-benefit assessment reports and therefore facilitate the access of new, safe 
and effective medicinal products (Hofer et al., 2015). EMA evaluated this initiative and concluded that 
the majority of applicants (76%) have used this service before pivotal trials, and those with EMA´s 
scientific advise had a higher marketing authorisation rate (78% vs 64%) compared to those without 
consultation (Hofer et al., 2015).  
This initiatives suggest that EMA and FDA are transforming from the role of gatekeepers (focusing of 
safety and risk reduction) to enablers who are leveraging innovative ideas, methods, frameworks and 
become scientific advisors (Ehmann et al., 2013). They are now working closely together aligning 
regulatory requirements as much as possible and facilitate the transformation of scientific results into 
regulatory frameworks (Goldman, Seigneuret, & Eichler, 2014). 
3.6.2 Regulatory Approval Process in Medical Imaging and Radiopharmaceuticals  
In FDA´s critical path report the agency acknowledged the unique role of medical imaging and 
biomarkers in the development of future medical products and initiated a workshop to routinely use 
new imaging techniques and biomarkers in the development process (Harapanhalli, 2010). The aim is 
to reduce drug attritions, delays and costs and as a result speed up the development cycle. However, 
the key players such as the National Health Institute (NIH), academic institutions and the industry 
highlighted the regulatory and technical challenges of (imaging) biomarkers and the effect on the drug 
development- and approval process (Harapanhalli, 2010; Kelloff et al., 2005). The primary challenge for 
imaging biomarkers is the limited consistency within and across different imaging hardware based on 
manufactures systems; limited consistency of the RPs because of various production possibilities/sites; 
regulatory acceptance/ validation of the imaging tracer or method; few probes with few molecular 
targets or pathways (Harapanhalli, 2010; Kelloff et al., 2005). Therefore the FDA, with the assistance of 
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the NIH initiated a public-private partnership called “The Biomarker Consortium” in 2006. Stakeholders 
from the industry with pharmaceutical, biotechnology, diagnostic and medical device background, non-
profit organisations, Medicare and Medicaid and academia were invited to help to accelerate the 
delivery of new successful technologies, drugs, therapies in the field of prevention, early diagnosis and 
treatment (Foundation for the National Institutes of Health, 2017). The European counterpart EMA also 
initiated a “Biomarker qualification process” in 2009 with the intention to advice on future study design 
and to demonstrate positive contributes. This is mainly achieved by getting the regulators agreement 
on objective and design of the studies, inform the regulators on current scientific progress and to 
establish an interdisciplinary discussion platform (Efthymios, Koch, Deforce, & Vamvakas, 2015).  
3.6.2.1 Regulatory Approval Process in the United States and the Central Approval Process in the 
European Union  
As in many other countries, radiopharmaceuticals have not been part of the original rules for medicinal 
products and procedures of marketing authorisation in Germany from day one. These products have 
frequently been ruled under national radiation protection regulations and pharmacopoeia monographs. 
In Europe, the European Council decided in 1989 to incorporate these products in Directive 89/343/EEC 
with the effect that the regulatory approval process is quite similar to classic medicinal products with 
just minor variations. These variations especially reflect the unique needs for safety and efficacy 
verification of imaging agents, and were tailored to reflect the use of imaging agents and biologics to 
diagnose and monitor diseases or conditions (U.S. Department of Health and Human Services Food and 
Drug Administration, Center for Drug Evaluation and Research (CBER), & Center for Biologics Evaluation 
and Research (CBER), 2004). This is for example outlined in the FDA report “Guidance for Industry: 
Developing Medical Imaging Drug and Biological Products” specifying which data can be partially or 
entirely waived like for example data on long-term and repeat-dose toxicity studies in animals; long-
term rodent carcinogenicity studies, reproductive toxicology studies et cetera. However, there may also 
be additional data requested like data on radiation exposure and absorption dose of the source 
tissue/organ and any other tissue, or specific data for paediatric patients. 
Due to the special nature of RPs, which may subsequently become a challenge in regulatory approval, 
regulators in Europe and the US have given applicants the option to request so-called "pre-submission 
meetings". Those are free of charge and it is said to have a positive impact on the success rate of an 
application in the U.S. (Hall & Carlson, 2014; Tiwari, 2015), and a smoother evaluation in Europe. Both 
the FDA and the EMA send a highly qualified team addressing product-specific, legal, regulatory and 
scientific issues in order to facilitate subsequent validation and the assessment of the application 
(European Medicines Agency, 2017c). A service which could especially be beneficial for small and 
medium enterprises, as those companies typically have less experience and knowledge within the 
company than large pharmaceutical companies (Pammolli, Magazzini, & Riccaboni, 2011).  
3.6.2.2 Regulations for Radiopharmaceuticals 
Radiopharmaceuticals are classified as “medicinal products” and consequently underlying the same 
regulations as “conventional pharmaceutical drugs” if the radiopharmaceutical contains at least one or 
more radionuclides (radioactive isotopes), and it is intended to be used for the medicinal purpose (The 
European Parliament and of the Council, 2001). Additional to the industrially prepared RPs, also 
radionuclide generators, radionuclide kits, and radionuclide precursors used in small-scale productions 
sites, in research facilities, and in hospitals need to have a marketing authorisation based on Article 6 of 
the Directive 2001/83/EC (The European Parliament and of the Council, 2001). Regulations protecting 
workers, general public and environment are also in place on national- and European level (Directive 
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2013/59/EURATOM; Council Directive 97/43/Euratom; EU Guidelines to Good Manufacturing Practice 
Medicinal Products for Human and Veterinary Use -Annex 3 “Manufacture of Radiopharmaceuticals”).  
Because of the unique nature of radiopharmaceuticals, the European legislator approved an 
“extemporaneous preparation” (Article 7 in Directive 2001/83/EC): 
“A marketing authorisation shall not be required for a radiopharmaceutical prepared at the time 
of use by a person or by an establishment authorised, according to national legislation, to use 
such medicinal products in an approved healthcare establishment exclusively from authorised 
radionuclide generators, radionuclide kits or radionuclide precursors in accordance with the 
manufacturer's instructions.” (The European Parliament and of the Council, 2001) 
The special preparation allowance reflects the need to prepare the product near the patient´s bedside 
because radionuclides used for medical purpose generally have a relatively short half-life. This 
allowance, however, also empowers European member states to legitimate some institutions, such as 
academic sites, hospitals and public-private research centres to use the products outside the marketing 
authorisation track, conduct clinical research and drive innovation. Many clinicians in some EU countries 
heavily use this exemption and prepare their RPs in either small-scale industrial sites with GMP license 
or a non-industrial site such as hospital pharmacies and nuclear medicine departments. As this 
extemporaneously prepared medicines are unlicensed medicines, and thus not overviewed by 
regulatory safeguards, they are associated with some risks for patients, healthcare staff and 
organisations (Jackson & Lowey, 2010). To reduce the risk and at the same time improve the quality in 
facilities without GMP license, the Radiopharmacy Committee of European Association of Nuclear 
Medicine (EANM) guides their members: “Guidelines on Good Radiopharmacy Practice (GRPP)” (Elsinga, 
Todde, Penuelas, & et al., 2010). However, Article 7 in Directive 2001/83/EC has been implemented 
inconsistently in each European member state, give some member states more or less freedom in the 
in the application of the products.  
Excursus:  
Radiopharmaceutical Regulation in Germany 
The use of radiopharmaceuticals is regulated in several national and international laws: The most important 
German law for pharmaceuticals, and consequently also for radiopharmaceuticals, is the Medicinal Products Act 
(Arzneimittelgesetz- AMG). But also other national laws regulate RPs such as the Pharmacy Practice Order 
(Apotheken Betriebsordnung –ApBetrO), the Ordinance of Radioactive Pharmaceuticals or Pharmaceuticals 
treated with Ionising Radiation (Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte 
Arzneimittel - AmRadV), provision governing the manufacture and distribution of pharmaceuticals and agents 
(AMWHV) and the radiation protection regulation (Strahlenschutzverordnung – StrlSchV). Contrary to the 
European definition of a radiopharmaceutical in Directive 2001/83/EC, Germany has not adopted the same 
definition. Whereas the European regulators differentiate between the radiopharmaceutical (Art. 1 (6) Directive 
2001/83/EC), radionuclide- generator (Art. 1 (7) Directive 2001/83/EC), - kit (Art. 1 (8) Directive 2001/83/EC) and 
-precursor (Art. 1 (9) Directive 2001/83/EC), the German regulators defined radionuclide precursors and 
generators to be seen as radiopharmaceuticals (§4 (8) AMG) and a “cold kit” as finished medicinal product. In 
contrast to the exemption for magistral and official formulation on a European level (Art. 3 (1,2) Directive 
2001/83/EC), the German law maker strictly prohibits the placement of a RP on the market without a marketing 
authorisation (§ 7(1) AMG) and also exempts hospital pharmacies to prepare magistral and officinal RP (§ 13 (2) 
AMG).  
But a loophole for radiopharmaceuticals exists in § 13 (2b) AMG: 
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“An authorisation referred to sub-section one shall not be required by a person who is a physician or otherwise 
authorised to practice medicine on humans in so far as the medicinal products are manufactured directly under 
his/her professional responsibility for personal use by a specific patient. [...]“ 
This exemption is now routinely used, especially after the abolishment of § 4 (a) AMD during the 15th amendment 
of the AMG in 2009. However, the Ordinance of Radioactive Pharmaceuticals or Pharmaceuticals treated with 
Ionising Radiation (AMRadV) further specifies the exemption of § 7 AMG for radioactive drugs (§2 (1-2) AMRadV): 
“The prohibition based in § 7 (1) AMG is not valid for radioactive pharmaceuticals, which […] Beyond it is not 
effective for radiopharmaceuticals, which are used: (1) To identify the condition, state or function of the body, (2) 
prepared in a clinical institution on the basis of a manufacturing license according to § 13 AMG, and (3) 
administered to not more than 20 patients in this institution per week, in accordance with state-of-the-art medical 
science and based on a patient-specific medical prescription.” (Bundesministerium für Justiz und 
Verbraucherschutz, 2017) 
In general, all RPs being commercially “produced” or “prepared” in hospitals according to the instructions of the 
marketing authorisation holder (§ 13 (2a) AMG) are subject to a manufacturing license (§ 13 (1) AMG) under the 
supervision of a qualified person (§ 15 AMG). Excluded from this manufacturing license are those pharmaceuticals 
which are “prepared by a physician or another authorised person to practice medicine on humans as the medicinal 
products are manufactured directly under his/her professional responsibility for personal used by a specific patient” 
(13 (2b) AMG). Still, all regulations concerning radiation protection need to be fulfilled, the manufacturing needs 
to be reported to the authorities (§ 67 AMG), the manufacturer is responsible for having an adequate quality 
management system to monitor compliance and the manufacturing process needs to be in conformity with the 
international pharmaceutical rules (§ 55 (8) AMG) (Schweim & Schweim, 2011). 
A comparison of the two central regulations for radiopharmaceuticals (AMG and AMRadV) shows that they 
contradict each other. Whereas the AMG allows the preparation of pharmaceuticals under the supervision of a 
physician (or otherwise authorised person to practice medicine in humans) the regulation AMRadV revoke this 
permit, probably because the legislation sees some risk in the use of ionising radiation. The legislator does not 
differentiate between those RPs with low radiation dose used for the diagnostic purpose and those with high 
radiation doses used for therapy. This is challenging for clinical routine and may not reflect the “real” risk 
associated with RPs. In the past, many believed that the marking of a carrier molecule with the radioisotope eluate 
could be performed under § 4 AMG “reconstitution”, exempting the institution to hold a manufacturing license. 
However, the Federal Ministry of Health clearly stated in the legislative proposal that reconstitution is an “easy 
process” transferring the already pre-finished pharmaceutical product into a ready-to-use product by dissolution, 
dilution or mixing. However, in the case of kit based RPs the pharmaceutical is not present before the carrier 
molecule is marked with eluate, thus in the process a new pharmaceutical is produced, and it's not under § 4 AMG 
“reconstitution” and needs to be reported to the authorities (§ 67 AMG) (Deutscher Bundestag, 2009).  
Radiopharmaceutical Regulation in other European Countries  
In the United Kingdom RPs are classified as medicinal products since the 1960s, thus had only minor changes in 
their national law due to Directive 89/343/EEC and later 2001/83/EC. Concerning the manufacturing 
requirements, there is no exemption for the production of RPs. Thus full GMP is required as for any other 
pharmaceutical drug (Schuessele, 2012). All RPs must be prepared in either a licensed facility (special 
manufacturing license) or by a pharmacist in a registered pharmacy. Thus this systems works on the regulation of 
people and premises and not the product, which works well in the UK (Dence, 2008). In France, RPs can only be 
prepared in pharmacies under the supervision of a responsible pharmacist. These pharmacies can also be outside 
of a hospital but are obliged to have authorisation by the Agence Francaise de la Securité Sanitaire des Produits 
de la Santé (AFSSAPS). Spain regulates radiopharmaceuticals in several different laws, and allows the preparation 
in “Hospital radiopharmacies”, exclusively prepare for in-house use of “extemporaneous RPs” from kit-based 
systems, blood-cell labelling and compounding of PET RPs. The “commercial centralised radiopharmacies” are 
either an authorised radiopharmaceutical laboratory or radiopharmacy unit, serve the nearby small hospitals and 
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nuclear medicine centre and do not support research and development activities. Directive 2001/83/EC does apply 
for the manufacturing of PET-RPs with marketing authorisation under GMP rules. Officinal preparation is prepared 
in the hospital radiopharmacies under national regulation (Good Pharmacy Practice) (Dence, 2008). Austria 
allowed the production and manufacturing of “magistral RPs” in (Institution-) pharmacies or nuclear medicine 
institutions or laboratories with a license and only for immediate application in patients (§63 AMG 
“Arzneimittelgesetz”). GMP is not required for the production of RPs. 
3.6.2.3 The Use of Radiopharmaceuticals in Clinical Trials 
Let's just briefly address the issue of the use of RPs in clinical trials because it has been a significant 
hurdle for these products so far. Investigational RPs for clinical trials has so far been regulated by the 
Directive 2001/20/EC “Implementation of Good Clinical Practice in the Conduct of Clinical Trials on 
medicinal products for Human Use”. The Ordinance demanded full GMP and a manufacturing license 
for all pharmaceuticals, including radiopharmaceuticals. This meant that in Germany the RP has/had to 
be approved by the ethics committee, the Federal Institute for Drugs and Medical Devices (BfArM) and 
the Federal Office for Radiation Protection (BfS). With the introduction of Regulation No. 536/2014 by 
the European Union in 2014, some significant changes have been proposed, which should improve the 
organisation, handling and efficacy of clinical trials in the European Union. 
Two changes will directly influence the use of radiopharmaceuticals in clinical trials: 
1. “The requirement to hold an authorisation for manufacture or import of investigational 
medicinal products should not apply to the preparation of investigational 
radiopharmaceuticals from radionuclide generators, kits or radionuclide precursors in 
accordance with the manufacturer's instructions for use in hospitals, health centres or clinics 
taking part in the same clinical trial in the same Member State.”  
2. “Investigational and auxiliary medicinal products should be appropriately labelled in order 
to ensure subject safety and the reliability and robustness of data generated in clinical trials, 
and in order to allow for the distribution of those products to clinical trial sites throughout 
the Union. […] Moreover, there are specific products, such as radiopharmaceuticals used as 
a diagnostic investigational medicinal product, where the general rules on labelling are 
inappropriate given the very controlled setting of the use of radiopharmaceuticals in clinical 
trials.” (The European Parliament and of the Council, 2014) 
This regulation still needs to come in force (expected in 2019; status: September 2018), but may then 
speed up the approval process due to the single- authorisation procedure. The official timeline says that 
the regulation will apply not earlier than 28th May 2016, and it seems that the technical requirements 
such as the EU portal/ database registering all European clinical trials have not been finalised (The 
European Commission, 2017).   
3.7 Uncertainty in Reimbursement and Revenue Planning 
3.7.1 The challenge of rising healthcare costs 
Over the last decades the healthcare spending, illustrated in rates of the gross domestic product, has 
risen substantially (Organisation for Economic Cooperation and Development (OECD), 2017). While 
spending in the 1970s was around two to six per cent in developed countries, this number has 
accelerated in the 1990s and the beginning of 2000s. Germany and Switzerland exceeded the 10% 
barrier of GDP already in 2002; other countries followed over the years (see Figure 15).  
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The sharply rising costs have been a challenge for many countries, and thus many are researching the 
influencing factors, changing existing health policies and trying to balance costs versus access to high-
quality healthcare. Several attributes have been identified: an ageing population, increased public 
demand and expectations, personal income growth, rising prices of physician and hospital services (e.g. 
labour costs) and inefficiencies in the organisation and payment of care (Sorenson, Drermond, & Khan, 
2013).  
Very often new medical technologies (new medical devices in imaging, medical and surgical procedures, 
new healthcare IT systems and new drugs) have been blamed as one of the key cost drivers. 
 “Most, if not all, economists and policy analysts believe that technologic advance is a key driver 
of health expenditure growth (Aaron, 1991; Chernew, Hirth, Sonnad, Ermann, & Fendrick, 1998; 
Fuchs & Sox, 2001; Gelijns & Rosenberg, 1994; Newhouse, 1993)” (Bodenheimer, 2005). 
But the relationship between medical technology and healthcare expenditures seems to be more 
complex (Sorenson et al. 2013). Results from a recent meta-analysis suggest that some new 
technologies have a significant role in healthcare expenditures, but at the same time can increase the 
benefit of an even more enormous amount. Alternatively, some technologies are cost-effective for 
some group of patients, but not in others (Sorenson et al., 2013). Thus the impact of medical technology 
innovation needs to be assessed individually and carefully, even if the evaluation is more complicated 
compared to therapeutic technologies. When evaluating the cost burden of a medical technology one 
has to ask the questions: Does the new medical technology supplements an existing treatment strategy, 
or is it a (full or partial) substitute for current approaches? How does this new approach affect other 
services such as hospital days, physician visits, and some adverse events? (Goyen & Debatin, 2009) 
We have to keep in mind that several other factors are driving the implementation of new technologies: 
demand by consumers with higher income, payment from some health insurances for new advances, 
Figure 15 Expenditure on Health Care in a percentage of the Gross Domestic Product (GDP) from 1970 to 2016 in selected 
countries worldwide (Source: Organisation for Economic Cooperation and Development (OECD), 2017). 
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the interest of professional health workers to better serve their patients and gain prestige and 
reputation, commercial interest of healthcare providers and the healthcare industry et cetera.  
3.7.2 Reimbursement – The Change of Systems 
Rising costs mean that legislators have to adjust the reimbursement system and reimbursement values 
without significantly restricting access. For this reason, they borrowed the tool of technology 
assessment, with the primary goal of making informed decisions about coverage of health care services 
and to improve patient outcome, to assist in cost containment (Institute of Medicine (US) Committee 
for Evaluating Medical Technologies in Clinical Use, 1985). 
The US, for example, implemented a National Center for Health Care Technology (NCHCT) in 1978 with 
the task to systematically assess new technology and to advice to the Health Care Financing 
Administration (HCFA) on safety, efficacy and cost-effectiveness. Over the period this had a significant 
impact on the federal reimbursement policy, primarily related to Medicare. The system changed from 
a “cost-based reimbursement” model, where all (e.g. technological) expenses had been retrospectively 
paid, to a prospective system where hundreds of illnesses with related costs, length of stay and resource 
consumption have been grouped to Diagnosis- Related Groups (DRGs) (Institute of Medicine (US) 
Committee for Evaluating Medical Technologies in Clinical Use, 1985). The DRG system aimed to train 
the institutions and payers to keep complete medical charts and identify their cost centres (resources) 
by analysing practices, equipment and a better view on their profits and financial losses. This way of 
thinking is well established among hospital managers, but not in the group of physicians, who do not 
weight into economic terms, but what they believe is best for their patients.  
The DRG system followed the idea that there is a mechanism behind the appropriate use of technology: 
“When a new technology becomes widely used, research and development costs will have been 
repaid, and volumes of services to which it is applied will increase. If there is a system in place 
for assessment, these forces should dictate a lower price for technology. If technology has a cost-
beneficial effect on patient care, such as reducing the number of hospital days or preventing 
certain complications, that too should decrease the hospital price. However, sporadic technology 
assessment applied to new equipment and procedures has not yet brought a reassessment and 
price decrease once widespread diffusion has occurred. 
The primary objective of a DRG price adjustment process is to maintain equality across DRGs in 
the ratios of price to the cost of efficient care. This objective implies that as new cost-saving 
technology becomes available for use in specific DRGs, the relative price of these DRGs should 
be adjusted downward to reflect the new efficiencies. Alternatively, the development of new 
cost-raising technologies that improve patient outcomes enough to justify their use should be 
met with increases in the prices of relevant DRGs (OTA, 1983). In order to make price 
adjustments, an ample supply of data will be required.” (Institute of Medicine (US) Committee 
for Evaluating Medical Technologies in Clinical Use, 1985). 
The DRG system is widely used in European- and other westerly countries and became the principle 
means to reimburse hospitals (Tan et al., 2014). At least in Germany, the DRG system can increase 
economic effectiveness and efficiency if the adverse effects (such as manipulation and up-coding) can 
be reduced (Böcking, Ahrens, Kirch, & Milakovic, 2005). Supplementary to the DRG cost-brake, many 
countries have also introduced a mandatory technological assessment before (and after) market 
introduction. In Germany, the responsible agency is called Institute for Quality and Efficiency in Health 
Care – IQWIG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen). Since 2004, it is by law 
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(§139a, 139 b, 139c, 35b, 130b, 137e, 303e “Social Security Code” V -SGB V) responsible to produce 
evidence-based reports and independently assess the benefit of drugs, non-drug interventions, 
diagnostic tests and screening tests, clinical practice guidelines and disease management programs 
(Institute for Quality and Efficiency in Health Care - IQWIG, 2017b).  
The institute´s methods rely exclusively on evidence-based medicine (EBM): “This proof should be 
obtained using the most objective scientific methods possible and provide reliable results” (Institute for 
Quality and Efficiency in Health Care - IQWIG, 2017b). As a consequence of this methodological 
approach, the institute always compares Option A vs Option B (Institute for Quality and Efficiency in 
Health Care - IQWIG, 2017a).  
“The term "benefit assessment" refers to the whole process of the assessment of medical 
interventions about their causal positive and negative effects, and compared with a clearly 
defined alternative active treatment, a placebo (or a different sham intervention), or no 
treatment.” (Institute for Quality and Efficiency in Health Care - IQWIG, 2017a) 
Criticism has been voiced because medical devices and diagnostic tests are evaluated according to the 
same scheme as drugs, including the same hard endpoints. But IQWIG argues that diagnostic tests can 
indirectly contribute to the mentioned patient relevant end-points by preventing risky interventions or 
changing the management towards different interventions (Institute for Quality and Efficiency in Health 
Care - IQWIG, 2017a). Information generated from diagnostic tests, which do not result in a benefit or 
harm to the patient and thus have no medical consequence, have no benefit from a social- law 
perspective. If either the diagnostic test has no predictive discrimination ability or the intervention 
resulting from the diagnostic tests is missing effectiveness, there is no benefit of the diagnostic test. 
Also in case of insufficient quality data, the IQWIG is not able to assess the medical innovation. Anyway, 
the IQWIG forwards their recommendation and reports to the Federal Joint Committee (GER: 
Gemeinsamer Bundesausschuss – G-BA), which decides on the inclusion or refusal of the service in the 
specification of all public health insurances. 
Consequently, also diagnostic procedures need to show an existing and documented benefit, using the 
same patient-relevant endpoints as therapeutic drugs (mortality, morbidity and health-related quality 
of life). Though, only trails with the highest quality and which meet the inclusion criteria (e.g. a study 
comparing option A to option B, ideally randomised) can be used for the evaluation. The institute 
recommends some study designs with high empirical evidence: unconformity design (GER: 
“Diskordanzdesign”), interaction design (GER: “Interaktionsdesign”), prospective-retrospective design 
(GER: “Prospektiv- Retrospektiv Design”) and of course randomised controlled trials (RCTs) (Institute for 
Quality and Efficiency in Health Care - IQWIG, 2017a). Some researchers have expressed concerns that 
these types of studies are difficult to perform in academic research institutions with limited resources, 
and the requested statistical significance may not be reached due to a smaller patient group in orphan 
diseases.  
3.7.3 Reimbursement of PET (PET/CT) Procedures and Imaging Biomarkers in Germany 
In this section, we will focus solely on the situation and challenges in Germany. Germany is one of the 
world's most advanced research locations for the development of new radiopharmaceuticals, partly 
because, in certain exceptions, the use of these products is also permitted outside of an official 
marketing authorization. However, this does not mean that the products are approved or even 
reimbursed by the statutory and private sick funds. The decision on the reimbursement of these 
products for statutory sick funds is subject to the Federal Joint Committee (GER: Gemeinsamer 
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Bundesausschuss – G-BA). This body evaluates the therapeutic benefit, the medicinal need and the 
efficiency of a new type of treatment in hospitals (§ 137c Social Security Statute Book V [§ 137c SGBV]) 
as well as in the ambulatory setting (§ 135 SGB V). Based on the evaluation the committee decides 
whether reimbursement is justified.  
In 2003, the German Federal Associations of Health Insurance Funds (GKV- Spitzenverband) asked the 
G-BA to evaluate Positron Emission Tomography (PET) for the use in the hospital setting based on § 137c 
SGB V, followed by a request from the Federal Association for Statutory Health Insurance Physicians 
(GER: Kassenärztliche Bundesvereinigung -KBV) in 2006. In the same year, the IQWIG was assigned to 
evaluate PET and PET/CT in several indications (Gemeinsamer Bundesausschuss, 2006).  
 
Based on § 137c (3) SGB V all diagnosis and treatment methods, to which the G-BA has not made any 
benefit/ reimbursement decision (§ 1) yet, can be unrestrictedly performed in German hospitals, if they 
offer an alternative treatment and perform according to the rules of the medical art. This highly 
favourable legislation permits doctors to test and use new and innovative treatment- or diagnostic 
procedures very quickly. However, if the G-BA comes to a decision, a negative assessment can limit the 
use of the new technology in a very short time. In the case of PET and PET/CT the G-BA awarded PET for 
small- cell lung cancer (SCLC) in 2008 and PET for non-small-cell lung cancer (NSCLC) in 2006/07 a 
favourable opinion and thus enabled reimbursement for hospitals and the office-based sector. In 
contrast, IQWIG could not find a benefit for the indications PET for head-neck tumours in 2011, PET and 
PET/CT in recurrent colorectal cancer in 2012, PET and PET/CT in malignant lymphomas in children in 
2013, and PET/CT in bone- and soft part in 2013. G-BA did not decide on the latter yet, but partially 
approved PET for head-neck tumours and allowed proving in the other two indications (see Table 24). 
Two comments concerning the reimbursement of RPs in Germany need to be mentioned: 
I. PET and PET/CT are just as useful as the underlying radiopharmaceutical can bind to a 
specific target and improve sensitivity, specificity, Negative Predictive Value (NPV) or 
Positive Predictive Value (PPV). The evaluation of “PET and PET/CT” in specific indications 
makes sense if the assessment is linked to a specific RP. Newer, and more effective tracers 
could substantially change the benefit of PET and PET/CT, and would, therefore, trigger 
every time another evaluation based on § 137c and §135 SGB V.  
II. The G-BA asked the IQWIG to evaluate the benefit of “PET/CT in bone- and soft part 
tumours”. The assessment report was negative, mainly because of missing evidence due to 
    Reimbursed in the setting: 
Indication Date Evaluated by The benefit of the 
assessment report? 
Hospital Ambulatory 
PET for small- cell lung 
cancer (SCLC)  
2008 Committee by G-
BA 
Positive Approved primary-, 
recurrence staging 
and metastases 
Approved primary-, 
recurrence staging 
and metastases 
PET for non- small- cell lung 
cancer (NSCLC) 
2006/ 
2007 
Committee by G-
BA 
Positive Approved primary-, 
recurrence staging 
and metastases 
Approved primary-, 
recurrence staging 
PET for head-neck tumours 2011 IQWIG Negative Partially approved Partially approved 
PET and PET/CT in recurrent 
colorectal cancer 
2012 IQWIG  Negative (not enough 
data) 
Approved for proving 
 
Approved for 
proving 
PET and PET/CT in malignant 
lymphomas in children 
2013 IQWIG Negative (not enough 
data) 
Approved for clinical 
trials 
 
Approved for 
clinical trials 
 
PET/CT in bone- and soft part 
tumours 
2013 IQWIG Negative No decision No decision 
PET, Positron Emission Tomography, CT, Computer Tomography, G-BA, Federal Joint Committee, IQWIG, Institute for Quality and 
Efficiency in Health Care 
Table 24. Overview of benefit assessment studies being performed in Germany based on § 137c and § 135 SGB V for specific 
indications of PET and PET/CT.  
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a low number of studies investigating the benefit of PET/CT and a lack of comparing- studies 
focusing on diagnostic accuracy. Neuroendocrine tumours, origin from the neural ectoderm 
(or neural tube epithelium), should have been included because, according to the definition, 
they fall into the range of soft tissue tumours. Unfortunately, the IQWIG assessment report 
did not consider any NET study, thus the extensively researched field of 111In-Octreotate or 
DOTATATE PET/CT imaging was excluded. Just in one study, used to assess PET/CT as a 
primary diagnostic tool for bone tumours, the term “neuroendocrine” appeared in the 
description of tumour pathology. Otherwise, the report solely focused on 
radiopharmaceuticals based on Fluor such as 18F- FDG and in the end did not find a patient-
relevant benefit (lack of not sufficient data) neither a superiority in the diagnostic and 
prognostic quality compared to standard diagnostic procedures. The conclusion of the 
IQWIG: lack of not sufficient data and non-adequate study designs/ methodological 
approaches of the included studies (Institut für Qualität und Wirtschaftlichkeit im 
Gesundheitswesen, 2012).  
3.7.4 Reimbursement as an area of uncertainty 
Reimbursement policies have a far-reaching effect on the adoption and the usage of medical technology 
(Office of Technology Assessment, 1982) and as a result of investors willing to support R&D activities. 
Already years back it was predicted that the current coverage and reimbursement might be insufficient 
to support the development of new technologies (Secretary’s Advisory Committee on Genetics Health 
and Society, 2008). Clarifying areas of uncertainty in regulatory and reimbursement issues will, 
therefore, facilitate the translation of new pharmacogenomics diagnostic tests into clinical practice 
(Fackler & McGuire, 2009; Faulkner, Annemans, Garrison, & Helfand, 2012; Secretary’s Advisory 
Committee on Genetics Health and Society, 2008).  
The FDA made clear that a new medical imaging agent intended for the indication diagnostic or 
therapeutic patient management must be able to improve patient management decisions or improve 
patient outcomes (U.S. Department of Health and Human Services Food and Drug Administration -
Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER), 
2004). Moreover, even if the imaging probe takes the hurdle of marketing authorisation, it is not 
guaranteed to get awarded with a sufficient reimbursement rate. As discussed in Chapter 3.2 “Market 
Size and Potential”, newer molecular imaging probes tend to be very target specific with the 
consequence that the market becomes very small and revenue decreases. Assuming the development 
costs for an imaging agent is at least $ 200 million, and using the general rule of thumb that the 
development costs must be equal to the peak yearly earning, this means that in markets with 100,000 
cases per year reimbursement must be around $ 2.000/case (Sinusas, Thomas, & Mills, 2011). This is 
out of sight, given the current cuts in health care spending by various governments. 
A worldwide company in the medical imaging and radiopharmaceutical sectors describes the challenges 
like this: 
“While these [access innovative medical Technologies] challenges vary by country, common 
challenges include misalignment between the value of a technology and reimbursement levels, 
cuts in government healthcare spending, higher requirements for evidence of clinical 
effectiveness for coverage, and opaque and complex reimbursement processes. […] Also, these 
challenges create disincentives for medical devices companies’ innovation because uncertainties 
about coverage for reimbursement make it difficult to predict whether investments in new 
technologies will provide sufficient returns.” (GE Healthcare, 2009) 
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Based on the US report of the “Committee on State of the Science of Nuclear Medicine” States, the lack 
of reimbursement and the regulatory obstacles are the most significant barriers for continuing 
development and the introduction of novel radiopharmaceuticals in nuclear medicine practice 
(Committee on State of the Science of Nuclear Medicine, 2007). Japan has already adopted their 
reimbursement policy for medical technology and introduced a new way to assess the cost-effectiveness 
of these technologies (Hernandez, Machacz, & Robinson, 2015; Shiroiwa, Fukuda, Ikeda, & Takura, 
2017). Overall, very few of health technology assessment (HTA) programs have specific methods to 
assess the clinical and analytic performance, clinical utility, and economic impact of molecular diagnostic 
technologies (Garfield et al., 2016). It was therefore recommended that HTA organisations should better 
align with the industry, improve transparency, collaboration, communication, better advise on the 
required evidence data, and explain the links between the HTA and funding decisions (Garfield et al., 
2016). 
3.8 Different Goals between Scientific Community and Investors/ Industry 
3.8.1 Different goals in Industry- and Academic Research 
A cornerstone of any university institution, at least in the fundamental idea back in the early 12th 
century, is the academic freedom given to Universities in the sense of teaching and research (extended 
in the early 19th century) (Altbach, 2001; Atkinson & Blanpied, 2008). Academic researchers are more 
focused on the question rather than the answer, which is fundamentally different to any question asked 
in business (Cutright, 2000). In this concept of “basic research” the investigator has a different 
motivation: 
“Basic research refers to research that is undertaken for its own sake – to advance knowledge; 
to develop theory; to solve an interesting theoretical puzzle; to address a curiosity of the 
researcher – without any immediate concern for whether doing so will produce anything “useful” 
or “practical” or “generalizable.” (Palys, 2008). 
The publicly funded basic research is on the one side an essential booster for future innovations 
(Organisation for Economic Cooperation and Development., 2007), but should also correct “market 
failure” (Salter & Martin, 2001). Over the last decades, the university system experienced substantial 
changes in the way of setting objectives in teaching and research. Support by governmental structural 
funds declined fundamentally, and competitive funds from the industries took their place (Aldo Geuna, 
2001). Universities were also encouraged (even by regulations) to collaborate more with private 
companies and get access to funds through problem-oriented or industry-oriented public programs (A. 
Geuna & Nesta, 2006; Aldo Geuna, 2001). This tighter collaboration between academic institutions and 
the industry segment was primarily seen in the field of life sciences, where the research converted from 
being independent to being fully interdependent and forced to commercialise the research (Powell & 
Owen-smith, 1998). Data from the US suggests that national funding for health research and 
development was overhauled by industry sponsoring in the late 1980s (Powell & Owen-smith, 1998). In 
1994, around 90% of the US companies doing research in life-science had a relationship with an 
academic intuition and thus had access to substantial funding (Blerenthal, Causino, Campbell, & 
Seashore, 1996). 
However, some specialities in life science sector, such as nuclear medicine, have not benefited much 
from this close industry engagement and collaborations. This branch is still highly dependent on public 
funding for basic and applied research (Committee on State of the Science of Nuclear Medicine, 2007; 
Schwaiger & Wester, 2011). One possible reason, among many others, is the complexity of the subject, 
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which is composed of technical, physical and medical knowledge. Without advances in the artificial 
production of radionuclides in nuclear reactors and accelerators, new chemical processes for 
synthetisation and new scanner technology, nuclear medicine would not be at the stage it is now 
(National Research Council (US) et al., 2007).  
If we remember that academic research is focused on curiosity and the generation of knowledge, it is 
not surprising that the research objectives are substantially different to the industry. For the individual 
academic investigator a publication in prestigious journals is a way to receive recognition, enhance 
his/her job prospects and receive other beneficial goods and services (Committee on Responsibilities of 
Authorship in the Biological Sciences, 2003). Academic researchers typically publish numerous 
publications in a short time (Laterre & Francois, 2015), which of course has some influences on the 
quality of the research results, ranging from good, bad, unnecessary or distorted (Evans, Thornton, 
Chalmers, & Glasziou, 2011). Academics are also more likely to address the efficacy of an intervention 
or drug in a more severe patient group, with higher mortality risk and unmet clinical need (Laterre & 
Francois, 2015). These clinical trials are usually more prominent in size, involve a wide range of patients 
and try to answer a medical question rather than gathering data for regulatory approval (Institute of 
Medicine (US), 2010). Typically, academic sites have limited access to resources specialised in clinical 
trial organisation/ management, lack investigator research knowledge, have problems in executing 
research ideas and may not be familiar with the extensive regulatory requirements (Croghan et al., 
2015). In biomedical and public research, and not explicitly in academic research, study designs are quite 
often not appropriate, sophisticated statistical methods are not used adequately and reproducibility is 
poor (Ioannidis et al., 2014).  
Unfortunately, many data from academic institutions are not sufficient in quality to back up the safety 
and efficacy evaluation of new molecular entities in the marketing authorisation process. A good 
example is the case of DOTATATE and the FDA´s opinion on the quality of the (so far) conducted, 
academic clinical trials: 
In July 2015, the applicant (Advanced Accelerator Application- AAA) handed in an NDA to the FDA 
including a review of scientific literature and one single centre study from Vanderbilt University 
Medical Center to support the clinical efficacy of NETSPOT (kit for the preparation of Gallium Ga 68 
Dotatate injection). Unfortunately the reviewers from the FDA noticed that none of the five studies 
(Deppen, Liu, et al., 2016; Haug et al., 2012, 2014b; Hofman et al., 2012; Srirajaskanthan et al., 2010) 
“contained randomised, prospective trials with independent blinded image review designed for drug 
development. Furthermore, they assessed incomplete information in the articles did not allow one to 
determine precise diagnostic test performance (sensitivity/specificity) or to evaluate the role of the 
new imaging information on patient management and patient outcome”. 
The reviewers recognised that the overall scientific literature supports the product efficacy, but 
mentioned that the level of evidence is generally low. They criticised the studies designs, mentioned 
a patient selection bias and incomplete ascertainment of false positive rates. The reviewers 
concluded: “These data although insufficient for the indication proposed by the sponsor, appear to 
support an indication similar to that for OctreoScan, i.e. localisation of tumours in patients with 
NETs.” (Center for Drug Evaluation and Research, 2016). 
In a follow-up meeting, the FDA explained that “[…] it expects to rely on evidence from adequate and 
well-controlled trials for diagnostic and patient management claims for imaging drugs. […]”, and 
mentioned “[…] that the agency has an interest in using data from the real clinical world experience 
for NDAs. This application provides an example of the challenges with this approach. […] DMIP (note: 
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Division of Medical Imaging Products) has developed guidance for imaging standards and actively 
encourages standardising product manufacturing and specifications for investigational drugs and the 
use of uniform clinical protocols.” (Center for Drug Evaluation and Research, 2016).  
No further documentation on the clinical efficacy discussion concerning the proposed indication is 
available. The necessary bridging study was performed by the Vanderbilt University Medical Center 
and was satisfying about safety, efficacy, and dose response in the U.S. ethnic group. 
This discussion highlights very well the different beliefs in “good quality” clinical trials and the challenge 
of complexity in clinical trial design. The regulatory agencies favour precise research plans, using 
randomised, prospective clinical trials with a systematic patient- and data monitoring. Academic 
research site may therefore never be able to contribute to “satisfying” clinical evidence for the FDA, as 
academic sites face the challenges of limited resources for medical research, reduced funding- and 
increasing costs for conducting clinical trials (Larkin et al., 2011; Sertkaya, Wong, Jessup, & Beleche, 
2016). Furthermore, there is a lack of formal training, promotional opportunities and an unpleasant 
allocation of workload for the research coordinators (Larkin et al., 2011). So even if academic institutions 
are willing to make changes to their study design and adapt the objectives, it may still not reach the 
regulators requested level.  
3.9 Limited Knowledge in the Scientific Community, outside the Nuclear 
Medicine Community 
The number of nuclear medicine procedures is continuously rising from 23.5 million (1980 - 1984) to 37 
million in the time from 1997 to 2007 (The United Nations Scientific Committee on the Effects of Atomic 
Radiation, 1988, 2008). The future even looks better: molecular imaging could improve cancer care 
through early detection and guide effective treatment (Hussain & Nguyen, 2014), and radionuclide 
targeted therapy shows promising results in end-stage cancer diseases (Bodei, Pepe, & Paganelli, 2010; 
Fendler et al., 2017; Rahbar et al., 2017; Rhee et al., 2016; Strosberg et al., 2017). Also, the successful 
implementation of 223Ra-dichloride for castration-resistant prostate cancer created high awareness and 
had a boost for the nuclear medicine community (Fahey, Zukotynski, Capala, & Knight, 2014). 
Previously, the benefits of nuclear medicine procedures in cancer detection and therapy were not 
widely acknowledged outside the nuclear medicine community (Zimmermann, 2013). This may have 
also been based on a general controversy and disagreements among scientific, technical or medical 
experts. In any medical discipline, the decision-making process became more complicated over the 
years also due to the sheer volume of information regarding risks, benefits, costs and preferences 
(Hunink et al., 2014). Many new treatments promise to improve the outcome for many conditions, but 
they may be “half-way” technologies as they improve, but do not cure (Hunink et al., 2014).  
However, decisions in healthcare generally have significant implications, and therefore knowledge and 
evidence is the basis for every choice: 
“In a decision analyses process we first make the problem and its objectives explicitly; then we 
list the alternative actions and how these alter subsequent events with their probabilities, values, 
and trade-offs; and finally we synthesise the balance of benefits and harms of each alternative.” 
(Hunink et al., 2014) 
In the medical field, the most important evidence derives from the concept of evidence-based medicine 
(EBM). It combines the individual expertise with the best available external clinical evidence from 
systematic research (Sackett et al., 1996; Sackett, Rosenberg, Gray, Hynes, & Richardson, 1997). It is 
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basically a translation from knowledge, starting with “creation” via primary research (e.g. randomised 
controlled trials), to “distillation” via implementation of recommendations in systematic reviews and 
guidelines, and the step “dissemination” via the appearances in journals and presentations (Straus, Ma, 
& Graham, 2009). In the step distillation, the knowledge from EBM is formed into clinical practical 
guidelines (CPGs) with the intention to guide physicians, educators, and healthcare practitioners on how 
to prevent, diagnose, treat and manage diseases, disorders, and other health conditions.  
“Clinical practice guidelines are statements that include recommendations intended to optimise 
patient care that is informed by a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options.” (Institute of Medicine (US), 2011).  
CPGs should set a standard of quality, allow measuring performance and assess the services delivered 
(Institute of Medicine (US), 1990). Both, EBM and CPGs have become an essential foundation for the 
international healthcare community in the 1990s and beyond (Lohr, Eleazer, & Mauskopf, 1998), even 
such guidelines existed in many European countries for much longer (Woolf, Grol, Hutchinson, Eccles, 
& Grimshaw, 1999a).  
The principal aim of CPGs is to improve the health outcome for patients, the quality of clinical decisions 
for the physician and the efficiency of the healthcare system (Woolf, Grol, Hutchinson, Eccles, & 
Grimshaw, 1999b). A comprehensive literature review by Smith & Hillner (2001) demonstrated that 
evidence-based guidelines in cancer care could optimise the length of stay, reduce complication rates 
and also financial outcomes. Other studies showed a significant improvement in the process of care 
(Grimshaw et al., 1995, 2006; Grimshaw & Russell, 1993) and an improvement of patient outcome 
(Grimshaw & Russell, 1993; Nuffield Institute of Health, Centre for Health Economics, & NHS Centre for 
Reviews and Dissemination, 1994). Not only did CPGs influence the physicians treatment decision, but 
they also affected payers in their reimbursement decisions and slowed down the excessive rise in 
healthcare expenditures (Institute of Medicine (US), 1990; Schaaf, Seashore, & Randolph, 2015; Steering 
Committee on Quality Improvement and Management Classifying, 2004; U.S. Preventive Services Task 
Force, 1989). However, the amount of studies investigating the effect of guidelines on the individual 
patient outcome is weak and less convincing (Lugtenberg, Burgers, & Westert, 2009). 
3.9.1 The Effect of Clinical Practice Guidelines on Nuclear Medicine Awareness 
In the case of DOTATATE, guidelines for NETs have not been multidiscipline for a long time. They 
primarily focused either on clinical aspects (e.g. surgical procedures in specific tumour types) or tumour 
markers (Sturgeon, 2002). In 2001, the first multidiscipline guideline for diagnosis and therapy of MEN 
1 and 2 (Brandi et al., 2001) was published, followed by the recommendations for carcinoma of 
unknown primary sites in 2003 (Bugat et al., 2003) and guidelines for the management of 
gastroenteropancreatic NETs in 2004 and 2005 (Kjell Öberg, Astrup, et al., 2004; Ramage et al., 2005). 
In 2004, the European Neuroendocrine Tumour Society (ENETS) published their first consensus 
statement on guidelines for diagnosis and treatment of neuroendocrine gastrointestinal tumours 
(Plöckinger et al., 2004). Most of these guidelines evaluated the use of 111In- Octreotide as a diagnostic 
tool, but it was only recommended as a supplement to CT, MRI and EUS in some instances (Brandi et 
al., 2001; Kjell Öberg, Kvols, et al., 2004; Plöckinger et al., 2004; Ramage et al., 2005). One of the reasons 
may be the low number of prospective, randomised controlled trials. Even for newer RPs the data from 
RCTs are still low, but the nuclear medicine community still achieved to work out the diagnostic benefit 
of somatostatin- receptor imaging (111In- Octreotide with SPECT and 68Ga DOTA-TATE, -TOC, - NOC). In 
many of the current CPGs dealing with NETs, the use of scintigraphy is recommended (Janson et al., 
2014; Öberg, Knigge, Kwekkeboom, & Perren, 2012). ENETS acknowledges the data from large series, 
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indicating a positive finding in many patients with certain primary tumours. Nevertheless the evidence 
to routinely recommend scintigraphy in high-grade gastroenteropancreatic NETs and neuroendocrine 
carcinomas is missing (Garcia-Carbonero et al., 2016). The current CPG for neuroendocrine tumours 
from the U.S. National Comprehensive Cancer Network (NCCN) does also not recommend the use of 
111In- Octreotide as a first line diagnostic procedure, but it may be used in appropriate cases (Kulke et 
al., 2015). In contrast to the European- and International working groups, the NCCN does not mention 
any of the new RPs being based on DOTA and used in PET and PET/CT (Kulke et al., 2015). Those working 
groups strictly follow the concept of evidence-based medicine, as it is currently the best available 
evidence in making clinical decisions (Lewiecki & Binkley, 2009). RCTs are the highest level of evidence 
(Abel & Koch, 1999; Byar et al., 1976; Hill & for International Organisations of Medical Sciences, 1960), 
thus a better awareness of the efficacy of nuclear diagnostic procedures can currently only be achieved 
via additional research evidence from prospective RCTs, such as the NETTER trial (Strosberg et al., 2017). 
3.10  Special Manufacturing, Distribution and Handling of 
Radiopharmaceuticals: 
3.10.1 Manufacturing: 
The majority of radioisotopes used for nuclear medicine are artificially produced, either in a nuclear 
reactor, a nuclide generator or in an accelerator. Approximately 80% of all diagnostic procedures use 
the radionuclide Tc- 99m, which is obtained from the reactor-produced radionuclide Mo- 99 (Krijger, 
Ponsard, Harfensteller, Wolterbeek, & Nijsen, 2013). Worldwide only eight reactors (NRU in Canada, 
HFR in the Netherlands, BR2 in Belgium, OSIRIS in France, MARIA in Poland, LVR-15 in the Czech 
Republic, SAFARI in South Africa and OPAL in Australia) can produce Mo-99 for Tc-99m generators. 
These eight reactors also produce the majority of other medical radionuclides used for targeted 
therapies (e.g. Yttrium-90, Lutetium-177, Rhenium-188) and brachytherapy (e.g. Cobalt- 60, Iodine- 125, 
Iridium- 192) (Krijger et al., 2013). There are seven additional reactors in the USA, Russia, Germany and 
Korea, Argentina and Indonesia which are capable of producing medical radioisotopes, plus some 
research reactors which could be upgraded. However, these upgrades are costly and time-consuming 
and may not be worth it from a logistic and cost-effective perspective. The main bottleneck is not the 
reactor capacity, but the low number of processing facilities capable of dissolving the irradiated targets 
and extracting the radionuclides of interest (Krijger et al., 2013).  
With regards to the production of Mo-99, the Nuclear Energy Agency (NEA) and Organisation for 
Economic Co-operation and Development (OECD) implemented a Full Cost Recovery (FCR) and Outage 
Reserve Capacity (ORC) policy in 2009, encouraging supply chain participants to continue producing Mo-
99 and reward them with full cost recovery. These additional costs should be covered by governments 
via higher reimbursement rates (High-level Group on the Security of Supply of Medical Radioisotopes, 
2014). Besides the production in reactors, several research groups are investigating how accelerators 
could be used for the production of these reactor-based radionuclides to secure the future supply of 
these radionuclides (Abbas et al., 2009; Mushtaq, 2012; Schmor, 2011). Another strategy is the 
substitution of reactor-based radionuclides with non-reactor radionuclides. However, the medical 
community and industrial partners first need to evaluate feasibility (Internal European Commission Ad 
Hoc Interservice Group, 2009). 
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3.10.2 The Challenge of Distribution and Logistics 
The literature also suggested that logistics may be a major concern for potential investors 
(Zimmermann, 2013). Typically, the radionuclides used for imaging and therapy have a short- or medium 
half-live. While a rapid distribution is essential for diagnostic PET radionuclides, there is significantly 
more time for radionuclides used in therapy. However, these products are more time sensitive  and 
require a well-organised production process and a secure, reliable and cost-efficient distribution 
network (Dash, Russ, Jr, & Pillai, 2013; Internal European Commission Ad Hoc Interservice Group, 2009).  
Regulators are concerned about the potential hazardousness element of transporting radioactive 
material and have thus implemented special requirements (IAEA Regulations for the Safe Transport of 
Radioactive Material (No. TS-R-1); UN Recommendations for the Transport of Dangerous Goods (Orange 
Book) and the modal regulations and agreements (e.g. ADR, RID, ADN) of the specialised international 
transport organisations; Community Regulations and Directives; a variety of international conventions, 
codes and agreements and of course country-specific National provisions) to protect people, property 
and the environment (Internal European Commission Ad Hoc Interservice Group, 2009). Even transport 
costs usually have a minor part in total costs of production, logistics and handling of medical 
radioisotopes (World Nuclear Association, 2017), country-specific requirements can have a substantial 
impact on effort, time and technical and financial resources (Internal European Commission Ad Hoc 
Interservice Group, 2009).  
“[…] there are indications that insufficient standardisation of international shipment standards 
or transport containers lead to repeated delays or denials with all related socio-economic 
consequences. Further, reduced commercial incentives for airlines to carry radioactive 
substances result in fewer carriers and fewer routes than historically available.  
The denial of shipment by some carriers, seaports and airports is a major issue for users of 
radioactive materials. There are problems with all modes of transport sometimes due to the 
perception of possible hazards rather than the reality.” (Internal European Commission Ad Hoc 
Interservice Group, 2009). 
Compared to the transportation of conventional pharmaceuticals, this additional effort and cost-burden 
is significant, requires specialised knowledge and may quench investors.  
3.10.3 Handling: 
Radiopharmaceuticals typically consist of a bioactive molecule, which can be prepared in advance, and 
a radionuclide with a short half-life, which needs to be labelled to the molecule by a qualified person 
shortly before application. In Germany, this labelling process is (§ 13 (1a) AMG) not seen as a 
reconstitution-, but a “production” process (Bundesministerium der Justiz und für Verbraucherschutz, 
2017). 
Clinical sites preparing RPs on site are therefore categorized as a production facility and need to comply 
with the codes of current good manufacturing practices (cGMP), national/regional health authority´s 
regulations, effective quality assurance, quality control, the employment of qualified personnel and the 
use of authorised equipment (International Atomic Energy Agency, 2008). In Germany these 
requirements are stringent and governed in numerous regulations such as the Medicinal Products Act 
(Arzneimittelgesetz- AMG); the Pharmacy Practice Order (Apotheken Betriebsordnung –ApBetrO), The 
Ordinance of Radioactive Pharmaceuticals or Pharmaceuticals treated with Ionising Radiation 
(Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel - AmRadV), 
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provision governing the manufacture and distribution of pharmaceuticals and agents (AMWHV) and the 
radiation protection regulation (Strahlenschutzverordnung – StrlSchV). 
All industrial, nuclear, chemical/radiopharmaceutical and clinical institutions producing 
radiopharmaceuticals, positron RPs, radioactive precursors and radionuclide generators need to follow 
those regulations (Deutsches Bundesministerium für Gesundheit, 2009). GMP is obligatory for the 
processes of chemical syntheses, purification, formulation and preparation and the aseptic step 
production or final sterilisation (see European Commission, 2017). Facilities preparing RPs for public 
pharmacies and hospital pharmacies need a production license (§ 13 AMG), specialised and expensive 
equipment, clean rooms and highly educated personnel (Bundesministerium der Justiz und für 
Verbraucherschutz, 2017; Bundesministerium für Erwelt Naturschutz und Reaktorsicherheit et al., 2017; 
European Commission, 2017). 
Consequently, the manufacturing, handling of radionuclides demands knowhow, time, investment and 
highly qualified employees. Due to the individual national & international regulations, the number of 
sites owning the equipment to manufacture and process radioactive products is limited.  
 
  
Type of production Not GMP GMP Part II & I (upward) including relevant supplements 
Radiopharmaceuticals Manufacturing process in 
a cyclotron or a reactor 
Chemical 
syntheses 
Purification 
steps 
Formulation and 
preparation 
Aseptic 
preparation or 
final sterilisation 
PET Radiopharmaceuticals 
Radioactive Precursors 
Radionuclide Generator Manufacturing process in 
a cyclotron or a reactor 
Processing 
Table 25 Requirements for the production and handling of radiopharmaceuticals including precursors and generators. 
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4 Empirical Results: 
In this section, we will analyse the data from the semi-structured interviews with the various 
stakeholder groups. For better readability, we have decided to include only representative statements 
in this chapter, all summarised statements can be read in the appendix. 
4.1 The Role of Imaging  
Definition: 
Biomedical imaging is one of the main pillars of comprehensive cancer care and has a substantial effect 
on the treatment and management of patients. In the clinical use, the application of imaging ranges 
from prediction to screening, biopsy guidance for detection, staging, prognosis, therapy planning, 
therapy guidance, therapy response recurrence, and palliation (Fass, 2008). Moreover, imaging is also 
used in research and development. Many major drug companies recognised the potential of imaging in 
the R&D process, established their own in-house imaging programs, and are using different imaging 
techniques in their preclinical and clinical programs (Higgins & Pomper, 2011a).  
 
 
Figure 16: Selected comments on the role of imaging biomarkers from interviewed stakeholders 
The findings from the relevant stakeholder groups (Nuclear Medicine Physicists, Oncologists/ 
Specialists, Pharmaceutical Industry, Radiopharmaceutical Industry) overall suggest that the use of 
Imaging plays a pivotal role, in either the clinical patient management or within the R&D efforts of the 
industry.  
All statements regarding this topic are in the appendix on page 200 
 
 
 
 
 
A Nuclear Medicine Physicist´s view:
"Because what is used so far are indeed methods that rely on
biopsy or on local tissue samples, or just on primary tumor
preparations.... But certainly in the course of pretreatment the
tumor pathology already changed. That means we have in
principle no real-time procedures, which can show the entire
tumor biology. At the same time, of course, this is the power of
imaging, especially biomarker-driven imaging. You can
visualize, quantify in a non-invasive way in real time,
throughout the body, in all lesions and not just a part of a
tumor."
An Oncologist´s view:
“My estimation, functional imaging will further develop…
what I have seen until now is fascinating… probably it will
also save costs, many people have not recognized this yet. If
we have the chance to avoid therapies in patients, stop a
pointless therapy and start with a more sensible therapy, by
using functional imaging or another method, this would
definitely be economical meaningful.”
A view from the Radiopharmaceutical Industry:
"It is all about the impact on whether the patients getting the
appropriate therapy. And some of these therapies are quite
expensive... Xofigo is a good example. So Xofigo it is quite
expensiv...Bone scans are not desperately sensitive, so you
know if you do bone scans and 10% of the patients are positive,
but actually the real data from a PET scan, which show that 20
to 25% of those patients already had disease already in the
bones ...So assuming you have positive bone scan then you got
Xofgio, well if you had a different scan that meant to see twice
as many patients, and then you clinical trial outcome should be
better. I think."
A view from the Pharmaceutical Industry:
"Themain reason why we developed this imaging agent was
as a research tool....biopsies are fine... but we want to see
how that changes in time, over treatment....so we want to
look at those kind of research questions and want to
understand what changes... the nice things about imaging is,
you cannot look at just one tumor you cannot just look of
parts of the tumor, you can look the whole tumor and at more
tumors throughout the body. And the hope is that this would
be more valuable and it would do a better job in predicting
patients response, but this is true or not time will tell."
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I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Value of imaging/in-vivo imaging 
biomarkers? 
 
 
As expected, nuclear physicians have rated the value of imaging in the patient management process 
very high. All interviewees see a higher impact of in-vivo imaging biomarkers compared to in-vitro 
biomarkers, especially because imaging is more precise in the location of the region of interest. 
“And the therapeutic goal is usually not the treatment of the entire organism, but the 
treatment of a certain target region. In such a case, imaging is the more accurate biomarker 
method compared to an in-vitro assay taken from the blood. “ 
Currently used methods such as biopsies, local tissue samples or primary tumour preparation show a 
local pattern of the disease, but not the overall heterogeneity and the disease dissemination.  
"Because what is used so far are indeed methods that rely on biopsy or local tissue samples, or 
just on primary tumour preparations. However, certainly, in the course of pre-treatment, the 
tumour pathology already changed. That means we have in principle no real-time procedures, 
which represent the biology of an entire tumour.” 
Overall, the interviewee´s pro arguments for in-vivo imaging biomarkers correspond with the arguments 
stated in the literature: precise localisation and characterisation of individual regions and organs,  real-
time visualisation and quantification, non-invasiveness et cetera (e.g. Carter, Halpenny, Ginsberg, 
Papadimitrakopoulou, & de Groot, 2017; MacFarlane, Shah, Wysong, Wortsman, & Herphreys, 2017; 
O´Connor et al., 2017; O´Connor et al., 2015). 
II. The Pharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Value of imaging/in-vivo imaging 
biomarkers? 
 
Also, the Pharmaceutical Industry has a noticeable interest in imaging biomarkers, but almost 
exclusively for Research & Development efforts. All of the interviewees had a favourable opinion of 
molecular imaging and the benefit of their R&D process. 
"But regarding an internal decision making we are using a number of these molecular ligands, 
and we have a very extensive back program where we are trying to develop ligands…. So we 
are using it for R&D decision making right now, for proof of mechanism on tissue markers, 
understand the distribution, understanding dosing. There are numbers of ways we are using 
radiopharmaceuticals….” 
One interviewee specified an example where molecular imaging is especially beneficial: e.g. proof of 
mechanism, proof of principles, proof of concept, and finding the dosing for Phase II. They mainly wish 
to get several questions answered which have a fundamental impact on R&D- attrition rates, success, 
and spending: “Does the drug hit the target? Does it engage with the target? Does it modulate the 
downstream physiology?”  
Another remarkable note came from one top executive from a big pharmaceutical company: 
"I can remember sitting at a top meeting one time and talking to one of our colleagues from [Big 
pharmaceutical company A], and that was actually before I was here, and someone from [My 
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Company] was saying „if we did this, and we tried, we knew we hit the target, and so when the 
study failed we walked away from it". And she talked to me and said „you know at [Big 
pharmaceutical company A], we did four clinical studies because we thought we did not hit the 
target hard enough, it was this and that, and we kept trying. And we had not got the target 
engagement via PET tracer. We would have been walking away after the first failure.”  
Another interviewee reported that they had a close race with a competitor on a similar indication, but 
lagged behind. To catch up, they decided to use a diagnostic test to enrich the population. In the first 
two indications this helped to gain quick approval, and since there was a high disease prevalence, the 
enrichment had no adverse effect on their market potential. However, in the third indication, they 
observed a drop in the market potential. 
“... when we were doing the advanced NSLC … we had a limited population that we could have 
the drug available for. Because we selected…. Whereas [our competitor] has spent the program 
for several years and they will be able to show that it worked in all the patients… So that kind of 
set us back for a little bit … oh, Jesus look what have we done? We have anchored ourselves…”  
However, since they have put much work into the characterisation, application of the technique, and 
information gathering, they went again for the highly enriched population and could once again show 
a clear benefit.  
"When we got our first line [therapeutic], we went again for the highly enriched population, we 
had shown a clear benefit, whereas [our competitor] didn´t do that. They went for a much lower 
bar, they did not look for the higher population, and their NSLC was a complete failure. 2 So 
obviously this was a big win and all of a sudden, wow Juhu the diagnostic is really, is critically 
important." 
III. The Radiopharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Value of imaging/in-vivo imaging 
biomarkers? 
 
As expected, the interview partners of the radiopharmaceutical industry valued the clinical usability in 
patient management very highly. 
“MRI and CT see the disease in about 15% of cases, [product name] sees the disease in about 
70% of cases. And for that particular disease, the location of the disease had quite an impact on 
patient treatment… radiotherapy is expensive and hurt patients and some are getting 
inappropriate radiotherapy because the disease is already in the bones.” 
The interviewees acknowledge opportunities for these products in disease areas such as cancer, 
cardiology and neurology, with higher prospects for the latter ones.  
"There are huge opportunities still in cardiology, I tend to think that cardiology and neurology 
are better." 
Nevertheless, the interviewees are also well aware of the challenges and barriers of these products, and 
how this affects the implementation in the clinical patient management process, and their revenue.  
IV. The Medical Specialist´s View:  
                                                          
2 Note: What the interviewee is referring to is the cutoff for PD-L1 positivity of ≥ 50%, whereas competitors have been using 1 % to 5%. The 
therapeutic was consequently approved for the treatment of advanced NSCLC patients whose tumours test positive for PD-L1 using a specific 
assay (Dang, Ogunniyi, Barbee, & Drilon, 2016). 
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 Strong Pro Neutral Strong Contra 
Value of imaging/in-vivo imaging 
biomarkers? 
 
Advanced imaging is also rated very highly by oncologists/ medical specialists, especially when the site 
of the tumour has a therapeutic consequence.  
“But if the patient has any consequence from the localisation of a tumour, which cannot be 
shown with Liquid Biopsy, then it is of course just a question of tumour “yes” or “no”. Or what 
kind of genetic alteration or mutation does the patient have. … And if this results has any kind 
of consequence… imaging with the appropriate sensitivity and specificity is still indispensable.” 
However, our interviewees would not generally favour imaging, but would consider all available 
biomarkers which are able to solve the problem.  
“It depends on the problem! I would say that if it is just about verifying therapy response… and 
everything else is not from interest, then you could wave imaging.”   
One experienced urologist explained that the in-vitro biomarker PSA (Prostate Specific Antigen), they 
have been using for decades, is easy to apply, cheap, and often very helpful. However, sometimes the 
treatment is not goal-oriented (in this case he refers to patients with biochemical recurrence) as the 
PSA rise cannot be assigned to a particular location. In consequence, the patient will receive systemic 
therapy.  
“…that was not a target-oriented treatment, but it was shooting into the forest, with a great 
deal." 
In the future oncologists/ specialists generally expect an even more precise localisation of metastases 
(distant- and lymph node metastases), mapping of the affection in a local tumour and consequently 
influence on the surgery planning with (evolving) imaging techniques. All physicians (100%) anticipate a 
combination of in-vitro and in-vivo imaging biomarkers. 
“I believe the added value lies in the reasonable combination of both. I do not think that one will 
replace the other. But a combination of both will then be able to represent the best possible 
status of the patient." 
V. Brief conclusion on “The Role of Imaging”: 
Overall our qualitative research results support the current opinion about imaging in the clinical routine 
and the value in R&D. Interviewees from the Nuclear Medicine area, Oncologist/ Specialist, and 
Radiopharmaceutical Industry emphasise the impact of imaging on patient management, and the need 
for further development. The pharmaceutical industry is pleased to have research tools with high 
sensitivity and specificity, which enables them to get an earlier and better insight in pharmacokinetics, 
pharmacodynamics, target binding and enrichment for clinical trials. It is conspicuous that there isn´t a 
real overlap between the physician´s and the industry´s area of application. The pharmaceutical industry 
made it very clear that they are not very enthusiastic about the commercialisation of these intrinsic 
imaging biomarkers.  
 
4.2 Radiopharmaceuticals  
In this section, the results are focused on radiopharmaceuticals, aiming at answering the reasons why 
investors are not willing to invest in the area of in-vivo, nuclear medicine imaging biomarkers and what 
attributes weight in the decision-making process?  
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There were numerous wide-ranging opinions of the interview participants, which we have coded in units 
and then grouped into categories as described in the methodology section. These challenges can be 
roughly divided into the areas of development, economics, regulations and technology. As in the 
previous section; the data is subdivided according to the stakeholder groups. The statements will show 
the stakeholder´s perspectives on the main barriers and challenges associated with the approval, 
commercialisation and use of diagnostic and therapeutic radiopharmaceuticals.  
 
 
 
 
 
 
 
 
An important detail: The data presented in Chapter 4.2 is linked to stand-alone in-vivo diagnostic 
agents/ in-vivo imaging biomarkers, the Chapter 4.3 dealing specifically with companion diagnostics. It 
is essential to differentiate between those responses as imaging biomarkers are subject to different 
utilisation, regulation, market potential and thus interest from the investors (Table 26). 
Categorization of Imaging Biomarkers 
In-vivo Diagnostic Agents: United States of America: 
Medical imaging agents are generally governed by the same regulations as other drugs or 
biological products. However, because medical imaging agents are used solely to diagnose and 
monitor diseases or conditions as opposed to treating them, development programs for medical 
imaging agents can be tailored to reflect these particular uses (U.S. Department of Health and 
Human Services Food and Drug Administration -Center for Drug Evaluation and Research 
(CDER) & Center for Biologics Evaluation and Research (CBER), 2004). 
Europe: 
Diagnostic agents are medicinal products used for diagnosis or monitoring of a disease. The 
evaluation of diagnostic agents is governed by the same regulatory rules and principles as for 
other medicinal products. The principles used for the evaluation of medicinal products with 
respect to quality, pharmacology, toxicology, pharmacokinetics and safety apply to diagnostic 
agents. However, since diagnostic agents are used to diagnose and/or monitor 
diseases/conditions and not intendent to treat, the clinical development programs should be 
adapted for these purposes (European Medicines Agency- CHMP, 2009). 
Complementary Diagnostic: A test, which is not essentially associated to the safe and effective use of a drug. The test 
identifies a biomarker-defined subset of patients that respond differentially to a drug and aids 
in the risk/benefit assessment for individual patients (Beaver et al., 2017). 
Companion Diagnostic: A companion diagnostic is a medical device, often an in-vitro device, which provides information 
that is essential for the safe and effective use of a corresponding drug or biological product. The 
test helps to determine whether a particular therapeutic product is beneficial for the patient 
and will outweigh any potential serious side effects or risks (U.S. Food and Drug Administration, 
2018a). 
Table 26: Differences between in-vivo diagnostic agents, Complementary Diagnostic and Companion Diagnostic as defined by 
the Food and Drug Administration in the US, the European Medicine Agency in Europe and the literature. 
Figure 17 shows the coded topics, which have been extracted based on the interviewees responses.  
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4.2.1 Issue with Reimbursement 
The reimbursement of molecular imaging procedures is globally very heterogeneous regulated, 
especially in PET/CT the coverage policies are variable and restrictive. Within the last years, there was 
increased coverage of oncological indications in the USA due to the “coverage with evidence 
development” (CED) program, whereas in the European Union the coverage still varies considerably and 
creates uncertainty (Fischer et al., 2016). Reimbursement policies have a far-reaching effect on the 
adoption and the usage of medical technology (Office of Technology Assessment, 1982), and 
consequently on the investor´s interest. 
Our empirical data suggests that 
reimbursement uncertainty is a challenge for the stakeholders who are developing 
radiopharmaceuticals, but also for the physicians using them. Nevertheless, the interviewees agree that 
the efficacy of new medical technology needs to be evaluated objectively before general 
reimbursement is granted. The criticism is more related to the heterogeneity in evaluation criteria, the 
extent of data requested and the speed at which a request is handled.  
 
All statements regarding this topic are in the appendix on page 201 
 
I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Is Reimbursement a Challenge?  
Typically, it is in the interest of the marketing authorisation holder to timely develop a strategy for 
product reimbursing in the key markets. However, since the development and authorization of RPs 
remains with the academic institutions, those are also responsible for getting appropriate 
reimbursement rates. Therefore, it is not surprising that four out of seven (57%) EU nuclear medicine 
physicists called reimbursement of RP unsolicited as a challenge.  
"Yes, reimbursement is a huge problem, clearly. Reimbursement of costs is one of the main 
limitations for PET overall." 
A Nuclear Medicine Physicist´s view: 
 
"Yes, reimbursement is a huge problem, clearly. 
Reimbursement of costs is one of the main limitations for PET 
overall." 
A Pharmaceutical Industry´s view: 
 
"Right, the question is from the payer’s 
perspective "how much better does it have to be 
to make it worth to pay for it?" For their 
perspective that added cost has to take out costs 
out of the system somewhere else. They don´t 
want to pay more to get the same result, they 
want to pay less to get the same result.” 
A view from the Molecular Imaging Technology 
Industry: 
"What one of the obstacles we are facing, at least in the US, 
we still have an automatic “No” from Medicare for any tracers 
outside of oncology. So the recent two approvals the Ga-
DOTATATE and Axumin are both oncologic tracers so they 
went to local coverage decisions and got reimbursement. But 
let´s say we have a new tracer for Alzheimer, infection or heart 
disease we still have a standing policy of automatic no 
coverage, unless you got a full national coverage decision and 
that´s quite a daunting obstacle that is in the way." 
A view from the Radiopharmaceutical 
Industry: 
 
"I think getting products reimbursed is the biggest 
challenge in Europe. Governments like to pay, just 
from a PET scan basis, governments like to pay 
for PET scan as an FDG rate." 
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The interviewees acknowledge the fact that the lack of an official marketing authorisation status also 
profoundly affects the reimbursement of these products.  
"The non-authorisation and the reimbursement goes hand in hand. So under our current 
legislation, the admission is not fundamentally the problem, but due to the lack of admission, 
there is no refund. You can turn as you want, ultimately it is about that: it has to be paid in some 
way. " 
The majority of interviewed experts believe that there is sufficient clinical evidence to demonstrate the 
substantial effect of PET on diagnostic accuracy and patient management in specific indications. 
Therefore those procedures should be reimbursed by the health insurances.   
“…and based on the German Social Code V PET/CT is actually a compulsory service of the 
statutory health insurance, in the pre-stationary area…. However, the health insurance 
companies simply refuse to pay the costs, and this sometimes leads to difficulties. So the patients 
have to file applications, the health insurance companies reject that in part, then contradictions 
are filed. This is sometimes a bit of a hassle, but it is just a relatively small part of the patients 
we are currently looking after. However, it could be easier. It would also make things easier, 
especially if the federal committee, which is responsible for approving or payment of RPs, would 
work a little faster.” 
II. The Pharmaceutical Industry View: 
 Strong Pro Not mentioned Strong Contra 
Is Reimbursement a Challenge? One interviewee (33%) acknowledges the challenge, 66% no answer  
Experts from the pharmaceutical industry have a good understanding of the pros and cons of imaging 
in the clinical workup. However, concerning the topic of reimbursement only one interviewee (33%) 
sees this as a challenge, the other two interviewees (66%) did not respond to this question. The 
interviewee who commented on this question primarily focused on the low reimbursement rate: 
"…the margins are very low in diagnostics, there is more money in therapeutics, and we focus 
on the diagnostics we need to get the therapeutics approved and to people.” 
Another interviewee did not refer to challenging reimbursement rates for the marketing authorisation 
holder, but to the high costs associated with imaging test in general. So the reimbursement rates, from 
a payer´s perspective, are substantially higher compared to in-vitro biomarker test which in fact could 
affect the number of users.  
“And when you think about an imaging diagnostic test, it is a lot more expensive than that [in-
vitro diagnostic test]. So the added value must be substantial … Right, the question is from the 
payer’s perspective "How much better does it have to be to make it worth to pay for it?" From 
their perspective, that added cost has to be taken out of the system somewhere else. They do 
not want to pay more to get the same result; they want to pay less to get the same result." 
Another statement is leading in the same direction. 
"From a business point of view: if the drug is cheap then they can afford to prescribe it to a lot 
of people, who won´t benefit as long as they are not harmed… And so tumour mutations has 
been a very productive area for cancer research, and in that area, you have to accept that 
imaging has a very difficult battle to fight. Because in many cases you can see these mutations 
in circulating free DNA…. Then if you have a 50 Euros test based on a blood sample, why would 
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you use a $1,000 test based on nuclear medicine? And from the payer's point of view: if the drug 
does not cause harm, you are maybe better off  treating more people Including those who do 
not benefit, then having a very expensive test to stratify." 
There is a double burden for the developers of an in-vivo diagnostic test: a low margin and pressure 
from health insurance funds due to the relatively high cost compared to in-vitro test. 
III. The Radiopharmaceutical Industry View: 
 Strong Pro Neutral Strong Contra 
Is Reimbursement a Challenge?  
The expert´s response is distinctive: 100% of the respondents see the reimbursement of the products 
as a great challenge, at least for the European market. The interviewees made clear that there are two 
markets to compete: one in the USA, with reasonable pricing and reimbursement, and secondly the 
European Union, with less favourable reimbursement rates.  
“No, I do not think so [that it is a challenge in the US]. I think they [diagnostic products] will not 
receive the reimbursement of a therapy… I think diagnostics will be appropriately reimbursed 
unless there are major changes in the structure of the US market. However, for Europe, it is 
probably the case. The average price of an oncology drug in Europe is 30% of the price in the US. 
And reimbursement of SPECT and PET scans are in most European countries, meaning the 
reimbursement of the pharmaceutical part, is under pressure. In fact, in some countries, there is 
no reimbursement of the pharmaceutical part but only the cost of the actual scan, the imaging 
part is reimbursed. And that is a problem. So two parts for that: No, not worldwide but yes in 
Europe." 
Heterogeneity in the reimbursement of PET for various indications creates uncertainty for investors. 
The interviewees made clear that a high portion of their investment decisions is based on the current 
reimbursement situation in the US, not so much in Europe. Statements indicate that if the US would 
have similar reimbursement rates/difficulties as in Europe, the industry´s investments in new 
radiopharmaceuticals would further decrease and/or products will not be introduced in some European 
countries. 
"If the market for all PET and SPECT diagnostics is payment at either a technetium bone scan 
rate or an FDG rate, if that is the future, from now forever, for payment for nuclear medicine 
then at some point people will stop commercialise products in Europe." 
However, even in the United States, the reimbursement of RP is not favourable for all indications. RPs 
for an oncological indication are reimbursed, but in other indications such as neurology, there are similar 
problems as in Europe. This interviewee gave the example of the new Alzheimer's RPs, which were 
approved in regulatory terms in 2012/13 but have not been reimbursed to date. Moreover, he predicts 
that this will continue for years to come. 
“Getting past the FDA is not that bad, it takes time and money, but it is doable if you have a 
focused indication. But getting passed payment is a big deal." 
Even in Europe, the reimbursement situation is not uniform but differs from country to country. Some 
countries have a more open position than PET; others are very restrictive. 
“So there are insanely conservative countries like England, which is perhaps 20 years behind 
Germany. There are advanced countries such as Denmark, where almost all indications are 
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reimbursed, or France where FDG is relatively broadly reimbursed. Italy, for example, has six 
times more PET/CT examinations per million inhabitants than Germany. Because simply the 
reimbursement is better regulated. That is extremely different.” 
Related to the issue of reimbursement, an interviewee mentioned another issue that, from his point of 
view, creates another difficulty: the legal manufacturing of unauthorised products in some European 
member countries. 
"I think getting products reimbursed is the biggest challenge in Europe….And, if you develop a 
Lutetium therapy in Europe, you always got the concerned effect that somebody could make it 
in their own facility, as an unlicensed product. Not always to GMP. So if you are factoring the 
costs of getting a product approved that makes... it creates a difficult European market. That is 
not true in all European markets; there are well-regulated markets in Europe that remain good 
opportunities for development." 
IV.  The Molecular Imaging Technology Industry´s View: 
 Strong Pro Neutral Strong Contra 
Is Reimbursement a Challenge?  
Two, very knowledgeable interviewees, whose companies have been engaged in R&D of 
radiopharmaceuticals for a long time, also experience reimbursement as a significant challenge for RPs. 
Both interviewees showed good knowledge on the current reimbursement systems in Europe and the 
US and would rate the current reimbursement issue as a/ the primary reason why their companies 
pulled back from the development of new radiopharmaceuticals. 
“If a new test is developed that does not necessarily show the therapeutic benefit and the utility 
yet, then, of course, the reimbursement is also difficult. Especially when it comes to PET imaging, 
the question is: how high does the reimbursement have to be to cover the costs? For example, 
in SPECT, with technetium-based radiopharmaceuticals, the reimbursement is not that high, but 
you can still cover costs, which is much more difficult with PET." 
Also one interviewee from this group mentioned the problem of the "no coverage rule" of Medicare & 
Medicaid with RPs outside of oncological indications. This rule has a high impact on businesses because 
of Medicare & Medicaid insures more than 55 million people in the United States. The new PET RPs 
Netspot (68Ga- DOTATATE) and Axumin (18F- Fluciclovine) benefited from this rule and got a local 
coverage decision and reimbursement.  
“But let´s say we have a new tracer for Alzheimer, infection or heart disease we still have a 
standing policy of automatic no coverage unless you got a full national coverage decision and 
that is quite a daunting obstacle that is in the way. " 
For one conversation partner, the situation in Europe is more difficult due to reimbursement via the 
Diagnosis Related Group (DRG) system. The bundled payments per case may mean that new, innovative 
technologies are not taken into account and thus not paid. This puts the user and the company under 
pressure.  
“We have a model of hospital bundled payments where they lerp the costs of RP in the general 
procedure code for the imaging procedure. So like a needle or gauche, and the bundled payment 
in many cases does not even cover the costs of the RP alone. So every procedure the hospital 
would do, they lose money, and that is a huge disincentive to then utilise the tracer and a huge 
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disincentive for the commercial developer to try to recoup their clinical trial cost by having a very 
expensive RP charged. So the Amyloid agents, and some of the new RPs which have just emerged 
on the market, are in the thousands of dollars because they are trying to recover, in their short 
IP window, their own R&D investment. And yet the hospital gets only paid something less they 
charge for the RP for each patient; there is a huge disincentive.” 
The young start-up companies also consider this particular “DRG challenge” as discouraging to invest in 
the development of new products, an expert explains.  
“And the potential start-up companies are very aware of that and watching this closely. So if we 
sometimes meet with the small start-ups, that is one of the daunting things they find 
discouraging about investing heavily in new PET tracers. You can do all of this, and then you 
want to charge $ 2.000 or 3.000 a dose in clinical practice, the hospital would lose money on 
every dose, and thus don´t want to order a single dose of it. A real limiting thing on the horizon 
that is a bit discouraging." 
V. Brief conclusion on the topic “Reimbursement” 
 Strong Pro Neutral Strong Contra 
Is Reimbursement a Challenge?  
The majority of stakeholders answering this question (67%) agree that reimbursement is currently a 
challenge with an impact on R&D decisions. From the physician´s point of view, adequate 
reimbursement leads to a successful clinical utilisation of new technology, since industry can better 
protect their investment. 
Investors, such as the radiopharmaceutical industry, are closely assessing current reimbursement 
rulings and aligning their investment decisions. The interviewees confirm that in addition to the clinical 
benefit of the diagnostic product, the data for a successful reimbursement must also be simultaneously 
collected. As one health technology specialist, from an independent scientific institute assessing the 
efficacy of medical technology and drugs in Germany, summarised: “If I just want to bring a diagnostic 
test in the market, then it is completely enough to prove that the test can show the results it is intended 
to show…. For the regulatory approval of the tracer that is enough. Er, then to proof that you have a 
beneficially changed in treatment is much more difficult. That is the way the world is, just prove that 
"there is something", that is no longer sufficient.” 
The only expert from the pharmaceutical industry responding to this questions acknowledges that the 
margins in the diagnostic business are too low to engage in R&D activities and commercialisation. For 
the radiopharmaceutical industry, this topic is critical and at the same time one of the most significant 
challenges. Especially in Europe, but also in non-oncological indications in America. Should there be a 
further tightening in Europe, from an expert's point of view, there is the chance that some products will 
not be launched in Europe. The interviewees from the molecular imaging technology industry agree 
with statements from the radiopharmaceutical industry experts and additionally challenge that the DRG 
system in Europe is not well positioned to implement innovative technologies. This further discourages 
start-up companies to invest.  
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4.2.2 Challenge with Regulations 
Medical imaging agents generally are governed by the same regulations as other drugs or biological 
products, in the USA and the European Union. Since 1989, radiopharmaceuticals are classified as 
“medicinal products” and consequently underlying the same regulations as “conventional 
pharmaceutical drugs” if the radiopharmaceutical contains at least one or more radionuclides 
(radioactive isotopes) and it is intended to be used for the medicinal purpose (The European Parliament 
and of the Council, 2001). However, additional to the Medicinal Product Acts, radiopharmaceuticals also 
have to follow specific national regulations on radioactivity such as the “Ordinance of Radioactive 
Pharmaceuticals or Pharmaceuticals treated with Ionising Radiation” and the “Radiation Protection 
Regulations”.  
“Radiopharmaceuticals are amongst the most highly regulated of materials administered to 
patients because they are controlled both as medicinal products and as radioactive substances” 
(Sampson, 1994) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As already outlined in chapter 3.6 the radiopharmaceuticals are possibly amongst the tightest regulated 
medicinal products worldwide. Even after several attempts of harmonisation since the 1980s, 
radiopharmaceuticals are still subject to different national regulations worldwide. In the constituent 
treaty of the European Union, health care remained a national competence, which is why different 
interpretations of European regulations occur within the member states. This permits some treating 
physicians in the EU to administer a non-licensed product to their patients, under their responsibility. 
This heterogeneity is also reflected in the statements by the interviewees. 
All statements regarding this topic are in the appendix on page 202. 
I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Is Regulation a Challenge?  
There are striking different views regarding the topic of regulation. German, Austrian and Swiss nuclear 
medicine physicists perceive the regulations to be too strict and many criticise that RPs should not be 
A view from the Molecular Imaging 
Technology Industry: 
"And I think everybody’s outlook got 
better, with the recently two approvals 
... and the fact that these companies 
successfully found more creative ways to 
get through the FDA process and got 
reimbursement. The mood in general is 
much better than it was a few years ago 
where it seems all the big companies got 
out." 
A view from the Radiopharmaceutical Industry: 
"We think that, we think the market will get more 
regulated. Er, we don´t think the market will get less 
regulated, so er so we think there is a fantastic 
opportunity. Ah, and it looks like a good place for 
investment. I think, so we think the regulation will kick 
in at some point. And it will become a more regulated 
market." 
A Nuclear Medicine Physicist´s view I: 
"And the problem that we have in the legislation, and 
I assume that this is more or less the same all over the 
world, that you have laws for medicines, and also PET 
tracers are classified as medicines. And on the other 
hand, you have the legislation for radioactivity, right? 
... It is simply that the approval of a new PET tracer, a 
diagnostic tracer, is simply laborious because it is 
classified as a drug." 
A Nuclear Medicine Physicist´s view II: 
"I don´t think that the regulatory 
agencies are the bottleneck here. 
Actually they are doing really well. They 
have an interest to get this done. I am 
actually fairly positive about their work" 
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categorised like therapeutics. Interestingly, some German nuclear medicine physicists believe that 
“Germany is very restrictive” although the German national regulations give doctors more freedom in 
the use of non-authorised products than in other European countries. Some perceive that the national 
rules in Germany are part of the success of the nuclear medicine research field in Germany. 
“So in Germany, it is not a problem. Part of our success is that we can work with non-approved 
drugs. However, we are very much dependent on the German framework conditions and if at 
some point, in the course of internationalisation/globalisation, these full rules are standardised 
and the same everywhere, then we get a problem in Germany. " 
Many nuclear medicine interviewees value the possibility of having quick first-in-man studies and 
experiments with new RPs, but there are also voices that criticise the quick administration. Two 
interviewees proactively mentioned that they feel that new RPs should follow more structured 
preclinical safety and dosimetry studies before being administered to the patients. 
“Germany leaves them any freedom, which I welcome. I think that is great, but the problem in 
Germany is that you have room to do scary things, and then, if you really want to introduce the 
tracer to the market, then the hurdles in Germany are even more prohibitive than they are here." 
Another interviewee believes that the current legislation in Germany supports research in Germany, but 
does not back up the nuclear medicine field as a whole “… that we in Germany tend to go with the 
substances very quickly in the patient and do not worry about how we can create sustainable evidence 
of benefits.” However, certainly the data, which has also been collected in Germany, is indeed beneficial 
for new drug approval applications, such as for a new diagnostic RPs being currently in the approval 
process in the USA:   
“… the requirements [for a USA drug approval application] where really minimal and we were 
allowed to use European data… So based on that idea, there was essentially no Phase I trial 
required…. in the process we kind of bypassed the Phase III trial, because we made the argument, 
that FDA seems to be open to it, that Phase III is not needed given the extended patient 
population which has been studied in Europe, and also a large number of patients we have 
done." 
The interviewee from the USA is generally more positive about the attitude of the regulatory agency 
compared to the physicists in Europe. “I do not think that the regulatory agencies are the bottleneck 
here. Actually, they are doing really well. They have the interest to get this done. I am actually fairly 
positive about their work...” He also believes that Europe will fail to bring new tracers on the market, 
and it will be the responsibility of the US to do so. In his belief the current regulations allow to generate 
valuable retrospective, but not prospective data which is needed for a successful drug application: 
"The strategy has to be that one goes through it in a structured and organised way, which cannot 
be done in Europe … So we have to, I think the FDA is very helpful, and you have to go through a 
stepwise process, and it may take a bit longer, but we are imaging already, and we are treating 
PSMA patients. We are behind Europe, but that is not so much because of the process, this is 
because we were in hibernation in the US and overslept the whole thing.” 
Last but not least, European nuclear medicine physicists hope that harmonisation in the EU will take 
place and a more reasonable standard will emerge. However, they are also aware that any change in 
rules can affect their national practice, positively and the negatively. A very knowledgeable interviewee 
expects the following: 
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“There are developments that barriers will decrease in countries with high barriers. However, 
there is also the tendency that for countries that have barely now barriers, new barriers will open 
up. So there are certain tendencies for harmonisation at the most diverse level. So on the side of 
the regulations themselves ... then, of course, also from the law enforcement authorities.” 
II. The Radiopharmaceutical Industry View: 
 Strong Pro Neutral Strong Contra 
Is Regulation a Challenge?  
In opposition to the majority of nuclear medicine physicist, the radiopharmaceutical also industry see 
“regulation” as a challenge. But in the sense that it is not strict enough, so 100 percent contrary to the 
view of nuclear medicine group. In general, they do not explicitly criticise the current regulatory 
requirements, but see good cooperation. 
"Yeah, so we have a good experience with the regulatory agencies. The regulations that are in 
place are clear, and er you can have guidance from them. So we think the regulatory bodies do 
a good job." 
However, the experts of the radiopharmaceutical industry criticise the permission to use non- 
authorised RPs. This allowance differs across the EU, depending on how the European directives have 
been implemented, but creates the challenge for the radiopharmaceutical industry to compete against 
unlicensed products. 
“Er, you know I think that there is an interesting research community, there is an interesting 
situation in Germany under § 13.2b regulations whereby doctors can administer a RP outside of 
a clinical trial process…” 
These exemptions are not explicitly for radiopharmaceuticals, but this field has made the most of this 
rule. It had a very positive effect on the research community, but on the other hand, limits the industry´s 
efforts in R&D and the authorisation of new products. The interviewees from this group visualize an 
opportunity if the market becomes more regulated with time. 
“We think that we think the market will get more regulated. Er, we do not think the market will 
get less regulated, so er so we think there is a fantastic opportunity.” 
So both, the nuclear medicine interviewees and the experts from the radiopharmaceutical industry 
believe that the regulation will change, but in a different way. One interviewee from the 
radiopharmaceutical industry group can imagine that the large pharmaceutical company, which has just 
recently entered the market with a new therapeutic radiopharmaceutical, will no longer tolerate the 
use of unlicensed products in the same indications. Even if those institutions would use a different 
compound. Pressure from a powerful pharmaceutical lobby group could especially stress federal 
exemptions in regulations in Europe. On the other hand, as one interviewee from independent 
international cooperation confirmed, there is a high-level task force consisting of many significant global 
nuclear medicine associations with the aim to harmonise regulations in the EU and “educate” 
regulators.  
III. Brief conclusion on the topic “Regulation” 
In the group of nuclear medicine physicists, the German, Austrian and Swiss experts generally perceive 
the regulations to be too strict and many criticise that RPs should not be categorised like other 
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therapeutic drugs. The chance to have first-in-man studies relatively quickly are perceived positive, but 
for half of the interviewees this is sometimes too fast.  
The radiopharmaceutical industry also regards regulation as a challenge, but in their eyes, this is not 
strict enough. They, therefore, expect regulations to become more stringent, which would result in a 
limitation in the production and use of unauthorised RPs in European countries. So presumably 
regulations are already in motion mainly in Europa, although it is not yet clear in which direction this 
will change. Both the academic side and the industry are both very confident that the regulations are 
moving in their direction.  
Within the group of nuclear medicine physicists, one group of interviewees generally do not believe that 
regulations will harmonise, others expect a positive harmonisation and the third group fear a change to 
their detriment. However, any change could have a significant impact on the use of 
radiopharmaceuticals, at least in European countries.  
4.2.3 The Issue with Market Potential  
In general market potential is defined as the entire sales value or sales volume of a market for a specific 
product and period. Especially in the health care sector, the sales volume is closely connected to the 
reimbursement rates of the product. A change in reimbursement rates can lower or increase the sales 
volume, thus increasing the potential revenue for the competing companies. In this case, the return on 
investment (ROI) is the return earned from the investment made by the company. The ROI in drug 
research and development by the pharmaceutical industry was 3.2% in 2017, continuously declining 
since 2010 (10.1%) (Terry & Lesser, 2017). With the declining ROI, the pharmaceutical companies have 
shifted their focus on specific therapeutic areas with higher prices enabling them to maximise their ROI 
such as in the field of central nervous system (CNS) and oncology (Terry & Lesser, 2017). 
 
 
 
 
 
 
 
 
 
 
 
All statements regarding this topic are in the appendix on page 204. 
 
 
 
 
 
 
A Nuclear Medicine Physicist´s view: 
"The profit margin you get with the commercialization 
of a diagnostic test, that's just not as high as with a 
therapeutic substance." 
A Pharmaceutical Industry´s view: 
"...the margins are very low in diagnostics, there is more money in therapeutics and we focus on the 
diagnostics we need to get the therapeutics approved and to people." 
A view from the Molecular Imaging Technology Industry: 
"Well, I would say the problem ... having a relatively specific patient population, then developing something 
with a very specific target, and then you have to do the full Phase I, II, and III studies, which will cost you 100 
to 150 million. And then, in the end, this is not necessarily a huge commercial market, and then it's a big 
problem. Because of course, the margin is not as large in PET imaging as it is in contrast media or in SPECT 
nuclear medicine. You need to create your own local infrastructure or work with companies that locally 
produce the PET molecule and then deliver it accordingly." 
A view from the Radiopharmaceutical 
Industry: 
"We think there is a fantastic opportunity … in 
molecular imaging." 
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I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Market Potential a Challenge?  
In the group of Nuclear Medicine physicists, five interviewees (83%) perceive low market potential to 
be a substantial challenge.  
"Well, I believe that in diagnostic tests, unfortunately, the profit margin that one has with the 
commercialisation of a diagnostic test so that just is not as high as having a therapeutic 
substance." 
Interviewees from Europe, especially Germany, are generally more pessimistic about the situation in 
their home market whereas the interviewee from the USA has a favourable view of the 
radiopharmaceutical market and the introduction of new products.  
Europe:          USA: 
 
 
 
 
 
The reason for this pessimism in Europe? Well, the market potential is very much affected by the existing 
regulations and the reimbursement rates, and many interview partners have highlighted this 
connection. One of the interviewees is very self-critical and says that the nuclear medicine community 
is partially to blame for this low market potential since they have developed and produced the new 
tracers themselves, lost the chance to patent them and thus lost the investor´s interest. 
Some of the interviewees do not believe that sufficient profits can be realised with diagnostic RP. 
“One thing is for sure, that with a ... diagnostic product ... it is difficult to generate returns. If I 
think of Fluor-18 marker now, for Fluor-18 I need infrastructure around that ... and writing 
pharmaceutical profits is very difficult ... plus, because it is just diagnostic, you can, of course, 
charge a lot less .... with Ga-68 kit markings, I do not have the problem of logistics, but ... the 
margins are still worse and all reimbursement systems ... are never ready to pay as much as for 
therapeutic drugs.” 
However, some interviewees are very keen on the concept of Theranostics and expect the approval of 
therapeutic RP will also boost diagnostic RPs. The situation with therapeutic RPs is entirely different, as 
explained by a very knowledgeable interview partner from the US. 
“AAA will charge 47.000$ per cycle DOTATATE… so that accounts for 80.000$ or so per patient. 
Let’s have 10.000 patients, 40.000 cycles so you can calculate the significant amount of money. 
Now if you think of prostate cancer, you suddenly have, conservatively estimating, 40.000 
patients for 160.000 cycles. And each of them is 20.000$ or 25.000$ or 30.000$ than you can 
calculate, that this is multi-billion Dollar business. So that is we are talking, now they are coming 
in and like that stuff. Money being made." 
“And, for example, in the field of outpatient care, 
only a few indications (PET/CT) have been added, 
and even in EBM PET/CT is still not anchored. So 
that's a big obstacle for the industry I think that's, 
of course, not so nice. But they are of course 
targeting the US as a market, which is a very large 
market and where the approval of new RP has 
recently increased significantly in speed.” 
"If you look at the list of companies that have 
entered the imaging market it is quite stunning. 
There are a quite bunch of companies that come 
in. And also pharmaceutical companies are 
attracted by theranostics because that is the 
market. There is a big need.” 
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Some interviewees anticipate that the concept of theranostic will not only attract new investors, but 
diagnostic tests will also be able to swim in the wake of this concept, allowing it to gain more and more 
acceptance and receive marketing authorisation in the end. 
II. The Pharmaceutical Industry´s View: 
 Strong Pro Not mentioned Strong Contra 
Market potential a Challenge?   
All interviewees of the pharmaceutical industry confirmed that market potential is a definite challenge 
and they currently have no interest in the commercialisation of imaging biomarkers.  
“…the margins are very low in diagnostics, there is more money in therapeutics, and we focus 
on the diagnostics we need to get the therapeutics approved and to people.” 
An expert told us that they needed an imaging biomarker for a therapeutic drug and refunded a 
company the full development cost, to get access to that tracer. Moreover, even though they paid for 
the whole development, they did not wish to enter this challenging, low-margin business segment. 
"There are companies out there, which are developing molecular diagnostics and they have the 
same problem. They have very small margins that is a tough business. And in fact what happens, 
we did not develop the PDL-1 tracer, but we paid the company to develop it. Every penny they 
needed for it because we needed to have that test." 
Another interviewer has told us a similar strategy, where a company has also developed various imaging 
biomarkers for R&D of new drugs. Although they invested quite a lot of effort and budget in the 
development of these various markers the company has no interest in marketing these imaging 
markers. 
“In fact, we are developing a number of these molecular markers with academics. But I think the 
real question is "Are we really developing to use it all the way into a Companion Diagnostic?" 
and "Are we using, are we developing it all the way to make a business?" The answer to the last 
two is: probably no. Because this is not our primarily stream business.” 
III. The Radiopharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Market potential a challenge?  
Contrary to the pharmaceutical industry, the respondents in the radiopharmaceutical industry do not 
see “market potential” as a great challenge. Three of the interview partners (60%) expect the RP 
business to be a good investment with excellent growth opportunities in both the diagnostic and 
therapeutic segment. At least in the USA, which accounts for approximately 40% of global demand 
(Dubois et al., 2015).   
"PET biomarkers are a fairly big business. The PET market in the US is about 275 million a year, 
this year 2018. That is all PET in the US, revenue. So 275 million…” 
However, one must note that the interview partners come from small and medium-sized companies 
and not from large pharmaceutical companies. So a market potential of 275 million Dollar is minor 
compared to the revenue of “big pharma”, as one interviewee also recognises.  
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“The market opportunity for such a product is a niche compared to a therapeutic drug… A 
pharmaceutical company would say "Actually it costs me a significant amount of money and the 
market opportunity is low.”  
However, there is a relatively positive view of the respondents concerning the market potential of new 
diagnostic RPs, of course, if the new product can show the clinical utility and gets reimbursement. 
“If you brought another biomarker to replace FDG, for example, you would never make a 
business case for this. Because FDG is good enough and it is cheap. But if you have a very specific 
unmet clinical need, you can find basically a niche market. That is what Ga-68 NETSPOT/ Ga-68 
DOTATATE did, that is very specific. Very small market, but they charge 5.000$ a dose. So it is a 
business!” 
However, while respondents have a positive assessment of the market potential in America, they are 
concerned about developments in Europe. Restrictive access to novel radiopharmaceuticals due to 
negative assessments by national authorities, lack of market authorisation or low reimbursement rates 
also creates problems for the current market participants (see more comments in the appendix on page 
204).  
"If the market for all PET diagnostics and SPECT diagnostics is payment at either a technetium 
bone scan rate or an FDG rate, if that is the future, from now forever, for payment for nuclear 
medicine then at some point people will stop commercialise products in Europe." 
A concern is also the self-production of unlicensed products in Europe, which was mentioned by a few 
interviewees. Industry cannot compete against these prices and would lose a significant share of the 
market. However, all interviewees from these stakeholder group expect a stricter regulation, which 
would strengthen their position in Europe. "We think that we think the market will get more regulated. 
… and it looks like a good place for investment.” 
The interviewees also expect the concept of Theranostics to give the RP market a boost, even attract 
big pharma. "The reason why AAA is worth 4 billion is not because of the Gallium diagnostic, is because 
of the Lutetium therapy.”  
IV. The Molecular Imaging Technology Industry´s View: 
 Strong Pro Neutral Strong Contra 
Market Potential a Challenge?  
Historically, the medical device industry has always been a significant contributor to the development 
of new radiopharmaceuticals. The major players in this division have bought up specific companies, and 
engaged in the development of new products. However, the drop in market prices accelerated a wave 
of consolidation and terminated R&D activities. Our interview partners from this industry, therefore, 
had good knowledge on the topic. 
“So we had a discovery program, at one point we had maybe seven tracers in various steps of 
clinical development, and ended up closing it down. So we are not actively in the discovery phase 
anymore… But the little start-up companies are doing well and finding creative ways to do 
things. Moreover, maybe this kind of innovation belongs, it is lean and quick and finds creative 
ways to get it done. So I think the mood, in general, is quite good." 
Moreover, these responders agree that the market is difficult because costs of development are 
comparable to other pharmaceutical drugs, but the revenue is much smaller.    
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V. Brief conclusion on the topic “Market Potential” 
Three out of four stakeholder groups agree that the low market potential of diagnostic 
radiopharmaceuticals is a challenge and may detain investors from the commercialisation of new 
innovative radiopharmaceuticals. The interviewees from the nuclear medicine physicians, the 
pharmaceutical- and the molecular imaging technology industry group agree that the market is tight 
and the profit significantly lower, compared to traditional pharmaceutical products. The 
radiopharmaceutical industry, on the contrary, sees excellent opportunities in the diagnostic- and 
therapeutic RP business, at least in the United States. In this market new diagnostic RPs with an oncology 
indication have achieved much higher reimbursement rates compared to FDG, which in effect 
dramatically increased the market potentials. However, the RP industry experts also acknowledge that 
there is an entirely different situation in Europe. Companies struggle with the reimbursement of the 
products and currently compete against hospital in-house production centres in some major European 
markets. However, both interviewees expect that the regulation will become stricter in Europe, 
increasing the attractiveness from a market potential point of view.  
4.2.4 The Issue with Research and Development  
The term Research and Development (R&D) describes “any creative, systematic activity undertaken in 
order to increase the stock of knowledge, including knowledge of man, culture and society, and the use 
of this knowledge to devise new applications (Organisation for Economic Cooperation and Development, 
2018)”. This covers activities from fundamental- to applied research and the development to the 
finished product. The pharmaceutical R&D process is said to be especially challenging because it is 
associated with high costs, long duration and high attrition rates in all stages of the R&D process 
(Schuhmacher et al., 2016). Even despite new approaches and technologies it is not precisely 
understood how drugs would work and late attrition in the costly phase III stage are still common 
(Retzios, 2009). Without a financially strong investor, it is provoking to get pharmaceutical products 
through the market approval process, especially the clinical (phase III) trials require a considerable 
amount of resources and capital to demonstrate the safety and efficiency criteria of the regulatory 
authorities. 
All statements regarding this topic are in the appendix on page 206. 
A Nuclear Medicine Physicist´s view: 
"You know what the major issue is really costs too, who pays 
for it. If you don´t have stakeholders like in the 
pharmaceutical industry, which is now changing a little bit 
with Novartis having bought AAA. That changes the game, 
but as long as you don´t have stakeholders with a lot of 
money who is paying for it? That is really complicated, who is 
paying for the development." 
A view from the Radiopharmaceutical Industry: 
"Yeah, I think the really shared challenges with other 
therapeutic platforms is the cost of exploiting them. So  I 
think the advantage currently in the RP world is that there is 
a recent history of home production and of clinical use of RPs. 
Meaning that projects have been de-risked and therefore less 
expensive." 
A view from a Regulatory Specialist: 
"The costs, the costs. If a study is complex and 
cheap then it is more likely to be done than if it is 
easy and expensive. 
 
A view from the Molecular Imaging 
Technology Industry: 
"Well, I would say the problem, especially in 
oncology, is that you have a relatively specific 
patient population. You develop a very specific 
target, and you have to do the full phase I, II, and III 
studies. This costs you 100 to 150 million and in the 
end there is commercially not necessarily a huge 
market." 
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The responses were wide-ranged. The literature search has linked the category "R&D" above all with 
the argument of the “costs of development”, but the interviews revealed other issues such as speed of 
development in the therapeutic sector, regulatory hurdles et cetera also play a role.  
I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Is Cost of Development a Major 
Challenge? 
 
The interviews have shown that all interviewees are very sensitive to the issue of cost, whether in 
connection with new product development or reimbursement. Due to the structure of the interview, 
the interviewees were not directly addressed on the subject of development costs, but they should 
name the biggest obstacles in the approval and the barriers and why there are no investors in the field 
of diagnostic radiopharmaceuticals. However, astonishingly, four out of seven responders (57%) 
mentioned costs of development being a challenge for new diagnostic RPs. 
“You know what the major issue is really cost too, who pays for it? … as long as you do not have 
stakeholders with much money, who is paying for it?”  
Another interviewee linked the costs of development in his response with the high burdens imposed by 
regulatory requirements and the rising study requirements. 
“So if we want to use a new tracer today ... just for research purposes, I have to spend 100,000 
CHF to do a toxicology study. This will stifle any research project immediately. So that is the 
problem with the PET tracers." 
However, in addition to the argument of costs, other challenges in R&D were also addressed. 
Interviewees mentioned that due to the rapid pace of development in the therapeutic field, diagnostics 
research is far behind and can usually not close this gap.  
"So there's a number [of challenges] and also keeping pace with the rapid development of new 
therapeutics. We cannot keep up with the development of diagnostics that would fit for 
therapeutics." 
Remarkably, nearly half the interviewees have also admitted errors in their actions regarding the 
development and commercialisation of new tracers. Three interviewees reflect on the expeditious 
administration of new, experimental diagnostic and therapeutic RPs in massively ill patients by the 
national regulation of § 13.2b AMG.  
"And that is actually a problem; I think that is a problem of our system that we in Germany tend 
to administer the substances very quickly in the patient and do not worry about how we can 
create sustainable evidence of benefits. So somewhere there should be a compromise… Although 
it is possible in Germany, but the global success is held back by the regulations." 
These interviewees acknowledge the fact that in order to have successful commercialisation of a new 
diagnostic RPs they would be happy to have the industry´s support to speed up the development of 
these new diagnostics, but also the desire to learn how to plan and conduct clinical trials.  
“... what we urgently need in academic research is the support from the industry. So the thinking 
of the development steps: of phase 0-III; what are the requirements? How can you do something 
specifically?” 
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Improving the quality of the trials by following the current EU regulations is a request by an experienced 
radiopharmacist, who is also engaged in an international committee and has a good overview on current 
academic research. 
“(Academic research must) conduct more clinical trials, and a clinical trial means, in accordance 
with current EU regulations, as notified drug trials. These studies need to generate data that is 
really usable for approval. Moreover, that is not as difficult as it is often portrayed. Of course, it 
takes money and time, yes. Moreover, it will not work for everything that you would like to 
have...and there is already pressure from the authorities and also (the nuclear medicine 
physicists) see the reason. There are already more controlled studies! For example, where, in the 
simplest case, one can accurately portray safety and say it is a registered study whose primary 
objective is safety. For example, this is something which was never done for DOTATOC.” 
II. The Radiopharmaceutical Industry´s View: 
 Strong Pro Not specifically mentioned Strong Contra 
Is Cost of Development a Major 
Challenge? 
 
The interviews with the radiopharmaceutical industry experts illustrate that the companies do not make 
one problem prescient, but factor in all the challenges that arise in the development process. Because 
there is such a strong correlation between costs of R&D initiatives, regulatory requirements of the 
approval process, and expected reimbursement rates, one needs to see all the challenges in context.  
“The PET biomarker industry in the US is very difficult, it is difficult to get approval from the FDA, 
and it is even more difficult to get reimbursement from CMS.” 
However, the interviewees also acknowledge the fact that due to academic research in the RP field, the 
development of specific RPs was de-risked because the compound has already been used in first-in-man 
studies, in compassionate use situations or tested in preclinical models by academic researchers. 
However, this does not mean that total investment will decrease. 
“So effectively, those initial data, what they have done is, they de-risked the chance that the 
therapy fails. However, they have not decreased the total investment you have got to make the 
product into eh, something the regulator will approve." 
Extensive research in the academic field may create more challenges than benefits for the industry. 
Many academic clinical studies do not meet the general- and quality requirements of the FDA and EMA, 
thus the data is not useful for an official approval process. One interviewee is especially surprised that 
in Europe non-authorised diagnostic RPs quickly find the way in the official guidelines, and to his mind 
this is not acceptable.  
"And then they want to get ahead of themselves. As soon, they do... they kind of proof that 
technology works, and then before it actually been through a formal approval process, they start 
to incorporate it into guidelines, and the European Association of Nuclear Medicine promotes a 
lot of unlicensed RPs. And it is probably not the correct thing for them to do.” 
It is confirmed that the cost or low efficiency in the development of new diagnostic RPs has deterred 
many of the "old" RP industry participants, leaving them out of the market.  
"I just wanted to stress that [our company] was in the biomarker development business in the 
US for a decade, spend a tremendous amount of money. Hundreds of millions of dollars and got 
out of it because it was such a drill hole." 
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However, the "new" start-up companies usually already have a sound concept to attract investors and 
have substantial knowledge of the costs of development. Moreover, it seems that these new actors are 
not bothering specifically about the cost of development, but rather about the high regulatory 
requirements in the approval process and costs associated with commercialisation.  
“But the little start-up companies are doing well and finding creative ways to do things. And 
maybe this kind of innovation belongs, it is lean and quick and finds creative ways to get it done.” 
We wish to briefly cover the therapeutic RPs research program because it seems that there will be some 
momentum going into this area. One interviewee expects that the acquisition of Advanced Accelerator 
Applications (AAA) by Novartis as not being the last acquisition we will see shortly.  
“From a discovery point of view, the one big advantage of RP will have, it will be possible to go 
back over the back-catalogue of large pharmaceutical companies and find compounds with very 
high specificity, but don’t have a therapeutic effect. So I think that will be an interesting and less 
expensive development in the next couple of years. Things that have failed and have been written 
of, because basically, they did not work. But they accumulated in a target; they might be of use 
if they can be labelled with radiation." 
III. The Molecular Imaging Technology Industry´s View: 
 Strong Pro Neutral Strong Contra 
Is Cost of Development a Major 
Challenge? 
 
It is no secret that many of the top molecular imaging technology manufactures have also engaged in 
R&D activities around new diagnostic radiopharmaceuticals, which is also true for the two interviewees 
in this study. Both companies sell molecular imaging equipment and service, one company also focuses 
on the “life cycle management” of their RP portfolio, whereas the other company also has an associate 
company, which produces and distributes radiopharmaceuticals on behalf of other enterprises.  
For these two companies, however, it is true that the enormous costs of development, combined with 
the low success rate of approved RPs, were the deciding factors to pull out of this business.  
"Well, I would say the problem, especially in oncology, is that you have a relatively specific 
patient population, you develop a particular target, and you have to do the full phase I, II, and 
III studies. This costs you 100 to 150 million, and in the end, there is commercially not necessarily 
a huge market." 
Some insights from one interviewee revealed that his company had launched an RP a few years back, 
which had development costs of around $ 100 million. Due to a challenging global market situation, this 
RP has not paid off yet. As a consequence, a new product for the same disease is put on hold. “… and 
(the company) has no interest in repeating that with the (new) imaging molecule." 
However, due to the close integration of radiopharmaceuticals with imaging devices, both interviewees 
reassure us that their companies will continue to support clinical trials and specific research institutions 
in their research effort.  
"We probably do not do enough, in my opinion, because we could do more. Of course, that is 
always a matter of money, and I still see much academic interest in developing new molecules. 
We internally decided not do discovery and early phase research anymore, but in principle, we 
should try to be a little bit more active. This would allow us to license promising projects at a 
later time. So the pipeline is no longer internally but externally, but so we can also boost research 
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through collaborative research. Thus that would be a logical consequence of deciding that we 
do not do so much by ourselves." 
VI. Brief conclusion on the topic “Research & Development”: 
 Strong Pro Neutral Strong Contra 
Is Cost of Development a Major 
Challenge? 
 
Among nuclear physicians and the industry, the topic of R&D is closely linked to the argument of costs. 
Together, the responders from all stakeholder groups see this issue to be a challenge (57% of total 
answers). However, there seem to be other challenges as well, which keep all stakeholders busy. On the 
nuclear medicine side, this is regulatory requirements for clinical research, as well as the collaboration 
with the industry or developers of new therapeutics. Moreover, some of the nuclear physicians have 
also realised that their research approach (especially in Germany with § 13.2b AMG) may negatively 
influence the global success of RPs. The radiopharmaceutical companies have not explicitly mentioned 
costs of development as being a significant challenge, probably because they are well aware of these 
costs and have taken sufficient account of them in their business plan. The administration and use of 
un-licensed RPs in some big European markets seems to be a greater challenge for the industry as it 
creates a secondary market the industry cannot compete.  
The interviewees of the MITG reported about their difficulties in the development of new 
radiopharmaceuticals, especially regarding cost and efficiency. These companies continue to support 
public and private institutions in developing new diagnostic radiopharmaceuticals and hope for a 
flourishing market in the future. Generally, R&D in the RP business has changed, with big companies 
leaving- and new start-ups entering the market: they are “lean and quick and find creative ways to get 
it done.” 
4.2.5 The Issue with Intellectual Property Rights (IPR): 
When speaking about Intellectual Property Rights (IPRs), we refer to the assigned rights through 
patents, copyrights and trademarks, which allow the holder to have an exclusive monopoly position 
over a specified period (Khemani & Shapiro, 1993). In general, IPRs stimulate innovation by “increasing 
private research investments in new technologies by allowing inventors to capture a higher share of the 
social returns to their inventions.” (Williams, 2015). Especially the healthcare industry experiences high 
R&D costs and relies heavily on IPRs since many of the pharmaceutical drugs are easy to replicate and 
thus have no technological barrier for competitors. However, IPRs are not excluded from country-
specific laws, which in effect could undermine those rights (Williams, 2015). The official allowance on 
the use of unlicensed products in hospital settings, in some European countries, needs to be considered. 
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All statements regarding this topic are in the appendix on page 208. 
The 
topic of intellectual property concerns all stakeholders and everyone is aware of the impact on the 
development of new radiopharmaceuticals. It turns out that industry experts are very knowledgeable 
in this area and can even pinpoint to the different types of patents. The view of the physicians is a bit 
more superficial, but they are also aware of the consequences.  
I. The Nuclear Medicine View:  
 Strong Pro Neutral Strong Contra 
Are IPRs a Challenge?  
Apart from one interviewer, the challenge of IPR was not independently mentioned by any of the 
interviewees. One interviewee did not directly use the word IPR but referred to the problem of lacking 
patenting with diagnostic RPs. "Well, we are partly to blame ourselves, because we do it ourselves 
because it is not patentable often."  
During the interview, the interviewer addressed the issue of IPRs to the experts, with five interviewees 
explicitly responding. Generally, the interviewees confirmed that there must be some protection to 
attract investors and enable further development. Three interviewees consider the issue of IPR as a 
challenge (60%), one response was categorised as “neutral” because he believes there are many options 
to protect your product. 
“Of course it helps if something is protected… In my opinion, it is not true that only products that 
are protected will be developed. It can also be a certain protection exclusivity of other things, for 
example, from a certain time advantage you have. “ 
Of the two respondents, who regard IPRs as a challenge, one believes that ultimately all existing 
problems are due to patents. The second responder took the opinion that a patent for a substance with 
low market potential -such as many diagnostic RPs- could prevent others from entering this disease area 
and therefore delay the introduction in the clinical routine. 
A Nuclear Medicine Physicist´s view: 
"They only get an industrial partner, if they really have a 
patent on their academically developed product. This has 
to be accelerated, and again it is important that this is 
simple to implement for the academics." 
A Pharmaceutical Industry´s view: 
"Well, IP is very broad. So if you have a tracers you can 
develop IP on the composition of matter, if you have an 
imaging biomarker which is based on a CT signature or we 
talked about Ferriscan, so the MRI R2* that is not a tracer 
that is a relaxation time and you don´t get IP on the 
relaxation time because it was discovered by physicists 50 
years ago or more. Where you can develop IP on is in 
copyright and business processes." 
A view from a medical specialist: 
"So completely different (situation between Europe and the USA). In every internal meeting there was always 
a lawyer present, which took me by surprise. He proactively approached us and offered to at least check 
whether a patent can be obtained. The hurdle was also relatively low, that the patent was filed. But when I 
developed this [idea], I called the [University in Germany] lawyer at the hospital. The hospital told me: "We do 
not have a Patent attorney anymore, that's what the university does itself." ...and he [the university attorney] 
said that it does not pay off at all, that's such a hassle and he does it only in justified exceptions." 
A view from the Radiopharmaceutical 
Industry: 
"I think that is the cause of everything we do, 
is having a strong IP position. So you know, if 
we had an academic collaborator coming to us 
and say that is great technology and it is not 
patented, that would be just a really big red 
flag for us. I know AAA effectively has a 
generic product and they have invested, er 
which is fantastic but er, from our perspective 
we would have looked for a reason with strong 
IP position." 
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“In the end, the problems are always related to patents. You have to own a patent so you can 
make money in the pharmaceutical industry. Moreover, if the regulatory hurdles are extremely 
high, then you have a patent, and so you can use all the crap it may take ten years. Then half 
has already expired." 
"I will give you a concrete example now, the Gallium PSMA-11 tracer. Which is probably the 
second most used clinical tracer, after FDG. If Gallium PSMA-11 had been patented, it would not 
be there today. Because it would have taken much longer for this to be implemented." 
However, there are also statements from experts who regard this story with a much more relaxed 
attitude because IPRs can readily be agreed on in advance. Especially in the "classical" industry-
academic partnerships, one interviewee sees this topic as “relaxed” and another “does not think this is 
a problem”. 
"Intellectual property is always a problem; you have to define it beforehand ... Researchers are 
also beneficiaries in my view because you have the same partner during exploitation and you do 
not completely lose the patent. … as a researcher you can be happy to participate financially. 
This is also just an advantage." 
However, regarding the negotiation and agreement of IPRs between industry and academic institutions, 
four interviewees believe that the academic aspect primarily causes the challenge. The responders 
explained that securing intellectual property is a complicated process in many universities.  
"I think the challenge is more on the university side, that such patenting can be done efficiently, 
non-bureaucratically and standardised. Nowadays, if you have something new and you have no 
patent, than it is not worth anything to the industry." 
"They only get an industrial partner, if they have a patent on their academically developed 
product. This has to be accelerated, and again it is important that this be simple to implement 
for the academics." 
Additionally, the topic of royalties became relevant. An experienced nuclear medicine doctor argues 
that the universities have the task of securing their rights, but need to be careful not to overstate their 
royalties and thus create another hurdle.  
"And when they (the university) starts to say:" I have to care that the university earns a stupid 
amount of money", then this patent can again have prohibitive/negative consequences." 
II. The Pharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Are IPRs a Challenge?  
We attempted to question the pharmaceutical industry about the topic of IPRs, because literature 
suggests that the pharmaceutical industry i.e. heavily relies on their patent rights (H. G. Grabowski, 
DiMasi, & Long, 2015).  
Unfortunately, the result is not representative because we received only one statement. This 
interviewee explained that he is very interested in IPR, but he also acknowledges the fact that there are 
multiple ways of protecting the compound/ product. Therefore, not having the patent of the chemical 
entity does not seem to be a reason for a complete blockade from his point of view. During the 
interview, it quickly became apparent that this company knows pretty well how to protect its products 
and developments.  
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"Well, IP is very broad. So if you have tracers, you can develop IP on the composition of matter, 
if you have an imaging biomarker which is based on a CT signature or we talked about Ferriscan, 
so the MRI R2* that is not a tracer that is relaxation time. You do not get IP on the relaxation 
time because it was discovered by physicists 50 years ago or more. Where you can develop IP on 
is in copyright and business processes. So with Ferriscan the IP there is on the copyright of the 
software, the business process, the whole procured for validating scans and giving the physician 
validate R2* measurements. Moreover, again I would urge you to think... Imaging is not just out 
of proprietary tracers, even in PET FDG has a very important role to play, and even there is no 
property to secure on that anymore.” 
III. The Radiopharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Are IPRs a Challenge?  
Following the withdrawal of large industrial companies from the radiopharmaceutical business, the 
current oncological market is increasingly composed of small and medium-sized (start-up) companies, 
with some big pharmaceutical companies still being engaged in the neurological RP field. This should be 
mentioned only briefly in advance because this has an impact on their capital structure and 
consequently on their view of IPR. 
If one summarises all the answers of the interviewees from this industry group, then IPR does not seem 
to be a challenge, but it is an essential aspect. In one case, it was difficult to evaluate the interviewee's 
answer, as on the one hand, he explained that without IPR nobody would invest in the product, but on 
the other hand, he sees “IPR as not too important”. We have therefore included both answers in the 
evaluation.  
“…So somebody stepping in… moreover, they will not do that unless there is… unless they can 
get patent protection on their investment. One thing that mitigates in the US a little bit, if you 
bring what is called a new chemical entity to the FDA… you get 5 years of exclusivity. 
Independent on any patent, the FDA will not approve another application with that biomarker 
for five years. So you have five years basically to try to recube your investment. … So the patent 
is not too important." 
One interviewee explained how they targeted IPR and built a "protective wall" around the product. He 
made clear that he would/could not wave the chemical property patent due to their external funding 
from an investment firm. 
“So from our perspective, when we build up our IP portfolio we don´t rely on one piece of IP. We 
like to have the chemical entity, and then we build a whole layer of onion around it. About 
different IP that covers the manufacturing process for the product, how the product is being used 
in the field. So you can build, but not having the chemical entity IP is definitely something that 
when we go to investors, to ask to invest in new ideas we got, the first question they ask is: 
“What is the IP position?” And it is a big red flag for them if you don´t have chemical entity 
protection, from an investor perspective. But the [pharma] guys also know that there are ways 
to get around it. But there aren´t always ways to explain that to investors (laughs).” 
This interviewee also comments on a move from a competitor, who decided to continue the 
development of a product with on expired patent. “I know AAA effectively has a generic product and 
they have invested, er which is fantastic, but er from our perspective we would have looked for a reason 
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with strong IP position.” AAA managed to have a patent on the labelling process, but also profits from 
the orphan disease status awarded by EMA and FDA with extended exclusivity protection rights. 
A further interlocutor talked about his experience with academic institutions and how they agree on 
license fees.  
“Er, no I don´t think so. I think the market will determine the price, so IP…. In terms of the royalty 
percentage for the IP, I think that is only market forces. Some universities take a very reasonable 
approach and have 3-4 % royalties. Others insist of a much higher percentage, and I think the 
market will just determine, so I don´t think that is a problem." 
Of course, the interviewees prefer the patent protection of the substance and see the responsibility in 
the hand of the universities.  
“And academic need to think about that IP and protecting it. So there is an asset worth investing 
in. (laughs).” 
“Academic institutions are very variable in their approach to IP. And you know there are some 
really smart about it, and they understand that they need to protect it and protect it well, and 
there are others. But I think, maybe the academic community understands that more every 
year." 
One interviewee explicitly stated the consequences, which could happen and had happened with a 
promising substance: “That was a big move for Heidelberg around Ga- PSMA PET, for instance, they 
didn´t patent it. And now there is a good technology that is available so could have relevance in prostate 
cancer. But there isn´t really a company who wants to invest in it. Because Heidelberg failed to patent 
it."  
Finally, the radiopharmaceutical industry sees the academic research community as a fruitful place for 
new ideas and products. Therefore they engage in close collaborations with the chance to gain early 
access to new ideas. But again, for this specific responder, they are happy to engage in further discussion 
if the offered technology or idea has protection or protection is still feasible. 
“Interviewer: So you also tried to gain IPR through these collaborations, is it a goal for you? 
Interviewee: Yes, yes. I think that is the cause of everything we do, is having a strong IP position. 
So you know, if we had an academic collaborator coming to us and say that is a great technology 
and it is not patented, that would be just a really big red flag for us.” 
IV. The Molecular Imaging Technology Industry´s View: 
In this case, just one interviewee answered the question about IPR, and his answer goes along with 
the other representatives of the industry.  
"Yeah, there is, if I can I will break that into two categories because there are some very 
interesting RPs they do not have IP protection anymore. Even they have never filed for a patent 
in the first place, or they have been around so long that the patent has effectively been 
expired. Moreover, those are interesting, but a company have not really get behind it because 
they would spend all the money on clinical trials and the approval process and then anybody 
could make a generic." 
 
 
VII. Brief conclusion on the topic “Intellectual Property Rights”: 
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 Strong Pro Neutral Strong Contra 
Are IPRs a Challenge?  
Summarizing: IPRs are regarded as necessary by all stakeholders, but overall it does not seem to be a 
challenge. The Nuclear Medicine Group acknowledges the relatively high R&D costs associated with 
the development of new agents and thus admits that this investment must be protected. For some of 
the European nuclear medicine interviewees, the universities have failed so far to establish a system 
where ideas and inventions can be registered quickly and non-bureaucratically. A medical specialist 
had himself experienced how fundamentally different the process of IPRs protection is handled in 
Germany and the United States. 
"So completely different (situation between Germany and the USA). In every internal meeting 
(in the USA) there was always a lawyer present, which took me by surprise. He has proactively 
approached us and offered to at least check whether a patent can be obtained. The hurdle was 
also relatively low that a patent was filed. However, when I developed this [idea], I called the 
[University in Germany] lawyer at the hospital. The hospital told me: "We do not have a Patent 
attorney anymore, that is what the university does itself." ...and he (a patent attorney from the 
university) said that it does not pay off at all, that is such a hassle and he does it only in 
justified exceptions." 
In a partnership with the industry, the nuclear medicine group does not regard IPRs to be a challenge, 
because terms can be defined and negotiated in advance. 
The interviewees from the industries confirmed that protection of their investment is essential. 
However, opinions differ about the type of protection. A pharmaceutical industry interviewee sees the 
possibilities of protection very versatile, with the patent on the chemical entity being not so 
important. In contrast, a radiopharmaceutical interviewee regards the patent on the chemical entity 
as very important. However, he agrees that there are other forms of IPR protection, but not having the 
patent on the chemical entity is a red flag for investors.  
4.2.6 The Issue with Manufacturing, Distribution and Handling 
Compared to conventional pharmaceutical products, radiopharmaceuticals pose a challenge to 
manufacturers and users regarding production, distribution and handling. The production is, compared 
to typical pharmaceutical production, on a small scale but the compliance of cGMP makes the 
production difficult and expensive (International Atomic Energy Agency, 2008). The regulation requires 
“qualified personnel, use of controlled materials and procedures, availability of qualified equipment, 
production of the products in designated clean areas, applying validated processes and analytical 
methods, full documentation of the process and release of the final product by a qualified person 
(International Atomic Energy Agency, 2008).”  
The radioactive substances itself, used to mark the biologically active compound, are either produced 
on site in a suitable facility (e.g. cyclotron for diagnostic RP) or are produced in large research reactors 
at short notice and then delivered immediately. The legal requirements for the transport, import and 
handling of these substances are detailed and require optimal logistics in order to bring these 
substances to the customer. For diagnostic RPs, the time component is essential because of the short 
half-life of radionuclides. Many institutions, therefore, use their own cyclotron for the production of, 
e.g. fluorine-18, or use a generator such as Gallium-68 to have the radionuclide available any time. 
Radionuclides used for therapy are mainly produced in reactors, have a longer half-life and therefore 
have a more suitable situation regarding distribution. 
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In general, the issue of manufacturing, distribution and handling was not a hot topic in all stakeholder 
groups. None of the interviewees proactively mentioned that this would be a "serious" problem. Still, 
the interviewee from the pharmaceutical industry stressed that this could be a problem if regarded an 
RP as being a companion diagnostic for their therapeutic drug. Otherwise, this topic was mostly 
mentioned in connection with the topic of reimbursement and regulations.  
All statements regarding this topic are in the appendix on 209.  
I. The Nuclear Medicine View: 
 Strong Pro Neutral Strong Contra 
Manufacturing, Distribution and 
Handling a Challenge? 
 
There were very few comments from this stakeholder group on this topic, assuming that manufacturing 
of RPs does not cause any significant obstacles. However, the complicated process has an impact on 
business margins: 
“Now, when I think of 18- Fluorine 18 labelling, for F-18 I need infrastructure ... and (pause) 
generating typical pharmaceutical profits is very difficult.” 
The short half-life of radionuclides is particularly challenging in the field of PET imaging but has been 
mitigated by the availability of Ga-68 generators and new labelling capabilities. Logistics becomes even 
more comfortable with therapeutic RPs, as the half-life increases significantly. 
"... these therapeutics typically have half-lives in the range of days and not in the range of hours. 
This changes the whole logistics. So they can produce Lutetium DOTATATE in Holland, and from 
there they can flood the world." 
II. The Pharmaceutical Industry´s View: 
The interviewees of the pharmaceutical industry currently have had hardly any experience with the 
manufacturing, distribution and handling of RPs, because it is not in their portfolio. However, they see 
challenges associated with the manufacturing and distribution of RPs.  
"When the drug company is developing the drug it is developing it for a global market… they 
think if you can sell it in the United States and EU, they are also thinking about China, Philippines, 
A Nuclear Medicine Physicist´s view: 
"And the problem with the radioisotopes, which are relatively 
short compared to SPECT with technetium, I consider not to be 
problematic. I believe that the availability of PET is not really a 
problem, at least in Germany, not even in the US, I do not 
think this is a problem in any industrialized nation." 
A Pharmaceutical Industry´s view: 
“… drug companies develop drugs for global markets and so 
the imaging also needs to be available in that global market. 
And that are really difficult problems, the academics often 
miss." 
A view from the Radiopharmaceutical Industry:  
“You have high fixed costs, a lot of cyclotrons, chemicals 
labors, people, but you can still make a good margin on that." 
A view from the Molecular Imaging 
Technology Industry: 
 
“On the other hand, PET is problematic because 
you need PET centers to make the tracers locally 
and thus the margin is always worse than in SPECT. 
And that's unlikely to change. Either you need your 
own infrastructure, which will increase base costs, 
or you'll be working with local partners who 
manufacture PET tracers." 
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Brazil, Indonesia. These are important markets! … If you are going to have diagnostic in your 
label you want to make sure it is available in every hospital in China, Philippines, Brazil otherwise 
you would not sell this drug. From that point of view you have PET agents... at least..., carbon is 
out of the question, fluorine can be challenging because of the half-life. Technetium is much 
more attractive. Gallium obviously with PET is more attractive, because you can use a generator 
and a nuclear medicine department can make it locally. Moreover, if I were looking at developing 
a personalised healthcare compound, I would be very cautious about the fluorine agent." 
So logistics is a topic from the pharmaceutical perspective. As we can see in the statement above this 
responder would even prefer an RP for SPECT, because it would at least simplify the logistics process. 
III. The Radiopharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Manufacturing, Distribution and 
Handling a Challenge? 
 
For the radiopharmaceutical industry, the manufacturing, distribution and handling of these products is 
a core competence. None of the interviewees from this group has proactively identified this topic to be 
a severe problem. However, one can see that the expansion of manufacturing needs to be planned 
carefully and gradually developed. 
"And what we are doing now is rolling out the manufacturing infrastructure to make the product 
available... That gives us an opportunity to provide a product that is Er, the same in all markets 
effectively." 
The production of these products is associated with high costs, consisting of costs for technical 
equipment, raw materials and qualified personnel.  
“You have high fixed costs, many cyclotrons, chemicals labours, people, but you can still make a 
good margin on that." 
In the meantime, there are even companies that produce the product and take over distribution on 
behalf of the license holders.  
"So [the company] is sort of, not an R&D organisation, we are a biomarker production and 
distribution company. We are the market leader in the US, we have 43 pharmacies, we have 
about 48% market share, we do about 1 million doses a year, and we supply these doses to about 
1 million patients a year… work with other partners, other businesses that are in this field and 
need a commercial outlet for the biomarker." 
IV. The Molecular Imaging Technology Industry´s View: 
One interviewee from this group, who has experience with manufacturing and distributing of RPs, did 
not complain directly about the high costs but points out the connection between production costs and 
reimbursement. 
“And in principle, especially as far as PET imaging is concerned, the question is how big 
reimbursement has to be to cover costs of the test… SPECT is much simpler. And especially 
technetium-based products, even reimbursement is not that high, you can still cover costs, which 
is much more difficult in PET." 
Moreover, the production costs of PET RPs may not decrease significantly in the future. Thus there will 
be continuous pressure on margins. One could also choose a subcontractor, but this would lead to an 
even greater trimming of the margin. 
132 
 
“On the other hand, PET is problematic because you need PET centres to make the tracers locally 
and thus the margin is always worse than in SPECT. Moreover, that is unlikely to change. Either 
you need your own infrastructure, which will increase base costs, or you will be working with 
local partners who manufacture PET tracers. Of course, they also want to have some of the 
profit, so the margin will always be worse than with SPECT. There are also certain countries 
where, apart from the big cities, logistics in SPECT is easier than in PET imaging.” 
V. Brief conclusion on the topic “Manufacturing, Distribution and Handling”: 
Each of the interview partners is aware that the manufacturing, distribution and handling of 
radiopharmaceuticals are not comparable to traditional therapeutics. Due to the short half-life of 
radionuclides, especially in the diagnostic field, logistics plays an important role. For the group of nuclear 
physicians, who have always “produced” the products in the radiopharmacies on their own, this is no 
new challenge. This topic is therefore not perceived as a “special” obstacle. The pharmaceutical 
industry, however, sees a potential issue in this more complicated process, mainly because these 
companies have a global marketplace in mind. The interviews revealed that the pharmaceutical industry 
is currently not interested in the commercialisation of imaging biomarkers, even if a RP serves as a 
companion diagnostic for one of their new therapeutic drugs. For the radiopharmaceutical industry 
manufacturing and distribution is a daily business, therefore they did not proactively complain either. 
However, the responders confirmed the high costs associated with the production of the products, with 
PET RPs remaining costlier than SPECT RPs or contrast media. Still, there seems to be a fair margin to be 
made, with the current reimbursement rates in the US.  
4.3 Diagnostic Radiopharmaceuticals used as Companion Diagnostics 
As discussed in chapter 4.2 diagnostic radiopharmaceuticals, as independent in-vivo diagnostic agents, 
are facing some challenges. Nonetheless, there have been two successful introductions with 18-F 
flucoclovine and 68-Ga DOTATATE in the USA and Europe in recent years. With the push towards new 
molecularly targeted cancer therapeutics, patients will be screened more often for the intended target 
in a sensitive, specific, cost-effective, quick, and robust way (Ludwig & Weinstein, 2005). Biomarkers 
should improve cancer staging, personalise the therapy and overall lead to a better outcome for the 
patients. Primarily in-vitro biomarkers, but also in-vivo imaging biomarkers, compete in this field and 
both have their assets and drawbacks. There was the hope by some nuclear medicine physicists that the 
widespread adoption of biomarkers will also push imaging biomarkers and the number of approved 
diagnostic RPs would rise.  
The big difference between such a companion test and a “standalone” in-vivo diagnostic agent: the 
companion test is linked to a specific therapeutic drug, can detect or monitor a disease according to 
regulatory requirements and decides whether the therapeutic drug can/should be administered or not 
(see Table 27). Consequently, the Companion Diagnostic (CD) provides essential information related to 
the safe and effective use of the corresponding drug or biological product. 
 
Complementary Diagnostic: A test, which is not essential the safe and effective use of the drug but the test 
identifies a biomarker-defined subset of patients that respond differentially to a drug 
and aids in the risk/benefit assessment for individual patients (Beaver et al., 2017). 
Companion Diagnostic: A companion diagnostic is a medical device, often an in-vitro device, which provides 
information that is essential for the safe and effective use of a similar drug or 
biological product. The test helps a health care professional determine whether a 
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particular therapeutic product’s benefits to patients will outweigh any potential 
serious side effects or risks (U.S. Food and Drug Administration, 2018a). 
Table 27: Differences between a Complementary- and a Companion diagnostic test from a regulatory view. 
Due to the combination of the (mandatory) diagnostic test with the therapeutic drug the whole 
economic situation for the diagnostic test changes. The Companion Diagnostic can be seen as a 
gatekeeper for the administration of drug, and therefore the pharmaceutical industry has an interest 
that those tests are simple, inexpensive and applicable everywhere. Due to the significant price 
difference between the costs of a therapeutic drug and a diagnostic test, the profit of the diagnostic 
test itself typically becomes secondary. The primary purpose of complementary and/or companion 
diagnostics is backing up the application of the corresponding therapeutic drug. So “…the drug developer 
wants the most accurate test available, to the greatest number of physicians, at the lowest cost, in the 
shortest period, with all attention focused on selling the greatest volume of pharmaceuticals”(Agarwal 
et al., 2015). 
The empirical data will highlight the stakeholder´s view on the potential use of diagnostic 
radiopharmaceuticals as a CD, the challenges associated with the classification and how CDs will, in 
general, affect the treatment of patients 
4.3.1 The Stakeholder´s Definitions of a Companion Diagnostic? 
In order to classify the stakeholder’s statements, we first had to check the interviewee’s knowledge on 
the term CD and their (personal) definitions. Our results confirm statements in literature, which suggest 
that experts have quite a different description, categorisation, and idea of a CD (e.g. J.P.B. O´Connor et 
al., 2017). Particularly the statements of nuclear medicine physicians and the industry differ 
considerably.  
 
All statements regarding this topic are in the appendix on page 210 
A Nuclear Medicine Physicist´s view: 
"A diagnostic test that directly influences the therapy decision, 
a key test that describes whether a patient is eligible for 
therapy or not. Later the results tells us if the therapy was 
successful or not." 
A Pharmaceutical Industry´s view: 
"So to my mind a companion diagnostic is a 
subset of predictive biomarker that specifically 
developed in conjunction with a therapeutic." 
A view from a medical specialist: 
"With the CD tool I have to be able to select patients who have 
the disease. Furthermore I have to identify in which stage the 
patient is... both with a certain prognostic relevance. Er, and 
thirdly it would be desirable that I can use the diagnostic as a 
predictive marker, i.e. as a marker for treatment response." 
A view from a regulatory specialist: 
"Companion biomarker and complementary biomarker, but 
understanding the difference in important. Complementary 
biomarker provides information on how they threated, a tool 
to monitor progression, monitoring success of the therapy. 
Companion diagnostic is a mandatory element in the therapy 
measure. So the companion is necessary if it is not part of the 
therapy." 
A view from the Molecular Imaging 
Technology Industry: 
“Sure, the companion diagnostic in general in 
my view qualifies a patient for a certain therapy 
and also monitor the patient on that therapy. 
The examples are in widespread use are very 
types of tissue markers, before put on a cancer 
drug like HER2, before getting Herceptin. And 
many many examples like that even if they are 
blood based or tissue based test before being 
put on a cancer chemotherapy. And because 
this is all about diagnostic imaging there has 
been some general lack of companion 
diagnostic using molecular imaging as that 
qualifying test before being put on a drug. And 
even though we keep holding out that it is 
potentially very interesting, we have some 
emerging areas that would probably fit the 
definition.” 
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I. The Nuclear Medicine View: 
In general, nuclear medicine practitioners have well described the use and meaning of companion 
diagnostics, but the answers show a different level of knowledge on this topic compared to 
representatives of the industry. Two of the interviewees imagine that a CD is purely an imaging test, 
and do not refer to other possibilities such as in-vitro companion diagnostics (ICD). 
"For me, the CD is medical imaging that stimulates follow-up. In a way, that compensation for a 
therapeutic drug are made if the CD test has been performed… So a practical example: … one 
would perform an FDG PET or PET after two months to show that a tumour is actually 
responsive." 
Others have presented an in-depth knowledge and have talked at length about the need of biomarkers 
and how they will add value to the patient management process. 
"In principle, in the age of precision or personalised medicine, we are increasingly seeking 
therapies for precise targets or target structures, because, say, there are modern biological 
therapies that are highly efficient, but where the patient selection is essential. Moreover, we 
know that current patient selection on the basis of, for example, tissue biopsies or on the basis 
of original primary tumour preparations is not sufficient. Because we assume that we are based 
on considerable genetic and proteomic tumour heterogeneity, we need procedures that predict 
the presence of treatment-relevant targets with greater accuracy." 
It turned out that the categorisation into prognostic and predictive biomarkers is not yet consolidated 
among the interview partners. However, this is not surprising as even the EMA has not yet agreed on a 
uniform definition of a CD. 
"Interviewer: That means we speak on the one hand of prognostic biomarkers, but also of 
predictive biomarkers? 
Interviewee: De facto it is the same. So if I make a prognosis, then I am making a prediction. " 
All interviewees agree that molecular imaging is very well suited as a CD and could play an essential role 
in both the selection process and also for therapy monitoring. 
"... we really see ourselves as a CD, so that patients can be assigned to the right treatment by 
the biological characterisation of the individual clinical picture." 
"Basically, the CD is the idea of better utilisation of therapeutic drugs, by using imaging tests to 
identify patients who are firstly eligible for the procedure and secondly responding to the 
procedure. So you could summarise this briefly.  Which in itself is a very good idea, under certain 
circumstances could improve the outcome of therapeutics, if substances are used only in patients 
where the appropriate target is available." 
II. The Pharmaceutical Industry´s View: 
Compared to nuclear medicine physicians, experts in the pharmaceutical industry have much more 
profound knowledge in this area. They specifically distinguish between companion- and complementary 
diagnostic, in-vitro and in-vivo biomarker, and prognostic and predictive markers. 
"The first thing to say is you really need to understand the difference between a prognostic 
biomarker and a predictive biomarker. Many cases people failed to understand that, and the 
literature is full of papers, even from people who should know much better, who think they have 
discovered predictive biomarker whereas, in fact, they have discovered prognostic biomarkers.” 
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“In the US we have these terms companion diagnostics and complementary diagnostics. A 
companion diagnostic means that you must have the diagnostic test done and have positive 
results to be able to use the drug. Complementary means there is a diagnostic that adds 
information to make a decision, but you do not need to use it." 
One interviewee explained how they have been using biomarkers in R&D and how this helped to close 
a gap between them and their competitor. 
"When we got our first line NSLC we again we went again for the highly enriched population we 
had shown a clear benefit, whereas [the other company] didn´t do that. They went for a much 
lower bar, they did not look for the higher population, and their NSLC was a complete failure. So 
obviously this was a big win and all of a sudden, wow Juhu the diagnostic is really is critically 
important." 
III. The Radiopharmaceutical Industry´s View: 
The radiopharmaceutical industry also has a good understanding of Companion Diagnostic, partly 
because the company of an interview partner himself was in a situation to decide whether the diagnostic 
test should be approved as a CD or as a standalone diagnostic test. 
"Yeah, so I think the regulatory definition for a CD is one which again [our company] would tend 
not to support. In other words, [our company] doesn´t see the value of calling its product a CD. 
Which gives it potentially a more restrictive application. Clearly, the diagnostic product will have 
an indication, or requests for indications from the regulators, based on the data that is in the 
file. Moreover, if that data involves diagnostic or prognostic, as well as therapy, then it will 
essentially be registered as a drug by in its own right. Not as a CD. So that is an important 
distinction." 
They decided to go for a “drug by its own right” approval for economic reasons. It seems that the 
interviewees from the radiopharmaceutical industry, as well as the pharmaceutical industry, primarily 
think about the regulatory and economic consequences resulting from the registration of a diagnostic 
test as a CD.  
"So in my definition of a CD agent, there would be two levels. One level would be; it is actually 
only approved label for the therapy. So the FDA would approve a therapy, and on its label, on its 
official use, it would say: you can only use the therapy once you have done this test. This would 
be a completely tied and connected CD. The other, maybe more practical version, is the payment. 
So insurers would say, I am not going to pay for this therapy until you have done this diagnostic 
test that shows me the application. So there. I have not seen a true FDA labelled CD; the FDA is 
not really supportive of that. However, insurers always require testing, proofing, especially for 
therapy which is expensive." 
IV. The Molecular Imaging Technology Industry Group´s View: 
Even the two experts in the MI technology industry know the term CD very well and know which tasks 
this test has to fulfil. 
“Sure, the companion diagnostic in general in my view qualifies a patient for a certain therapy and 
also monitor the patient on that therapy. The examples are in widespread use are very kinds of tissue 
markers, before put on a cancer drug like HER2, before getting Herceptin. Moreover, many many 
examples like that even if they are a blood-based or tissue-based test before being put on cancer 
chemotherapy. Moreover, because this is all about diagnostic imaging, there has been some general 
lack of companion diagnostic using molecular imaging as that qualifying test before being put on a 
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drug. Even though we keep holding out that is potentially very interesting, we have some emerging 
areas that would probably fit the definition.” 
V. The Medical Specialist Group´s View: 
Within the group of specialists there were the most deviations from the definition of CD. One 
interviewee had a good understanding of the term CD: 
"With the CD tool, I have to be able to select patients who have the disease. Furthermore, I have to 
identify in which stage the patient is... both with certain prognostic relevance. Er, and thirdly it would 
be desirable that I can use the diagnostic as a predictive marker, i.e. as a marker for treatment 
response." 
…for others, one must assume that they are not yet familiar with the term or the currently prevailing 
definitions of literature. 
"Yes, we have several, I would not call it a companion diagnostic, but a diagnostic agent that one 
uses in certain indications, because you cannot use everything for everything. But one has to know 
exactly which investigation is best. Of course, what I've been busy with lately is the PSMA scan." 
One of the interviewees is a medical specialist and additionally leads a laboratory team researching the 
development of new molecular in-vitro CDs. For him also PET is a CD that dramatically supports the 
treatment of patients with lymphoma. 
"Among CD's, I would also see PET. It helps us to make therapy decisions on some lymphoma entities, 
in Hodgkin's, at least in clinical trials. We really value having PET-positive findings, which we then 
treat accordingly such as irradiation. Otherwise, my lab is doing much research on biomarkers, but 
we are far from seeing this in clinical use. One lab is looking at genetic markers, especially gene 
mutation in molecular lymphoma because there is nothing stratified what has long bothered me as 
a clinician." 
VI. The regulatory specialists: 
Compared to the US Food and Drug Administration (FDA), the European Pendant (EMA) still has no 
official definition of a CD. This is being drafted, and the new regulation will enter into force in 2022. The 
definition will be based on the content of the American definition, but according to the statement of an 
interview partner not be identical.  
“Okay, so when you ask about the definition I mean at the moment there is no agreed definition, 
at least in Europe. Obviously, there is a definition around the FDA providers, but in the 
regulations, I am sure you read it, the definition going forward in terms of CD is very similar, but 
not identical to the FDA definition. You are aware of the new regulation that will come into effect 
in 2022, correct?” 
Another expert from a national authority in Europe defined the meaning of a CD very carefully and 
described the regulatory requirement at its core. 
“God oh god. For me, a CD in the narrower sense is a diagnostic procedure, in the sense of a yes 
/ no answer, which is linked to a drug via a registration document. So actually, CD's are just the 
diagnostic tests that are required according to the registration, which is really defined in that 
document. So it is not optional, but a must-have-criterion that needs to be performed so a drug 
can be administered. After all, drugs are classically approved for a tumour mutation, and then it 
is clear that I can prove these tumour mutations with a biomarker." 
Finally, one interviewee made an obvious statement regarding the use of RPs as CD: 
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"I think in the future the CD will have to be well certified. Meaning that there will be an 
assessment biomedicine, if it meets the definition of a CD… PET RP would not fall into the new 
regulation, only if they work in the device regulation…. However, pharmaceuticals should not be 
affected." 
This statement suggests that in-vivo biomarkers are either not included in the regulation, or that the 
prescriptions in the regulation will not apply to RP because they are still defined as drugs and therefore 
generally more stringent safety requirements and efficiency. 
VII. Brief conclusion on the definition of Companion Diagnostic: 
In general, most of the stakeholders show a good understanding of the role of a CD. Above all, the 
nuclear medicine doctors described in their statements how they believe that CD will impact patient 
management and stratification. The industrial representatives already show a detailed knowledge 
regarding the categorisation of these biomarkers into predictive and prognostic markers. They also 
differentiated between the companion- and complementary diagnostic and seemed to be aware of how 
CDs will influence their business. 
Representatives of the molecular imaging industry are also well aware of the importance of a CD. The 
group whose definitions differ mostly from the opinion prevalent in the literature are specialists in the 
field of oncology. Also in the group of the national regulatory authority experts, the definition varied 
reasonably. The interview partners from the international regulatory authority did not wish to speculate 
about the definition as this term is currently being developed and will be implemented in 2022. 
According to this statement, radiopharmaceuticals are not included in this regulation. 
4.3.2 The Benefits and Challenges associated with Companion Diagnostics in General 
Currently, there are few companion diagnostics approved by the FDA or the EMA genuinely meeting the 
definition of a CD. By 2014, a total of 19 CDs were approved by the FDA (U.S. Food and Drug 
Administration, 2014), compared to a total of 1.453 approved drugs in the USA (data until 31/12/2013) 
(Gaffney, 2014). A better patient stratification, more targeted use of new therapeutics and improved 
patient monitoring are expected. Despite the benefits, only a few of these individual diagnostics have 
received regulatory approval to date. We have therefore asked the stakeholders what reasons this may 
have. 
A Pharmaceutical Industry´s view: 
“… using that method, we had a limited population that we 
could have the drug available for. Because we selected, have 
pre-selected, to have the enrichment to be able to get 
approval. Whereas [the other company] has spent the 
program for several years and they will be able to show that 
it worked in all the patients…. So that kind of set us back for 
a little bit, and there was a lot of... you can imaging… oh Jesus 
look what we have done. We have anchored ourselves…” 
 
A view from the Molecular Imaging Technology 
Industry: 
"I think that is a very interesting step into theranostics 
that will get a lot of things opened up.” 
A view from the Radiopharmaceutical Industry: 
“When Pharma uses RP they can end up with a really 
small indication, and your return is even harder to get. 
Where a broad indication in a diagnostic is much 
better, because you have many more opportunities to 
sell you scan." 
A view from a regulatory specialist: 
“The difficulty, of course, is that these subgroups get smaller 
and smaller. So in tumor mutation, there are two or three 
mutations that cover most of the patients, 80% maybe 90%. 
For the last 20% I need a lot more tumor mutations and I have 
to take a closer look. These are rare mutations and, of course, 
relatively small subgroups remain at the end, which are 
difficult to study and of course are not that lucrative.” 
A view from a medical speci list: 
"The interest of the clinicians is of course there, but 
they will wait, I think, for a long time. Because such a 
development is similar to a development of a drug. 
That costs millions, you have to say that very clearly.” 
A Nuclear Medicine Physicist´s view: 
“…which is a very good idea in itself and could possibly improve the outcome of therapeutics, if substances are used only 
in patients where appropriate target exists." 
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All statements regarding this topic are in the appendix on page 213. 
I. The Nuclear Medicine View: 
Benefits: 
The great benefit of a CD is the ability to stratify patients more efficiently before treatment begins: 
"Treatment would be more restrictive but more targeted.”, with the idea that this improved stratification 
may also lead to a better outcome, at least that is the prediction of several interviewees. 
“…which is a very good idea in itself and could possibly improve the outcome of therapeutics if 
substances are used only in patients where appropriate target exists." 
Also, the pharmaceutical industry could benefit from the use of these biomarkers, since a more targeted 
selection of the study population significantly increases the likelihood of the success of a new 
therapeutic drug. 
“On the other hand, it is the case that the therapeutic substances ... are targeted only to hit the 
tumour cell, i.e. targeted therapy. Moreover, if they treat the same 100% again, then in many 
cases they will get a negative result. The conclusion would be: the therapeutic substance is not 
effective. Now, if you identify and treat the right 30%, then they will see the therapy is highly 
effective. If the industry really wants to make tumour-specific substances, targeted therapy, and 
want to obtain approvals, then they are extremely interested in the CD." 
Challenges: 
The main concern for the majority (57%) of interviewees is that there is no added value for the 
pharmaceutical industry, but on the contrary, the market becomes limited. Interviewees do not expect 
industry to pursue this development.  
"It is not a good incentive for the industrial side to implement such diagnostic tests in our system 
right now. The academic community has an extreme interest in it, but the industry partners not 
necessarily." 
"Biggest obstacle: there is no financial gain for those who offer a therapeutic agent." 
"The snag is that it sounds good, but it is often not so interesting for the pharmaceutical 
companies that are supposed to be the driving force. Because of course, in a nutshell, they have 
a commercial interested that their substances are broadly applied and not in selected cases." 
Also, some interviewees see a challenge in the availability and validation of a CD, especially an imaging 
CD in the clinical setting. In some cases even more than one biomarker must be used to demonstrate 
the target structures. 
"The other is the situation that there can be multiple positives, positive for breast cancer, but 
still for another factor. That would require multiple imaging procedures, which is certainly 
difficult." 
Summarizing, this group is very positive about the benefit of a CD but fear that the challenges not so 
easy to overcome. For an interviewee it is relatively simple: either the Nuclear Medicine Community 
manages to provide the proof of the efficacy of the CD itself, or a drug producer realizes that there is 
any benefit for himself. 
II. The Pharmaceutical Industry´s View: 
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Benefits: 
The pharmaceutical industry interviewees confirmed that a diagnostic test, able to detect an 
appropriate target, leads to an increased therapeutic benefit. 
“…if the mutation is not there they have no chance to responding. If the mutation is there, they 
have a good chance to respond. However, there is not black and white with the checkpoint 
inhibitors. Which makes it complicated." 
One of the interviewees had an excellent historical overview of the use of predictive biomarkers and 
CDs and could precisely name the fields of disease in which these markers had an influence and which 
previously had brought little benefit. 
"There are four disease areas where predictive biomarkers and companion diagnostics, 
personalised medicine, has really had an impact historically. 1. Cancer, 2. Infection, 3. Rare 
diseases and 4. Drug metabolism… And as you know many cancers are driven by tumour 
mutations, and so you can identify, by the right mutation, you can choose the right drug. It is 
less true that predictive biomarkers/ CDs had an effect on major diseases like asthma, 
myocardial infarct, diabetes, dementia, depression, psychosis. " 
We also wish to highlight a statement that illustrates very clearly the usefulness of CDs in the 
development of new therapeutics. With this specific biomarker, the company was able to catch up to a 
close competitor with a similar indication. 
"When we got our first line [disease] we again we went again for the highly enriched population 
we had shown a clear benefit, whereas [the other company] didn´t do that. They went for a 
much lower bar; they did not look for the higher population and their [product] was a complete 
failure. So obviously this was a big win and all of a sudden, wow Juhu the diagnostic is really is 
critically important." 
Challenges: 
The last statement shows very clearly the benefits of a CD, but also the impact of this tool on the market 
potential and thus sales number of individual companies.  
"Ah in [this indication] it helped us to get an approval rapidly, but when we were doing the 
advanced [indication] the... ah... we using that method, we had a limited population that we 
could have the drug available for. Because we selected, have pre-selected, to have the 
enrichment to be able to get approval. Whereas [the other company] has spent the program for 
several years and they will be able to show that it worked in all the patients. And in the advanced 
[indication] patients you get a benefit to chemotherapy by using the [drug], and you did not need 
to enrich it with the diagnostic. So that kind of set us back for a little bit, and there was a lot of… 
Oh, Jesus look what we have done. We have anchored ourselves…" 
Another interlocutor points to another challenge, associated with the reimbursement of therapy if the 
CD test shows negative results. Since a CD test does not always detect the target, the drug may still be 
useful.  
“However, even if you do not see [the target], also these patients respond. So it is in the interest 
of the dynamics between the oncologists, who want to make certain that the patients have any 
chance to benefit from the drug that could help them. Moreover, the payer who are saying “well 
wait a minute, this is an expensive drug, and we cannot give it to every patient”, who might be... 
We have to focus on the patients who do benefit. So the way it plays out varies from country to 
country." 
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Additionally, the close link between the diagnostic test and the therapeutics can have substantial 
economic implications, especially for the company providing the CD test.   
“As you know in drug development, in every hundred projects the industry starts, if they are lucky 
one becomes a medicine. So you have huge, you have huge attrition. And of course, you have 
attrition in the diagnostic. So for the academics working on Etarfolatide and indeed for the 
company developing it, they got nothing out of it. Even it was a great tracer when the 
therapeutic died the market for the diagnostic died as well. So it is a very unattractive place to 
be in.” 
III. The Radiopharmaceutical Industry´s View: 
Benefits: 
The positive statements regarding CDs are limited in this group, even though they have already 
acknowledged that CDs will have a great benefit for patients (Chapter 4.3.1). 
“…if you select, for HER2 for instance, HER 2 and HER receptors you know, Herceptin does not 
work unless you got HER receptor breast cancer. So that is a fantastic combination of patient 
selection…” 
Challenges: 
Only two of the five interview partners commented on the challenges of the CD and agreed that the 
economic impact for the developer/ manufacturer is enormous. Registering a diagnostic test as a CD 
limits the market and thereby aggravates the problem of profitability. 
“When pharma uses RP, they can end up with a really small indication, and your return is even 
harder to get. Where a broad indication in a diagnostic is much better because you have many 
more opportunities to sell you scan." 
Another argument that has already emerged in the nuclear medicine- and molecular imaging technology 
expert’s groups: the risk that the diagnostic test will be successfully implemented, but the therapeutic 
fails or that another therapeutic agent works better in this indication. The combination of the test with 
the drug increases the economic risk. 
“I guess part of it is how broad the indication is… By the time you come out … you do not actually 
have a really big patient pool to sell to. Because you can only sell it to patients in that cancer 
(laughs), with that therapy. And there is always the risk that a different pharmaceutical company 
… finds a different therapy that is better in that cancer. Er, the whole linking to pharmaceuticals 
is really difficult from a commercial perspective because your market potential is quite small.” 
Discussions with experts in this group show that they do not see any advantage in classifying their 
(future) products as CD unless it is a commissioned work by a pharmaceutical manufacturer.  
“… [the company] doesn´t see the value of calling its product a CD, which gives it potentially a 
more restrictive application.” 
IV. The Molecular Imaging Technology Industry ´s View: 
Benefits: 
The interlocutors of this group are once again using their experiences of the Radiopharmacy Business 
to provide concrete answers to the benefits and challenges. Both emphasised benefits in stratification 
and therapy monitoring: 
“... the diagnostic testing partly helps to decide which patients are likely to respond to certain 
therapies and therefore should or should not get this therapy.” 
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“And in the course of the therapy give information on how successful the therapy is and which 
interventions should take place ... So to get confirmation that the therapy is effective and can be 
continued." 
An interviewee from this group also expects much from the concept of Theranostics: "I think that is a 
very exciting step into Theranostics that will get many things opened up.” 
Challenges: 
The answers match the statements of the stakeholder groups. One interviewee has detailed strong 
arguments for each challenge in the area of, "technical & scientific", "economic constraints" and 
"regulatory”. 
"The challenges of both technical and scientific nature. First, you really have to develop this CD 
so that the test itself works as a CD." 
"But on the other hand, of course, there are the economic challenges, because the diagnostic 
test is linked to the success of the therapy." In general, the success chances of a diagnostic test 
is greater than the chance of success of a new drug. So the chances to launch a product on the 
market decreases for the developer of the CD. " 
“Of course, the third challenge is the regulatory side ... obviously, there is no way to submit the 
diagnostic test and therapy as a package to the BfArM, EMA or FDA. One has to negotiate with 
each authority, so there are also challenges." 
Especially in the field of Molecular Imaging, an interviewee expects RPs to have a hard time being used 
as a CD. According to his discussions with the pharmaceutical industry, the method is too complicated, 
too expensive and the availability is low. The pharmaceutical industry would always look for ways 
around imaging biomarkers, unless they are forced to do so by the regulatory authorities. 
"And I believe that is because the pharmaceutical companies do not want a potential market 
limiting step on the way using their drug. I had some conversation with the imaging teams inside 
big pharmaceutical companies, which gave me that hint, not as an official policy but they believe 
that MI is used widely in their clinical trial process, but they never wanted it to be a mandatory 
step underway using their drug. Because unlike a blood test driven tissue test, they still looking 
at MI as a complex, expensive hard to find the thing that would limit their market for their drugs. 
So even if it could lead to a better patient population that take the drug, they view that as market 
limiting and unless the regulatory body or payer absolutely required it, it tried to find a way to 
get the drug approved without it." 
V. The Medical Specialist´s View: 
Benefits: 
This group again speaks about the benefits from a medical point of view and what benefits the CD will 
have for the patient.  
“With the current therapies, we can control the disease in many, many patients. However, there 
are approximately 20 to 25% of patients who have a rapidly progressive course, which die very 
early… We must stratify these patients early for other therapies, experimental therapies. We 
have access to these therapies, but we only use them when the standard therapies have failed. 
But if we could predict that the standard therapies would not work in the first place, we would 
help a lot."  
Challenges: 
142 
 
The challenges are also taken from a medical point of view, i.e. validation and thus specificity and 
sensitivity.  
"Well, biomarkers have to be first established, validated so we can use them in clinical routine. 
It needs to be robust, reproducible, which also means harmonisation and standardisation.” 
Moreover, another specialist sees the tumour specificity or tissue specificity as a challenge, but an even 
more significant challenge is the detection of the small quantities.  
Another responder reported from his personal experience, how the industry neglected to support the 
development of a biomarker in this institution.  
"And we have got a relatively large lab, and we have been trying to develop biomarkers. That 
costs money and the company, I do not name them, that sells [the product] ultimately gave us 
no money. Understandably, why should they sponsor a biomarker development that in the end 
says: "Okay, in this case, you should not give this drug"? They hold us back for a long time, but I 
knew from the beginning that they would not give us any money. So I would say the development 
of these biomarkers will be difficult." 
VI. The Regulatory Specialist´s View: 
In one interview with a regulatory specialist, we directly questioned him if industry may lack interest in 
developing CDs for their new therapeutics. The answer of this interview partner was conclusive: 
"So probably we need to distinguish broad categories of drugs where say the more traditional, 
even if not very clearly targeted drugs, where the biomarker simply means a restriction in 
indication. So you try to avoid to develop it too specifically, to target a bigger population that 
could be the industry´s interest. But I think the whole other bunch of drugs, which unless you are 
very specific and fish out what is the right population, they will simply not work. " 
Again, we heard arguments that partially agreed with other groups, but also new arguments/ 
challenges. One regulatory specialist believes that the low rate of approved CDs also results from the 
lack of cooperation between the "diagnostic" and the "therapeutic" industry. 
“And the second reason why there are not so many CDs, because the world of industry is set up 
differently. There were and are classic drug manufacturers, they were just looking after 
therapeutics, and on the other hand, there are diagnostics manufacturers, who only took care 
of diagnostics. Moreover, yes, only in the last 10 to 15 years has there been this realisation that 
with molecular oncology, it is actually necessary that the industry there work much closer 
together to bring successful products to the market.” 
And while we have heard in the previous statements that small patient subgroups are financially not 
attractive, the regulatory expert believes that there is no way to avoid it from a technical/ scientific 
point of view. 
“The difficulty, of course, is that these subgroups get smaller and smaller. So in tumour mutation, 
there are two or three mutations that cover most of the patients, 80% maybe 90%. For the last 
20%, I need a lot more tumour mutations, and I have to take a closer look. These are rare 
mutations and, of course, relatively small subgroups remain at the end, which is difficult to study 
and of course are not that lucrative… So I have to do a lot of screening work, in clinical trials, 
until I find the patients.” 
VIII. Brief conclusion on the benefits and challenges associated with Companion Diagnostics in 
general: 
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All interviewees who commented on the "benefits of CDs" also see an advantage in these individual 
diagnostic tests. Benefits include more targeted therapy, better outcome, better patient stratification, 
and better clinical trial outcomes.  
Regarding challenges, we again see the different perspectives of the stakeholder groups. The physicians 
are increasingly concerned with the topics of efficiency generation, validation and standardisation, 
while industry recognises, above all, the economic constraints that can arise from this classification. The 
medical professionals argue that CD will have a complicated way ahead because there are currently no 
incentives for the industry to implement those tests. On the contrary, the therapeutic drug market will 
most likely become limited. The interviewees from the radiopharmaceutical industry group made clear 
that it is out of the question that they would register a new diagnostic test as a CD on their own. This 
classification would negatively affect their already small market potential. Interesting, but not very 
surprising, was the testimony of an interviewee from the Molecular Imaging Technology Group who 
learned in personal discussions with the pharmaceutical industry that molecular imaging will have a 
hard time to be accepted as a CD. The hurdles are just too high compared to blood- or tissue tests. 
Finally, the statements of the experts from the group of regulators were very informative. They 
acknowledge that implementation will be a challenge, especially for small subgroups, but new, specific 
therapeutics will not be able to prove their benefits unless they have identified the right population by 
CD in advance. 
4.3.3 Pros and Cons of In-Vivo Imaging Biomarkers compared to In-Vitro (molecular) 
Assays 
 
A biomarker is a “defined characteristic that is measured as an indicator of normal biological processes, 
pathogenic processes or responses to exposure or intervention, including therapeutic interventions” 
A Nuclear Medicine Physicist´s view: 
"The differences are clear! A blood sample will characterize the 
patient as a whole, but imaging can accurately characterize 
individual regions and individual organs. At least with our nuclear 
medicine techniques, we visualize the whole body and we can look 
at individual regions. You cannot do that with a systemic marker, 
and the main goal of therapy is not to treat the entire organism, 
but to treat a certain target region.” 
 
A Pharmaceutical Industry´s view: 
"In oncology imaging has a different burden, 
imaging is more like a clinical workup scenario… 
You do use imaging a lot, readout and protocol 
itself….they are not really a stratification or 
something in diagnostic use." 
A view from the Molecular Imaging 
Technology Industry: 
"Well, I would say, one thing we have not discussed 
so much yet, which is very important to me. What 
are the disrupters, what is threatening molecular 
imaging? ... As you can see on the amyloid side, 
there is already the CSF test and there is intensive 
research on blood-based tests.  And the disruptive 
innovation for molecular imaging is if a test exists 
which is much simpler and has the same amount of 
information. In the end the question arises: "Why 
do I have to image?" 
A view from a medical specialist I: 
“And I do not think that one will replace the other. I 
believe the added value in the reasonable 
combination of both.” 
A view from the Radiopharmaceutical Industry: 
“…I think the problem that pharma companies always had with 
PET is the availability of the product. And so if you were to compare 
testing the Cerebrospinal fluid, with PET then effectively anyone, 
who can do a lumbar puncture, can get cerebrospinal fluid… If you 
used CFS testing then maybe you therapy get access in 90% of the 
available patients, if you got a PET/CT scan in front of it then you 
go to reduce the access of your therapy to patients." 
A view from a medical specialist II: 
“Will Molecular Imaging have a role in new, future therapeutic 
strategies?” 
"It depends on the topic of treatment and if you have a biomarker 
that is good enough that the concentration of the biomarker tells 
us" ok, does the patient have a response or not? ". … then you 
could do without the imaging diagnostics.” 
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(Biomarkers Definitions Working Group, 2001; O´Connor et al., 2017). Fundamentally, two different 
types of biomarkers can be distinguished whose task is to diagnose-, monitor the disease, to identify 
risks and to select the best individual therapy in the sense of personalised medicine. The most widely 
used type is molecular diagnostics, which uses in-vitro assays to detect biological markers in the genome 
and proteome. For these tests, a small amount of blood is enough to detect the smallest amounts of a 
molecule and to characterise a tumour based on the molecular signature (DNA and mRNA) (Jain, 2015). 
A keyword in this area is also Liquid Biopsy, a method using a blood sample to detect circulating tumour 
cells and cell-free tumour DNA in cancer diagnostics. The second method is in-vivo imaging, which can 
noninvasively, and in real time, visualise cellular processes at the molecular or genetic level. Compared 
to the in-vitro assays, however, in-vivo imaging can additionally visualise the anatomy and represent 
the origin of the physiological and molecular function (Bleavins, Carini, Jurima-Romet, & Rahbari, 2011) 
 
All statements regarding this topic are in the appendix on page 217.  
I. The Nuclear Medicine View: 
As expected, the Nuclear Medicine Group agrees that the benefits of molecular imaging being used as 
a CD are very high. The unanimous opinion is that in-vivo imaging biomarkers (IVIBs) can accurately 
represent specific regions in the body, which is not possible with in-vitro companion diagnostics (IVCDs). 
The IVCD test can only give a general status over the entire body. 
"The differences are clear! A blood sample will characterise the patient as a whole, but imaging 
can accurately characterise individual regions and individual organs. At least with our nuclear 
medicine techniques, we visualise the whole body, and we can look at individual regions. You 
cannot do that with a systemic marker, and the main goal of therapy is not to treat the entire 
organism, but to treat a certain target region.” 
The interviewees very often address exact localisation, visualisation of the tumour's heterogeneity, real-
time quantification and non-invasiveness. 
“In other words, we do not have [relating to in-vitro assays] any real-time procedures there that 
can represent the biology of an entire tumour. Moreover, of course, this is the strength of 
imaging techniques, especially biomarker-driven imaging techniques. Because you can basically 
visualise and quantify in real time, realistic, non-invasive the entire body, so all the lesions and 
not just part of a tumour." 
The interview partners also do not shy away from the comparison with the gold standard, the biopsy. 
For an interviewee therapy decisions being made on a biopsy results are "outdated" since it is first of all 
hard to take the sample from the right place, and secondly the tumour pathology changes in the course 
of therapy. 
“Yes, well, the in-vitro assays, you have to say brutally, almost exclusively focus on the primary 
tumour. So the tissue that was removed during the primary tumour surgery will be used, at a 
later time if there is a recurrence, to decide on the further therapy. Of course, it is often the same, 
but if you look for example at breast cancer, then you know that in about 30% of women, who 
express Herceptin receptors in a primary tumour, the status will change. 
The precise localisation of a tumour plays an important role, not only in primary diagnostics but also in 
therapy monitoring. While the IVCD can most likely accurately predict if a recurrence has occurred, the 
IVIB test can accurately pinpoint to the recurrence and detect metastasis, which may be surgically 
treatable. 
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“Of course, imaging is important in many situations: if a tumour disseminates in the body and 
extracts a substance, then ultimately an integral value, which is the tumour marker, really does 
help us a lot. It may be that certain clones respond to the therapeutic, but others do not, and so 
you cannot treat them specifically." 
"In principle, you can have a patient with liver metastases, or lymph node metastases in the 
lungs and metastases in the lungs respond to the therapeutic drug, but the liver metastases 
continue to grow. Thus [with imaging] you can specifically tell if you need surgery or not. " 
One interviewee agrees that IVIB have many advantages, but he also tried to be realistic. From his point 
of view, it just does not need an imaging biomarker for everything. One should focus on areas that 
create added value. 
"You know Imaging people usually are quite limited in their understanding of medicine. They are 
tunnel blinded … Because they believe that you will be able to have, for any drug, a biomarker, 
an imaging biomarker. That is, of course, total nonsense. So you have to focus on the stuff that 
is really needed." 
Another interviewee noticed that molecular imaging is an expensive procedure, which is why he also 
believes that nuclear medicine should focus more on areas where stratification would be beneficial due 
to the high cost of therapy. 
“The main disadvantage is the cost ... that it is much more laborious and comes with costs ... I 
would not develop a PET biomarker for cold medicine. Because if a snuff preparation costs 20 €, 
then I cannot make a PET scan for 500 €. However, if that is a new generation 
immunotherapeutic for € 100,000, then perhaps a PET is indexed.” 
II. The Pharmaceutical Industry´s View: 
Pros: 
The distribution of pro, neutral, and contra-statements shows very clearly that the group of 
pharmaceutical industry experts is very contrary to nuclear medicine. Few opinions would favour IVIB 
over IVCD, besides using them as a research tool in R&D (see chapter 4.1). 
"But the motivation for us to develop it is that we want to see how that changes in time 
overtreatment … one of the reasons you have a higher response rate with chemotherapy and 
checkpoint inhibitors [product name] is that in those patients the chemotherapy killing of cells, 
you got all kind of DNA, and the immune systems are activated trying to clean things up. Then 
you get the checkpoint inhibitor in there, and it can really just finish it off. So we want to look at 
that kind of research questions and see to understand what changes... we are also trying to 
develop tracers for CD8 and other aspects of the immune system. To really use it as a research 
tool." 
Above all, the interviewees appreciate the possibility of considering the heterogeneity related to a 
primary tumour as well as the metastases invasively and over a specified period. 
“So when you do IHC [immunohistochemistry] you have a limited sample of a tumour... so what 
the nice things about imaging are, you cannot look at just one tumour you cannot just look of 
parts of a tumour, you can look a whole tumour and at more tumours throughout the body. And 
the hope is that this would be more valuable, and it would do a better job in predicting patients 
response, but this is true or not time will tell." 
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However, in general, it has to be said very clearly that the people in this group are not interested in 
using molecular imaging as companion diagnostics. According to a statement, maybe also because so 
far “We do not have many good examples of an imaging assay that is a companion diagnostic." 
Cons: 
These pharmaceutical experts, who are specifically dealing with the topic of molecular imaging or 
companion diagnostics in their companies, have several arguments against the use of IVIB as a CD.  
"Imaging has the entire business of radiopharmaceuticals and its maturity in the clinics. Right, if 
something that is in my view more relevant in terms of therapeutic diagnostics. So something 
which is established, like a perfusion scan with technetium, those I can still see as clinical criteria 
for treatment and maybe reference criteria. But I do not think there is any example outside of 
oncology that is using it as a CD." 
Specifically, in oncology, IVIB have difficulties in portraying the entire tumour’s mutations, whereas in-
vitro assays can detect all mutations in a single test. 
However, really for tumour mutations (imaging) has a tough struggle. It is also the truth, the 
case that the imaging tools we have are not as precise as the free circulating DNA tools. In the 
MICAD [Molecular Imaging and Contrast Agent Database] database there are hundreds of eGFR 
tracers, but remember there are many mutations, such as mutations which yet are discovered. 
And ideally, you would need to profile every molecular imaging tracers against all mutations, 
known and unknown. Which is almost an impossible thing to do.” 
In addition to the scientific barriers, there are also regulatory and economic hurdles that are not 
favourable for an IVIB. A very knowledgeable interviewee narrates that for the regulatory dossier you 
need to get the patient segmentation is locked down from the beginning, which is easy for a blood test, 
but a challenge for the imaging test. 
“In order to get the regulatory dossier, for registration, you need to have your patient’s 
segmentation done right from the beginning of Phase II or even Phase I in oncology. And that is 
actually quite easy to do if you have a blood test. But it is very very difficult to do it with an 
imaging test. To get an imaging test logged in before you have seen any patient. That is the 
challenge." 
And finally, high costs and low global availability of PET/CT are against their use. The sale of the 
therapeutics and therefore the gatekeeper should be as easy as possible to overcome. 
“The other side, one of the lessons I learned working on the IHC diagnostics... Firstly I see it is 
much more of an issue in Europe, where there is a lot more cost consciousness. There are 
hospitals given a certain amount of resources to take care of the patients, and that is it. In the 
USA there is no control, the only control is that the label says you cannot administer this if you 
do not have the test. So you get the test done, the same thing can happen in Germany. The 
German government was tough for us and with our organisation. They are going to say "yeah 
ok, so you need to have that test done, but 125 Dollars is too much. We do not have the money 
in our system to pay 125 Dollars for this test. So, we need to get that test for 45 Dollars." 
III. The Radiopharmaceutical Industry´s View: 
We can keep this analyses short and concise because most of the arguments have already been 
mentioned in other chapters. The representatives in this qualitative research would not take the path 
to develop a CD. There are pro-arguments, but few. For example, one interviewee believes that there is 
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even more significant potential for IVIB markers in cardiology and neurology. Another interviewee 
reports that his company has also been approached by pharmaceutical companies with the request to 
develop a suitable imaging biomarker that can be used in clinical trials as an inclusion criterion. 
"Pharma has recognised that biomarkers and imaging are critical in the disease development… 
Today they recognised the use of biomarkers in the drug development, using imaging biomarker 
as inclusion criteria. Pharma companies are clearly coming to us with the intention of 
appropriate patient selection. They are very interested in researching biomarkers, in the 
development point of view." 
However, in principle, the interviewees believe that IVIBs will have a hard time being used as a CD. An 
important argument, which was already mentioned by an expert from the pharmaceutical industry is 
the availability of PET and PET/CT. Easy access is the fundamental prerequisite for a CD. Otherwise, the 
therapeutic drug cannot be used at all according to regulatory requirements. 
“…I think the problem that pharma companies always had with PET is the availability of the 
product. And so if you were to compare testing the Cerebrospinal fluid, with PET then effectively 
anyone, who can do a lumbar puncture, can get cerebrospinal fluid… If you used CFS testing then 
maybe your therapy gets access in 90% of the available patients, if you got a PET/CT scan in front 
of it then you go to reduce the access of your therapy to patients." 
IV. The Molecular Imaging Technology Industry´s View: 
Similar to the other industry groups, there are few pro-arguments. In this case only one, but it is 
important to note that only answers in which the IVIB is used as a CD were considered. The pro-
argument concerns the possibility of IVIBs to provide information such as localisation of metastases, the 
inclusion of lymph nodes et cetera. Demonstrating the value of imaging is crucial.  
“In oncology, with secondary diseases such as metastases, the involvement of lymph nodes, and 
so forth, you can see that imaging can provide more information than a PSA test ... Hopefully, 
imaging can deliver much more information such as localisation or spreading of the disease. You 
really have to find the sweet spot of molecular imaging. Show that the test as such also makes 
sense and provides the information that contributes to the management of the patients.” 
Otherwise disruptive innovations such as new in-vitro tests could be dangerous for molecular imaging. 
The interviewee recommends careful observation of these new techniques and consideration of the 
added value of MI. 
"Well, I would say, one thing we have not discussed so much yet, which is very important to me. 
What are the disrupters, what is threatening molecular imaging? ... As you can see on the 
amyloid side, there is already the CSF test, and there is intensive research on blood-based tests. 
And the disruptive innovation for molecular imaging is, if a test exists which is much simpler and 
has the same amount of information. In the end, the question arises: "Why do I have to image?" 
The second interlocutor agrees that MI lacks availability and is too expensive to compete against in-vitro 
biomarkers. 
“Because unlike a blood test driven tissue test they (pharmaceutical industry) still looking at MI 
(Molecular Imaging) as a complex, expensive, hard to find the thing that would limit their market 
for their drugs.” 
Using an example from Alzheimer's diagnostics, an interviewee predicts that if blood tests achieve 
equivalent information as the imaging tests, imaging will soon decline and will only be used in selected 
cases. 
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“However, if the CSF test, and the future blood tests, can provide information that is equivalent 
to the information of the imaging test, then I can well imagine that at least the use of imaging 
will decrease and you will first perform a cheap blood test. Moreover, for those who need an 
additional imaging test, for whatever reason, the imaging test will be performed in certain 
groups." 
V. The Medical Specialist´s View: 
The group of specialists commented very positively on the possibilities of molecular imaging, but not in 
the context of the CD. Although the question was formulated this way, the interviewees unfortunately 
talked only about current experience with existing diagnostic tests and not about imaging biomarkers 
as CDs. Therefore, no pro-arguments can be noted. 
However, some statements have been summarised under the point "Neutral". For example, one such 
statement is that this urologist does not wish to give advantage to the in-vivo imaging marker over the 
in-vitro marker since he is only interested in getting any kind of useful marker that supports his work. 
"No, whether that is a liquid biopsy or something else, actually, I do not really care. We have 
been looking for a better marker, compared to the PSA value, for years. PSA is not a good marker 
in primary diagnosis, but it is the best that we have, and one we have learned to deal with." 
Those statements that predict a combination of both test variants were also neutral. Half of the 
respondents believe that there will be a combination of both procedures and that in the future this will 
be the best way to describe the status of the patient. 
“And I think there will be a combination. I do not think that one will replace the other. However, 
a combination of both will be able to represent the best possible status of the patient." 
For an interviewee, Liquid Biopsy is the future, because it will be easy to get the molecular information 
out of blood and potentially get a prognostic and predictive market. 
“The big cue of the future is Liquid Biopsy. That one gets the molecular information about a 
tumour by markers in the blood, be it circulating tumour cells, exosomes or something similar. 
You get a prognostic or predictive marker." 
IX. Brief conclusion on the topic “Pros and Cons of In-Vivo Imaging Biomarkers vs In-Vitro Assays” 
Not surprisingly, the group of nuclear physicians is very positive about the use of imaging biomarkers as 
companion diagnostics. The many pro-arguments highlight the advantages of imaging compared to 
blood and biopsy tests. These arguments range from the possibility of the exact localisation of the target 
structure, detection of heterogeneities, monitoring of changes in tumour pathology in the course of 
therapy, as well as the detection of metastases and many more. One interviewee from the nuclear 
medicine group, however, believes that many of his colleagues may be asking too much and one must 
be realistic and accept that imaging does not make sense everywhere. Amongst others, molecular 
imaging is expensive so his advice would be to focus on areas where the test makes sense. 
The pharmaceutical industry is not as receptive to the topic of the use of imaging biomarkers as a CD. 
Although they recognise the value of the method, which they also used extensively in the area of R&D, 
they believed that IVIBs have, compared to the in-vitro panel tests, a particular disadvantage in the field 
of oncology. Since new therapeutics will target tumours with a specific mutation(s) and imaging test will 
not accurately show the mutation spectrum. So a pretty big hurdle. 
Two of the interview partners from the pharmaceutical industry believe that imaging has established a 
strong foothold, especially in the clinical workup process, but is unlikely to be suitable for stratification. 
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The radiopharmaceutical industry also sees the benefits of molecular imaging but believes its low 
availability is an obstacle for the pharmaceutical industry. Also, these interviewees have already stated 
on another topic that they would not classify their future products as CD, but as a stand-alone diagnostic 
product. 
The interviewees from the molecular imaging technology industry are aware of the danger that the in-
vitro test outdoing the imaging tests. Since a simple, cheap test provides the same information provides 
it will be difficult to survive. 
Finally, the group of medical specialists who would not prefer the in-vivo imaging over the in-vitro tests, 
but want a useful CD test. Both liquid biopsy and an imaging marker would be an alternative, but in 
general, they believe a combination of both techniques will get the best result. 
4.3.4 Should Biomarkers Be Mandatory Prescribed by Regulatory Authorities? 
Since the successful launch of the HercepTest, as one of the most widely used companion diagnostic 
test to date, there has been hope that many more companion diagnostics will follow. However, so far, 
instead one hears that the development is slower than expected (Towse, Ossa, Veenstra, Carlson, & 
Garrison, 2013), that the potential is not yet realised (Trusheim et al., 2011) and the utilisation is 
constrained (Luo et al., 2016). So we asked the nuclear medicine, the pharmaceutical industry, the 
medical specialist and the regulatory specialist groups the provocative question, whether they believe 
that biomarkers will soon be mandatorily prescribed for new (expensive) therapeutics?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All statements regarding this topic are in the appendix on page 221. 
I. The Nuclear Medicine View: 
 Strong Pro Possibly Strong Contra 
Mandatory Companion Diagnostic?  
 
The Nuclear Medicine Group supports the idea that biomarkers should be used, while the majority 
foster the idea to have those mandatorily prescribed (83%).   
A Nuclear Medicine Physicist´s view: 
"... the way we really have to go! Whether it's easy to walk, I 
vaguely doubt it. But that's the only true way." 
A Pharmaceutical Industry´s view: 
"Well, the regulators are not concerned about the cost of the 
drug. That is a different question for the health care systems.” 
A view from a medical specialist: 
"That's a good question. I can imagine, I can just imagine it. 
Right now, of course, it's fictional, because there's no marker 
that's so good that it could justify that. But I could imagine that 
the health insurances say: “yes only this and this patient we will 
cover costs”. It also depends a little bit on the fact that 
biomarkers driven clinical trials need to be performed… And 
that something is prescribed by law is absolutely conceivable! 
The question is, of course, this is contrary to the interests of the 
pharmaceutical industry. That will be interesting to see. Of 
course they want everyone to get it." 
A view from a regulatory specialist: 
“Well, I mean such would not be the right 
concept. But if a CD would be required to 
identify a patient population that benefits 
from the drug in some way, yes. Because 
if you need a test to identify the right 
patient population for your drug, I think in 
an indirect way you could, you know 
someone would use the word mandatory, 
but you know the company would need to 
show the evidence and that is sort of in an 
indirect way. They would need to have the 
evidence to support that.”  
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"... the way we really have to go! Whether it is easy to walk, I vaguely doubt it. However, that is 
the only true way." 
It is interesting to note that almost all the interview partners mainly have the costs of drugs in mind and 
have fewer arguments on the impact of this test on patient health/ outcome. Only one doctor explained 
that it is unethical for him to continue exposing patients to chemotherapy, even though there is no 
benefit. 
"I think there should be CDs; I think there should be biomarkers to select patients appropriately. 
Yeah absolutely, because there are two ways in oncology. There is one way that you try 
something and treat, and you got six cycles of chemotherapy, and in the end, you may know if it 
worked or not. To me, that is unethical, especially after one or two cycles you could do a simple 
FDG glucose metabolic imaging and see if the treatment works or doesn´t… that would be my 
first biomarker requirement. Is your glucose metabolism going down? If not, stop the treatment. 
However, we have not reached that point." 
The rest of the interviewees mostly recognise the possibility to save costs. As one interlocutor explained: 
PET will not save lives of patients with bronchial carcinoma, but it will save costs.  
“Yes, I think that will happen more and more. Because our health care system is already groaning 
enormously under the current costs. Moreover, in the future, the new therapeutics will certainly 
not be cheaper but rather more expensive. If you compare the costs of new therapies such as 
KART cells, ranging from € 200,000 to € 300,000 or more per treatment cycle, and costs of 
therapeutic agents such as 5-fluorazil, which have been developed in the '90s and' 80s and have 
total lifetime costs of less than 100 D-Mark or Euro per patient have, than you just see the 
gigantic difference.” 
However, some nuclear physicians believe that the path of introduction will not be accessible. In 
principle, from the point of view of an interviewee, the authorities could effectively even been regarded 
as allies and actually should have the interest to implement CDs to save costs. However, there is the 
belief that such a political process can only be initiated if the costs become uncontrollable due to 
expensive drugs. Moreover, even then, the authorities first have to realise that a diagnostic test can 
reduce costs. 
Finally, there is still the question of what kind of diagnostic test is required. From a discussion partner, 
this will be decided above all by the pressure and the commitment of the industry. 
“Yes, they will be demanded, definitely. It is just the question which tests required. Of course, the 
pressure and commitment of the industry will be crucial regarding which detection methods and 
biomarkers are required. However, that will come as surely as that Amen in the church! It is 
already happening now." 
II. The Pharmaceutical Industry´s View: 
 Strong Pro Possibly Strong Contra 
Mandatory Companion Diagnostic?  
In this group, only one interviewee has answered the question and denies that CDs will be mandatory, 
at least not for every new drug. 
"I do not think it is going to be mandatory for every drug; it is going to depend from drug to drug, 
indication by indication." 
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In principle, however, the interviewees expect that it will be used more frequently in the future. 
However, the argumentation of an interviewee is clear that if the manufacturer manages to prove the 
benefit of the average population, then there is no benefit to the diagnostic and the product will be 
approved without this CD. 
"What benefit does the diagnostic have? …If you can show in all common population, right, 
without a diagnostic that the benefit to the patients is substantially more, without the 
diagnostic, the current therapy, right, so if you can improve the outcome significantly, they will 
approve the drug. Certainly, outside the US, they approve the drug, but the payers are not going 
to pay for it. So I think the way the diagnostics come in, the primary driver for that is there are 
two drugs. The one is "do you need to select that population to show a significant benefit", right, 
that is the one. Moreover, the second one is "if you do not have the diagnostic to show a 
significant benefit, is that given the costs of the drug, is that significant benefit enough to not 
have to use a diagnostic".” 
Specifically, outside the United States, three interviewees expect the payer to drive the use of 
biomarkers. 
"Interviewer: Will they (regulatory authorities) demand a CD, maybe an imaging CD for like 
very expensive therapeutic drugs?: 
Interviewee: So yeah, very short: it could become important, it does not say it is right now, but 
it could become important either by the regulatory agency or by the sphere (e.g. insurance 
companies). And the sphere could be a big driver/ player here.  
“The payers have a similar view because they want to maximise the cost-benefit regarding 
patients who benefit and minimise the cost of harm." 
An interviewee differentiates very clearly between the regulatory authorities and other actors in the 
health system. Because to his mind, the regulatory authorities are only interested in the fact that the 
use of a biomarker increases the patient´s benefit and lowers harm effects. 
“So I think regulatory authorities are very interested in stratifying patients so you identify as 
many as possible who benefit and as few as possible who will have harm. … You could stratify 
patients with purely clinical observation, stratify them by standardised biomarkers you have in 
any lab: PSA, lung functional. Or you could stratify them on the basis of a brand newly developed 
biomarker which is approved at the same time, in other words, a Companion diagnostic. But 
don't think the regulatory authorities care how you do it, all they care about it is whether you 
maximise the number of patients who benefit and minimise the number who have harm.  
Moreover, an interviewee predicts that molecular imaging will not be used as a CD, the hurdles for a 
pharmaceutical company are too high. 
"No (Molecular Imaging used as a CD), as far as the costs are concerned of molecular imaging 
tracers in cancer research. The three things you need to look at. Firstly, the assay needs to be 
locked down before you start and that is extremely difficult. Secondly, if you are competing with 
a 50$ blood test that could be done in a lab, it is hopeless. And thirdly, the drug companies 
develop drugs for global markets, and so the imaging also needs to be available in that global 
market. Moreover, that are really difficult problems, the academics often miss." 
III. The Medical Specialist´s View: 
 Strong Pro Possibly Strong Contra 
Mandatory Companion Diagnostic?  
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All physicians in the group of specialists envision that CDs will possibly be mandatory in the future, three 
(75%) believe that it will undoubtedly be mandatory. However, they believe that this process will take 
some time. Two of the interviewees instead see the implementation of biomarkers into clinical routine 
through guidelines: 
“…I am firmly convinced that if you show the clinical benefits ... that the authorities require these 
measures. As it is already the case with acute leukaemia, where a detailed molecular diagnosis 
is carried out. This is also required according to the WHO classification, and there is no reason 
that this should be different in my area of research. This will almost certainly happen with 
lymphoma." 
However, the interviewed specialists argue that this is only possible if good biomarkers for stratification 
are available. 
"That is a good question. I can imagine, I can just imagine it. Right now, of course, it is fictional, 
because there's no marker that's so good that it could justify that.” 
From a specialist’s point of view, it will be interesting to see how industry will react to this initiative 
because the introduction of starting CDs is contrary to the interests of industry. 
IV. The Regulatory Specialist´s View: 
 Strong Pro Possibly Strong Contra 
Mandatory Companion Diagnostic?  
Except for one responder, no one believes that these biomarkers will become mandatory. An 
interviewee from an international regulatory authority does not believe that this is the right concept. In 
his opinion there will be no way around using biomarkers anyway, because only with the help of these 
markers can the right patients for clinical studies be selected and thus a significant benefit can be 
proven. 
“Well, I mean such would not be the right concept. However, if a CD would be required to identify 
a patient population that benefits from the drug in some way, yes. Because if you need a test to 
identify the right patient population for your drug, I think in an indirect way you could, you know 
someone would use the word mandatory, but you know the company would need to show the 
evidence and that is sort of in an indirect way. They would need to have the evidence to support 
that.” 
Another interviewee from a national authority also denies that this could be imposed. It is up to the 
companies to make that decision. 
"No, no under no circumstances, under any circumstances ... If the company says they would 
need it in combination, we will look at it. And if the company says they will go without it, then 
we will also look at it." 
Only one interview partner can imagine that. He does, however, refer to the situation that the 
pharmaceutical entrepreneur, who wishes to gain approval for the therapeutic drug, submits results 
from the clinical trials where biomarker(s) have been used to stratify the study population. 
“Yes, I think that is very real. This is a situation where a positive study shows that a drug helps 
in marker-positive patients. Moreover, the approval would say that it can be used in these 
marker-positive patients. Now the Joint Federal Committee (GBA) is facing the decision, what to 
do? So you have to join this dichotomy in marker-positive and marker negative. The alternative 
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either would be that you do not reimburse the drug, which would be a disaster! Because the drug 
also has a benefit. And vice versa, the other alternative would be that the GBA releases the drug 
for all patients, regardless of marker status. This would also be a disaster because that is a 
charter for non-complying use of approved drugs. So that does not work either, so there is no 
way around it…” 
V. Brief conclusion on the topic “Mandatory Prescription of Biomarkers by Regulatory 
Authorities” 
Again, there are apparent differences in the statements between the group of physicians (nuclear 
physicians and specialists) and industry and the regulatory authorities. The majority of nuclear medicine 
physicians can well imagine that regulatory authorities will require biomarkers in the future. Their 
argumentation is not so much based on medical benefits (one argument), but more on the burden of 
costs for the health system caused by novel, very expensive therapeutics. Most of the nuclear medicine 
doctors assume that a biomarker test will come sooner or later, the question is which type of test will 
prevail. 
The pharmaceutical industry's answers to this question are not explicit, except for one. This interviewee 
assumes that biomarkers will not be compulsory, at least not for all medications. The decision will be 
made on a case-by-case basis. However, all interviewees expect this issue to become more critical in the 
future.  
The majority of the final group of regulatory experts do not expect mandatory biomarkers but believe 
that the companies must decide this for themselves.  
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4.4 What is the Stakeholder's Stake in a Public Private Partnership (PPP)? 
The concept of public-private partnership (PPP) has increased significantly in recent decades, especially 
in the area of public infrastructure in Europe. The idea is to involve the private sector in the 
development, financing and supply of community projects. There is no exact definition of PPP, but it can 
be described as “a long-term contract between a private party and a government agency, for providing 
a public asset or service, in which the private party bears significant risk and management responsibility” 
(World Bank Group, 2018). This concept has also been transferred to the life science sector, hoping to 
launch new products in less-researched areas. In 2008 the European Federation of Pharmaceutical 
Industries and Associations (EFPIA) and the European Union (EU) launched the largest PPP worldwide 
in the field of life sciences. So far, also 16 imaging projects have been initiated, ranging from amyloid 
imaging in Alzheimer's Disease (AMYPAD), research into new markets in carcinogenesis (MARCAR), 
surrogate markers as hard endpoints in diabetes disease (SERMIT), and imaging biomarkers for the safe 
use of drugs (TRISTAN).  
Due to the weak interest in the development and commercialisation of new, innovative diagnostic 
radiopharmaceuticals, we evaluated whether the concept of PPP could help to allow more diagnostics 
RPs approved. Because this topic also concerns the partnership of the stakeholders, we asked the 
interview partners how cooperation works well or not. 
 
 
A Nuclear Medicine Physicist´s view: 
“In principle, I think that makes very much sense. In 
Germany, this has often failed due to the extremely strict 
regulatory framework. It is not simply a PPP to the 
mutual benefit, it should be a win-win situation for both. 
From my experience, putting this on a solid legal basis so 
it can be a success is the biggest problem. Because there 
is so much bureaucracy associated with it, it also looks 
daunting. I think that needs to be greatly simplified to be 
successful." 
 
A Pharmaceutical Industry´s view: 
"But now coming on to PPP. The first thing I should say, 
that IMI is an experiment. It is a 5 billion Euro experiment, 
it is not guaranteed to work. Historically the drug industry 
has been very bad a PPP. If you look at other industries: 
defense, transportation, agriculture. A lot of the R&D risk 
is shared by the public and private sector. When even in 
the USA, the pentagon carries a lot of R&D risk for the 
defense. In the EU we are very used to the idea that 
agriculture works in PPP. For historical reasons the drug 
industry is been very happy to carry the entire risk of R&D 
on its own. And then get the entire benefit to 
exclusivity…in comparison to other industries that is a 
very unusual model…” 
A view from the Molecular Imaging Technology 
Industry: 
“Concerns are that it is sometimes difficult to get 
consensus between all partners. We are also involved in 
a few IMI projects, and you see that the academic side 
thinks academically, and the industrial partners come 
with the industrial mindset into the project. Agreement 
is not so easy, in the sense that it works for everyone.” 
A Radiopharmaceutical Industry´s View: 
"Er, I guess the probably needs to be a better 
understanding in the academic community of the 
difference between having a technology that shows 
interesting data from non-prospective studies (laughs). 
So when, for a lot of these agents that look interesting 
and therapies that look interesting, to get approval for 
it you need to get back to the drawing board to do a 
proper dosimetry study to support that.”  
 
A view from a Medical Specialist: 
Example of a Disadvantage: 
“The pharmaceutical industry has the legitimate interest 
to make profit, but they slightly tried to dominate the 
study design and the rational of the study. And I see that 
as a problem. The concrete shortcoming that different 
companies are difficult to bring together and to work 
together." 
A view from a Regulatory Specialist: 
"Now in this sense you are going into subpopulations, 
small, rare cancers etc. that is normally the area where 
collaborations between industry and academia is 
stronger, because really industry then needs the 
academic, needs centers of references, networks and all 
of this stuff. And perhaps those could be right, right 
frameworks for some of these PPP.” 
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All statements regarding this topic are in the appendix on page 224. 
I. The Nuclear Medicine View: 
 Strong Pro Neutral Strong Contra 
Value of Public-Private 
Partnership   
 
In the group of nuclear medicine experts, 5 out of 7 interviewees (71%) answered this question, and 
from those 60% are in favour of Public-Private Partnerships (PPP). However, we must assume that some 
of the interviewees may have thought of a “classic collaboration”, not necessarily about the concept of 
PPP. The following statement may suggest this assumption:  
"So the value is tremendously high, PPP is basically what drives the bulk of the research. The 
otherwise publicly funded research, so by DFG or EWIF, consists of 90% mechanistic research, 
which is also important, but has nothing to do with the whole issue of implementation… PPP 
research is exactly what drives the field, which we are extremely interested in." 
However, particularly one German interviewee sees the challenge in setting up such a PPP. The legal 
basis must be robust to have a win-win situation for both partners, and currently bureaucracy is still too 
complicated.  
"The industry partner wins because he gets better diagnostic tests, or tests in general, for his 
therapy and the area of application. Moreover, on the other side, the academic partner wins 
because he has a better sense of where, in the future, the things he or she is dealing with 
scientifically, could have a clinical relevance on a broader spectrum." 
Two of the experts disagree as to whether such a PPP is more straightforward to be implemented in 
Germany or the United States. Again, suspicion is expressed that both interviewees had a different 
concept of collaboration in mind. 
The interviewee is talking about…  
The United States                     …another about Europe:  
 
 
 
 
 
 
 
 
Another interviewee commented “neutral” on this topic, seeing such collaboration as an "instrument 
that does not harm". However, he argues on difficulties in the arrangements, since the interests of the 
partners can be very different, and he experiences the imbalance of power.  
“There are other examples, where this was purely driven by academic, and only at the very end 
someone has put it on a commercial track... The IMI is something special, which always had the 
constraint ... an instrument where the industry forces the others what to do… The EU has 
initiatives where it promotes cooperation with companies. Companies can join, but the academic 
"I think government agencies are not well suited to 
invest. The reason is that then the whole story starts, 
what is the payback? That is something even the NIH 
never tried. Because the NIHs provides grants for all kind 
of stuff, so then you could get IP which was in part 
funded by taxpayers. So therefore money should go back 
to the NIH also to the FED. That never has been done, 
because than it gets so complicated. That you cannot 
ask the Americans to do that. The American philosophy 
is more we support you, you make the money and then 
taxpayer revenue comes in anyway.” 
 
“Yes, I think they are extremely useful. Er, there 
are many more approaches possible, not so 
much in Germany. In the United States more 
often, where they are trying to create a PPP 
between industry and certain university 
research institutions or even public research 
institutions. So I think that makes extraordinary 
sense.” 
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side is stronger. This is normally areas where the industry is not interested. There are federal 
instruments that provide incentives to participate. For example, we participate there.” 
Collaboration with the industry to develop a Biomarker? 
 Very good Neither good nor bad Very bad 
Collaboration to develop a biomarker?    
In this context, the interview participants were asked whether they are currently working with an 
industrial partner to develop companion diagnostics. This question has been answered by five 
interviewees, two confirmed cooperation, two denied and one participant explained that a different 
partnership exists. Also, in this case, there is a suspicion that some interviewees may not be explicitly 
participating in a PPP, but collaborate in a “traditional” partnership.  
“Yes, we do that ... we were once part of a study where a companion diagnostic was evaluated, 
but then, unfortunately, it failed (“ging in die Hose”). That was not necessarily a success story.” 
“No! That would be a PPP; we do not have that. What we do is we collaborate in research 
collaborations with other departments that develop therapeutics and then have them patented. 
Moreover, there we are trying to test the effectiveness of these substances at a preclinical level, 
just as early as possible.” 
How the collaboration with the industry works 
In a further question, the interviewees were asked how the cooperation with the partner, in this case, 
the industry, works. This question was answered by two interviewees (28%), one sees the collaboration 
as "neither good nor bad", the other one extensively described various projects, but a clear statement 
cannot be identified. 
"It varies from company to company, but I could not say that everything is good or bad ... It 
depends a lot on the companies because we have partners from the technology industry who do 
not have that much money. That is a whole different order of magnitude, so you cannot expect 
[company name] to be able to fund big clinical trials. They do not have budgets for those things. 
They are trying to support us, but not in a huge way. Also because we in Germany are no longer 
the largest market.” 
II. The Pharmaceutical Industry´s View: 
 Strong Pro Neutral Strong Contra 
Value of Public-Private 
Partnership 
 
All interviewees responded to the question, with two-thirds of the respondents having a positive 
perception of this concept (67%). One of the interviewees has a leading role in two IMI projects. 
The industry values PPPs in areas where the development of tools does not bring a competitive 
advantage but is essential to all industrial partners.  
"No matter what the context, the main value of that is, it allows us to address issues that are 
important for the field as a whole, but none of us has the resources to do ourselves. Of each of 
us is trying to do it ourselves, it is completely inefficient. And there no competitive advantage to 
doing that. So that is biggest value: bringing all these people together, focusing on issues of 
common problems that cross the border to move the field forward to give us the tools we need 
to." 
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The statements show that the industrial experts value the work of the academic institutions very much 
and that this expertise is urgently needed for research and development, be it in connection with a PPP 
or other partnership.  
"We do not have all the expertise internally, so we need to be able to partner as a company... 
Partnerships are absolutely critical. You cannot do anything without them. That is not something 
which is unique to PPP. You do not need PPP for that, that is my point.” 
The interviewees also talked about their experiences from such PPP projects and to what extent their 
companies have participated so far. In this PPP concept, the interviewees value not only the 
performance of the academic capacity, but also the input of other partners. As we will hear later, this 
cooperation is not always smooth, because there are distinct cultural differences between the partners. 
"But there are many many examples [company name] is working with PCs (public consortia) 
particularly in neuro. So we do not think we have all the answers and we are working with all 
the external partners to integrate science as best as we can, really. And not just the academics 
in those consortia, of course, other pharmaceutical colleagues of us from other industries, from 
other companies. Short answer: We rate this very highly." 
One of the interlocutors, who also participates in the IMI (Innovative Medicines Initiative) project, has 
readily revealed his thoughts on the subject. He told us why the pharmaceutical industry is, compared 
to other industries, still opposed to the concept of risk sharing and why this may is currently in the 
change. 
"But now coming on to PPP. The first thing I should say, that IMI is an experiment. It is a 5 billion 
Euro experiment; it is not guaranteed to work. Historically the drug industry has been very bad 
a PPP. If you look at other industries: defence, transportation, agriculture. A lot of the R&D risk 
is shared by the public and private sector. When even in the USA, the Pentagon carries a lot of 
R&D risk for the defence. In the EU we are very used to the idea that agriculture works in PPP. 
For historical reasons, the drug industry is very happy to carry the entire risk of R&D on its own. 
And then get the entire benefit to exclusivity…in comparison to other industries that is a very 
unusual model. So the idea of IMI is partially based on that the exclusive model that the 
pharmaceutical industry historically has had might not work forever…So the idea is to try to find 
a way for the public and private sector to work together. This is an experiment, as you know a 
100 different projects are running under IMI. And to be honest, some will be more successful 
than others.” 
This expert indicates that these projects are searching for solutions and tools that apply to all market 
participants, and a significant number of different products. None of the participants has an individual 
interest in the development for various reasons.  
The project… TRISTAN is developing imaging tools, which be used to predict not drug efficacy, 
but drug harm. And those, as you can imagine, are many different classes of drugs can cause the 
same type of harm. We are focusing on a number of different areas of harm. One of which is 
drug-induced lung disease. Now there are over 300 drugs which cause that harmful effect so 
that potential imaging biomarkers could sweep a wide range of drug programs. And there will 
be difficult to protect IP on so that the imaging companies will not develop them. Drug 
companies’ won´t develop them, just for one drug. So this seems to be an ideal place for a PPP." 
The reasons for participating in these projects are many-sided, in principle, the participants naturally 
hope for an advantage in various areas such as R&D, stratification, monitoring, et cetera Imaging is only 
one part of it. 
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Relationship with Academic and Public Funded Institutions 
This group was also asked how they regard the cooperation with the academic institutions. No one 
wanted to comment on it accurately, which is why the answer "neither good nor bad" leads again with 
a two-thirds opinion (67%). One interviewee deviated to another topic during this question. 
Reaching consensus seems to be the most laborious task (100% consents). The answers indicate that 
industry has a high interest that their goals be achieved in the project. 
"It really comes down to the common interest. We are partnering with academics who are 
focused on questions and developing things which are relevant to the things we need to do. And 
we are able to come up with an agreement, this is a specific thing that needs to be done, and 
there is the focused on it. People actually deliver what is needed, that works out pretty well." 
This statement can also be applied correctly to the PPPs, whereby the more significant number of 
participants can cause further complications. “So it is kind of the same things with the smaller ones 
(partnerships), but the more cooks you have, the more complex things get." 
However, from the perspective of one interlocutor, the great advantage of PPP is that industry is in the 
driver´s seat and can dictate what should be developed. 
"And the big advantage for the drug companies in there (PPP) is, that the drug companies are in 
the driving seat and they can say very strongly “we want you to develop a tool that looks like 
this because if you develop something like this, it would be very useful to us”. And not just a tool, 
which makes a nice paper in Nature or something like that.” 
III. The Radiopharmaceutical Industry´s View: 
 Very good Neither good nor bad Very bad 
Value of Public-Private Partnerships  
All interviewees of this group tried to answer the question, but half of the participants had no opinion.  
"Hm, that is difficult. I felt that I do not have enough experience to answer that, unfortunately. I 
have not been involved. My answer would be that they have not been particularly successful. 
But I would not high trust on that answer because I have not been close enough involved. But I 
do not believe there weren´t any big successes." 
One of the experts commented positively, but on the topic of industry-academic partnership in general, 
not referring primarily to the concept of PPP. 
"I think there is a very strong role for academia. I feel that there is, and there will always be a 
very strong role for academia. And because especially the RP companies rely very heavily on 
people in the university. They have the expertise, and I think that will continue without a doubt. 
Obviously, big pharma companies have a large in-house, and they have large organisations, but 
there will always be a mixture of a private company working with a large academic [institution] 
in Europe.” 
Challenges in collaboration with academic institutions 
The statements are similar to the opinions of experts in the pharmaceutical industry. Among other 
things, it concerns finding consensus on the results you wish to achieve, the timetable, and the speed 
with which your projects are carried out. 
"Well, I think fundamentally they have different goals, and you always have to deal with that. 
The academic institutions are not, in general speaking, not results driven, and not scheduled 
driven. They are knowledge driven. The businesses… they borrow it (money) from themselves, or 
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somebody gave them a bunch of money, and they have a timescale, they need to go on the 
market, and so they are very sensitive to results. They are very focused. They want this result. 
The academics would be happy with almost any results, right? (Laughs)” 
The academic community must also comprehend that the "interesting data" from their studies, is not 
sufficient from study design and quality perspective for filing with the regulatory agencies. The academic 
aspect should work in a more concise clinical trial process.  
"Er, I guess the probably needs to be a better understanding in the academic community of the 
difference between having a technology that shows interesting data from non-prospective 
studies (laughs). So when, for a lot of these agents that look interesting and therapies that look 
interesting, getting approval for it you need to get back to the drawing board to do a proper 
dosimetry study.” 
Moreover, an interesting final argument discusses the ownership of inventions that have been 
developed together in a partnership.  
“So once you understand that those (the participants in the partnership) have fundamentally 
different motivations, there can be issues about who owns the co-development. Like a product 
or a feature, or something that is innovative and new, which comes out of the working together. 
Obviously the business wants to have the right to do it and the institution, a lot of institutions 
especially in the US have business offices that try to monetarize their research... And they want 
to get a piece of that deal. So that there is this IP relation, and funding, always funding." 
IV. The Molecular Imaging Technology Industry´s View: 
 Strong Pro Neutral Strong Contra 
Value of Public-Private Partnership   
 
Due to the semi-structured style of the interviews, this questions was only answered by one 
interviewee. Above all, this interviewee sees a significant financial benefit in a consortium approach. 
However, otherwise, he is more restrained regarding consensus building in the selection of the study 
design or the definition of the research question. Although many academics have exciting research 
questions that would undoubtedly make an excellent publication, they are not very helpful from an 
industry perspective. To give an example: his company is involved in one of the IMI projects, and he 
would prefer to study designs that can prove the usefulness of the product and thus influence 
reimbursement issues.  
“In the IMI projects, we have seen that it is difficult to design the study design to be as rigorous 
as one would expect from the commercial development of an imaging test.” 
His summary regarding the benefits of a PPP: “…you should not screw the expectations of the industrial 
side too high. Well, such an IMI project may be a good way to do some research, but it is not the panacea 
for developing imaging tests differently." 
V. The Medical Specialist´s View: 
 Strong Pro Possibly Strong Contra 
Value of Public-Private Partnerships  
From the group of specialists, all interviewees answered the question and half of the respondents are 
positive about the PPPs. One interviewee is against, while one has a neutral opinion. Also in this group, 
it is reasonable to assume that some of the interviewees talk about classic partnerships and not 
specifically about PPPs. Therefore, the results should be treated with caution. 
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For one of the interviewees the benefits is a win-win situation. On the one hand it allows clinicians to 
get access to a new and good diagnostic tool, and on the other hand industry could make money from 
it. 
“I think that is an absolutely important part. And there's nothing wrong with that because, on 
the one hand, the industry has some interest in monetising it, but we also have an interest in 
getting a biomarker, or a diagnostic tool, that supports us and is good… So we both have the 
same interest." 
Another interlocutor is unconvinced because the participation of public institutions usually complicates 
the conversation: "Yes, if it helps, then it is good". However, every interviewee acknowledges the fact 
that academic research would no longer be possible without industry. 
“I am extremely open-minded ... I actually get a not inconsiderable share of research funds from 
the pharmaceutical industry…Earlier, in the last 5-10 years, we have had IITs, we continue to try, 
but now it is no longer possible without support from the pharmaceutical industry.” 
However, this partnership also has drawbacks, such as the industry's attempt to dominate the study 
design.  
“…you have to be very critically. Because I have said it before, the sponsors determine what we 
do... the (research) question you would like to have answered for yourself are actually not 
funded, but they tell us what we have to do.”  
VI. The Regulatory Specialist´s View: 
 Strong Pro Neutral Strong Contra 
Value of Public-Private Partnership   
There were only two statements: First, one interviewee had no idea and could not answer the question, 
and for the other, it is imperative that industry and academia work together. He believes, however, that 
the concept of PPP works only in the non-competitive area. 
"Now in this sense you are going into subpopulations, small, rare cancers et cetera that is 
normally the area where collaborations between industry and academia are stronger because 
really industry then needs the academic, needs centres of references, networks and all of this 
stuff. And perhaps those could be right, right frameworks for some of these PPP.  
 
“IMI is good at non-competitive stuff, so basic methodology, technology et cetera. Now in this 
phase of the CD I was not thinking immediately on something like IMI, because I thought the 
companies would be very interested in the certain type of biomarker, a certain type of drug. How 
can that be non-competitive? But I am thinking of this for the first time, so maybe the answer is 
a bit superficial." 
 
 
VII. Brief conclusion on the topic “Public-Private Partnerships” 
 Strong Pro Neutral Strong Contra 
Value of Public-Private 
Partnership 
 
The interviews with the experts show that almost all groups have a positive attitude towards academic 
and industrial collaborations. We deliberately only use the term collaboration, because some interview 
partners may have thought during the interviews more about "classic" partnerships rather than PPPs. 
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However, in general the interviewees from the medical physician groups acknowledge the fact that a 
partnership with industry is desperately needed to drive the nuclear medicine field forward. Still, in 
matters of PPP, the set- up, e.g. in Germany could be challenging, as there is currently no natural process 
to do so. 
Also the pharmaceutical industry values collaborations with the academic world in general, and the 
concept of PPP for tools, which are essential to many partners but does not generate a competitive 
advantage for a single company. It seems that reaching consensus on study design with the academic 
world seems to be challenging in a partnership. Due to the different motivations, working together can 
sometimes be provoking.  
For the radiopharmaceutical industry, a PPP is neither good nor bad, also because many of the 
interviewees had no experience with the concept of PPP. A few challenges named by this group: finding 
consensus, different expectations on the timetable, the speed of research, ownership of inventions et 
cetera. But generally the experts speak very positively about the partnership between themselves and 
the academic community.  
Most medical specialists also value the concept of PPP, but we must again assume that some of the 
interviewees had “traditional” collaborations in mind. However, they also mentioned the drawbacks of 
such partnerships such as the industry´s attempt to dominate the study design and -rationale.  
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4.5 The Focus in Research and Development and the Future Role of Molecular Imaging 
We asked the stakeholders about their research focus, the industry´s mission and objective and how 
molecular imaging (MI) may have a role in the future of patient management. Among other things, we 
asked the interviewees if R&D will remain focused on PET (PET/CT and PET/MRI) and/or what role 
SPECT (SPECT/CT) will play. The interview partners were also interviewed on the topic "Research Focus 
in the area of Molecular Imaging", and individual stakeholder groups should give their opinion on 
where research in the field of MI has to catch up. 
All statements regarding this topic are in the appendix on page 229 
I. The Nuclear Medicine View: 
Nuclear physicians have a relatively clear idea of what the future holds. Four interviewees believe that 
FDG PET/CT will continue to play an essential part in the clinical routine: “Certainly FDG has taken its 
place and it will expanded here or there, and perhaps there are alternatives which will limit its use.” 
However, more and more radiopharmaceuticals will bind to a specific target structure. This will not be 
limited to oncology, but also increasingly expanding into neurology and cardiology. 
"It is quite possible that FDG PET will continue to be a very important pillar ... but the next area 
where PET prevails or will solve a lot is neurology, but also in the cardio area ... " 
Continuing, specific drug-related targets will be developed for oncology, but the question remains as to 
how many of these research results will be translated into clinical routine. 
"And of course, research is now increasingly moving in the direction of visualising and 
quantifying very specific, drug-relevant targets. Including modern developments such as 
immunocheckpoint inhibitors or things like PDL-1, PD-1. There are already compounds available 
A Nuclear Medicine Physicist´s view: 
“It is quite possible that FDG PET will continue to be a very 
important pillar ... but the next area where PET prevails or 
will solve a lot is neurology, but also in the cardio area ... " 
PET vs SPECT: 
"No, no, you can forget about SPECT. In this case I'm brutal. 
But that's very striking." 
A Pharmaceutical Industry´s view: 
"…From that point of view you have PET agents... at least... 
carbon is out of question, fluorine can be challenging because 
of the half-life. Technetium is much more attractive. Gallium 
obviously with PET is more attractive, because you can use a 
generator and a nuclear medicine department can make it 
locally. And if I were looking developing a personalized 
healthcare compound I would be very cautious about the 
fluorine agent.” 
A view from the Molecular Imaging 
Technology Industry: 
"... since then, we have focused more on Life Cycle 
Management and push projects in the R&D pipeline, 
which are already more advanced in the development 
stage, so in Phase II or III. And in terms of personalized 
medicine, we initiated a study with an “old-fashioned” 
product ... to see if [product name] can predict that a 
patient needs a defibrillator (ICD) or not." 
A Radiopharmaceutical Industry´s View: 
"Both [SPECT and PET] are adequate and given the 
cost circumstances both will remain, but PET will grow 
in the future. The opportunity to modify small 
molecules without significant influence on 
biodistribution is a clear advantage. With Fluorine the 
supply chain is already there." 
 
A view from a Medical Specialist: 
"So in prostate cancer, if imaging gets even better, focal treatment for prostate cancer may play a significant role. Such 
as brachytherapy, local photodynamic therapy, HIFU (High intensity focused ultrasound), or such treatments. I don´t see 
drugs in local therapy, there will always be physical energy applied, which irradiates the tumour locally.... Otherwise, at 
an advanced stage, the individualized target therapy will play a role.” 
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for CXC4 or chemokine receptors. But this is the path taken in research, relatively little is 
translated into the clinic." 
Three interviewees are convinced that the concept of Theranostics will continue to offer promising 
opportunities in the future. Moreover, research in this area is not limited to academic institutions, 
because not only some small, but also larger pharmaceutical companies have recognised the potential 
of this area and have initiated a clinical research program. 
“There are several tendencies: ... for a while, there were doubters who thought the therapeutic 
application in the NUK has no future. Which cannot be said any more today... PSMA is a very 
promising therapy ... But there are also a lot of other companies ... that initiated controlled 
studies. The PSMA found its way out of academia, but there are some radioactively labelled 
antibodies, or some alpha-therapies, where small, but also large players in the pharmaceutical 
sector, invest a lot of money.” 
One conversation partner has already mentioned new fields of disease, where he believes that the 
concept of Theranostics could also be successful. He favours some promising candidates without even 
knowing who will win the race. 
“…And in the forefront of the success of Theranostics and the therapy, of course, enormous 
efforts are now made to establish further target structures, which are suitable for the theranostic 
approach. For me, this currently covers three areas: breast cancer ... lung cancer, third is colon 
carcinoma and fourth ... pancreatic adenocarcinoma.” 
Is the future in PET or SPECT? 
 PET Both SPECT 
Future in PET or SPECT?  
Also, we wished to know from the nuclear medicine physicians whether the future will solely be focused 
on PET technology, or whether SPECT will have a comeback. The majority (57%) see the future in PET 
and give the SPECT little chance.  
"Clearly in PET. SPECT, that's nonsense you have to be clear. Of course, it's easier and more 
accessible, but it is anachronistic! You have to move to PET, that's just the rethinking. You cannot 
work with a “Volksempfänger” if you could have a flat screen. That's of course nonsense. If you 
look at it short-sighted, to get it expanded quickly, you can think about SPECT. But if you want 
to go to a high level, you have to push PET and not SPECT.” 
The remaining 43% of respondents do also see the future in PET, but would expect SPECT to still play a 
role.  
"SPECT will definitely play a role... still purely because of capacity. If you look at it globally, SPECT 
has probably ten times more capacity than PET ... Of course, PET has technological advantages, 
such as sensitivity and resolution for certain applications. For PSMA, PET has clear advantages, 
because the resolution creates a benefit. But there are applications where resolution is not what 
matters most.” 
The pro PET- statements range from: flexibility in labelling, higher image resolution and thus better 
characterising of the tumour biology. The interviewees’ don´t regard that the shorter half-life PET 
radionuclides to be a problem, at least not in the western industrialised countries. 
"And the problem with the PET radioisotopes, which are relatively short compared to the SPECT, 
I consider no problem. I believe that the availability of PET is not really a problem, at least in 
Germany. Not even in the US, I do not think that's a problem in any industrialized nation.” 
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Three interviewees independently belief that SPECT (SPECT/CT) will have a role in the concept of 
Theranostic, in specific disease areas. A SPECT scan could verify the target structure in the outpatient 
setting and refer the patient to the appropriate institution. 
“If so, perhaps SPECT/CT will have a certain chance, again in the wake of substances that have 
already been successful in PET/CT. An example is, e.g. so-called technetium-labelled 
somatostatin analogous ... It is also called the PET/CT of the poor man, yes. (Laughing). The 
advantage is that these SPECT tracers can be billed in the outpatient area because there is an 
existing billing structure. The colleagues in the outpatient area can thus use the substances. The 
same is true for technetium PSMA... But I think a big success will continue to be PET/CT.” 
Furthermore, one interview believes that the use of SPECT (SPECT/CT) has also an active political and 
supply-related component. SPECT is reimbursed in the outpatient setting in Germany, which does not 
apply to PET. Looking beyond Europe, SPECT technology has higher availability and a more competitive 
price compared to PET. Additionally, those SPECT RP can use technetium, which is more cost-efficient 
and has logistical advantages. 
II. The Pharmaceutical Industry´s View 
 PET Both SPECT 
Future in PET or SPECT?  
The result from this group is not representative, because unfortunately there is only one statement. For 
the sake of completeness, however, we want to publish this answer.  
This interviewee would prefer SPECT to PET. The availability of scanners and radionuclides is crucial for 
this interlocutor, especially when considering that a radiopharmaceutical should be used as a 
companion diagnostic. His view: Pharmaceutical companies think globally, and PET has disadvantages 
especially in developing countries or countries with currently low imaging infrastructure. 
"When the drug company is developing the drug, it's developing it for a global market. So when 
[company name] is developing they are not just thinking of, certainly they think if you can sell it 
in the United States and EU, they are also thinking about China, Philippines, Brazil, Indonesia. 
These are important markets! If you going to have a diagnostic in your label you want to make 
sure it is available in every hospital in China, Philippines, Brazil otherwise you would not sell this 
drug. From that point of view you have PET agents... at least..., carbon is out of the question, 
fluorine can be challenging because of the half-life. Technetium is much more attractive. Gallium 
obviously with PET is more attractive, because you can use a generator and a nuclear medicine 
department can make it locally. And if I were looking developing a personalised healthcare 
compound, I would be very cautious about the fluorine agent.” 
III. The Radiopharmaceutical Industry´s View: 
We also wished to know the R&D mission and objectives of the radiopharmaceutical industry group. 
Two interviewees told us that their companies have specialized in the development of new diagnostic 
agents, mainly in the field of PET. While one of these companies is focusing on cardiology, the other 
company has recently successfully launched a new prostate PET diagnostic product and believes it may 
be useful in other tumour entities as well. So they are pursuing this idea and hoping for further 
possibilities. 
The third company specialises in the development of a theranostic platform. 
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"Okay, so I would say that the mission of [company name] is to develop theranostic platforms. 
So drugs, which have both a diagnostic and therapeutic component, which is shared. Not 
necessarily identical compounds, but they are shared. So that the personalised medicine is 
essential that patients who benefit from a therapeutic agent are identified by the diagnostic 
component." 
Is the future in PET or SPECT? 
 PET Both SPECT 
Future in PET or SPECT?  
Compared to the group of nuclear physicians, the radiopharmaceutical industry´s experts are not so 
sure which technology will dominate in the future. Our empirical results indicate a trend towards PET, 
but all interviewees also see SPECT (SPECT/CT) as a variable option. 
From the point of view of an interview partner, the dissemination of the technology may depend on the 
costs of the respective unit of spatial resolution. SPECT´s technology has evolved over the years and is 
a good alternative to PET and other imaging modalities.  
"I think SPECT is definitely still an option. So the difference between SPECT and PET is based 
around the resolution, the spatial resolution of the imaging device. Not necessarily based around 
basic physical properties. So if the SPECT cameras become more sophisticated, as it appears they 
are, then I think SPECT and PET will have a role to play. Moreover, ultimately spatial resolution 
for a given price will determine how much SPECT and PET, not necessarily one or the other but 
rather how cheap the camera is for a given spatial resolution." 
The third interviewee believes that PET would be preferred, if the challenge of costs did not exist. The 
labelling options and existing supply chain are certainly better. 
"Both are adequate, and given the cost circumstances both will remain, but PET will grow in the 
future. The opportunity to modify small molecules without significant influence on 
biodistribution is a clear advantage. With Fluorine the supply chain is already there." 
IV. The Molecular Imaging Technology Industry´s View: 
We have also questioned the Molecular Imaging Industry group about their current mission and 
objectives, as well as their assessment of which technology will play a role in the future. 
Concerning their mission, an interviewee explained that there is less adaptation from the technological 
point of view as the market is mainly driven by radiopharmaceuticals. The only adaption from a 
hardware aspect may be the scope of software, as was the case with the Alzheimer tracers. 
"Unlike as in CT and MRI, in MI, when you want to expand the clinical indications, it is generally 
tracer driven and probably requires a new specific tracer for that clinical area you want to go 
pursue... So and those new tracers might or might not drive something on the technology side…” 
The second interlocutor, whose company recently discontinued early research projects of new RPs, sees 
the company's mission in the demonstration of the utility of the diagnostic tests. The goal is to get the 
tests reimbursed and integrate them in current patient management processes. He calls it “Life Cycle 
Management”. However, also projects currently in Phase II and III, such as finding new 
applications/indications for existing products, will be pushed. 
Well, I would say current mission and objective is the development of (pause) it is actually more 
(break) I would say the safety and efficacy is now self-evident, but the mission actually goes 
further in the utility of diagnostic tests. Because it is clear that safety and efficacy are not enough 
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to bring diagnostic products on the market, get reimbursement and integrate them into the 
appropriate patient management. So currently the objective is to perform much more advanced 
phase III studies. We have to think about utility and of course health economics in the 
development of such products." 
Is the future in PET or SPECT? 
 PET Both SPECT 
Future in PET or SPECT?   
Experts expect both technologies to play a role in the near future. However, they also agree that the 
most significant growth is likely to be in the PET segment. 
One interviewee sees advantages for PET on the technological side, with logistical hurdles of 
radionuclides limiting this advantage. On the other hand, the resolution of SPECT detectors is improving 
and can compete with PET. 
"So I would say that still ... we see future in both areas.... PET is a tough market, but has a future 
because certain PET tracers will rather be produced than SPECT tracers. Purely from the technical 
view. On the other hand, PET is problematic ... because you either need your own infrastructure 
... or you work with local partners ... There are also certain countries where SPECT has, aside 
from the big cities, advantageous logistics compared to PET. And because of the CZT solid-state 
detectors, the resolution in SPECT approaches the resolution of PET." 
V. The Medical Specialist´s View: 
This group of interview partners was asked to evaluate new, innovative treatment options (on the 
technological side and pharmaceuticals) and the importance of molecular imaging in the future.  
As far as innovative therapeutic approaches are concerned, experts expect a better risk stratification 
and consequently a more personalised therapy approach, a more widespread use of immunotherapy 
such as the checkpoint inhibitors, an improvement in diagnostic capabilities through liquid biopsy and 
improved imaging techniques. But some disease areas, such as local prostate cancer, may not profit 
much from new pharmaceutical innovations, but will continue to be treated with physical energy. An 
urologist expects that if imaging further evolves, there will be many new treatment options possible. 
"So in prostate cancer, if imaging gets even better, focal treatment for prostate cancer may play 
a significant role. Such as brachytherapy, local photodynamic therapy, HIFU (High intensity 
focused ultrasound), or such treatments. I don´t see drugs in local therapy; there will always be 
physical energy applied, which irradiates a tumour locally.... Otherwise, at an advanced stage, 
the individualized target therapy will play a role.” 
Half of the interviewees expect that immunotherapy therapeutics to enter the market since they are 
currently “en vogue”. Also 50% of responders believe that diagnostic capabilities will improve due to 
evolving technologies. 
“What is also generally en vogue is the immunotherapy ... So the keyword is PDL-1 inhibitors, et 
cetera. This is a brand new drug class that is just very in vogue. But I think the big keyword of 
the future is the topic of liquid biopsy ... but also in general, to come back to the subject of nuclear 
medicine, the keyword theranostic is already big in the trend, high in the class." 
Two more statements should be briefly mentioned: First, one interviewee believes that in the future 
there will be a kind of artificial intelligence for the treatment of cancer, which will evaluate all the 
information and markers and suggest the best treatment option. Secondly, another interviewee finds it 
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worrying that millions and billions are spent for the treatment of metastatic patients, but completely 
disregards prevention and early diagnosis. 
Will Molecular Imaging have a role in new, future therapeutic strategies? 
 Strong Pro Possibly Strong Contra 
MI still important in new therapies?  
Two-thirds of the respondents are very convinced that imaging will play an important role: "Absolutely 
yes."! For the third interviewee, it will depend on the question as to the possibility of another biomarker, 
such as therapy response, being able to provide a reliable answer to the question. 
"It depends on the topic of treatment and if you have a biomarker that is good enough that the 
concentration of the biomarker tells us" ok, does the patient have a response or not? ". … then 
you could go without the imaging diagnostics. If, however, the patient has any consequence 
because of the localisation of the tumour … imaging with corresponding sensitivity and 
specificity is still indispensable.” 
In general, new diagnostic options will improve treatment while also providing an advantage from an 
economic point of view. 
"My assessment is that functional imaging is evolving just as well ... however, what I have seen 
so far is fascinating ... secondly, I think MI will continue to evolve as much as we do (In-vitro 
Companion Diagnostics – IVCD). Many people are probably not yet aware that we even save 
costs. If we can use functional imaging, and/or other methods, to save patients from 
unnecessary therapies, or stop meaningless and start more meaningful therapies, that certainly 
also makes economic sense.” 
VI. Brief conclusion on the topic “The Focus in Research and Development and the Future Role of 
Molecular Imaging.” 
The stakeholder´s statements have provided a good overview on current research focus. For Nuclear 
medicine experts, research will continue in the field of PSMA and DOTATATE, but will increasingly 
address new, specific targets in other diseases. Recent success in the field of Theranostics will continue 
to shape research and development of academic institutions. For the two discussion partners of the 
radiopharmaceutical industry, focus is on the development and further development of diagnostic PET 
tracers for oncology and the design of a theranostic platform. The molecular imaging technology experts 
expect RPs to drive the market, but there will be no particular influence on the development of the 
technological aspect. These companies continue to focus on selling their scanners and demonstrate 
utility.  
When asked which of the nuclear medicine technologies in the field of Molecular Imaging (PET vs. 
SPECT) will shape the future, the interviewees are not in agreement. The majority of nuclear physicians 
expect PET to be in the leading role, with SPECT still playing a (minor) role. A little contrary are the 
responses of the radiopharmaceutical- and molecular imaging industry, which see a balance in both 
SPECT and PET technology. Almost all of the interlocutors of these industry groups agree that PET has 
technological advantages but still has to overcome hurdles such as e.g. the availability of radionuclides 
and the reimbursement of the procedure. Interviewees of industry do not regard PET to be mature 
enough to be used as a means of companion diagnostics. 
Medical specialists expect new treatment options in the future, ranging from immune checkpoint 
inhibitors; high intensity focused ultrasound to an artificial intelligence system that will recommend 
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therapy options. Mainly a better diagnosis is supposed to help them to be risk-adaptive or, e.g. better 
imaging will enable the treatment of local prostate cancer with new technologies. For this group, 
imaging will continue to play an important role. There may not be a need for imaging everywhere, 
especially if other biomarkers can also provide an equivalent answer. 
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5 Discussion: 
Innovation is crucial to the future of healthcare from a business perspective but is also essential to tackle 
diseases, a fact which will become a social, political, economic and humanitarian challenge. All 
stakeholders in the healthcare sector are therefore feverishly looking for a novel application that will 
significantly benefit the individual, the group, or the broader society (N. Anderson, De Dreu, & Nijstad, 
n.d.; M. West & Faar, 1990). In The “Theory of Economic Development” Schumpeter imagined the cycle 
of innovation to be never-ending, introduced mainly by small- and medium-sized enterprises (SMEs) 
that will drive the technological advances (Schumpeter, 1934). A market in perfect competition, where 
all producers lack market power is “inferior in internal, especially technological, efficiency” 
(Schumpeter, 1975). He suggested that the rate of technological advances will also be better if only a 
few large firms, which would be more willing to finance risky R&D initiatives, dominate the market 
(Schumpeter, 1975). He regards market power (monopoly at its best) as a “superior method” because 
some large companies have the experience and the financial resources and protection to compete 
“against a temporary disorganised market” (Schumpeter, 1975). Unlike Schumpeter, Kenneth Arrow 
believes that “the incentive to invent is less under monopolistic than under competitive conditions.” 
(Arrow, 1962).  
Over the decades, the pharmaceutical industry has mainly developed drugs for high prevalence 
diseases, with minor investments in medicines with low prevalence, which are expected to be an 
unproductive venture (Swoboda, 1999; Trouiller et al., 2002). Observable is that the pharmaceutical 
market is not a perfectly competitive market, but may behave more like a monopoly because several 
assumptions for the perfectly competitive market structure are violated (Rattinger, Jain, Ju, & Mullins, 
2008). With their market power, the pharmaceutical industry is driving innovation in the drug market 
and strategically invests in new technologies. Some large pharmaceutical companies have also managed 
to use their market power to influence drug regulations, government decisions and influence regulatory 
agencies (Abraham, 2002). Even though the tightening of drug´s current marketing authorisation 
regulations has increased the effort for existing market participants, this more challenging and time-
consuming regulatory process also serves as an entry barrier for new competitors (DeSanti & Cohen, 
2001). This is also the reason we don´t see any “garage inventors” in the pharmaceutical market, 
compared to other industries (Carrier, 2008). 
Industry has struggled in recent years with the increasing speed of new product development, the 
intensity of early generic competition, the exposure to loss of revenue following patent expiration and 
higher regulatory hurdles on top of a declining R&D productivity (Schiraldi, 2014). Those challenges have 
forced the industry to adjust their strategies and risk-reward ratio. Manufacturing and other operations 
were shifted overseas, the research pipelines were reorganised, human resources capital was notably 
reduced in manufacturing and research, and products from smaller, more innovative companies were 
acquired to fill the R&D pipeline (U.S. Department of Commerce -International Trade Administration, 
2016). Also, the area of nuclear medicine has not been spared by these structural challenges, seeing big 
companies leaving the market or reducing R&D efforts. For this reason, new innovative ideas are almost 
exclusively discovered and developed in academic institutions. Some products reached the market, with 
the help of an industrial investor, but others have failed to pass the translation gap due to financial 
constraints (Clarke, 2018). However, new, but un-authorized, diagnostic and therapeutic 
radiopharmaceuticals have still be used in clinical routine and were administered under certain 
conditions on the basis of national exemptions, mainly in Europe. Over the years, the data and 
publications from these un-licensed applications have demonstrated the benefit of these diagnostic and 
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therapeutic products, attracting small and medium-sized businesses and led to the approval of at least 
three RPs. 
So why did it take so long for some diagnostic and therapeutic RPs to receive market authorisation? Is 
nuclear medicine technology clinically inferior? Could it be a market failure as can be seen with the 
neglected diseases in developing countries?  
The question of whether it is a market failure, or whether other forces are preventing the rise of these 
products, can only be answered by evaluating the efficiency of the technology itself. We have therefore 
evaluated the clinical effectiveness of two innovative radiopharmaceuticals used in the diagnosis and 
treatment of Neuroendocrine Tumours (NETs) and Prostate Cancer (Pc) in the first section of this thesis. 
5.1 Evaluation of Clinical Efficacy  
Unfortunately, the interpretation of the efficacy is not straightforward as the majority of published 
literature has a retrospective study design, is mainly single arm and has a variety of treatment regimens 
(doses and number of cycles). For NETs the most meaningful study is the randomised, controlled, 
comparative NETTER-1 trial (Strosberg et al., 2017). Several Phase II and III randomised, prospective 
trails are currently running for prostate cancer; which will better indicate the influence of technologies 
on overall survival and clinical benefit (U.S. National Library of Medicine, 2018).  
 
a) Discussion of Case 1 – Clinical Efficacy of RPs in Diagnosis and Therapy of Neuroendocrine 
Tumours  
Imaging: 
NETs are frequently sporadic, unpredictable, have an unusual biological behaviour and thus the 
diagnosis is often delayed and the outcome poor (Modlin et al., 2008; Öberg, 2015; Ramage et al., 2005). 
Conventional radiological technologies such as CT and MRI have often missed or misdiagnosed some 
tumours/metastases (Hiramoto et al., 2001; Modlin et al., 2008; Zimmer et al., 2000), but with the 
introduction of PET Somatostatin receptor ligands the diagnostic quality- as well as patient management 
significantly improved (e.g. Geijer & Breimer, 2013; Alexander R Haug et al., 2014). Today, PET/CT with 
Somatostatin analogues shows a high clinical utility in terms of high diagnostic accuracy and high impact 
on patient management in patients with advanced disease, and therefore should be considered as first-
line diagnostic imaging modality for tumours with a high expression of SSTRs, such as gastrointestinal- 
and pancreatic NETs (P. Sharma, Singh, Bal, & Kumar, 2014). Extensive literature on the use of these 
diagnostic agents exists, although most of them are retrospective and are not meeting the current 
quality requirements of regulatory agencies. However, recently 68Ga- DOTATATE successfully passed 
through the regulatory process of the FDA and EMA and has received marketing authorisation. We, 
therefore, believe that imaging RPs can be judged to be efficient and useful, at least in specific diseases 
and patient groups. 
Therapy: 
Due to the great success in imaging, and the good binding affinity and targeting of the ligand, the next 
logical step was to label the biological compound with therapeutic radionuclides such as 177- Lutetium 
and 90- Yttrium and treat patients with advanced metastatic disease. So far the clinical results are very 
encouraging, and also a recent Phase III trial (NETTER-1) confirmed initial results of the academic trails 
and showed markedly longer progression-free survival and a significantly higher response rate than 
high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumours (Strosberg et 
al., 2017). More prospective, comparative studies with a standardised clinical protocol and a control 
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group can be expected and are needed to finally evaluate the new approach. However, based on 
currently available data (see Chapter 2.2.5) we would also rate the therapy with these RPs as efficient. 
Since 177Lu DOTATATE has recently been successfully approved in Europe and the US by EMA and FDA 
for the treatment of patients with advanced NETs, new clinical results can be expected. 
 
a) Discussion of Case 2- Clinical Efficacy of RPs in Diagnosis and Therapy of Advanced Prostate 
Cancer  
Imaging: 
Prostate cancer (PC) has a very complex behaviour ranging from relatively harmful to highly aggressive 
and thus with various options of treatment (Ferlay et al., 2014; Fuchsjäger, Shukla-Dave, Akin, Barentsz, 
& Hricak, 2008; Giovannucci, Liu, Platz, Stampfer, & Willett, 2007). So far TRUS (transrectal ultrasound) 
was the imaging modality of choice, for biopsy guidance and brachytherapy placement, but is not well 
suited for local staging (Fuchsjäger et al., 2008). MRI and CT improved staging, but still had challenges 
in advanced cancer stages, especially in biochemical recurrence. 68Ga-PSMA-HBED-CC, a highly prostate 
specific target transmembrane type II protein used in PET, remarkably improved the sensitivity, 
specificity and detection rate especially in advanced tumour stages (e.g. Afshar-Oromieh et al., 2017). 
In some cases, PSMA PET/CT was able to detect metastases, which have been occult in CT (Lenzo, 
Meyrick, & Turner, 2018) and multiple studies showed the superiority to choline PET/CT (Afshar-
Oromieh et al., 2014; Morigi et al., 2015). Using PSMA PET/CT also radiotherapy planning has changed 
in 20% to 60% of patients who received a 68Ga- PMSA PET/CT prior to radiotherapy (Bluemel et al., 2016; 
Calais et al., 2017; Habl et al., 2017; Schiller et al., 2018; Schmidt-Hegemann et al., 2017). In a relatively 
short period, 68Ga-PSMA PET/CT was implemented in many countries for the detection of biochemical 
recurrence. Based on the current available literature we would also rate this PET RP to be efficient and 
useful, at least in patient with biochemical recurrence and unclear metastatic status. 
Therapy: 
PSMA receptors have additionally proved to be an excellent target for therapy, since it is highly 
expressed in metastases even after multiple cycles of therapy (Pyka et al., 2016) and allows repeated 
intravenous applications (Rahbar et al., 2017). Several studies could show a benefit for most patients, 
who have already completed every treatment option available and have been running out of 
alternatives. In these specific patient group, several studies could show that around 30% to 100% of 
patients experienced more than 50% reduction in serum PSA, and >58% of patients experienced any 
PSA decline (Ahmadzadehfar, Eppard, Kurpig, et al., 2016; Ahmadzadehfar et al., 2015; Baum, Kulkarni, 
et al., 2016; Fendler, Reinhardt, et al., 2016; Ferdinandus et al., 2016; Matthias M. Heck et al., 2016; 
Kratochwil, Giesel, et al., 2016b; Rahbar et al., 2017; Tagawa et al., 2013; Weineisen et al., 2015; Yadav 
et al., 2016). Therapy with Lutetium-177 PSMA showed comparable treatment response to currently 
used chemotherapy agents such as Mitoxantrone and Cabazitaxel (change in PSA >50%: Mitoxantrone: 
17.8%; Cabazitaxel: 39.2%), with a significantly lower rate of adverse events (Rahbar et al., 2016). 
Results, which have also been confirmed in a large German multicentre study with a total of 145 patients 
with mCRPC (Rahbar et al., 2017).  
Again, based on current available literature we would also rate this therapeutic RP to be efficient and 
useful, with a very low probability of high-grade haematotoxicity and a prolongation of overall survival 
in mCRPC patients with distant metastases and progressive disease. 
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5.2 The Challenges and Barriers Associated with the Development and 
Approval of Radiopharmaceuticals 
The analysis of (predominantly retrospective) clinical data suggests that these diagnostic and 
therapeutic RPs are at least not inferior to currently used technology. Therefore, there must be other 
reasons why these products are not taken up, and developed by investors. Few studies have addressed 
the challenges and barriers associated with the development and marketing authorisation of 
radiopharmaceuticals, those only consider the challenges from the point of view of a single stakeholder 
group and the statements are seldom based on reliable empirical data (cf. Henderson et al., 2005; Nunn, 
2006, 2007a, 2007b, Zimmermann, 2008, 2012b, 2012a). In our study, which is unique from our point 
of view, we have used a holistic and structured approach. Since new product development is seen as an 
organisational activity, where it is necessary that all stakeholder groups get involved from the beginning 
to contribute to a successful product (Haque, Pawar, & Barson, 2000), we have integrated opinions form 
all stakeholders who may play a role in the process. In our case, these groups are nuclear medicine 
physicists (NMG), medical specialists (MSG), the radiopharmaceutical (RIG) and pharmaceutical 
industries (PIG), the manufacturers of scanner technology (MTIG), and the regulatory authorities (RAG). 
Interviewing so many different experts also allows us to rank the challenges and barriers according to 
their priority. 
Value of Imaging: 
Before we dive into the specific challenges, we should first mention that all interviewees consider 
molecular imaging as very valuable. The practising physicians from the NMG and MSG especially valued 
imaging as an indispensable technique in their treatment process. Interviewees from both groups 
particularly highlighted the possibility to non-invasively, localise and visualize the heterogeneity and 
spreading of a disease in real time (cf. Carter, Halpenny, Ginsberg, Papadimitrakopoulou, & de Groot, 
2017; MacFarlane, Shah, Wysong, Wortsman, & Herphreys, 2017; O´Connor et al., 2017; O´Connor et 
al., 2015). Also, the pharmaceutical industry is using imaging tools regularly, almost exclusively for their 
R&D programs, to precisely identify target structures, quickly prove the overall concept, finding the right 
dose, and continuously tracking the distribution of the compound in the body. Experts of the 
1) What is the clinical efficacy of Somatostatin Analogs and PSMA ligands diagnostic and 
therapy? 
Based on the analysis of published literature, the diagnostic and therapeutic radiopharmaceuticals 
for neuroendocrine tumours, as well the RPs for advanced prostate cancer, can be considered 
clinically efficient. Meanwhile, a company has further developed the diagnostic agent 68Ga-
DOTATATE (NETSPOT® and Somakit DOC®) and the therapeutic RP 177Lu-DOTATATE (Lutathera®) 
which are now officially approved for the diagnosis and treatment of patients with neuroendocrine 
tumours. This company has since been acquired by a major pharmaceutical company for $ 3.9 
billion, most likely because of the therapeutic drug. 
Compared to the Somatostatin analogues, PSMA has made a very rapid entry into clinical routine. 
Within a few years, the 68Ga- PSMA research ligand from the University of Heidelberg (68Ga-PSMA-
HBED-CC) was used globally for the diagnosis of patients with biochemical recurrence. Even within 
a very short time, a therapeutic agent was developed and successfully applied similar to the concept 
of DOTATATE. This rapid entry into clinical routine is also a strong indicator for clinical efficacy. 
Currently a few companies have started a clinical development program for PSMA therapeutic RPs. 
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pharmaceutical industry confirmed that these new molecular imaging techniques are a better internal 
decision making tool, and helped them to speed up the R&D process, improved the patient stratification 
process for clinical trials and in the end saved much money. Our results are therefore in line with current 
statements from the literature (e.g. Lin et al., 2015; O’Farrell, Shnyder, Marston, Coletta, & Gill, 2013; 
Rudin & Weissleder, 2003). 
Some studies briefly addressed the industry challenges with imaging biomarkers (IBMs) such as the 
selection of the right imaging technology for a specific question (Pien, Fischman, Thrall, & Sorensen, 
2005), the validation of imaging biomarkers i.e. as a surrogate endpoint (Schuster, 2007) and the quality, 
validity and quantification of the imaging measurement (J. C. Waterton & Pylkkanen, 2012). So even if 
IBMs seem to be beneficial in the R&D process, our data indicated that the pharmaceutical industry has 
minor interest in commercialising IBMs or even use them as a companion diagnostic. The reasons for 
the low commercial interest on the part of investors are versatile, but we can use our data to categorise 
and describe these barriers more precisely. 
The hurdle that stands out as number one among the diagnostic RPs is “market potential”. This issue 
was highest ranked by all stakeholder groups but was only partially discussed in the literature so far 
(Zimmermann, 2008). 
5.2.1 Low Market Potential 
Rising R&D costs, high attrition rates in the development process as well as shrinking revenue has put 
pressure on the shareholder-driven pharmaceutical industry (Kola & Landis, 2004). In effect, the 
industry started to prioritise those projects with the highest net present value (Stewart et al., 2001) and 
reduced efforts for medical innovations, which generated sales lower than $ 600 million per year 
(Tollman et al., 2011). Unfortunately, nuclear medicine was one of these “lower-interest” segments 
since the global nuclear/radiopharmaceutical market only has a total market potential of $ 4.67 billion 
(estimate for 2016) (Markets and Markets, 2016). The market for the diagnostic RPs is very small and 
thus does not seem to be attractive enough for the big pharmaceutical industry: “…the margins are very 
low in diagnostics, there is more money in therapeutics...”. This was evident in the late 1990s/early 
2000s, when several large pharmaceutical companies left the diagnostics RP market. Even though new 
cancer therapeutics become increasingly more targeted (Habeeb et al., 2016), and patient stratification 
will become more important, many large pharmaceutical companies seem nonetheless unwilling to 
include diagnostics in their portfolio. However, radiopharmaceuticals are by no means unattractive to 
large pharmaceutical companies, as demonstrated by the Novartis acquisition of Advanced Accelerator 
Applications (AAA) in 2017. Novartis had special interest in the recently approved 177Lu-DOTATATE 
therapeutic agent, which fits well within the Novartis oncology portfolio in the NET area (Novartis Media 
Relations, 2017). We therefore expect the big pharmaceutical industry to make strategic acquisitions in 
therapeutic (and/or diagnostic) RPs, but they will not be a primary investor for the development of new 
diagnostic RPs. 
Thus, the development and commercialisation of diagnostic RPs may remain solely in the hands of small 
and medium-sized enterprises (SMEs). In fact, it seems that the development of diagnostic RPs fit very 
well within this segment since smaller firms are more flexible, traditionally focus more on domestic 
markets, create or re-engineer products or services to meet new market demands, but in general 
conduct less R&D compared to larger firms (Organisation for Economic Co-operation and Development, 
2000). Our interviewed experts from SMEs confirmed that they have continued the development of 
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diagnostic RPs, which have proven to be pre-clinically or 
clinically effective and have a high chance of receiving 
adequate reimbursement in the United States. The U.S. market 
seems to be of special interest and was described as a “fairly 
big business”, a “good investment” with “good growth rates”. 
In fact, recent estimates indicate the U.S. PET RP market potential to be around $ 275 million and in 
connection with the “good conditions” this market is currently driving the global development of new 
diagnostic RPs. “Good conditions” are described to be good reimbursement values for oncological 
diagnostic products, and the relatively “quick” local Medicare and Medicaid reimbursement due to 
favourable regulation. So interviewees from the RIG and the NMG therefore see a far better outlook for 
the US market, since the market is very differently structured and offers more possibilities for revenue 
(Kuttner, 2008). 
For Europe the situation is much different, maybe even worrying in the eyes of some experts. Europe 
has the extraordinary situation that drug applicants can apply for a Europe wide centralised 
authorisation for their drug, but the decision on reimbursement remains a national competence and 
has to be negotiated with each national health authority. The challenge: the requirements for evidence 
of benefit (i.e. medical efficacy data, health economic data) differ from member state to member state 
and application forms need to be adapted for each country. Our interviewees from the European NMG 
even fear that the low market potential in Europe could even become a challenge for the introduction 
of future diagnostic RPs. This fear was directly confirmed by an expert from the RIG:  
"If the market for all PET diagnostics and SPECT diagnostics is payment at either a technetium 
bone scan rate or an FDG rate, if that is the future, from now forever, for payment for nuclear 
medicine, then at some point people will stop commercialise products in Europe." 
The situation in Europe is not based on strict conditions by health authorities, but also rests on the non-
engagement of the industry. Typically the industry has a market access strategy and starts very early to 
collect data on safety, efficacy and evidence of benefits. But since the pharmaceutical industry has not 
engaged much in nuclear medicine, also the difficult issue of reimbursement was left with academics. 
Accordingly, many of the studies miss a structured process and have not met the requirements of 
national HTAs or the national/ international regulatory authorities. For example, the German Institute 
for Quality and Efficiency in Health Care (IQWIG), which is responsible for the independent assessment 
of the benefits of drugs and technologies, exclusively relies on the concept of evidence-based medicine. 
Consequently, only trials with the highest quality and for example compare option A to option B (ideally 
randomised) can be used for the evaluation. Patient-relevant endpoints (mortality, morbidity and 
health-related quality of life) need to be reached in randomised controlled trials. Also diagnostic 
pharmaceuticals are evaluated after the same procedure, even it is more difficult for those product 
group to show an existing and documented benefit on the outcome (Institute for Quality and Efficiency 
in Health Care - IQWIG, 2017a).  
In summary, our data show that the issue of market potential, which is i.e. closely linked to the 
reimbursement issue, represents the greatest challenge for diagnostic RPs in Europe, and must be 
urgently addressed. It is to be expected that large pharmaceutical companies will not be generous in 
the field of molecular imaging outside of their currently running R&D efforts. This leaves the 
development of new, innovative products in the hands of SME and the academic community. While 
SMEs have a creative, quick and efficient approach to solving challenges, they often lack specific 
expertise and staff to, e.g. solve national reimbursement hurdles. There are currently some challenges 
in Europe (to be discussed in the next pages), which have a significant impact on the market potential 
"PET biomarkers are a fairly big business. 
The PET market in the US is about 275 
million a year, this year 2018. That’s all 
PET in the US, revenue. So 275 million…” 
(Manager Radiopharmaceutical Industry) 
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and eventually detain SMEs to introduce these new diagnostic products in the European market. A non-
introduction of diagnostic RPs in Europe would be fatal from the perspective of patient care, which is 
why we believe it is urgently necessary to (1) get national/ international regulatory- and reimbursement 
support for SMEs, (2) line up contemporary and adequate reimbursement for innovative technologies 
in the DRG system, and (3) tighten the cooperation with academic institutions. 
5.2.2 Reimbursement 
The second most crucial hurdle (67% agreement across all stakeholder groups), which we have already 
briefly mentioned, is the issue of reimbursement. Reimbursement policies have a far-reaching effect on 
the adoption and the usage of medical technology (Office of Technology Assessment, 1982) by 
restricting access or supporting the spread of the drug or medical technology. In molecular imaging, 
especially in PET/CT, the reimbursement of procedures is globally very heterogeneous regulated and 
coverage policies are often variable and restrictive, especially in Europe (Fischer et al., 2016). In the U.S., 
reimbursement for oncological indications has increased in recent years due to “coverage with evidence 
development” (CED) program.  
Getting a product reimbursed is time-consuming and complicated. Pricing and reimbursement is usually 
a national competence and countries have different approaches and processes to assess the value of a 
new drug and subsequently decide on the listing by public- insurance companies (Barnieh et al., 2014). 
Our interviewees have pointed out some critical issues that have led to the problematic reimbursement 
situation in Europe: Missing formal authorisation of RPs, high regulatory requirements to prove utility, 
and inadequate study designs/ data from academic studies. In particular, the incompatibility of the 
requirements outlined by the competent authority (e.g. IQWIG in Germany) and the feasibility of the 
academic institutions should be emphasised. Whereas doctors from academic institutions typically want 
to get medical questions answered, authorities also want to see evidence of benefit from a socio-
economic point of view. Typically, it is the responsibility of the company which is developing the new 
drug to timely set up a process and collect reimbursement relevant data. But since many of the 
diagnostic RPs have mainly been developed by academic institutions in many European countries, the 
challenge of reimbursement was left in the academic sphere. A recent study evaluated the 
reimbursement system in five European countries and outlined the similarities and difference in their 
processes, showing the challenges, and revealed how much multidisciplinary knowledge is needed 
(Franken, le Polain, Cleemput, & Koopmanschap, 2012). The academic community has neither the 
knowledge nor the financial resources to cover this issue.  
Even for the industry reimbursement for their products is not simply achievable, as one expert from the 
RIG confirmed: „Getting past the FDA is not that bad, it takes time and money, but it is doable if you 
have a focused indication. But getting passed payment is a big deal.". Medical imaging is furthermore 
accused of being a principal driver for burgeoning expenditures (Baker, 2001; Bodenheimer, 2005; 
Smith-Bindman, Miglioretti, & Larson, 2008; Sorenson et al., 2013), which may increase demands on 
clinical- and economic benefits data by governmental institutions.  
We conclude that the reimbursement situation in the U.S. is favourable for the introduction of new 
oncologic diagnostic RPs, making it the currently most important market for the radiopharmaceutical 
industry. Even the current push by the U.S. government to decrease national healthcare spending, by 
forcing pharmaceutical companies to lower drug prices (Block, 2018), may not have a short-term effect 
on the reimbursement system in the U.S. Especially in Europe, with its state-funded healthcare system, 
the heterogeneity of reimbursement systems (Franken et al., 2012), decreasing reimbursement rates 
for imaging procedures (Merchant, 2010), and restrictive reimbursement decisions by national health 
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technology assessment agencies (e.g. Institute for Quality and Efficiency in Health Care - IQWIG, 2018; 
C. Wild, Patera, Küllinger, & Narath, 2015) will have a substantial effect on the introduction of new RPs. 
Due to a higher cost pressure, payers may to see more evidence, from well-designed Phase 3 trials, with 
clinically meaningful endpoints such as Quality of Life, morbidity and mortality (Oye et al., 2015).  
On the other hand, there have been initiatives by the FDA and EMA to speed up approval for new drugs 
with orphan diseases status by partially lowering the approval requirements (Giannuzzi et al., 2017). 
Companies who may want to introduce innovative new products get free and early-stage scientific- 
and/or reimbursement advice by EMA and FDA (Henshall, Mardhani-Bayne, Fronsdal, & Klemp, 2011; 
Wonder, Backhouse, & Hornby, 2013). This initiative may particularly help small and medium-sized 
companies, as they usually have less in-house knowledge compared to big pharmaceutical companies 
(Pammolli et al., 2011). We further assume that the academic community will continue to drive the 
development of new diagnostic RPs. However, we believe that academics need to implement a more 
process-oriented, rigorous study program/-quality in order to generate more clinically and economically 
relevant data that can also be used for market authorisation and reimbursement decisions. We see that 
this understanding is already being perceived in the group of nuclear physicians:  
“What we urgently need in academic research is industry support. So the thinking of the industry: 
what are the development steps of phase 0,1,2,3? What are the requirements? How can you do 
something like that?” (Nuclear Medicine Physicists from Germany) 
5.2.3 Regulation 
Radiopharmaceuticals are possibly among the tightest regulated medicinal products worldwide and 
have to obey the national law on drugs, national and international radiation protection ordinance, 
special employment protection regulation et cetera. For all drugs, the marketing authorisation (MA) 
process has refined over the decades, and modern approval processes requested much more clinical 
data, more randomised controlled trials and more data on safety and efficacy (Woodcock & Woosley, 
2008). Since diagnostic RPs are regulated similar to classic pharmaceutical drugs, they have to follow 
the general drug approval process (The European Parliament and the Council of the European Union, 
2001; U.S. Department of Health and Human Services Food and Drug Administration et al., 2004) even 
diagnostic RPs do not have any pharmacological effect (Saha, 1984). Despite lacking pharmacological 
effect, there are cases of acute adverse events including serious side effects (~ 38%) (Laroche, Quelven, 
Mazère, & Merle, 2015).  
However, if the product is an imaging agent some data can be waived and other additional data may be 
requested (radiation exposure, absorption dose of the source tissue/organ and any other tissue et 
cetera) (U.S. Department of Health and Human Services Food and Drug Administration et al., 2004). 
Extraordinary is the allowance of “extemporaneous preparation” (Article 7 in Directive 2001/83/EC) in 
Europe, which empowered member states to legitimate some institutions to prepare the product near 
the patient´s bedside and waive the marketing authorisation (The European Parliament and of the 
Council, 2001). But Article 7 was not transposed uniquely in all countries, and today some countries 
enjoy more freedom than others. In Germany, this exemption is continuously use by clinicians, who 
prepare their RPs in either small-scale industrial sites with GMP license or non-industrial sites such as 
hospital pharmacies, and nuclear medicine departments, and administer the diagnostic and therapeutic 
RPs to patients (§ 13.2b AMG).  
177 
 
Literature suggested that the topic “regulation” is highly 
ranked (Henderson et al., 2005; Nunn, 2007a; O´Connor et al., 
2017; Zimmermann, 2013), however, our empirical data 
suggests that this challenge may not be perceived as of great 
importance to all stakeholder groups. It is interesting to note 
that the opinions of the experts of the NMG and the RIG are 
completely contrary. For both groups the regulation is a 
challenge, but for the NMG group it is too tight and for the RIG 
not stringent enough. Overall European nuclear medicine 
physicists perceive the regulations for diagnostic RPs to be too 
strict and these products should not be categorised equally as 
therapeutic drugs. Some European interviewees value the 
possibility to have quick first-in-man studies, but also half of 
them criticise the rapid use in humans. Their concerns are related to patient safety and uncoordinated 
collection of proof of utility: trial designs may not meet current requirements, data may not be 
efficiently used for approval or reimbursement processes and therefore create obstacles for the whole 
nuclear medicine field. It is the opinion of one expert that Europe will not be able to approve new RPs 
due to the unstructured process. However, it can be argued that European data, recorded in 
retrospective “individual medical treatment” cases, has been accepted by the agencies for backing up 
the approval of new diagnostic RPs. 
Unexpectedly, the radiopharmaceutical industry perceives regulatory requirements to be not stringent 
enough, at least in some European member states. While RIG experts recognise the benefits of the 
administration of unlicensed products to the community and patients outside of clinical trials, the 
companies struggle with this “secondary market” and cannot compete from a business perspective. For 
the U.S. market, the interviewees are satisfied with the FDA´s cooperation and support, also because 
there are distinctive formulated requirements/ guidelines. Furthermore, the administration of 
unauthorised RPs, outside registered clinical trials and without a new drug application (NDA) status, is 
prohibited (Vallabhajosula, 2009).  
Our interviewees from the RIG anticipate a strengthening of European regulations, with the result that 
the possibility of “in-house production” will become limited. Some European nuclear medicine 
physicists agree with this assessment, yet the field is divided. A few don´t expect any regulatory 
harmonisation, whereas others await a positive harmonisation and the third group fears that the 
regulators will change to their detriment. From today's point of view, it cannot be predicted in which 
direction these changes will progress. One expert told us that the lobby groups from the nuclear 
medicine associations and pharmaceutical industry seem to be in intensive talks with regulators to 
compile their statements. We can expect the radiopharmaceutical industry and occasionally large 
pharmaceutical companies to limit the use of un-authorised products (at least in their indications), a 
fact which may affect clinical practice and academic research. However, previously introduced European 
regulations and directives have dealt with general health/medical-legal issues (Directive 2001/83/EC, 
Regulation (EC) No 726/2004, Regulation EU No 536/2014, et cetera), but not specifically with a group 
of products. The harmonisation process may take time and could perhaps be introduced via 
recommendations in guidelines, code of practices or even GMP regulations.  
“Germany leaves them any freedom, which 
I welcome. I think that's great, but the 
problem in Germany is that you have room 
to do scary things, and then, if you really 
want to introduce the tracer to the market, 
then the hurdles in Germany are even 
more prohibitive than they are here."  
(Nuclear Medicine Physicist from Europe) 
“I don´t think that the regulatory agencies 
are the bottleneck here. Actually they are 
doing really well. They have an interest to 
get this done. I am actually fairly positive 
about their work...” 
(Nuclear Medicine Physicist from the USA) 
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5.2.4 Research and Development 
In literature the term R&D is primarily connected to the perception of costs, but our empirical data 
suggests that there are also other concerns outside of costs such as speed of research, the sophistication 
of industrial and academic research, and research related mistakes made by academics.  
Thus, while the majority of nuclear medicine physicians (57%) see R&D costs as a challenge, none of the 
experts from the radiopharmaceutical industry has explicitly mentioned this topic. So “R&D costs" 
seems not to be a provoking challenge to all stakeholder groups. Possibly physicians have little business 
knowledge on the development of new drugs and cannot put the millions of dollars in relation, whereas 
the industry is continuously calculating investments vs. expected return on investment (Schuhmacher 
et al., 2016). One has to say that the development of a new RP is significantly less expensive compared 
to a new biologically active drug. It was specified that costs for a new diagnostic radiopharmaceutical 
are between $ 100 to 200 million (Nunn, 2006), whereas Zimmermann (2008) estimates costs of $ 26 to 
35 million (in 2017 USD) for a radiodiagnostic - and $ 52 to 82 million (in 2017 USD) for a 
radiotherapeutic compound. We would assume, based on the statements from our interviewees and 
the published financial reports from relevant companies that the real costs for a diagnostic RP would be 
between $ 65 million and $ 100 million. Although that sounds like a lot of investment, it is many times 
less than the development of a therapeutic agent (cf. R&D costs published by: DiMasi et al., 2016, 2003; 
Kaitin & DiMasi, 2011; Prasad & Mailankody, 2017).  
The assumption that extensive basic research of academic institutions reduces development costs does 
not seem to be valid, at least that is the opinion of an industry expert. Academic research may somehow 
de-risk the investment, but has no large effect on overall costs. A reason: the quality of the data is not 
sufficient to meet demands of regulatory agencies:  
 “.. the Agency has an interest in using data from real clinical world experience for NDAs… 
however, the literature review contained no randomised, prospective trials with independent 
blinded image review designed for drug development. Incomplete information in the articles did 
not allow one to determine precise diagnostic test performance (sensitivity/specificity) or to 
evaluate the role if new imaging information on patient management and patient outcome… 
the totality of the clinical experience … may be used to support approval” (comment from the 
FDA in connection with the approval of a new diagnostic RP; Center for Drug Evaluation and 
Research, 2016).  
Surprisingly even some nuclear physicians admitted that academic studies have room for improvement 
regarding quality. However, this may only be achieved with the support and knowledge of the industry. 
It is also interesting that half of the NMG interviewees admitted possible mistakes in the development 
and commercialisation of new diagnostic RPs. From their point of view, some substances were too 
quickly used in patients, abandoning a structured and coordinated approach with the result of having 
weak evidence of benefits. Also, some nuclear medicine physicist’s interviewees are concerned about 
the speed of development in the therapeutic segment. In recent years the approval rate for drugs, 
mainly targeting rare diseases and sub-types of cancer, has increased in many big markets such as the 
US, Europe and China (Hirschler, 2018). Those new products have often used a new scientific paradigm 
which was developed by young biotech companies (Hirschler, 2018). Due to the lack of collaboration 
between the therapeutic manufacturers and the diagnostic companies or academic institutes, the 
development of diagnostic tests is lagging far behind. A catch up is hard to achieve and may not be 
feasible in some cases. For this reason, a closer and quicker cooperation with the industry may be 
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beneficial, although it is doubtful that the pharmaceutical industry shares their "industrial secrets" with 
an outside third party at an early stage. 
A positive sign is the current commitment of new small and medium-sized start-up companies in R&D 
of new diagnostic and therapeutic RPs. So far those SMEs have proved to have a creative and innovative 
approach and have successfully and quickly implemented some of their R&D projects. Even those 
companies tend to have a less experienced development teams and fewer resources than large 
companies (Hay, Thomas, Craighead, Economides, & Rosenthal, 2014), but tend to take a greater risk 
(Hay et al., 2014). They compensate these disadvantages through tighter collaborations with academic 
institutions, profiting from their know-how and access to the patient population.  
5.2.5 Intellectual Property Rights (IPR): 
IPR is extensively discussed in connection with the development of new drugs (Dutfield, 2003; Williams, 
2015), also in connection with the development of new radiopharmaceuticals (Zimmermann, 2008, 
2012a, 2013). Once again, our data shows that there are significantly different opinions within the 
stakeholder groups. While most nuclear medicine interviewees (60%) confirmed that IPR is a challenge, 
the PIG and RIG did not perceive this as the primary barrier.  
It has long been known that universities play an essential role in the national innovation system 
(Fagerberg, Mowery, Mowery, & Sampat, 2009) and contribute to economic growth and international 
competitiveness (Furman, Porter, & Stern, 2002). This is achieved on the one hand by the education of 
the students and by the creation of knowledge through university research. While Europe produces a 
high academic research output, European universities are lagging behind the US in technology transfer 
(Baldini, Grimaldi, & Sobrero, 2006; A. Conti & Gaule, 2011). Since universities have not done well in the 
commercialization and development of products, universities have established so-called technology 
transfer offices (TTO) to improve competence and secure the university´s intellectual rights (Karjala & 
Kiskis, 2011). The TTO´s mission is “to evaluate, patent where warranted, and exploit faculty creativity, 
through licensing or the creation of new spin-off companies.”, which has worked for many U.S. 
universities so far but was globally not encouragingly successful (Fisch, Hassel, Sandner, & Block, 2015; 
Karjala & Kiskis, 2011). European universities file fewer patent applications than the U.S. and Asian 
counterparts, which causes those universities to lag behind technology transfer (Fisch et al., 2015).  
Our data indicates an in-efficient IPR process within the university system. This can be illustrated by a 
story of one of the German interviewee who told us that in a (large) German medical university there is 
no patent attorney employed at all, but an attorney from the University takes over the responsibility. 
However, this lawyer, in turn, holds little of patents "…because it does not pay off, and he does it only 
in exceptional cases". In reality, however, usually not only the royalties paid to the universities, but the 
protection of the idea is more important to the investor as it gives the opportunity to pursue the idea 
in the first place. Most interviewees from the NMG have now realized that there must be some form of 
protection to gain the interest of the investor, with some physicians being self-critical about their 
approach in the development and the usage of new RPs (as discussed in chapter 5.2.4 “Research and 
Development”). 
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Industry representatives regard academic research as a valuable means (not only of gaining) access to 
ideas and products, but also expect more engagement of universities regarding IPR. Some industrial 
representatives already see an improvement in some universities, but overall the situation could 
improve. Generally, some protection is necessary and essential for the industry, but the patent on the 
chemical entity is not an ultimate must (for some it is still mandatory). Thus the situation is overall not 
challenging as there are many possibilities of protection and industrial experts have built a protective 
wall around a product.  
Moreover, one can say that the pharmaceutical industry is very good at protecting it IPR, and extensively 
uses the product- and process patents in comparison to almost every other industry (Cohen, Nelson, & 
Walsh, 2000).  
A recent example shows that IPR is not as much in the forefront of academic research as rapid 
publication and medical application:  
Scientists at the German Cancer Research Centre at the University of Heidelberg have quickly 
published results of the 68Ga-PSMA HBED-CC RP in June 2012, and due to the “non-patented 
status” the tracer rapidly spread worldwide. Interestingly some interviewees from the NMG and 
RIG believed that no one had ever applied for a patent for that compound, and see this as a 
missed opportunity. However, the German Cancer Research Centre, University of Heidelberg 
assigned a patent in October 2013 (Patent application number: EP3038996A1) and other related 
applications followed in the years after (numbers: EP20140799340, EP3038996A1), but up to 
date none of these applications have been granted. Nonetheless, the patent status, the quick 
publication of first results in humans (Afshar-Oromieh, Haberkorn, Eder, Eisenhut, & Zechmann, 
2012; Schäfer et al., 2012) has allowed a useful tracer to spread very rapidly and has since 
successfully influenced patient management in many patients. At present, some companies are 
researching new biomolecules that also have PSMA as their target, especially in the field of 
therapy but also in a few cases in the field of diagnosis. However, PSMA HBED-CC is currently 
no further research in Phase I to III trials (U.S. National Library of Medicine, 2018), possibly due 
to the challenges with IPRs. 
5.2.6 Manufacturing, Distribution and Handling 
The production, distribution and handling of radiopharmaceuticals are undoubtedly more complex, 
challenging and costly compared to most other pharmaceutical products (World Health Organisation, 
2008). Radionuclides used in imaging and therapy typically have a short- or medium half-life, which 
require a well-organised production process and a secure, reliable & cost-efficient distribution network 
(Dash et al., 2013; Internal European Commission Ad Hoc Interservice Group, 2009). Transport costs are 
typically substantially higher for medical isotopes compared to conventional drugs (World Nuclear 
Association, 2017) and country-specific higher requirements could further increase effort, time and 
technical and financial resources (Internal European Commission Ad Hoc Interservice Group, 2009).  
“So from our perspective, when we build up our IP portfolio we don´t rely on one piece of IP. We like to 
have the chemical entity, and then we build a whole layer of onion around it. About different IP that covers 
the manufacturing process for the product, how the product is being used in the field…but not having the 
chemical entity IP is definitely something that when we go to investors, to ask to invest in new ideas we 
got, the first question they ask is: “what is the IP position?” And it is a big red flag for them if you don´t 
have chemical entity protection…”  
(Expert from the Radiopharmaceutical Industry) 
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This is definitely a deterrence for the pharmaceutical industry since this industry branch thinks and sells 
globally and must ensure that everyone has access to the product. Global access is hardly achievable 
using PET radionuclides, SPECT with technetium could be a better option. Zimmermann (2013) has 
considered this point of manufacturing and handling in more detail, divided challenges into the areas of 
radiochemistry, selection of radionuclides and costs of infrastructure. From our data, we can only say 
that the selection of radionuclides and access to this technology is crucial for the pharmaceutical 
industry.  
For the NMG and RIG the manufacturing process, distribution and handling is nothing new. Therefore, 
these interviewees have not recognised this as a “special” obstacle. However, what was described as a 
challenge in literature, especially for the self-producing academic institutions, was the requirements of 
good manufacturing practice (GMP) introduced in recent years (Deutsches Bundesministerium für 
Gesundheit, 2009). In Europe it is up to the national authorities to decide whether the production and 
quality control of RPs in non-industrial institutions should be GMP-compliant, but we have seen that 
this was implemented in many European countries. GMP production is more demanding as it requires 
unique infrastructure, equipment, training for employees, documentation and a detailed labelling 
process, which in turn results in significantly higher costs (Gerrits, Woerdenbag, Luurtsema, Hooge, & 
Boersma, 2017). However, after none of the respondents from the NMG has identified this as a 
challenge, it looks as if the academic institutions have come to terms with the new requirements.  
Short Excursion- Therapeutic Radiopharmaceuticals 
Compared to diagnostic RPs, many interviewees from all groups see a bright future for therapeutic RPs. 
The successful introduction of the theranostic concept in NETs, and most likely also in prostate, will lead 
to more discoveries and developments in diseases areas with high market potential such as breast 
cancer, lung carcinoma, colon carcinoma and also pancreatic adenocarcinoma.  
Therapeutic RPs have significantly better commercial- but also product-relevant premises, which makes 
it more attractive to large pharmaceutical companies. With the acquisition of AAA already a big 
investor´s showed interest, primarily in the therapeutic drug Lutathera® and the already advanced 
developments in the therapeutic drug for advanced, metastatic prostate cancer. A primary reason is the 
significantly better market potential compared to the diagnostic RPs. Even though the number of 
patients who benefit from this radiopharmaceutical therapeutic approach may be small (compared to 
block buster drugs), the current reimbursement rates are comparable or even higher than currently 
available chemotherapeutics drugs in many international markets (National Institute for Health Care 
Excellence (NICE), 2017). Just for comparison, the global monoclonal antibody therapeutics market was 
valued at approximately $ 108 billion in 2017 (Zion Market Research, 2018), whereas the total global 
radiopharmaceutical market was valued at US$5.2 billion (Transparency Market Research, 2018). From 
a regulatory point of view, therapeutic RPs pose no big challenges to the pharmaceutical industry as 
they are treated the same as other medicines and this knowledge is sufficiently available. Also, the 
development of therapeutic RP does not pose a significant challenge to the companies, the unique 
concept of theranostics may open up new avenues. For example, it would be conceivable that the 
companies trawl through their “biomolecule libraries” and identify targets with high binding affinities, 
which may not have been developed further due to little or no therapeutic effect. However, labelling 
these highly selective molecules with a therapeutic radionuclide may result in a useful, inexpensive new 
product. In the context of diagnostic RPs we have also discussed the challenges of manufacturing and 
distribution, which, however, are not of concern in the therapeutic field. Due to the significantly longer 
half-life of therapeutic radionuclides they can be distributed over long distances without significant 
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problems. For example, the short-range therapeutic beta-emitter Lutetium-177 has a half-life of 6.7 
days, while the diagnostic beta plus emitter Fluor-18 only has a half-life of 109 minutes.  
Therapeutic RPs, therefore, have good prospects to be increasingly developed and approved in the 
future. It is also likely that larger investors will invest in this area more often, fuelling the field of nuclear 
medicine. Some nuclear physicians have expressed the hope that diagnostic RPs can also float in the 
success- wave, giving rise to more diagnostic products with marketing authorization. However, in our 
view, this would only be the case if the whole theranostic concept would be applied: mandatory use of 
the diagnostic test, in the sense of a companion diagnostics, before the application of the therapeutic 
agent. However, based on available empirical data and our assessment, companies will avoid this 
approach as much as possible.  
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2) What are the biggest challenges of diagnostic (and therapeutic) radiopharmaceuticals and 
why are they mostly developed in public research facilities and have not received a marketing 
authorisation? 
Our analysis and empirical data suggest that the low market potential, in combination with the 
currently challenging European reimbursement rates, are the main barriers for successful 
commercialization and introduction of new diagnostic radiopharmaceuticals. Furthermore, also the 
availability of short-lived radionuclides is especially provoking for the pharmaceutical industry. 
Small and medium-sized enterprises (SMEs) therefore take on this task and engage more and more 
in R&D activities. The currently active SMEs in the RP business have proven to have a creative, fast 
and effective approach in recent years and managed to get several new products approved. They 
will likely continue their research and development program in disease areas with a slightly bigger 
market size, but will not engage in the development of companion diagnostics by itself. Our data 
also suggest that some of the challenges, which have been extensively discussed in the literature, 
may be important to a single stakeholder group, but not for others. Regulation is such a challenge, 
which is highly ranked within the nuclear medicine stakeholder group but not so important to 
others. Some nuclear medicine physicists believe that the regulatory requirements are too high and 
diagnostic RPs should not be regulated similarly to therapeutic drugs. Contrary, the 
radiopharmaceutical industry experts request a tightening with the aim to limit self-production of 
public institutions. The great divergence of these statements may be explained by the regulatory 
intensification regarding production, quality control, clinical trials et cetera. in recent years, which 
especially targeted the academic community. Also, over the last decade the academic institutions 
have increasingly engaged in R&D of new RPs, but due to higher regulatory requirements for clinical 
trials, missing knowledge on how to conduct proper clinical trials and tight budgets, it has become 
increasingly difficult to carry out these studies. Also the topic Intellectual Property Rights popped 
up regularly in the literature, and our data suggests that it is important but not a big challenge. From 
an industry perspective, IPR is essential and the patent on the chemical entity is desired, but they 
also made clear that there are several ways to protect a product. It turned out that nuclear medicine 
physicists increasingly acknowledge the importance of protecting ideas and admit that this mistake 
is more likely to be on the side of universities, which often have not implemented an efficient 
process. 
Therapeutic radiopharmaceuticals are less likely to face these challenges, as the main challenges 
“market potential” and “reimbursement” have much higher values, and also the “manufacturing” 
and “distribution” of therapeutic RPs is easier. The reasons for the previous lack of interest may be 
based on the fact that there have not been any new, useful examples of success. With the successful 
introduction of Lutathera®, we may see other big players entering the market. Further promising 
disease fields such as mammal, lung-, colon- and pancreatic adenocarcinoma are already being 
researched. 
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5.3 Diagnostic Radiopharmaceuticals used as Companion Diagnostics 
Since the topic of personalized medicine and the associated use of biomarkers is so up-to-date, we asked 
our expert about the general value of companion diagnostics (CDs). Additionally, whether molecular 
imaging can take on the task of a companion- or a complementary diagnostic, and what challenges 
would be associated with it. 
Benefits and Challenges Associated with Companion Diagnostics in General 
As already discussed in the theoretical part, a CD is a diagnostic test that provides essential information 
on the safe and effective use of a similar drug or biological product (U.S. Food and Drug Administration, 
2018a). Intensive research on the cellular and molecular biology level allowed us to differentiate cancers 
based on their molecular aetiology, the natural course of the disease and also their reaction on 
therapeutic interventions (Cheng, Koch, & Wu, 2012). The great hope is to stratify patients according to 
their specific (molecular) characteristics and administer the targeted therapy only to those patients who 
are more likely to benefit (Trusheim & Berndt, 2015). 
In our study, there is substantial agreement among stakeholder groups regarding the benefit of these 
diagnostic tests in general, ranging from more targeted therapies, improved outcome, better patient 
stratification, and superior clinical trial outcomes. Keywords that can also be found in the current 
literature (cf. Kalia, 2013; Mansfield, 2014; Papadopoulos, Kinzler, & Vogelstein, 2006; Simon, 2008). 
The groups are less united when it comes to the challenges of CDs. For medical specialists the discussion 
is around efficiency generation, validation and standardisation. They also believe that the successful 
introduction of these tests will be complicated since there is no commercial benefit for the industry. On 
the contrary, the market will be cut off. This could explain the slow and disappointing adoption of CDs 
(M. Hughes, 2013; Meckley & Neumann, 2010) with divergent interests of the stakeholders regarding a 
(fast) implementation of these CDs (Satanove, 2016). We can also support this testimony by three 
statements from our experts:  
i. An expert from the pharmaceutical industry indirectly confirmed that they would generally 
prefer to introduce a product without a CD. For example, in two pivotal studies, they 
successfully used a CD for patient stratification, but in some cases a pre-selection via a CD 
would not have been necessary. “And in the advanced lung cancer patients… you did not need 
to enrich it with the diagnostic…So that kind of set us back for a little bit…oh, Jesus look what 
we have done. We have anchored ourselves…”  
ii. The second statement is from a medical specialist, whose group was working on a biomarker 
for the stratification of patients with advanced prostate cancer. He also confirmed that the 
industry had little interest in supporting his research group: "… we have been trying to develop 
biomarkers. That costs money and the company… hold us back for a long time, but I knew from 
the beginning that they would not give us any money.”  
iii. Another interviewee from the PIG describes the stalemate when the CD delivers a positive 
result but also those patients, who should not belong to the preferred group according to the 
test, respond to the therapy. 
The lack of interest of the industry to offer appropriate diagnostic agents (CD) to their 
therapeutics can be illustrated by a real case: The FDA recently approved the in-vitro assay 
(Ventana® PD-L1) to assess the PD-L1 status on patients with metastatic urothelial cancer 
(mUC), who are considering treatment with the monoclonal antibody atezolizumab 
(Tecentriq®). The assay was used in the Phase III registration trial and showed a higher objective 
response rate in patients with higher PD-L1 expression, but also a response rate in patients 
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with minor PD-L1 expression (Rosenberg et al., 2016). Ventana® was therefore not registered 
as a Companion- but a Complementary Diagnostic and thus is no prerequisite for the 
administration of the therapeutic agent.  
Our data suggests that PIG experts are well aware that CDs could restrict patient access to their 
therapeutic drug. Thus these group is not so keen to move ahead quickly, even payers would be happy 
to see a quicker implementation since the market gets more restrictive and costs are reduced (Danzon, 
2014). From the CD developer perspective, CDs may also not be a big commercial win. They would face 
limited applicability of the diagnostic test, and our experts even envisage the danger of the entire 
development being in vain if the therapeutic drug fails in a (late) stage. In combination with the low 
prices for the test, this could be very unattractive for the diagnostic companies (Jerel, Ma, & Sutaria, 
2010; Satanove, 2016), which is why it probably will not succeed without the financial support of the 
pharmaceutical entrepreneur in the sense of a compensation payment (Jerel et al., 2010).  
Radiopharmaceuticals being used as Companion Diagnostics? 
We were particularly interested if radiopharmaceuticals would be a suitable CD? Based on the 
statements of the interviewees from the NMG one could assume that molecular imaging becomes the 
CD of choice. The responders are convinced that imaging biomarkers have much higher accuracy and 
higher value in monitoring and staging than in-vitro assays. The statements correlate with those from 
the predominantly nuclear medicine literature: more precise localisation (M. D. Farwell, Clark, & 
Mankoff, 2015), real-time and non-invasive procedure (Pauls et al., 2007; Weissleder & Pittet, 2008), 
depiction of the heterogeneity of the target tissue et cetera (Abramyuk et al., 2009; Bleavins et al., 2011; 
Krause, Beck, Souvatzoglou, & Piert, 2006).  
In principle, medical specialists agree that molecular imaging is an essential tool in patient management 
but they would not generally prefer imaging biomarkers over in-vitro assays. What they want is any 
biomarker with high sensitivity, specificity and selectivity. In their mind, the future will most likely be a 
reasonable combination of imaging- and in-vitro tests, with some interviewees expressing great hope 
in liquid biopsy. So far, literature on the subject of CD deals mainly with in-vitro tests (Agarwal et al., 
2015; Alix-Panabières & Pantel, 2012; Crowley, Di Nicolantonio, Loupakis, & Bardelli, 2013; Jørgensen, 
2013; Mansfield, 2014; Scheerens et al., 2017; Ziegler, Koch, Krockenberger, & Großhennig, 2012), only 
a few studies show the advantages and disadvantages of imaging biomarkers (Idée, Louguet, Ballet, & 
Corot, 2013; O´Connor et al., 2017; Scheerens et al., 2017; Van Heertum et al., 2015) 
We understand the desire of nuclear medicine doctors to get more diagnostic RPs approved via the 
concept of CD, but we generally do not see the chance of success as great. The main reason: for our 
interviewed pharmaceutical industry experts imaging biomarkers lack global availability, low prices, 
convenience and easy application, high accuracy, detection of multiple mutations, simple use in Phase 
I to III trials, natural patient segmentation et cetera. 
"And I believe that is because the pharmaceutical companies’ don´t want a potential market 
limiting step on the way using their drug. I had some conversation with the imaging teams 
inside big pharmaceutical companies, which gave me that hint, not as an official policy but 
they believe, that MI is used widely in their clinical trial process, but they never wanted it to be 
a mandatory step underway using their drug. Because unlike a blood test driven tissue test, 
they still looking at MI as a complex, expensive hard to find the thing that would limit their 
market for their drugs. So even if it could lead to a better patient population that take the 
drug, they view that as market limiting and unless the regulatory body or payer absolutely 
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required it, they try to find a way to get the drug approved without it." (Expert from the 
Molecular Imaging Technology Group) 
Moreover, our interviews suggest that even for the radiopharmaceutical industry the development of 
an imaging companion diagnostic is currently not attractive. In their opinion, the market for a CD is too 
limited (cf. Kulkarni, Ma, Furstenthal, & Evers, 2013; Satanove, 2016), the commercial risk is higher 
compared to classic diagnostic products since there is a chance that either the therapeutic will fail or a 
new development will replace the therapeutic agent or that the test will not be reimbursed (cf. Moore, 
Babu, & Cotter, 2012). Since the CD is just a vehicle of the therapeutic drug, and the pharmaceutical 
industry has a great interest to keep it cheap and simple, the developer may not receive much revenue 
for of the imaging biomarker (Conti, Veenstra, Armstrong, Lesko, & Grosse, 2010). Amongst other 
things, these considerations have led AAA to register 68Ga-DOTATATE as a stand-alone diagnostic test 
and not as a CD of Lutathera® (177Lu-DOTATATE).  
To summarize, our data suggest that it will be difficult for RPs to be accepted as companion 
diagnostics. Experts of the pharmaceutical industry describe the disadvantages as too numerous, 
which is why they will continue to use imaging biomarkers for R&D purpose with no intention of 
getting it commercialized. Unfortunately, even small and medium-sized radiopharmaceutical 
companies would currently not engage in the development of CDs themselves since the profit margin 
and market potential are low.  
Should biomarkers be mandatory? 
Latest figures show a steadily growing CD market (Agarwal et al., 2015) with one-third of the newly 
developed therapeutics have a connection to a genomic or proteomic marker (Kulkarni et al., 2013). 
However, other experts mention that the development is slower than expected (Towse, Ossa, Veenstra, 
Carlson, & Garrison, 2013), the potential is not yet realised (Trusheim et al., 2011), the utilisation is 
constrained (Luo et al., 2016) and the pharmaceutical industry does not prioritise the development of 
CDs (Jerel et al., 2010). Therefore, we wanted to know, if CDs should be mandatorily requested, 
especially for expensive therapeutic approaches.  
Again, opinions differed between the group of physicians, industry and the regulatory authorities. The 
majority (83%) of nuclear medicine physicians can well imagine that some biomarker tests could be 
required by regulatory authorities in the future, with the main argument being the cost burden for 
particular therapeutics. Also, medical specialists envision that CDs possibly be mandatory: 75% of 
responders from this group expect the test to be undoubtedly mandatory, but it will take some time to 
be implemented. There is no explicit answer from the pharmaceutical industry's experts just a hint 
through the testimony of an interview participant: he believes that biomarkers will not be compulsory, 
at least not for all medications, but the decision will be made on a case-by-case basis. Moore et al. (2012) 
claimed that in several recent guidance documents some regulatory organisations have already required 
the use of a companion diagnostic (in some instances) before the administration of a personalised 
therapeutic. 
On the other hand, we have the testimony of two experts from an international medical agency who 
think that the mandatory development of a CD for every new drug is not the right concept. In their 
opinion, evidence of benefit for newer, very specific therapeutics, which target a very specific patient 
subpopulation, will no longer be readily available without Companion Diagnostics. So specific 
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biomarkers/CDs will most likely enter the market, the decision on how to prove the benefit, how to 
stratify the patients, and which products therefore need a CD should remain by the industry.  
  
  
3) What are the Benefits and Challenges of Companion Diagnostics in general, and are 
Radiopharmaceuticals suitable for the use as a Companion Diagnostics? 
There is strong agreement among the interview partners on the benefits of companion 
diagnostics and the associated better patient stratification, more targeted therapies, and possibly 
better outcome. But there are also numerous challenges that have been mentioned by different 
interview partners. On the one hand, the physicians are thinking of proof of efficiency, i.e. 
validation and standardization, and currently, don´t believe that the pharmaceutical industry will 
drive the CD development forward since it will downscale their drug´s market. This was indirectly 
confirmed by a pharmaceutical industry expert who´s company has used a biomarker in the 
development of a therapeutic agent, although it probably would not have been necessary “…oh 
Jesus look what we have done. We have anchored ourselves…”. Also from the point of view of the 
diagnostics industry, a CD is not extremely lucrative. The direct link to the therapeutic drug limits 
the use of the test, and currently, these CDs are poorly reimbursed. Furthermore, there is a risk 
that the therapeutic fails in the development phase or is replaced by a more effective 
(competitive) therapeutic drug. In both cases, the CD would be almost worthless. 
With regard to the question of whether molecular imaging could be a useful CD, the nuclear 
medicine doctors have a obvious answer: YES. In their view, the method is clearly superior to the 
in-vitro test in many questions that are important for the treatment of patients. And also the 
representatives of the industries (PIG, MITG, RIG) have a clear answer: NO. For the 
pharmaceutical industry, imaging biomarkers cannot meet the needs of the industry which are: 
global availability, low priced, convenience and easy application, high accuracy, detection of 
multiple mutations, simple use in Phase I to III trials, etc. The radiopharmaceutical industry 
complains about the market size, which is even smaller than for stand-alone diagnostic tests, the 
additional commercial risk that the linked therapeutic drug fails and thus also the CD, the 
restrictions in pricing, and the currently low reimbursement rates. 
And because the benefits of CDs are highly praised, but the introduction is progressing hesitantly, 
we also wanted to know whether CDs should be mandatory requested? Nuclear physicians and 
medical specialists are very fond of this idea and believe by the majority that CDs will become 
mandatory in the future. The pharmaceutical industry has not given a clear answer except one 
interview participant who assumes that it will be a case-by-case decision. From the perspective 
of the experts of the regulatory authorities, CDs will not become mandatory since it does not 
seem to be the appropriate concept. However, from their point of view, there will be no way 
around the development and use of CDs since newer drugs target sub-subpopulations and the 
proof of benefit can only be achieved by a precise stratification of patients. 
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5.4 Alternative Drug Development Process for Diagnostic 
Radiopharmaceuticals? 
Over the decades, the regulatory requirements for the approval of new drugs has become more 
stringent, although due to extraordinary events such as the thalidomide scandal with severe side effects 
in pregnant women in the late 1950s (Hilts, 2003). As a result, these stricter regulations also increased 
the company´s R&D expenses and subsequently shifted the focus on diseases with a high patient 
population (Haffner, Whitley, & Moses, 2002). However, as a result, there has been little development 
in diseases with low prevalence and governments decided to implement specific laws such as Orphan 
Drug Act (1983) in the US and the Regulation (EC) No 141/2000 in Europe, to provide an incentive for 
companies to invest in such R&D activities. Subsequently, the number of approved orphan drug 
indications has risen continuously over time and has been called a success in America and Europe 
(Lanthier, 2017; The Committee for Orphan Medicinal Products and the European Medicines Agency 
Scientific Secretariat, 2011). 
Currently approved diagnostic- (18F-Fluciclovine, 68Ga-DOTATATE) and therapeutic RPs (177Lu- 
DOTATATE) have also benefited from this orphan drug status in the U.S. and Europe. With higher 
reimbursement rates and more significant market potential for therapeutic RPs, it is likely that investors 
will continue to develop these drugs to market. For diagnostic RP, our empirical data and experience 
suggest that these products will continue to struggle to find an investor. We, therefore, evaluated, if 
there could be an alternative to the “traditional” pharmaceutical drug development process, which may 
support the development of these products. For rare disease medications, the concept of public-private 
partnerships (PPPs) have been suggested as an alternative (Buse & Walt, 2000a, 2000b; Nwaka & Ridley, 
2003; Trouiller et al., 2002; Yildirim et al., 2016). The principle idea of such a partnership is that for-
profit institutions from the private sector (e.g. pharmaceutical industry) meet with institutions from the 
public sector (e.g. academics, international organisations, governments) and share their knowledge, 
expertise, resources and investment to work on complex challenges, which may not be accomplished 
by a single institution (Trouiller et al., 2002). Numerous studies have evaluated various projects and 
described the advantages and disadvantages of PPPs (e.g. Amiri & Michel, 2015; de Vrueh & Crommelin, 
2017; Laverty & Goldman, 2014; Vaudano, 2013; Wellenreuther, Keppler, Mumberg, Ziegelbauer, & 
Lessl, 2012), the structure (competitive and non-competitive area), the types of participants, and the 
scope and duration of the project (Yildirim et al., 2016). An example in the private sector would be a 
collaboration by two private parties to develop a companion diagnostic (Fridlyand et al., 2013) but more 
common are collaborations between private and public institutions or multi-partner consortia such as 
the “Innovative Medicines Initiative (IMI)”. IMI is currently the largest PPP worldwide in the field of life 
science, supported by the European Union and the European Pharma Association (EFPIA) (Yildirim et al., 
2016).  
The majority of our interviews with all stakeholder groups (NMG, PIG, RIG) see a high value in the 
concept of PPP, two partners (RIG, MITG) have a neutral view. However, we believe that some 
interviewees were less familiar with the concept of PPP and we assume that some responses are based 
on their experience with a "normal" partnership/ collaboration. Both groups of physicians (NMG, MSG) 
valued the concept very highly, probably because these stakeholder groups appreciate the access to 
funding and knowledge to conduct their research. At the same time, some interview partners criticise 
the industry for trying to dominate the study design: “…you have to be very critical. Because I have said 
it before, the sponsors determine what we do.” This asymmetrically distributed power has already been 
identified in other studies (e.g. Singh & Prakash, 2010) and is also a result of the short-term projects, 
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which usually involve small amounts and are mainly focused on applied research or development 
projects (Blumenthal, Causino, Campbell, Louis, & Seashore, 1996). Another challenge mentioned by 
the academics is the creation of such partnerships, especially meeting the legal- and partner´s 
requirements and still having a win-win situation. Khanom (2010) confirmed conceptional constraints 
in his study and showed that governance, management and policy design is important, as well as the 
nature of cooperation, inter-organisational arrangements, financial relationships, commitment, roles, 
the purpose of the PPP et cetera. Concerning “purpose” and “arrangement” the pharmaceutical 
industry seems to have a clear opinion: “Moreover, the big advantage for the drug companies in there 
[the IMI project] is that… the drug companies are in the driving seat, and they can say very strongly “we 
want you to develop a tool that looks like this because if you develop something like this, it would be 
very useful to us”.  
The interviewees made clear that the big advantage of a PPP is the cooperation with various partners, 
which allows them to address issues that are important to the whole field, but no one has the resources 
to do it themselves. The industry sees some stumbling blocks when it comes to working with the 
academic institutions: (a) consensus-building, which even gets worse the more stakeholders are 
involved, (b) speed and (c) the "not results driven" attitude. Nonetheless, universities are a vital source 
of innovation, knowledge and new ideas, which is why all major pharmaceutical companies have close 
relationships with prestigious academic institutions (Perkmann & Walsh, 2007).  
In our opinion, the concept of PPP may be too difficult to implement for the development of new 
diagnostic RPs. Diagnostic markers cannot usually satisfy the needs of many partners, which is the 
primary motivator of PPP. However, after the assessment we even believe that the traditional 
development process is suitable for the approval of new diagnostic RPs. What may be needed is closer 
co-operation and coordination within academic institutions, as well as a co-ordinated approach with 
small and medium-sized enterprises (SMEs). SMEs are the backbone of the European economy and key 
for future economic growth, innovation, job creation, and social integration within the EU (The 
European Commission, 2018). To further support SMEs, also in the development of new drugs and 
medicinal technology, the European Commission and the European Medicine Agency have introduced 
special programs in the field of regulatory work, scientific advice and support in the marketing 
authorisation process. 
From our point of view, SMEs are best suited to drive the development of new diagnostic RPs since they 
have a good understanding of pathology & human biology, close collaborations with academic 
institutions, a flexible and rapid decision-making process and they are willing to take risks (Love & Roper, 
2015; A. Moore, 2003). Collaborations usually built on a bidirectional flow of knowledge, training, skills 
and expertise where every partner has the right to provide input regarding the course of the project 
(Ross et al., 2010). This ideal is rarely achieved in reality since there is usually a partner with more 
influence, who uses that imbalance to impose unfavourable conditions on the others (Essabbar, Zrikem, 
& Zolghadri, 2016). This power imbalance may lead to an increasing commercialisation and dependence 
of research in the medical field (Ajai Singh & Singh, 2005), which contradicts with the fundamental 
interests of academia to pursue free, long-term, disinterested, fundamental research (Lee, 1996). In 
general, academics are more focused on the question rather than the answer (Cutright, 2000) and 
publications are a way to receive recognition and thus enhance job prospects and other beneficial goods 
and services (Committee on Responsibilities of Authorship in the Biological Sciences, 2003). Something 
which can also be seen in the field of nuclear medicine, where several study groups and individuals have 
gained considerable recognition with their quick first-in-man, theranostic trials.  
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So in future, both partners need to adjust their behaviour and approach in the partnership to allow 
more ideas to become final products: 
i. In order to level the balance of power, and to assess the benefit and commercial profitability 
of university inventions (Siegel, Veugelers, & Wright, 2007) it is wise to set up a national and/or 
international technology transfer offices (TTOs). These independent TTOs should pool 
scientific, regulatory, legal and economic expertise and evaluate research ideas, use their 
network to attract investors and subsequently enter into negotiations at eye level. Since the 
majority of university-TTOs are non-profitable and funds even cannot cover operation costs 
(Abrams, Leung, & Stevens, 2009) the focus should be on national and/or an international TTOs 
on the level of nuclear medicine associations. For example, the Society of Nuclear Medicine 
and Molecular Imaging (SNMMI), a “nonprofit scientific and professional organisation that 
promotes the science, technology and practical application of nuclear medicine and molecular 
imaging” has already set-up councils and centres of excellence to facilitate the development 
of new molecular imaging discoveries (Society of Nuclear Medicine and Molecular Imaging, 
2018). The SNMMI has successfully supported two SMEs in designing their clinical trial program 
and launching new diagnostic- and therapeutic RPs. 
ii. The academic challenge is to realise that some of their (applied) research may have a higher 
likelihood of technology transfer and these ideas need to be protected to increase the interest 
of an outside investor and allow more patients to have access to the new technology. This may 
delay publications due to the time frame of the IPR process and increase the risk that other 
study groups may overtake them. 
iii. A simple and efficient IPR process, which is controlled either via the university or the TTO, 
should be available. It is necessary to have a clear strategy and make sure that “IP is clean, well 
defined, and protected before trying to raise commercial interests. This involves costs regarding 
recruiting sufficient expertise or paying for external advice. The ownership of IP needs to be 
resolved. The IP and patent strategy should thus consider what technology is proprietary to the 
department, which is licensed on an exclusive base, and which parts are licensed on a non-
exclusive basis.” (Siegel et al., 2007).  
iv. Academic trials need to meet the design requirements of the regulatory authorities to allow 
the usage of the data for the application process. This would result in increased quality and 
further decrease the investor´s investment risk and the total investment. This could further 
attract more investors with the chance to have an increase in R&D investments due to higher 
competition (Aghion, Bechtold, Cassar, & Herz, 2014). 
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4) What are the Challenges and/or Success Factors of Public- Private Partnerships (PPP) in 
Context of the Development and Marketing of Diagnostic (and therapeutic) 
Radiopharmaceuticals? What could be an alternative to the traditional development process? 
The concept of PPP has entered the healthcare sector in various forms to finance, provision, and 
research the health care market (Baru & Nundy, 2008), to help governments coping with increasing 
healthcare costs and decreasing governmental budgets (Blanken & Dewulf, 2010). The concept of 
PPPs has some advantages and some risks compared to “classic” collaborations (Akintoye, Beck, & 
Hardcastle, 2008). We wanted to know, if this concept may be an alternative to the traditional 
pharmaceutical development process and if it would be suitable to push the development of new 
diagnostic RPs?  
However, based on our evaluation we believe that a PPP may not be the right concept, at least if 
the investor is from the pharmaceutical industry rather than a patient support group, pressure 
group or public institution. Typically, PPP projects are non- competitive, deal with fundamental 
methodology and technology and are important to more than one institution. A possible field of 
application: the development of a new tracer, which for example would be able to accurately 
monitor therapy success in a variety of diseases. FDG-PET is already a very good tool that can fulfil 
this task in many oncological issues. The strength of future diagnostic RPs is likely the high 
selectivity, binding affinity and this sensitivity for very specific diseases (even in subpopulations 
with specific receptor expressions). The intersection with other companies is therefore likely to be 
very low, thus also the interest and engagement of these companies in such PPP projects. Also for 
therapeutic RPs this concept seems not to fit.  
Questions as to the challenges such collaborations entail, the interviewees addressed consensus-
building (all stakeholder groups), the complicated legal framework to set-up a PPP (nuclear 
medicine physicist), asymmetric balance of power in favour of industry (physicians), speed and 
non-result-oriented work by academics (industry), the complexity to agree on goals and study 
designs in large PPPs (industry) and the quite different general motivations and goals between the 
stakeholders (industry).  
We therefore believe that there is no need for a new development process in the field of nuclear 
medicine, but that cooperation between academic institutions and the SMEs should be promoted. 
Lived reality should be modified and supported by independent national and/or international 
Technical Transfer Offices (TTOs). Academic researchers should protect certain ideas more 
regularly, clinical trials should more often meet current regulatory requirements, and universities 
should set-up a simple and efficient IPR process. To assess these ideas from a scientific, legal and 
economic point of view, we suggest national and/or international technology transfers offices 
(TTOs) which can support researchers/universities with their expertise. Having central TTOs could 
improve efficiency since many TTOs have problems in funding and generating enough revenue to 
cover operating costs (Abrams et al., 2009). SNNMI is already a well-established non-profit 
organization, which has already successfully assisted SMEs in the implementation of their clinical 
trial program, the submission of regulatory dossiers and the approval of the products.  
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5.5 Future Outlook of Molecular Imaging 
With the push towards personalised medicine and the associated development of more targeted, 
specific target structures for therapeutics, molecular imaging will continue to have an essential role in 
daily clinical routine and research & development (Kircher et al., 2012). Literature suggests that both 
PET/CT and SPECT/CT will have a share in the detection, staging & restaging, monitoring of therapy 
response, and prognosis of various diseases (e.g. Farwell, Pryma, & Mankoff, 2014; Hoffman & Gambhir, 
2007; Pysz, Gambhir, & Willmann, 2010; Sinusas et al., 2011).  
Interestingly, our experts from the NMG see the future of molecular 
imaging primarily in PET/CT. SPECT/CT & SPECT will still play a role, 
but may not experience the growth of PET / CT. PET/CT will continue 
to be dominant in cancer, especially in the visualisation and 
quantification of specific drug relevant targets, but will also find 
widespread use in neurology and cardiology. 
Of course, the radiopharmaceutical- and medical device industry also 
believes in a bright future for molecular imaging, but does not 
commit itself to one or the other technology. Particularly advances in 
SPECT detector technology has improved the resolution significantly (Niimi, Nanasato, Sugimoto, & 
Maeda, 2017), and there is still a cost advantage for users (e.g. Chua, Gnanasegaran, & Cook, 2009; van 
der Wall, 2014; van Waardhuizen et al., 2016). Based on our evaluation we assume that both 
technologies take their share, with SPECT/CT remains an important pillar in specific indications in 
developed countries and having technological advantages in less developed countries. Anticipating a 
more widespread use of the theranostic approach, the PET/CT availability of scanners and 
infrastructure, the cost per scan and the capacity could be possible limiting factors. In this case, 
SPECT/CT could take over the validation of the target structure, stratify patients and assigning them to 
the relevant competence centres. As already highlighted, our experts from the pharmaceutical industry 
have expressed little interest in using imaging biomarkers as a stratification/companion diagnostic tool, 
but if, then they would undoubtedly prefer SPECT (/CT) due to more comfortable handling and global 
extension. Anyway, advice from a pharmaceutical expert to the academics would be: “…not to try to 
develop new tracers for drugs for tumour mutations, but look at other types of cancer drugs such as 
tumour immunologic, hypoxia et cetera. And develop good imaging biomarkers for tracking therapies, 
and you also may be much more successful in developing CDs for other diseases." 
Our medical specialists expect new therapeutic approaches, initiated by a better stratification, with e.g. 
a more widespread use of immunotherapy, improved diagnostic capabilities through liquid biopsy, more 
precise and new radiotherapy approaches due to improved imaging. The majority of these interviewees 
expect molecular imaging to continue to play an essential role in this process, a statement also current 
publications support (Jung Kyung-Ho Lee Kyung-Han, 2015; Sinusas et al., 2011; Society of Nuclear 
Medicine and Molecular Imaging (SNMMI), 2018). In particular, some specialists place high hopes in the 
liquid biopsy, which, if successful, could challenge some molecular imaging applications. Blood-based 
biomarkers will undoubtedly play an important role in predicting tumour progression, response to 
therapy, therapy resistance, or even early diagnosis (Quandt et al., 2017). However, liquid biopsies will 
not merely replace PET/CT or other molecular imaging technologies, but will preferably have a guiding 
role, indicating when imaging is needed and help to interpret the imaging results (Wong, Tothill, 
Dawson, & Hicks, 2017). However, as also mentioned by a specialist from the MITG, molecular imaging 
needs to position itself and elaborate the advantages of the technology. The challenge, molecular 
"Clearly in PET. SPECT, that's 
nonsense you have to be clear. 
Of course it's easier and more 
accessible, but it's anachronistic! 
You have to move to PET, that's 
just the rethinking. You cannot 
work with a “Volksempfänger” if 
you could have a flat screen.” 
(Nuclear Medicine Physicists, 
Europe) 
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imaging must tackle against large PPPs in the EU and US, which are explicitly working on the further 
development of in-vitro assays/ liquid biopsies, with substantial financial support (Neumann, Bender, 
Krahn, & Schlange, 2018). Currently, the majority of the interviewed experts, from all stakeholder 
groups, recognise the advantages of molecular imaging over in-vitro biomarkers. However, molecular 
imaging needs to be further engaged in building high- quality evidence of the benefits of imaging in 
clinical routine, and in allowing technology to be reimbursed.  
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6 CONCLUSION 
The radiopharmaceuticals (RPs) DOTATATE and PSMA can already be named as a clinical success story 
since those RPs have considerably changed patient management in patients with advanced 
Neuroendocrine Tumours (NETs) and metastatic castration-resistant prostate cancer (mPc). Extensive 
research of academic institutions has enabled both diagnostic compounds to become the method of 
choice in diagnosis, and have shown the potential of these high-affinity receptor ligands in treatment 
using the radionuclides Lutetium-177 and Yttrium-90. With the current engagement of the 
pharmaceutical industry in the development of new therapeutic RPs, there will be more and more 
prospective, randomised data showing the benefit of this Peptide Receptor Radionuclide Therapy 
(PRRT) approach in new areas of disease. The first successful prospective, randomised trial (NETTER 1) 
has already enabled the establishment of PRRT in international guidelines.  
In contrast to therapeutic RPs, diagnostic RPs experience little interest of the large pharmaceutical 
industry, and R&D is performed primarily by small and medium-sized companies (SMEs). Our data 
indicate that this is due to the fact that diagnostic products are confronted with low market potential, 
a problematic reimbursement situation, intellectual property rights issues and much more. Whereas the 
US has a more favourable situation for diagnostic RPs, and thus currently drives the industrial 
development of new oncologic diagnostic RPs, Europe is fighting against the non-authorisation status 
of the products, negative health assessment reports and thus non-reimbursement by health insurances 
in some member states. However, some physicians in European member states profit on generous 
national exemptions permitting them to administer these products to patients in the clinical routine, 
which have led to a world-class research position. From the industry´s perspective, i.e. this allowance is 
a great challenge, creating a secondary market and therefore further decreasing the market potential 
in Europe. As a consequence of the low reimbursement rates, the SMEs active in the 
radiopharmaceutical industry may even be considered stopping the commercialisation of diagnostic RPs 
in Europe, if reimbursement rates for new products are in the same order of magnitude as current rates 
for PET and SPECT RPs. However, most industrial experts, as well as some nuclear medicine physicians, 
expect the regulatory requirements in Europe to traverse through a process of harmonisation, which in 
the end will reduce the possibilities to use unauthorised products in clinical routine and research 
activities, especially in currently “liberal” European markets.  
With the general push towards personalised medicine, we may also anticipate increased use of 
diagnostic tests, which help to stratify patients, monitor therapy response and make a prediction on the 
outcome. In contrast to the opinion of the majority of nuclear medicine physicians, the pharmaceutical, 
radiopharmaceutical and medical technology stakeholders see an increased role of logistically more 
favourable SPECT RPs for targeted diagnostics based on the recent advancements of technology. 
Although this could be a chance to attain approval for more diagnostic RPs, unfortunately the 
pharmaceutical companies currently show little interest in imaging biomarkers being used as 
companion diagnostics. Responses from interviewees suggest that imaging biomarkers cannot meet the 
pharmaceutical industry´s needs such as global availability, low priced, convenience and easy 
application, high accuracy, detection of multiple mutations et cetera. And for the radiopharmaceutical 
industry, the market is not attractive enough, which means that these companies would not register a 
diagnostic test as a CD. The companion diagnostic market is therefore expected to be dominated by in-
vitro molecular diagnostic tests, with increased use of a liquid biopsy. An increased role of imaging 
biomarkers may only be triggered if regulatory bodies would request the mandatory use of imaging 
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biomarkers in patient selection. However, our interviewees from the regulatory stakeholder group did 
not favour a mandatory selection by imaging (although they regard this as a valuable option).  
Due to the low interest of potent investors, we have evaluated whether the concept of public or private 
partnership (PPP) may be beneficial to accelerate the approval of new diagnostic RPs. Unfortunately, 
we must conclude that this concept is not very helpful. However, from our point of view, it does not 
provide an improvement to the current approval/development concepts.  
Recent developments in diagnostic RPs are primarily driven by the US market, which is very attractive 
regarding size and revenue for SMEs. The European market also has the potential to become more 
attractive, if well- designed trials can show that the benefit and reimbursement can be resolved in 
significant markets. Currently, the regulatory environment and legal framework in France, Spain and 
Italy is more favourable for the introduction of new RP by the industry compared to Germany. In 
Germany the self-production based on § 13.2b AMG is seen as a major obstacle, although the potential 
of innovation is recognised by all stakeholders. Data derived from § 13.2b AMG application, however, 
do not produce sufficient evidence from the point of view of the regulatory authorities and national 
Health Technology Assessment Centres to justify authorisation and reimbursement. This is mainly based 
on the inadequate study designs of the academic studies conducted so far. However, the academic 
community is not to blame for these inadequate study designs since the financial resources by far 
exceed their financial capabilities and in many cases the in-depth knowledge on how to conduct a clinical 
study program is limited. The academic community makes the best use of the legal possibilities and has 
contributed significantly to recent advances in molecular imaging and therapy by providing valuable 
information on diagnostic accuracy, toxicity, dosimetry et cetera. From empirical data derived from the 
interviews, we anticipate a more structured process for investigational substances in Europe due to the 
regulatory harmonisation process, we hope that more of the academic clinical trials will be conducted 
in accordance to current regulations outlined by the FDA and EMA. Moreover, even without a possible 
regulatory harmonisation process, new diagnostic ligands should follow the official marketing 
authorisation track to give patients and the community the highest possible access.  
Given the current situation, a higher rate of approval for diagnostic RPs can only be achieved through 
close cooperation between SMEs and the academic/public institutions since large pharmaceutical 
companies do not show interest in this limited market, and PPP are not suited for this approach. 
Collaborations between academic institutions and SMEs, should be more rigorously supported by 
national/ international technology transfer offices (TTOs). These TTOs have already been successfully 
implemented in the US, where traditionally there is a closer interaction between the industry and the 
academic institutions. The function of these TTOs would be the assessment of academic discoveries 
concerning their scientific and economic benefits by a team of experts, help to set-up a well-structured 
clinical trial program, and use their network to get access to private- and public funds. This organisation 
usually pools expertise on, e.g. intellectual property, manufacturing, radiochemistry, clinical trial 
programs et cetera. We believe that it is necessary to execute projects, regarding RPs with high clinical 
potential, at the national/international level since university TTOs are primarily unable generate 
sufficient funds, and good nuclear medicine knowledge in these unspecialised institutions is rare. A 
positive example, is the Society of Nuclear Medicine and Molecular Imaging (SNMMI) which has already 
set-up specific councils and centres of excellence, shared valuable expertise as a partner to the industry 
and serves as an interface on an industrial level to established universities and research organisations. 
We assume that such a national/ international TTO has faster access to funding, professional 
negotiations could increase the chances of fair royalties for the universities, and (hopefully) more 
academic discoveries will be developed further and may skip the problem of a translation gap. 
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Limitations: 
Our study has some limitations which have to be pointed out. The low number of interviewees in some 
stakeholder groups such as the pharmaceutical-, radiopharmaceutical industry, the national regulatory 
experts, and the missing experts from health insurance group may restrict the informative value in some 
research questions. Since we considered third-party recommendations and personal descriptions from 
job portals in our expert´s selection process, we cannot exclude a subconscious bias. And while we also 
tried to eliminate the bias of the author in the evaluation and interpretation of the data as far as 
possible, we would recommend further studies with a quantitative and qualitative research approach 
to validate the data and pinpoint the exact motivations of stakeholders in the development and 
commercialization of innovative diagnostic RPs. 
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Abstract 
 
Objective The dissertation evaluates the current status of radionuclides in diagnosis and therapy of 
Neuroendocrine Tumours (NET) and Prostate cancer from (I) a medical perspective by reviewing existing 
medical studies and (II) the identification of current challenges in the development, authorisation and 
commercialization of these radiopharmaceuticals (RPs). Furthermore the intention of this study is to 
evaluate if molecular imaging, such as diagnostic RPs, can be used as biomarkers to stratify patients, 
monitor therapy response and make a prediction on the outcome. Finally we evaluate if an alternative 
drug development process may solve some barriers and increase the authorization of new RPs. 
 
Design The study uses a quantitative research methodology for the evaluation of the medical efficacy 
of DOTA compounds in the diagnosis and therapy of NETs, and PSMA ligands used for diagnosis and 
therapy in advanced prostate cancer. The qualitative research part includes twenty five expert 
interviews with interviewees from different industry branches (pharmaceutical, medical technology and 
radiopharmaceutical), medical specialists from the nuclear medicine and oncology field, as well as 
interview partners from national and international regulatory bodies.  
 
Results Based on the analysis of published literature, the diagnostic and therapeutic RPs for NETs, as 
well the RPs for advanced prostate cancer, can be considered clinically efficient. Concerning challenges 
in the authorisation of these radiopharmaceuticals our analysis and empirical data suggest that the low 
market potential, in combination with the currently challenging European reimbursement rates are the 
main barriers for a successful commercialization and introduction of new diagnostic RPs. Other factors 
such as availability of short-lived radionuclides, regulation, intellectual property rights and 
manufacturing & distribution are important to some, but not all stakeholder groups. Molecular imaging 
may also not be an ideal companion diagnostic in the view of the representatives of the industry since 
imaging biomarkers cannot meet the needs of the industry in regard to proof of efficacy, validation and 
standardization. Finally the qualitative data suggest that there is no need for a new development 
process in the field of nuclear medicine, but that cooperation between academic institutions and the 
SMEs should be promoted, supported by national/ international technology transfer offices (TTOs). 
 
Conclusion The radiopharmaceuticals (RPs) DOTATATE and PSMA can already be named as a clinical 
success story since those RPs have considerably changed patient management in patients with 
advanced NETs and metastatic castration-resistant prostate cancer (mPc). With the current engagement 
of the pharmaceutical industry in the development of new therapeutic RPs, there will be more and more 
prospective, randomised data showing the benefit of this Peptide Receptor Radionuclide Therapy 
(PRRT) approach in new areas of disease. But there is currently a lack of interest for diagnostic RPs since 
these imaging biomarkers cannot meet the pharmaceutical industry´s needs and there are significant 
commercial barriers. The companion diagnostic market is therefore expected to be dominated by in-
vitro molecular diagnostic tests, with increased use of a liquid biopsy. Given the current situation, a 
higher rate of approval for diagnostic RPs can only be achieved through close cooperation between 
SMEs and the academic/public institutions, clear benefit data from well- designed trials and solving 
reimbursement issues in the main markets. These collaborations between academic institutions and 
SMEs, should be more rigorously supported by national/ international technology transfer offices 
(TTOs). 
Zusammenfassung 
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Ziel In der Dissertation wird der aktuelle Status von Radiopharmazeutika (RP) in der Diagnose und 
Therapie von neuroendokrinen Tumoren (NET) und Prostatakrebs aus (I) medizinischer Sicht, auf Basis 
der Evaluation von aktuellen medizinischen Studien und (II) den aktuellen Herausforderungen bei der 
Entwicklung, Zulassung und Vermarktung bewertet. Darüber hinaus soll untersucht werden, ob die 
molekulare Bildgebung (z. B. diagnostische RP) als Biomarker zur Stratifizierung von Patienten, zur 
Überwachung des Therapieansprechens und zur Vorhersage des Outcomes verwendet werden können. 
Eine weitere Fragestellung ist, ob ein alternativer Arzneimittelentwicklungsprozess einige Hindernisse 
lösen und die Zulassung neuer RP erhöhen kann. 
Design Die Studie verwendet eine quantitative Forschungsmethode zur Bewertung der medizinischen 
Wirksamkeit von DOTA-Verbindungen bei der Diagnose und Therapie von NETs, und von PSMA-
Liganden bei der Diagnose und Therapie des fortgeschrittenen Prostatakarzinoms. Der qualitative 
Forschungsteil umfasst 25 Interviews mit Experten aus verschiedenen Industriezweigen 
(Pharmazeutische Industrie, Medizintechnik und Radiopharmazeutische Industrie), Fachärzten aus 
Nuklearmedizin und Onkologie, sowie Interviewpartnern von nationalen und internationalen 
Aufsichtsbehörden. 
Ergebnisse Basierend auf der Analyse der veröffentlichten Literatur können die beschriebenen 
diagnostischen und therapeutischen RPs für NETs, sowie die RPs für das fortgeschrittene 
Prostatakarzinom als klinisch effizient angesehen werden. In Bezug auf die Herausforderungen bei der 
Zulassung dieser Radiopharmazeutika legen unsere Analysen und empirischen Daten nahe, dass das 
geringe Marktpotenzial in Kombination mit den derzeit herausfordernden europäischen 
Erstattungssätzen die Haupthindernisse für eine erfolgreiche Vermarktung und Einführung neuer 
diagnostischer RPs darstellt. Andere Faktoren wie die Verfügbarkeit kurzlebiger Radionuklide, 
gesetzliche Bestimmungen, Rechte an geistigem Eigentum und Herstellung & Vertrieb sind für einige, 
aber nicht alle Interessengruppen wichtig. Die molekulare Bildgebung ist aus Sicht der 
Branchenvertreter möglicherweise auch kein idealer Biomarker/ Begleitdiagnostikum, da bildgebende 
Biomarker die Anforderungen der Branche hinsichtlich Wirksamkeitsnachweis, Validierung und 
Standardisierung nicht erfüllen können. Schließlich legen die qualitativen Daten nahe, dass im Bereich 
der Nuklearmedizin kein neuer Entwicklungsprozess erforderlich ist, sondern dass die Zusammenarbeit 
zwischen akademischen Einrichtungen und klein und mittelgroßen Unternehmen (KMU) gefördert, und 
von nationalen / internationalen Technologietransferstellen (TTOs) unterstützt, werden sollte. 
Schlussfolgerung Die Radiopharmazeutika DOTATATE und PSMA können bereits als klinische 
Erfolgsgeschichte bezeichnet werden, da diese RPs das Patientenmanagement bei Patienten mit 
fortgeschrittenen NETs und metastasiertem kastrationsresistentem Prostatakrebs (mPc) erheblich 
verändert haben. Angesichts des gegenwärtigen Engagements der Pharmaindustrie in der Entwicklung 
neuer therapeutischer RPs wird es zunehmend mehr prospektive, randomisierte Ergebnisse geben, die 
den Nutzen der Peptidrezeptor-Radionuklid-Therapie (PRRT) in neuen Krankheitsbereichen belegen 
werden können. Derzeit besteht jedoch ein Mangel an Interesse an diagnostischen RPs, da diese 
bildgebenden Biomarker die Anforderungen der Pharmaindustrie nicht erfüllen können und es 
erhebliche kommerzielle Hindernisse gibt. Es wird daher erwartet, dass der Markt für Begleitdiagnostika 
von molekulardiagnostischen In-vitro-Tests, mit verstärkter Verwendung einer Flüssigbiopsie, dominiert 
wird. Angesichts der gegenwärtigen Situation kann eine höhere Zulassungsrate für diagnostische RPs 
nur durch eine (I) enge Zusammenarbeit zwischen KMU und den akademischen / öffentlichen 
Institutionen, (II) neuen Daten zum Nutzen dieser Produkte aus gut konzipierten Studien und (III) der 
Lösung von Erstattungsproblemen in den Hauptmärkten erreicht werden. Die Kooperationen zwischen 
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akademischen Einrichtungen und KMU sollten von nationalen / internationalen 
Technologietransferstellen (TTOs) vermehrt unterstützt werden. 
  
200 
 
Appendix: 
i. Statements made regarding the Value of Imaging/In-Vivo Imaging Biomarkers (Chapter 4.1, The 
Role of Imaging, page 103) 
 
Category Pharma- 
ceutical Industry 
„The Role of Imaging“ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statement made 
regarding the value of 
imaging/in-vivo 
imaging biomarkers  
 
 
 
 
 
 
 
 
 
 
 
 
 "The primary reason we developed this imaging agent was as a research 
tool." 
 “But the motivation for us to develop it is, what we want to do is, to see how 
that changes in time over treatment. And how does it change when you 
treat…” 
 “So we want to look at that kind of research questions and see to 
understand what changes... we are also trying to develop tracers for CD8 and 
other aspects of the immune system. To really use it as a research tool." 
 “One of the most telling slides the pathologist in our group likes to show is... 
he shows two different slices, and one of them has very, very, just a ton of 
PDL-1, the other has nothing. And he shows on the next slide/imaging that 
they are both from a same tumour.” 
 “…the nice things about imaging is, you cannot just look at one tumour, you 
cannot just look on parts of the tumour, you can look at the whole tumour, 
and at more tumours throughout the body. And the hope is that this would 
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 “The differences are clear, a blood sample indeed characterises the patient 
as a whole, but imaging can precisely characterise individual regions and 
individual organs…”  
 “And the therapeutic goal is usually not the treatment of the entire 
organism, but the treatment of a certain target region. In such a case, 
imaging is the more accurate biomarker method compared to an in-vitro 
assay taken from the blood. “ 
 "Because what is used so far are indeed methods that rely on biopsy or local 
tissue samples, or just on primary tumour preparations. But certainly, in the 
course of pre-treatment, the tumour pathology already changed. That 
means we have in principle no real-time procedures, which represent the 
biology of an entire tumour.” 
 “…in real time you can visualise and quantify, in a realistic and non-invasive 
way, […] the entire body, so all lesions and not just part of a tumour." 
 “So the localisation succeeds of course only with imaging, not with blood 
tests. That is basically how it is." 
 "You know Imaging people usually are quite limited in their understanding of 
medicine… they believe that you will be able to have, for any drug, a 
biomarker, an imaging biomarker. That is, of course, total nonsense. So you 
have to focus on the stuff that is really needed." 
 
 “My estimation, functional imaging will further develop… what I have seen 
until now is fascinating… probably it will also save costs; many people have 
not recognised this yet. If we have the chance to avoid therapies in patients, 
stop a pointless therapy and start with a more sensible therapy, by using 
functional imaging or another method, this would definitely be economically 
meaningful.” 
 "Yes, a huge one [role of MI in new therapeutic strategies]. Imaging will get 
better and already got better. If you look at the pictures, a magnetic 
resonance tomography delivered ten years ago… we now have a new 3 Tesla 
device, one of the most modern generations. 'It looks like a CT; it is crazy. It 
will go on, I am sure.” 
 "It depends on the problem! I would say that if it is just about verifying 
therapy response, and you have got a biomarker that's so good that the 
biomarker's concentration tells us “ok, the patient responds or does not 
respond to therapy? And everything else is not from interest” then you could 
wave imaging. 
But if the patient has any consequence from the localisation of a tumour, 
which cannot be shown with Liquid Biopsy, then it is of course just a 
question of a tumour “yes” or “no”. Or what kind of genetic alteration or 
mutation does the patient have. … Moreover, if this results in any kind of 
consequence… imaging with the appropriate sensitivity and specificity is still 
indispensable.” 
 “And I think that will be more in combination (Note: in-vivo and in-vitro 
biomarkers). I do not think that one will replace the other. However, a 
combination of both will then be able to represent the best possible status 
of the patient." 
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be more valuable and it would do a better job in predicting patients 
response, but this is true or not time will tell." 
 "...we tried to use imaging, and would say we have tried to use imaging to 
generate, maybe more inclusion/ exclusion kind of criteria for the 
enrichment of our trials.” 
 “…we are using it for internal decision making." 
 “In fact, we are developing a number of these molecular markers with 
academics. But I think the real question is "Are we really developing to use it 
all the way into a CD?" and "Are we using, are we developing it all the way to 
make a business?" The answer to the last two is: probably no. Because this is 
not our primarily stream business.” 
 “Now, imaging has some advantages: you can look at all the lesions, your 
metastatic lesions, some have mutations some don´t, some … there are a lot 
of academic reasons why imaging might be nice to have. But really for 
tumour mutations has a very hard struggle. It is also the true, the case that 
the imaging tools we have are not as precise as the free circulating DNA 
tools.” 
 "Of course drug companies use imaging biomarkers a lot in their research 
and development as pharmacodynamics biomarkers, proof of mechanism, 
proof of principles, and proof of concept, set the dose in phase II.” 
 “They are asking the question: Does the drug reaches the target, does it 
engage the target, does it modulated the downstream physiology, and so 
on…  “ 
 "But in terms of an internal decision making we are using a number of these 
molecular ligands, and we have a very extensive back program where we are 
trying to develop ligands…. So we are using it for R&D decision making right 
now, for proof of mechanism on tissue markers, understand the distribution, 
understanding dosing there are a number of ways we are using 
radiopharmaceuticals…. So we have a lot of interest in this field, in some 
cases, we have the product in some cases we have the decision making 
criteria internally.” 
 
 “MRI and CT see the disease in about 15% of cases, [our product] sees the 
disease in about 70% of cases. And for that particular disease, the location of 
the disease had quite an impact on patient treatment… radiotherapy is 
expensive and hurt patients and some are getting inappropriate 
radiotherapy because actually the disease is already in the bones.” 
 "There is huge opportunities still in cardiology, tend to think that cardiology 
and neurology are better" 
 
ii. Statements regarding the Challenge of “Reimbursement” (Chapter 4.2.1, Issue with 
Reimbursement, page 108) 
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 "Yes, reimbursement is a huge problem, clearly. Reimbursement of costs is 
one of the main limitations for PET overall." 
 "The non-authorisation and the reimbursement goes hand in hand. So 
under our current legislation, the admission is not fundamentally the 
problem, but due to the lack of admission, there is no refund. You can turn 
as you want, ultimately it's about that: it has to be paid in some way." 
 “…today we have a considerable range of tracers that can be used clinically. 
And then also in the aftermath, we have been relatively successful to get 
these tracers reimbursed by the health insurances [country outside the EU]. 
And that is a catastrophe in Germany because you have to make special 
contracts with every health insurance company.” 
 “Yes, that is clearly the financial aspect. So PET-CT imaging… is 
unfortunately not cheap. And the substances that are mainly used at the 
moment are Somatostatin analogues and PSMA ligands. They are still not 
authorised in Germany, so they are also not reimbursed in the outpatient 
practice and not in the clinic setting. So you can do the imaging, and we do 
it, but it is not paid. And in the outpatient setting certainly not … only FDG 
in two indications…” 
 “…and based on the German Social Code V PET-CT is actually a compulsory 
service of the statutory health insurance, in the pre-stationary area…. But 
the health insurance companies simply refuse to pay the costs, and this 
sometimes leads to difficulties. So the patients have to file applications, the 
health insurance companies reject that in part, then contradictions are 
filed. This is sometimes a bit of a hassle, but it's just a relatively small part 
of the patients we're now looking after. But it could be easier. It would also 
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make things easier, especially if the federal committee, which is responsible 
for approving or payment of RPs, would work a little faster.” 
 
 "I think getting products reimbursed is the biggest challenge in Europe. 
Governments like to pay, just from a PET scan basis, governments like to 
pay for PET scan as an FDG rate. And so this is true for SPECT as well.” 
 "If the market for all PET diagnostics and SPECT diagnostics is payment at 
either a technetium bone scan rate or an FDG rate, if that is the future, 
from now forever, for payment for nuclear medicine then at some point 
people will stop commercialize products in Europe." 
 “.. I think they will not receive the reimbursement of a therapy… I think 
diagnostics will be appropriately reimbursed [in the US], unless there are 
major changes in the structure of the US market. However, for Europe, it is 
probably the case [reimbursement issue]. The average price of an oncology 
drug is in Europe 30% of the price in the USA. And … reimbursement of 
SPECT and PET scans are in most European countries … under pressure. In 
fact, in some countries, there is no reimbursement of the pharmaceutical 
part. It is only reimbursed of the cost of the actual scan, the imaging part. 
And that is a problem. So two parts for that: No, not worldwide but yes in 
Europe." 
 "The greatest barrier to get a commercial biomarker is payment. Because 
the government agency, that pays for it, has a specific non-payment rule. In 
other words, if you develop an oncology diagnostic agent, there is a pass to 
payment. If you develop a neurology or a cardiology PET diagnostic agent, 
there is no reimbursement. You have to go through the TED trial [Coverage 
through evidence discovery trial]. For example, Amivid, Neuraceq, and 
Vizamyl are three PET biomarkers for amyloid, right? All approve 2012 or 
2013. None of them has reimbursement, none of them will have 
reimbursement for years. So those companies who brought that forward, 
have paid for the trials, paid for the filing and have been struggling to make 
a business out of it ever since. " 
 “Getting past the FDA is not that bad, it takes time and money, but it is 
doable if you have a focused indication. But getting passed payment is a big 
deal." 
 "...the other major consideration: "what price can you get?", “Is it 
reimbursed?” But an awful lot of the RPs are not reimbursed. This is a big 
issue for a lot of companies.” 
 “We need to get pricing, reimbursement which allows us to make a 
profitable proposition. We are not there yet; we are not there yet." 
 “So there are insanely conservative countries like England, which is perhaps 
20 years behind Germany. There are advanced countries such as Denmark, 
where almost all indications are reimbursed, or France where FDG is 
relatively broadly reimbursed. Italy, for example, has 6 times more PET-CT 
examinations per million inhabitants than Germany. Because simply the 
reimbursement is better regulated. That is extremely different.” 
 
iii. Statements regarding the topic “regulation” (Chapter 4.2.2, Challenge with Regulations, page 113) 
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 “So in Germany, it is not a problem that is part of our success that we can 
work with non-approved drugs. But we are very much dependent on the 
German framework conditions and if at some point, in the course of 
internationalization / globalization, these whole rules are standardised and 
the same everywhere, then we get a problem in Germany. " 
 “And that is actually a problem … that we in Germany tend to administer 
the substances very quickly in the patient and do not worry about how we 
can create sustainable evidence of benefits.” 
 “I hope! There is also the hope for the EU that we can still find a more 
reasonable standard. Because Germany is very restrictive, strict. Also, as far 
as the EU regulations are concerned, it would be nice, I have some hope ...” 
 Interviewer: “But in comparison to other countries, a tracer can also be 
used in Germany via the national exemption, where other countries also ...” 
Interviewee: “Yes for first-in-man applications, that's right. But in the end, 
we are very limited. In principle, we can do a lot of experimental things, but 
officially very little ... It is amazing how much research comes from 
Germany, although we fight so hard with the reimbursement. It's a huge 
problem.” 
 “Sure, it's an advantage that you can have first-in-man studies very quickly! 
But even there, you would have to find a rule that allows it so synonymous 
because the risk is indeed very low. That is in itself completely excessive, 
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the fears which are discussed, especially in view of the fact that nothing has 
ever happened. So it's a total hysteria. The guidelines are far too strict, and 
we just cannot compare PET Tracer with a new therapeutic drug. That's a 
completely different order of magnitude. And the huge advantage of PET 
that one can work with molecular quantities is obviously not understood.” 
 “…that in principle it would be easier to obtain approval for the PET Tracer 
and to obtain a first-in-class approval, rather than with the caveats of a full 
AMG study. That's certainly nonsense. That's not rational.” 
 "And the problem we have in the legislation, and I assume that this is more 
or less the same all over the world, that you have laws for medicines and 
that PET tracers are classified as medicines. And on the other hand, you 
have the legislation for the radioactivity, the tracers are radioactive! Now, 
these legislatures are always made for, for important, for just. .. I say heavy 
duty, and heavy duty means that if I give a medicine, of course, that should 
be pharmacological effective and if it has a pharmacological effect, it can 
kill the patient as well. " 
 “It's just that the approval of a new PET tracer, a diagnostic tracer, is very 
complicated because it's a medicine.” 
 “I don´t think that the regulatory agencies are the bottleneck here. Actually 
they are doing really well. They have the interest to get this done. I am 
actually fairly positive about their work... I think the study design is an issue 
that has to be done right, and for the treatment trials of course there you 
have to be, they are concern about pharmacology and toxicology. So you 
have to provide them with some data." 
 “In Germany, this is definitely the case that the challenge is too high, yes. 
So you can also see that in comparison to other countries, e.g. France ... the 
whole approval process took less than 1 year for all oncological indications. 
It already takes 12 years in Germany. And as I said we have only 3 
indications in which this has been confirmed, and still no billing rate. This is 
simply a political catastrophe, but the political will. Because the health 
insurance companies just see millions or hundreds of millions of costs 
approaching them if there is a wide-scale approval. That, of course, more 
effective control of the therapy is possible, and above all, unnecessary 
operations are avoided in many cases, the health insurance companies just 
do not want to see.” 
 “... the regulations are extremely heterogeneous. It is rather that the 
interpretation of the regulations is very heterogeneous ... I put it this way 
now: There are developments that barriers will decrease in countries with 
high barriers. But there is also the tendency that for countries that have 
barely known barriers that new barriers will open up. So there are certain 
tendencies for harmonisation at the most diverse level. So on the one hand, 
on the side of the regulations themselves ... then, of course, also from the 
law enforcement authorities. The authorities…, whose knowledge partially 
increased in this area.” 
 “But there is the recognition of the regulators that certain rules should be 
there, that they should be reasonably consistent, and that certain rules 
simply do not fit. And there should actually be simplifications.” 
 
 "We think that we think the market will get more regulated. Er, we don´t 
think the market will get less regulated, so er so we think there is a 
fantastic opportunity. Ah, and it looks like a good place for investment. I 
think, so we think the regulation will kick in at some point. (Laughs). And it 
will become a more regulated market. Lots of markets are quite regulated 
in this area, so in the US, France, Italy, there are countries that follow the 
regulation process and so there is still a great opportunity in those 
markets." 
 “So now what is the very debatable point, which requires an ongoing 
unfolding discussion with all the parties’ concerned, which includes 
regulators (FDA and EMA). Two things: the first thing is relating to 
dosimetry … and the second thing involves the future design of clinical trials 
and the use of real-world data to perform the full personalization of full 
theranostic platform.” 
 "I think the opportunities [self-production of RPs] will decrease because as 
the drugs are commercialized, the large pharmaceutical companies will no 
longer tolerate the use of unlicensed products in the same indications.  
Even as they are different compounds. So I think the opportunity of home 
production will decrease, and that means that RP will be competing on a 
level playing field with the other modalities. And it is cost."  
 Interviewer: "Do you expect that the regulation globally will meet at a 
specific level and that some countries, such as Europe, may get stricter 
regulations?” Interviewee: “Yeah, I do think that. Yes definitely." 
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 "Well, I believe that in diagnostic tests, unfortunately, the profit margin 
that one has with the commercialization of a diagnostic test so that just is 
not as high as having a therapeutic substance." 
 "... I, therefore, believe that the connection between diagnostic substance 
and therapy, which on the one hand must be natural and on the other hand 
also forced a bit, then the new diagnostic test can be successful.” 
 "Well, we are partly to blame ourselves, because we do it ourselves. Then it 
is often not patentable, and thus there is no one who wants to invest 
because there is no money to earn." 
 "If you look at the list of companies that have entered the imaging market 
it is quite stunning. There are a quite bunch of companies that come in. And 
also pharmaceutical companies are attracted to theranostics because that 
is the market. There is a big big need. AAA will charge 47.000 Dollars per 
cycle DOTATATE. So that’s four times what it saved in the US so that 
accounts for 80.000 $ or so per patient. Let´s have 10.000 patients, 40.000 
cycles so you can calculate the significant amount of money. Now if you 
think in prostate cancer you suddenly have, conservatively estimating, 
40.000 patients for 160.000 cycles. And each of them is 20.000 $ or 25.000 
$ or 30.000 $ than you can calculate, that this is multi-billion Dollar 
business. So that’s we are talking, now they are coming in and like that 
stuff. Money being made." 
 “…there is not enough money especially with the Gallium compound.” 
 “And, for example, in the field of outpatient care, only a few indications 
(PET/CT) have been added, and even in EBM PET-CT is still not anchored. So 
that's a big obstacle, for the industry, I think that's, of course, not so nice. 
But they are of course targeting the US as a market, which is a very large 
market and where the approval of new RP has recently increased 
significantly in speed.” 
 “One thing is for sure, that with a ... diagnostic product ... it is difficult to 
generate returns. If I think of Fluor-18 marker now, for Fluor-18 I need 
infrastructure around that ... and writing pharmaceutical profits is very 
difficult ... plus, because it's just diagnostic, you can, of course, charge a lot 
less .... with Ga-68 kit markings, I do not have the problem of logistics, but 
... the margins are still worse and all reimbursement systems ... are never 
ready to pay as much as for therapeutic drugs.” 
 
 “…the margins are very low in diagnostics, there is more money in 
therapeutics, and we focus on the diagnostics we need to get the 
therapeutics approved and to people.” 
 "There are companies out there, which are in business developing 
molecular diagnostics and they have the same problem. They have very 
small margins, that´s a tough business. And in fact what happens, we didn´t 
develop the PDL-1 tracer, but we paid the company to develop it. Every 
penny they needed for it because we needed to have that test." 
 “In fact, we are developing a number of these molecular markers with 
academics. But I think the real question is "Are we really developing to use 
it all the way into a Companion Diagnostic?" and "Are we using, are we 
developing it all the way to make a business?" The answer to the last two 
is: probably no. Because this is not our primarily stream business.” 
 “As you know in drug development, in every hundred projects the industry 
starts, if they are lucky one becomes a medicine. So you have huge, you 
have huge attrition. And of course you have attrition in the diagnostic, so 
for the academics working on Etarfolatide the tracer and indeed for the 
company developing it, they got nothing out of it. Even it was a great 
tracer, when the therapeutic died the market for the diagnostic died as 
well. So it is a very unattractive place to be in.” 
 
 "The reason why AAA is worth 4 billion is not because of the Gallium 
diagnostic, is because of the Lutetium therapy.” 
 "We think there is a fantastic opportunity there. We think there is a 
fantastic opportunity in molecular imaging." 
 "We think that we think the market will get more regulated. … and it looks 
like a good place for investment.” 
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 “Novartis, one of the major players in oncology, has acquired AAA and have 
started a radiopharmaceutical platform insight Novartis. And that includes 
searching, as they said publicly, for other compounds. So PET tracers that 
have useful prognostic information for a therapy. And also they made it 
publicly clear that this does not necessarily only relate to oncology, also in 
other areas of medicine, it might be useful to have a diagnostic targeting 
moiety, which if diagnostic and prognostic insulation and then has 
associated therapy, which can produce a therapeutic benefit. Even if the 
disease is not in cancer. It would be in other disease areas, in 
cardiovascular, in orthopaedics, not necessarily wherever radiation destroy 
tissue in a targeted way." 
 Interviewer: "What do you think about the market potential, is it a problem 
for diagnostic RP to compete?” 
Interviewee: No, I don´t think so. I think they will not receive the 
reimbursement of therapy, the levels of reimbursement for innovations 
will, as we see with fluciclovine in the USA. So certainly the USA market, I 
would say no. I think diagnostics will be appropriately reimbursed unless 
there are major changes in the structure of the US market. However, for 
Europe, it is probably the case. The average price of an oncology drug is in 
Europe 30% of the price in the USA. And the regulations of reimbursement 
of SPECT and PET scans are in most European countries, meaning the 
reimbursement of the pharmaceutical part, is under pressure. 
 “So then you can use Axumin. Well, that was a very strong unmet need, and 
dose sells have been very good. They are small, relatively to FDG. FDG is 
used for oncology, up to 1.8 million doses of FDG are sold a year, 20.000 
maybe 40.000 of Axumin. But Axumin costs 40 times what FDG costs. So 
from a revenue standpoint, it is significant, so we are seeing... If you 
brought another biomarker to replace FDG, for example, you would never 
make a business case for this. Because FDG is good enough and it is cheap. 
But if you have a very specific unmet clinical need, you can find basically a 
niche market. That is what Ga-68 NETSPOT/ Ga-68 DOTATATE did, that is 
very specific. Very small market, but they charge 5.000$ a dose. So it is a 
business!” 
 "PET biomarkers are fairly big business. The PET market in the US is about 
275 million a year, this year 2018. That’s all PET in the US, revenue. So 275 
million, and PETNET has about half of that. Er, and if you operate your 
business profitably, it can be a good business. You have high fixed costs, 
you a lot of cyclotrons, chemicals labours, people, but you can still make a 
good margin on that. " 
 "The growth is projected to be fairly dramatic, the new biomarkers that are 
coming out are extremely er, well the revenue is much more as the revenue 
from the majority, which is FDG. So FDG in the US is about 150 Dollars a 
dose, picking just an average. Where for example the new prostate drug on 
the market is 4000 dollars a dose, it is like 30 times more expensive." 
 “Highly competitive market, very low margins and actually it wasn´t good 
business. As a consequence, huge consolidation in the market.” 
 The market opportunity for such a product is a niche compared to a 
therapeutic drug… A pharmaceutical company would say "Actually it costs 
me a significant amount of money and the market opportunity is low.” The 
other major consideration "what price can you get?" Is it reimbursed? But 
an awful lot of the RPs are not reimbursed. This is a big issue for a lot of 
companies.” 
 "The return on that investment! Return on investment … and revenue is 
smaller than in therapeutics." 
 
 “... that you have a relatively specific patient group and develop something 
with a very specific target and you have to do the full phase I, II and III 
studies. That will cost 100 to 150 million, the development. And then, in the 
end, that's not necessarily a huge market commercially. Then it's just a big 
problem. As already mentioned, in PET imaging, of course, the margin is not 
nearly as big as with contrast media or with SPECT nuclear medicine 
tracers. Due to the need to create your own local infrastructure, or to work 
together with companies that locally produce the PET molecule and then 
deliver it accordingly." 
 "And then… there is even limited commercial interest in the ones which do 
have IP protection because we don´t have a great track record of success 
stories here. … So ever since that acquisition (Avid being bought by Elli Lilly 
because of their Amyloid imaging RP), they have been struggling and not 
been successful achieving reimbursement for the amyloid imaging agents 
for PET.” 
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 "And that is actually a problem; I think that is a problem of our system that 
we in Germany tend to go with the substances very quickly in the patient 
and do not worry about how we can create sustainable evidence of 
benefits. So somewhere there should be a compromise… Although it is 
possible in Germany, but the global success is held back by the regulations." 
 ".... that we begin very early, still in the field of preclinical research, with 
our diagnostic tests and work together with the experts in the development 
of therapy.” 
 "And, of course, research is now increasingly moving in the direction of 
visualizing and quantifying very specific, drug-relevant targets, including 
modern developments like immunocheckpoint- inhibitors or things like 
PDL-1, PD-1 ... But this is the path taken in research, and relatively little is 
translated into the clinic, one has to be very clear. " 
 "So there's a number (of challenges) and also keeping pace with the rapid 
development of new therapeutics. We cannot keep up with the 
development of diagnostics that would fit for therapeutics." 
 “Well, we are partly responsible for that! Because we do it ourselves, thus 
it is not patentable anymore. And therefore nobody is investing, because 
there is no money to earn. " 
 So if we want to use a new tracer today ... just for research purposes, I just 
have to spend 100,000 CHF to do a toxicology study. This will stifle any 
research project immediately. So that's the problem with the PET tracers. " 
 "The problem with therapeutic tracers is a completely different one ... 
when you start to treat (with therapeutic RPs), you have a pharmacological 
effect. And if you have a pharmacological effect, then you need to prove 
that using this medicine will benefit the patient more than it harms him. 
That requires Phase III studies ... " 
 "You know what the major issue is really cost too, who pays for it. If you 
don´t have stakeholders like in the pharmaceutical industry, which is now 
changing a little bit with Novartis having bought AAA. That changes the 
game, but as long as you don´t have stakeholders with a lot of money who 
is paying for it? That is really complicated, who is paying for the 
development." 
 “... what we urgently need in academic research is the support from the 
industry. So the thinking of the development steps of phase 0,1,2,3, what 
are the requirements, how can you do something specifically.” 
 “And then everyone starts again to re-invent the wheel, and there would 
have to be better cooperation. Just a promotion from the side of politics, 
indeed from the ivory towers of the University to bring the research then 
really directly into the industry.” 
 “And in my opinion, there would have to be a lot more going on to 
translate the results as quickly as possible into practice, well as you say 
from Bench to Bedside. So to implement preclinical research or early 
clinical research quickly into practice. And to implement the clinical trials, 
there is a great shortage there.” 
 “(Academic research must) make more clinical trials, and a clinical trial is 
called in accordance with current EU regulations, as notified drug trials. 
These studies need to generate data that is really usable for approval. And 
that's not as difficult as it's often portrayed. Of course, it takes money and 
time, yes. And it will not work for everything that you would like to 
have….and there is already pressure from the authorities and also (the 
nuclear medicine doctor) see the reason. There are already more controlled 
studies! For example, where, in the simplest case, one can accurately 
portray safety and say it is a registered study whose primary objective is 
safety. For example, this is something you never did for the DOTATOC.” 
 “..not without anyone (investor) to the “ready for the market” phase. But 
for early first studies quite well, where then possibly an investor is even 
more interested.” 
 
 "Yeah, I think the really shared challenges with other therapeutic platforms 
is the cost of exploiting them. So I think the advantage currently in the RP 
world is that there is a recent history of home production and of clinical use 
of RPs.”  
 “I think people forget about the costs of development and they also forget 
about the actual costs of commercializing RPs… So there is a really large 
cost infrastructure about getting products approved. And there is a large 
cost infrastructure about maintaining products in the market." 
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 "Er, I guess the probably needs to be a better understanding in the 
academic community … so when, for a lot of these agents that look 
interesting and therapies that look interesting, to get approval for it you 
need to get back to the drawing board to do a proper dosimetry study. You 
need to do the rat model to show; you need to still got through Phase I, II, 
III process in lots of these instances. Because the FDA and the EMA wants 
to have properly designed clinical trials in this area. I think either the 
academic community works in a more followed clinical trials process, so 
when they develop agents, they actually got data ready for regulators or 
that it got an understanding that even you got interesting data in people, 
you will, actually for the regulators, still have to go through this proper 
regulatory process. So effectively those initial data what they have done is 
they de-risked the chance that the therapy works, but they haven´t 
decreased the total investment you have got to make the product into ah, 
something the regulator will approve." 
 “From a discovery point of view, the one big advantage of RP will have, it 
will be possible to go back over the back-catalogue of large pharmaceutical 
companies and find compounds with very high specificity, but don’t have a 
therapeutic effect. So I think that will be an interesting and less expensive 
development of the next couple of years. Things that have failed and have 
been written of, because basically they didn´t work. But nevertheless, they 
accumulated in a target; they might be of use if they can be labelled with 
radiation." 
 "I just wanted to stress that Siemens was in the biomarker development 
business in the US for a decade, spend a tremendous amount of money. 
Hundreds of millions of dollars and got out of it because it was such a drill 
hole. Yeah, so we are willing to let other people develop the biomarkers 
and proof the clinical utility and then they have to come to us because we 
are half the market in the US anyway." 
 “So effectively those initial data what they have done is they de-risked the 
chance that the therapy works, but they haven´t decreased the total 
investment you have got to make the product into ah, something the 
regulator will approve." 
 
 "Well, I would say the problem, especially in oncology, is that you have a 
relatively specific patient population, you develop a very specific target, 
and you have to do the full phase I, II, and III studies. This costs you 100 to 
150 million, and in the end, there is not necessarily a huge market 
commercially." 
 "So we agreed on watch status, because ... (the new product) may continue 
to be interesting, but the development of (product X) depends on how you 
expect it, but it has to do with the $ 100 million and has not yet paid off, 
and (the company) has no interest in repeating that with the (new) imaging 
molecule." 
 "We probably do not do enough, in my opinion, because we could basically 
do more. Of course, that's always a matter of money, and I still see a lot of 
academic interest in developing new molecules. We internally decided not 
do discovery and early phase research anymore, but in principle, we should 
try to be a little bit more active. This would allow us to license promising 
projects at a later time. So the pipeline is no longer internally but 
externally, but so we can also boost research through collaborative 
research. Thus that would be a logical consequence of deciding that we do 
not do so much by ourselves. " 
 “So we are not actively in the discovery phase anymore, but I am sure A. 
mentioned, we do quite a bit of clinical trials for others, but we don´t 
charge them for the costs of things. It is sort of a small side business for us 
with the hope to get some more tracers on the market. And then we do 
investments in like we gave support to the SNMs clinical trials network on 
getting the Gallium PSMA project moving. So we do funding of others we 
think it is worthwhile, help to accelerate to get these tracers done." 
 “… there are some very interesting RPs they don´t have IP protection 
anymore. Even they have never filed for a patent in the first place, or they 
have been around so long that the patent has effectively been expired. And 
those are interesting, but a company have not really get behind it because 
that would spend all the money on clinical trials and the approval process 
and then anybody could make a generic.” 
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 "I think the challenge is more on the university side, that such patenting 
can be done efficiently, unbureaucratically and standardised. Nowadays, if 
you have something new and you have not patented, then it's not worth 
anything to the industry." 
 "They only get an industrial partner, if they really have a patent on their 
academically developed product. This has to be accelerated, and again it is 
important that this is simple to implement for the academics." 
 "Intellectual property is always a problem; you just have to define it 
beforehand ... Researchers are also beneficiaries in my view because you 
have the same partner as during exploitation and you do not completely 
lose the patent. … as a researcher you can be happy to participate 
financially. This is also just an advantage." 
 "This is always this tightrope walk, I see that extremely relaxed (concerning 
the negotiations of IPR in a partnership)." 
 "I do not think that's a problem (concerning the negotiations of IPR in a 
partnership)." 
 "Well, we are partly to blame ourselves, because we do it ourselves 
because it is not patentable often." 
 In the end, the problems are always related to patents. You have to own a 
patent so you can make money in the pharmaceutical industry. And if the 
regulatory hurdles are extremely high, then you have a patent, and so you 
can use all the crap it may take 10 years. Then half has already expired." 
 "And when they (the university) starts to say:" I have to care that the 
university earns a stupid amount of money", then this patent can again 
have prohibitive / negative consequences." 
 "I'll give you a very specific example now, the Gallium PSMA-11 tracer. 
Which can now be named as the second most used clinical tracer, after 
FDG. If Gallium PSMA-11 would have been patented, it would not be there 
today. Because it would have taken much longer for this to be 
implemented." 
 Of course, it helps if something is protected, but it must have happened 
before the clinical trial anyway. On the other hand, it is not like many 
people think. In my opinion, it is not true that only products that are 
protected will be developed. It can also be a certain protection exclusivity 
of other things, for example, from a certain time advantage you have. Or I 
know a company that has a patent on a particular marking technology. It 
marks an unprotected product with its marking technique and then is a 
little exclusive in the case, not?  
 
 "Well, IP is very broad. So if you have a tracer you can develop IP on the 
composition of matter, if you have an imaging biomarker which is based on 
a CT signature or we talked about Ferriscan, so the MRI R2* that is not a 
tracer that is relaxation time. You don´t get IP on the relaxation time 
because it was discovered by physicists 50 years ago or more. Where you 
can develop IP on is in copyright and business processes. So with Ferriscan 
the IP there is on the copyright of the software, the business process, the 
whole procured for validating scans and giving the physician validate R2* 
measurements. And again I would urge you to think... Imaging is not just 
out proprietary tracers, even in PET FDG has a very important role to play, 
and even there is no property to secure on that anymore. Many other PET 
tracers don´t have a composition patent; there are other good uses for 
them." 
 
 “That was a big move for Heidelberg around Ga- PSMA PET, for instance, 
they didn´t patent it. And now there is a good technology that is available 
so could have a relevance in prostate cancer. But there isn´t really a 
company who wants to invest in it. Because Heidelberg failed to patent it." 
 Interviewer: "So you wouldn´t go if there is no protection for you? 
Interviewee: “Yeah I think it is difficult to do that because because you can 
have a generic competitor. And it costs a lot of money if you think...  I think 
people forget about the costs of development and they also forget about 
the actual costs of commercializing RPs.” 
 Interviewer: "So you also tried to gain IPR through these collaborations, is it 
a goal for you? 
Interviewee: “Yes, yes. I think that is the cause of everything we do, is 
having a strong IP position. So you know, if we had an academic 
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collaborator coming to us and say that is great technology and it is not 
patented, that would be just a really big red flag for us.” 
 “I know AAA effectively has a generic product and they have invested, er 
which is fantastic but er from our perspective we would have looked for a 
reason with strong IP position.” 
 “And academic need to think about that IP and protecting it. So there is an 
asset worth investing in. (laughs).”  
 “Academic institutions are very variable in their approach to IP. And you 
know there are some really smart about it, and they understand that they 
need to protect it and protect it well, and there are others. But I think, 
maybe the academic community understands that more every year 
(laugh)." 
 “So from our perspective, when we build up our IP portfolio we don´t rely 
on one piece of IP. We like to have the chemical entity, and then we build a 
whole layer of onion around it. About different IP that covers the 
manufacturing process for the product, how the product is being used in 
the field. So you can build, but not having the chemical entity IP is definitely 
something that when we go to investors, to ask to invest in new ideas we 
got, the first question they ask is: “what is the IP position?” And it is a big 
red flag for them if you don´t have chemical entity protection, from an 
investor perspective. But the [pharma] guys also know that there are ways 
to get around it. But there aren´t always ways to explain that to investors 
(laughs).” 
 Interviewer: “What about the IP- rights issue? Is it a problem for you as a 
company to go ahead in the development of such compounds?” 
Interviewee: “Er, no I don´t think so. I think the market will determine the 
price, so IP…. In terms of the royalty percentage for the IP, I think that is 
only market forces. Some universities take a very reasonable approach and 
have 3-4 % royalties. Others insist of a much higher percentage, and I think 
the market will just determine, so I don´t think that is a problem." 
 “Again, from our business we are not going to reach out to an academic in 
Europe and pay for their development. So somebody stepping in who is in 
the biomarker developing business is necessary and they won´t do that 
unless there is, unless they can get patent protection on their investment." 
 "One thing that mitigates in the USA a little bit: if you bring what is called a 
“new chemical entity” to the FDA and the FDA defines that this is a 
chemical that they have never approved for any utilization … you get 5 
years of exclusivity. Independent on any patent, the FDA will not approve 
another application with that biomarker for 5 years. So you have 5 years 
basically to try to recoup your investment. So even you don´t have patent 
protection, so somebody could bring Ga-68 PSMA to the market in the US, 
then you are for 5 years the only entity to make it. " 
 "So the patent is not too important." 
 "I think it depends on the intersection of that. IP pops out of public 
institutions. There are clear-cut mechanisms where the industry can 
interact. " 
 
 "Yeah, there is, if I can I will break that in two categories because there are 
some very interesting RPs they don´t have IP protection anymore. Even 
they have never filed for a patent in the first place, or they have been 
around so long that the patent has effectively been expired. And those are 
interesting, but a company have not really get behind it because they 
would spend all the money on clinical trials and the approval process and 
then anybody could make a generic." 
 
vii. Statements regarding the topic “Manufacturing, Distribution and Handling” (Chapter 4.2.6, The 
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Item Manifestation Example of literal expressions 
Category Nuclear Medicine 
Physicians 
 
 
 
 
 
 
 
 
 
Statements 
concerning the topic 
“manufacturing, 
distribution and 
handling” 
 
 
 
 
 
 
 "And the problem with the radioisotopes, which are relatively short 
compared to the SPECT with technetium, I don´t consider this to be 
problematic. I believe that the availability of PET is not really a problem, at 
least in Germany, not even in the US. I do not think this is a problem in any 
industrialized nation." 
 "... these therapeutics typically have half-lives in the range of days and not 
in the range of hours. This changes the whole logistics. So they can produce 
Lutetium DOTATATE in Holland, and from there they can flood the world." 
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 “Now, when I think of 18- Fluorine 18 labelling, for F-18 I need 
infrastructure ... and (pause) generating typical pharmaceutical profits is 
very difficult.” 
 “... there are developments like the Ga-68 kit labelling. Now I do not have 
the problem of logistics, but ... the margins are still worse in comparison ... 
to therapeutics." 
 
 "When the drug company is developing the drug it's developing it for a 
global market… they are thinking if you can sell it in the United States and 
EU, they are also thinking about China, Philippines, Brazil, Indonesia. These 
are important markets! … If you going to have diagnostic in your label you 
want to make sure it is available in every hospital in China, Philippines, 
Brazil otherwise you would not sell this drug.  From that point of view you 
have PET agents... at least..., carbon is out of the question, fluorine can be 
challenging because of the half-life. Technetium is much more attractive. 
Gallium obviously with PET is more attractive, because you can use a 
generator and a nuclear medicine Department can make it locally. And if I 
were looking developing a personalised healthcare compound, I would be 
very cautious about the fluorine agent." 
 “… drug companies develop drugs for global markets, and so the imaging 
also needs to be available in that global market. And that are really difficult 
problems, the academics often miss." 
 
 "And what we are doing now is rolling out the manufacturing infrastructure 
to make the product available... That gives us an opportunity to provide a 
product that is Er, the same in all markets effectively." 
 "So [the company] is sort of, not a R&D organisation, we are a biomarker 
production and distribution company. We are the market leader in the US, 
we have 43 pharmacies, we have about 48% market share, we do about 1 
million doses a year, and we supply these doses to about 1 million patients 
a year… work with other partners, other businesses that are in this field and 
need a commercial outlet for the biomarker." 
 “You have high fixed costs, a lot of cyclotrons, chemicals labours, people, 
but you can still make a good margin on that." 
 “Hospitals have been producing their product and also supplied several 
hospitals around them. For years that was under the radar, the regulation 
got tighter on the national level and controlled.” 
 
 “Then already mentioned, in PET imaging, of course, the margin is not as 
good as with contrast media or with SPECT nuclear medicine. Due to the 
need to create their own local infrastructure or to work together with 
companies that locally produce the PET molecule and then deliver it 
accordingly. " 
 “And in principle, especially as far as PET imaging is concerned, the 
question is how big reimbursement has to be to cover costs of the test… 
SPECT is much simpler. And especially technetium-based products, even 
reimbursement is not that high, you can still cover costs, which is much 
more difficult in PET." 
 “On the other hand, PET is problematic because you need PET centres to 
make the tracers locally and thus the margin is always worse than in SPECT. 
And that's unlikely to change. Either you need your own infrastructure, 
which will increase base costs, or you'll be working with local partners who 
manufacture PET tracers. Of course, they also want to have some of the 
profit, so the margin will always be worse than with SPECT. There are also 
certain countries where, apart from the big cities, logistics in SPECT is easier 
than in PET imaging.” 
 
 
viii. Statements concerning the definition of a “Companion Diagnostic” (Chapter 4.3.1, The 
Stakeholder´s Definitions of a Companion Diagnostic?, page 133) 
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 "A diagnostic test that directly influences the therapy decision, a key test 
that describes whether a patient is eligible for therapy or not. Later the 
results tell us if the therapy was successful or not." 
 "Companion Use is a methodology to overcome these general limitations of 
conventional diagnostics, and there are several possible models for this: On 
the one hand, for example, it would still be possible to identify specific 
target structures based on therapeutic results, i.e. Immunohistochemistry, 
211 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category  
Pharmaceutical Industry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statements 
concerning the 
definition of a 
“Companion 
Diagnostic” 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
but also tissue-based or genetic- or proteomic analysis. But one could also 
imagine getting this information out of the blood since liquid biopsy is such 
a cue. But you could also use nuclear medicine techniques to get 
information on the expression of the target structure. It is only a 
companion use if the RP based diagnostic can identify the therapy-relevant 
target structure or any other method. Only then one should be able to treat 
these target structures with these specific therapeutics.”  
 “I would also add, now that Artificial Intelligence, bioinformatics is taking 
over, I would also add radiological procedures that do not identify target 
structures, but where machine-learning algorithms predict the probability 
of target expression." 
 "Basically, CD is the idea of better utilization of therapeutic drugs, by using 
imaging tests to identify patients who are firstly eligible for the procedure 
and secondly responding to the procedure. So you could summarize this 
briefly.  Which in itself is a very good idea, under certain circumstances 
could improve the outcome of therapeutics, if substances are used only in 
patients where the appropriate target is available." 
 "Especially with many new oncological therapies, but also with neurological 
therapies, where one increasingly relies on individual therapies. With a CD 
you could just optimise that. Bronchial carcinoma is not just bronchial 
carcinoma, but one could individualize it with imaging." 
 "For me, the CD is medical imaging that stimulates follow-up. In a way, that 
compensation for a therapeutic drug are made if the CD test has been 
performed… So a practical example: … one would perform an FDG PET or 
PET after 2 months to show that the tumour is actually responsive." 
 "Interviewer: That means we speak on the one hand of prognostic 
biomarkers, but also of predictive biomarkers? 
Interviewee: De facto it is the same. So if I make a prognosis, then I'm 
making a prediction. " 
 “Well, there are two terms that you can connect with it. One is in-vitro 
testing, which has been in use for over 20 years now. In part, the 
immunohistochemical methods, e.g. Herceptin diagnostics.... The second 
term, which of course is close to us as a nuclear medicine physicist is in-vivo 
molecular imaging diagnostics with PET tracers. For example, before a 
planned therapy, in the sense of theranostic imaging, or for the follow-up 
of therapeutic procedures.... But a true companion diagnostic means that 
the diagnostic agent and the therapeutic agent are identical, except for the 
radioisotope.” 
 “... starting from the regulatory definition, it is actually the parallel 
development of a diagnostic procedure. But that can be very broad, that 
can be a genetic marker, a laboratory parameter or just an imaging 
biomarker... And the idea behind it that it will be included as part of the 
regulatory approval. It does not really come from the 
radiopharmaceuticals. The radiopharmaceuticals may well be CD, the 
easiest case may be FDG ... But it does not just have to be PET, it's SPECT 
too.” 
 
 "So what I think of a companion diagnostic is something that is proven with 
some certainty that certification against that is showing a therapeutic 
advantage and those are not stratified against that do not have that 
certified advantage… So it is not good enough just to say it is positive in my 
essay and get a better response, you also have to show those you are 
negative and therefore calculate the exact specificity and sensitivity of an 
assay. And that’s the high bar too often clear with an imaging readout 
simply because of logistics and large patient populations that are required… 
Right now I would say if you look at the imaging assay, right any imaging 
assay is very rare to find anything which is mature enough to call 
companion diagnostic. Unlike the ICD (In-vitro companion diagnostic field.” 
 "So to my mind a companion diagnostic is a subset of a predictive 
biomarker that specifically developed in conjunction with a therapeutic." 
 "The first thing to say is you really need to understand the difference 
between a prognostic biomarker and a predictive biomarker.  Many cases 
people failed to understand that, and two literature is full of papers even 
from people who should know much better.  Who think they have 
discovered predictive biomarker whereas in fact, they have discovered 
prognostic biomarkers.” 
 “So the idea of a prognostic or predictive biomarker … can forecast the 
clinical outcome… On the other hand, a predictive biomarker is one, and I 
think occasionally you see the term prescription biomarker, which is rarely 
used, what is a much better term.  So that forecast whether the patient 
responds to a specific treatment, the forecast of benefit or harm. A purely 
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predictive biomarker does not improve your forecast up to the patient 
outcome unless you specified the treatment." 
 "When we got our first line NSLC we again we went again for the highly 
enriched population we had shown a clear benefit, whereas [the other 
company] didn´t do that. They went for a much lower bar, they didn´t look 
for the higher population, and their NSLC was a complete failure. So 
obviously this was a big win and all of a sudden, wow Juhu the diagnostic is 
really is critically important." 
 “In the US we have these terms companion diagnostics and complementary 
diagnostics. A companion diagnostic means that you must give the 
diagnostic test done and have positive results to be able to use the drug. 
Complementary means there is a diagnostic that adds information to make 
a decision, but you don´t need to use it." 
 
 "I think that the idea of a diagnostic that selects the patients to the relevant 
therapy is er probably the relevant bit… So I think the CD should be 
probably selecting the appropriate patient for that particular therapy. 
There are quite a few people talking about CD for a therapy monitoring 
perspective, and I think that is probably a mistake in the community, 
because er from a regulatory perspective, regulators don´t really like you to 
have the same target for a therapy monitor as a therapy provider." 
 "Yeah, so I think the regulatory definition for a CD is one which again [our 
company] would tend not to support. In other words, [our company] 
doesn´t see the value of calling its product a CD. Which gives it potentially a 
more restrictive application. Clearly, the diagnostic product will have an 
indication, or requests for indications from the regulators, based on the 
data that is in the file. And if that data involves diagnostic or prognostic, as 
well as therapy, then it will essentially be registered as a drug by in its own 
right. Not as a CD. So that is an important distinction." 
 "So my definition of a CD agent would be one, so there are two levels. One 
level would be, it is actually only approved label for the therapy. So the FDA 
would approve a therapy, and on its label, on its official use, it would say: 
you can only use the therapy once you have done this test. This would be a 
completely tied and connected CD. The other, maybe more practical 
version, is the payment. So insurers would say, I am not going to pay for 
this therapy until you have done this diagnostic test that shows me the 
application. So there.. I have not seen a true FDA labelled CD, the FDA is not 
really supportive of that. But insurers always require testing, proofing, 
especially for therapy which is expensive. " 
 "Companion biomarker and complementary biomarker, but understanding 
the difference importance. Complementary biomarker provides 
information on how they threated, a tool to monitor progression, 
monitoring the success of the therapy. Companion diagnostic is a 
mandatory element in the therapy measure. So the companion is necessary 
if it is not part of the therapy." 
 
 "For me, it's a diagnostic test that's linked to therapy and helps as a 
companion in the therapeutic management ... So it may mean that, for 
example, the diagnostic tests can help determine which patients are likely 
to respond to certain therapies and therefore should receive or not receive 
the therapy. And, of course, in the course of therapy, it can also provide 
information about how successful the therapy in a patient is and what 
interventions should take place ... So that would be the high-level 
definition." 
 “Sure, the companion diagnostic in general in my view qualifies a patient 
for a certain therapy and also monitor the patient on that therapy. The 
examples are in widespread use are very kinds of tissue markers, before 
put on a cancer drug like HER2, before getting Herceptin. And many many 
examples like that even if they are blood-based or tissue-based test before 
being put on cancer chemotherapy. And because this is all about diagnostic 
imaging, there has been some general lack of companion diagnostic using 
molecular imaging as that qualifying test before being put on a drug. And 
even though we keep holding out that is potentially very interesting, we 
have some emerging areas that would probably fit the definition.” 
 
 "Among CD's, I would also see PET. It helps us to make therapy decisions on 
some lymphoma entities, in Hodgkin's, at least in clinical trials. We really 
value having PET-positive findings, which we then treat accordingly such as 
irradiation. Otherwise, my lab is doing a lot of research on biomarkers, but 
we are far from seeing this in clinical use. One lab is looking at genetic 
markers, especially gene mutation in molecular lymphoma because there is 
nothing stratified about what as a clinician has long bothered me." 
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 "For me, that's the combination of imaging and the most specific tumour 
labelling possible. That's what we want to achieve… The biggest challenge is 
that they really have to be tumour-specific, or at least tissue-specific." 
 "Yes, we have several, I would not call it a companion diagnostic, but a 
diagnostic agent that one uses in certain indications, because you cannot 
use everything for everything. But one has to know exactly which 
investigation is best. Of course, what I've been busy with lately is the PSMA 
scan." 
 "With the CD tool, I have to be able to select patients who have the 
disease. Furthermore, I have to identify in which stage the patient is... both 
with certain prognostic relevance. Er, and thirdly it would be desirable that 
I can use the diagnostic as a predictive marker, i.e. as a marker for 
treatment response." 
 
 Okay, so when you ask about the definition I mean at the moment there is 
no agreed definition, at least in Europe. Obviously there is a definition 
around the FDA providers, but in the regulations, I am sure you read it, the 
definition going forward it terms of CD is very similar, but not identical to 
the FDA definition. You are aware of the new regulation that will come into 
effect in 2022, correct? 
 "I think it’s part of the definition, it should be essential to identify the 
patients in which the drug will work. That is the main one, for oncology. Or 
where you can identify patients are particularly susceptible to certain side 
effects." 
 "I think in the future the CD will have to be, well certified. Meaning that 
there will be an assessment biomedicine if it meets the definition of a CD… 
PET RP they wouldn´t fall into the new regulation, only if they work in the 
device regulation…. But pharmaceuticals should not be affected." 
 "So a companion diagnostic, so what I know. One is the diagnostics you 
have, the choline or FDG, where you just check every now and then as a 
tumour develops. And on the basis of that one can treat again, develop or 
cancel depending on the results. And the latest thing I've heard: if there are 
antibody therapies, those antibodies are connected to a chelator with a 
nuclide and can make something visible. Of that second group, I have only 
heard something so far, no application has been on my desk so far.” 
 “God oh god. For me, a CD in the narrower sense is a diagnostic procedure, 
in the sense of a yes / no answer, which is linked to a drug via a registration 
document. So actually, CD's are just the diagnostic tests that are required 
according to the registration, which are really defined in that document. So 
it is not optional, but a must-have criterion that needs to be performed so a 
drug can be administered. After all, drugs are classically approved for a 
tumour mutation, and then it's clear that I can prove these tumour 
mutations with a biomarker. " 
 
ix. Statements concerning the topic “Benefits and Challenges associated with Companion Diagnostics 
in General” (Chapter 4.3.2, The Benefits and Challenges associated with Companion Diagnostics in 
General, page 137) 
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Benefits: 
 "Treatment would be more restrictive but more targeted." 
 "That means we need methods that predict the presence of treatment-
relevant targets with greater accuracy." 
 “…which is a very good idea in itself and could possibly improve the 
outcome of therapeutics if substances are used only in patients where 
appropriate target exists." 
 "..and if this companion biomarker really identifies patients, they really 
benefit from this treatment...“ 
 “On the other hand, it is the case that the therapeutic substances ... are 
targeted only to hit the tumour cell, i.e. targeted therapy. And if they treat 
the same 100% again, then in many cases they will get a negative result. 
The conclusion would be: the therapeutic substance is not effective. Now, if 
you identify and treat the right 30%, then they will see the therapy is highly 
effective. If the industry really wants to make tumour-specific substances, 
targeted therapy, and want to obtain approvals, then they are extremely 
interested in the CD." 
 
Challenges: 
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 "Biggest obstacle: there is no financial gain for those who offer a 
therapeutic agent." 
 "It's not a good incentive for the industrial side to implement such 
diagnostic tests in our system right now, but we academically have an 
extreme interest in it, but the industry partners are not necessarily." 
 "So the biggest challenge is certainly the availability, it needs methods that 
are available on the spot, i.e. where the therapy is performed." 
 "Er, secondly the evidence has to be proven of course ... So there are trials 
that show that it works well and others that are more critical. In Phase 3, 
there are prospective, randomised trials that show different results. So the 
evidence that these procedures and I do not mean imaging yet, but 
generally biomarker-based target identification methods, does not work 
out that way." 
 "The snag is that it sounds good, but it's often not so interesting for the 
pharmaceutical companies that are supposed to be the driving force. 
Because of course, in a nutshell, they have a commercial interested that 
their substances are broadly applied and not in selected cases." 
 “With the many different individual forms of therapy, it will not be 
explainable with a single biomarker. You might have to do different imaging 
tests to find out which factors are expressed in the patient. " 
 "The other is the situation that there can be multiple positives, positive for 
breast cancer, but still for another factor.  That would require multiple 
imaging procedures, which is certainly difficult." 
 "The other problem is the follow-up because the biomarkers that allow the 
choice of therapy is not necessarily suitable to evaluate the response of the 
therapy because it is often the case that the good old FDG PET can be used 
meaningfully again." 
 "They have to show high positive and negative predictive value! So 
Outcome.” 
 “That is clearly the financial aspect. So PET-CT imaging, as in-vivo biomarker 
/ CD is not cheap, unfortunately.” 
 “Well, from the industrial side, this also has two medals. So, if you have a 
diagnostic procedure, which could be done theoretically by the 100% of the 
patients, but you push away 70% ... then, of course, this is a loss for the 
industry.” 
 “The Nuclear Medicine Community can show in various studies how good 
FDG is or ... that is more difficult now, someone who has an approved drug 
says "okay we'll add this because we have a benefit". But there must be a 
benefit, and that must be reflected in a somewhat broader application, 
ultimately in more money.” 
 
Benefits: 
 “…if the mutation isn´t there they have no chance to responding. If the 
mutation is there, they have a good chance to respond. But there is not 
black and white with the checkpoint inhibitors. Which makes it 
complicated." 
 "When we got our first line [disease] we again we went again for the highly 
enriched population we had shown a clear benefit, whereas [the other 
company] didn´t do that. They went for a much lower bar; they didn´t look 
for the higher population and their [product] was a complete failure. So 
obviously this was a big win and all of a sudden, wow Juhu the diagnostic is 
really is critically important." 
 "…certainly yeah, there is no doubt about the evidence.” 
 "There are 4 disease areas where predictive biomarkers and companion 
diagnostics, personalised medicine, has really had an impact historically. 1. 
Cancer, 2. Infection, 3. Rare diseases and 4. Drug metabolism… And as you 
know many cancers are driven by tumour mutations, and so you can 
identify, by the right mutation, you can choose the right drug. It is less true 
that predictive biomarkers/ CDs had an effect on major diseases like 
asthma, myocardial infarct, diabetes, dementia, depression, psychosis. " 
 
Challenges: 
 “… using that method, we had a limited population that we could have the 
drug available for. Because we selected, have pre-selected, to have the 
enrichment to be able to get approval. Whereas [the other company] has 
spent the program for several years and they will be able to show that it 
worked in all the patients…. So that kind of set us back for a little bit, and 
there was a lot of... you can use imaging… oh Jesus look what we have 
done. We have anchored ourselves…” 
 “However, even if you don´t see [the target], also these patients respond. 
So it is in the interest of the dynamics between the oncologists, who want 
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to make certain that the patients have any chance to benefit from the drug 
that could help them. And the payer who are saying well wait a minute, this 
is an expensive drug, and we can´t give it to every patient, who might be... 
We have to focus on the patients who do benefit. So the way it plays out 
varies from country to country." 
 “As you know in drug development, in every hundred projects the industry 
starts, if they are lucky one becomes a medicine. So you have huge, you 
have a huge attrition. And of course, you have attrition in the diagnostic. So 
for the academics working on Etarfolatide and indeed for the company 
developing it, they got nothing out of it. Even it was a great tracer, when 
the therapeutic died the market for the diagnostic died as well. So it is a 
very unattractive place to be in.” 
 
Benefits: 
 “…if you select, for HER2 for instance, HER 2 and HER receptors you know, 
Herceptin does not work unless you got HER receptor breast cancer. So that 
is a fantastic combination of patient selection…” 
 
Challenges: 
 “I guess part of it is how broad the indication is… By the time you come out 
at the end of there, you don´t actually have a really big patient pool to sell 
to. Because you can only sell it to patients in that cancer (laughs), with that 
therapy. And there is always the risk that a different pharmaceutical 
company … finds a different therapy that is better in that cancer. Er, the 
whole linking to pharmaceuticals is really difficult from a commercial 
perspective because your market potential is quite small.” 
 “When pharma uses RPs, they can end up with a really small indication, and 
your return is even harder to get. Where a broad indication in a diagnostic 
is much better because you have many more opportunities to sell you 
scan." 
 “… [the company] doesn´t see the value of calling its product a CD, which 
gives it potentially a more restrictive application.” 
 "Pharma has recognised that biomarkers and imaging are critical in the 
disease development. 15 years ago Merck walked away to a very promising 
therapeutic play, there is no biomarker marker. Today the recognised the 
use of biomarkers in the drug development." 
 
Benefits: 
 “... the diagnostic testing partly helps to decide which patients are likely to 
respond to certain therapies and therefore should or should not get this 
therapy.” 
 “And in the course of the therapy give information on how successful the 
therapy is and which interventions should take place ... So to get 
confirmation that the therapy is effective and can be continued." 
 "I think that is a very interesting step into Theranostics that will get a lot of 
things opened up.” 
 
Challenges: 
 "The challenges of both technical and scientific nature. First, you really 
have to develop this CD so that the test itself works as a CD." 
 "But on the other hand, of course, there are the economic challenges, 
because the diagnostic test is linked to the success of the therapy." In 
general, the success chances of a diagnostic test is greater than the chance 
of success of a new drug. So the chances to launch a product on the market 
decreases for the developer of the CD. " 
 “Of course, the third challenge is the regulatory side ... obviously there is no 
way to submit the diagnostic test and therapy as a package to the BfArM, 
EMA or FDA. One has to negotiate with each authority, so there are also 
challenges." 
 "And I believe that is because the pharmaceutical companies’ don´t want a 
potential market limiting step on the way using their drug. I had some 
conversation with the imaging teams inside big pharmaceutical companies, 
which gave me that hint, not as an official policy but they believe that MI is 
used widely in their clinical trial process, but they never wanted it to be a 
mandatory step underway using their drug. Because unlike a blood test 
driven tissue test, they still looking at MI as a complex, expensive hard to 
find the thing that would limit their market for their drugs. So even if it 
could lead to a better patient population that take the drug, they view that 
as market limiting and unless the regulatory body or payer absolutely 
required it, it tried to find a way to get the drug approved without it." 
 
Benefits: 
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 “With the current therapies, we are able to control the disease in many, 
many patients. But there are approximately 20 to 25% of patients who have 
a rapidly progressive course, which die very early… We must stratify these 
patients early for other therapies, experimental therapies. We have access 
to these therapies, but we only use them when the standard therapies have 
failed. But if we could predict that the standard therapies would not work 
in the first place, we would help a lot."  
 
Challenges: 
 "Well, biomarkers have to be first established, validated so we can use 
them in clinical routine. It needs to be robust, reproducible, which also 
means harmonization and standardisation.” 
 "The biggest challenge is that they really need to be tumour-specific, or at 
least tissue-specific. Which is probably the case with PSMA (PET/CT). The 
even greater challenge, of course, is that detection should also be possible, 
especially in relapse patients, in the 1mg PSA range and below. You have to 
move the limit down, the detection limit." 
 "The interest of the clinicians is of course there, but they will wait, I think, 
for a long time. Because such a development is similar to a development of 
a drug. That costs millions, you have to say that very clearly.” 
 "To simply validate them, that's the tricky thing ... and of course the price 
for the patients or for our health care system. Very often additional 
markers like that PCR3 or PHI are partially not paid by the health insurance 
companies." 
 "And we've got a relatively large lab, and we've been trying to develop 
biomarkers. That costs money and the company, I do not name them, that 
sells [the product] ultimately gave us no money. Understandably, why 
should they sponsoring a biomarker that says, "Okay, in this case, you 
should not give this drug". They hold us back for a long time, but I knew 
from the beginning that they would not give us any money. So I would say 
the development of these biomarkers will be difficult." 
 
Challenges: 
 "So probably we need to distinguish broad categories of drugs where say 
the more traditional, even if not very clearly targeted drugs, where the 
biomarker simply means a restriction in indication. So you try to avoid to 
develop it too specifically, to target a bigger population that could be the 
industry´s interest. But I think the whole other bunch of drugs, which unless 
you are very specific and fish out what is the right population, they will 
simply not work. " 
 “But that also means that in order to be successful you must have both 
components functional. So if the drug does not work, then there is no result 
and if the test picks the wrong people, then, of course, the study fails. And 
that makes it relatively difficult.” 
 “And the second reason why there are not so many CDs, because the world 
of industry is set up differently. There were and are classic drug 
manufacturers, they were just looking after therapeutics, and on the other 
hand, there are diagnostics manufacturers, who only took care of 
diagnostics. And yes, only in the last 10 to 15 years has there been this 
realization that with molecular oncology, it is actually necessary that the 
industry there work much closer together to bring successful products to 
the market.” 
 “The difficulty, of course, is that these subgroups get smaller and smaller. 
So in tumour mutation, there are two or three mutations that cover most 
of the patients, 80% maybe 90%. For the last 20% I need a lot more tumour 
mutations, and I have to take a closer look. These are rare mutations and, 
of course, relatively small subgroups remain at the end, which is difficult to 
study and of course are not that lucrative.” 
 “So I have to do a lot of screening work, in clinical trials, until I find the 
patients.” 
 “And a third problem may be in the end in the application of these 
therapies. Sometimes it happens that the actually high-quality CD is 
replaced by a simpler test ... It cannot be that we have a great drug with 
more than 8 years of patent protection, which is really expensive and in the 
selection, you use a copied test or a test which is tinkered by the hospital 
laboratory itself. And you have a significantly worse test quality than the 
underlying, and from the regulatory agencies approved test procedure." 
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Pro: 
 "The differences are clear! A blood sample will characterize the patient as a 
whole, but imaging can accurately characterize individual regions and 
individual organs. At least with our nuclear medicine techniques, we 
visualize the whole body and we can look at individual regions. You cannot 
do that with a systemic marker, and the main goal of therapy is not to treat 
the entire organism, but to treat a certain target region.” 
 “In such a case, imaging is the more accurate biomarker method compared 
to an in-vitro assay taken from the blood. It is a bit different when we 
speak about biopsy data. Then the problem would be that the biopsies 
need to come from the right regions, but you just do not know it as well as 
you know it with imaging." 
 "Because what has been used so far are methods that rely on biopsy or 
local tissue samples, or even on primary tumour preparations. But the 
tumour pathology changes in the course of pre-treatment.” 
 “In other words, we do not have [relating to in-vitro assays] any real-time 
procedures there that can represent the biology of an entire tumour. And, 
of course, this is the strength of imaging techniques, especially biomarker-
driven imaging techniques. Because you can basically visualize and quantify 
in real time, realistic, non-invasive the entire body, so all the lesions and 
not just part of a tumour." 
 "So the big advantage (note: the imaging biomarker) is evidence of 
heterogeneity. In principle, one can prove if a patient has a large number of 
metastases and he may be positive for any biomarker, but one does not 
know where it comes from. So the localisation only succeeds with imaging, 
not with a blood test. That's basically how it is.” 
 "The second is the scale of the disaster: Alzheimer's disease has a 
biomarker for detecting amyloid pathology, but ultimately it's difficult to 
say how far pathology has progressed. You can only do that with imaging 
markers in this form." 
 "So in many cases, imaging will be superior, but I think the ideal form will 
be a combination. Cheap gatekeeper tests in the form of blood tests that 
can be easily and quickly used to screen. In case of positive findings, 
imaging should be supplemented." 
 “Of course, imaging is important in many situations: if a tumour 
disseminates in the body and extracts a substance, then ultimately an 
integral value, which is the tumour marker, really does help us a lot. It may 
be that certain clones respond to the therapeutic, but others do not, and so 
you cannot treat them specifically." 
 "In principle, you can have a patient with liver metastases, or lymph node 
metastases in the lungs and the metastases in the lungs respond to the 
therapeutic drug, but the liver metastases continue to grow. Thus [with 
imaging] you can specifically tell if you need surgery or not. " 
 "There the question is really, is the target expressed, and is it uniformly 
expressed at it is prostate cancer, where 90% will have high expression of 
PSMA. That is not the case for Somatostatin receptor. There are of course 
in-vitro biomarkers also, but you know to survey the whole body where you 
can have a mixed expression in different lesions, is quite important. If you 
have lesions that have low or no expression of you target, then the patient 
will not respond in the long run." 
 “While eventually, the cost of taking the blood and analysing the blood is 
low, but validating the marker is going to be as expensive as by imaging. So 
what the blood biomarker does not tell you… let’s say it is circulating cells 
or circulating DNA … or you just take some urine marker, you never know 
where it comes from. You never know if it is homogeneously expressed...”  
 “Yes, well, the in-vitro assays, you have to say brutally, almost exclusively 
focus on the primary tumour. So the tissue that was removed during the 
primary tumour surgery will be used, at a later time if there is a recurrence, 
to decide on the further therapy. Of course, it is often the same, but if you 
look for example at breast cancer, then you know that in about 30% of 
women, who express Herceptin receptors in a primary tumour, the status 
will change. 
 “In-vivo imaging shows, at the time of therapy decision, what the patient's 
actual receptor status or antigen status is.” 
 “… the value of in-vivo companion diagnostic is certainly much higher than 
in-vitro diagnostics. But of course, it is considerably more expensive.”  
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 “So the advantage is the picture, and in the picture, I have more 
information than in a generalized blood biomarker. 
 “An important topic is certainly oncology. When I do a response evaluation, 
I often have metastatic patients and see if he may respond to individual 
metastases or not. And not just a general response, that's certainly the 
general advantage.” 
 
Neutral: 
 "It's not always just in-vitro biomarkers, but it does not matter which 
biomarker, the biomarkers as such are still under-used." 
 
Con: 
 "You know Imaging people usually are quite limited in their understanding 
of medicine. They are tunnel blinded … Because they believe that you will 
be able to have, for any drug, a biomarker, an imaging biomarker. That is of 
course total nonsense. So you have to focus on the stuff that is really 
needed." 
 “…for instance if you have an intermediate endpoint biomarker, so you 
want to know if the patient responds to the prostate cancer, there I don´t 
think I need imaging. There I just want to have a PSA. Take blood and show 
me that this PSA is going down, I am quite happy. If the PSA is going up, all 
the stuff does not work. Imaging people tend to think that everything can 
be solved by imaging that is of course not true." 
 “The main disadvantage is the co ... that it is much more laborious and 
comes with costs ... I would not develop a PET biomarker for a cold 
medicine. Because if a snuff preparation costs 20 €, then I cannot make a 
PET scan for 500 €. But if that is a new generation immunotherapeutic for € 
100,000, then perhaps a PET is indexed.” 
 
Pros: 
 "But the motivation for us to develop it is that we want to see how that 
changes in time overtreatment … one of the reasons you have a higher 
response rate with chemotherapy and checkpoint inhibitors [product name 
is that in those patients the chemotherapy killing of cells, you got all kind of 
DNA, and the immune systems is activated trying to clean things up. Then 
you get the checkpoint inhibitor in there, and it can really just finish it off. 
So we want to look at that kind of research questions and see to 
understand what changes... we are also trying to develop tracers for CD8 
and other aspects of the immune system. To really use it as a research 
tool." 
 “So when you do IHC (immunohistochemistry) you have a limited sample of 
a tumour... so what the nice things about imaging are, you cannot look at 
just one tumour you cannot just look of parts of a tumour, you can look a 
whole tumour and at more tumours throughout the body. And the hope is 
that this would be more valuable, and it would do a better job in predicting 
patients response, but this is true or not time will tell." 
 “Now, imaging has some advantages: you can look at all the lesions, your 
metastatic lesions. Some have mutations some don´t, some … there are a 
lot of academic reasons why imaging might be nice to have.” 
 
Neutral: 
 "The primary reason we developed this imaging agent was as a research 
tool." 
 "There are people who are interested, not [company name]. But there are 
other companies that are interested in developing immune-oncology 
tracers…” 
 Interviewer: "So from your mind and your company, do they build on 
imaging as a CD or would they prefer a simple blood-test also from 
regulatory and reimbursement perspective? 
Interviewee: I think to have it before an imaging assay, yes…. So I think yes 
if we look at some companion diagnostic phase today I would say 99% is 
probably some receptor status IVCD (in-vitro companion diagnostic). We 
don´t have many good examples of an imaging assay that is a companion 
diagnostics." 
 
Cons: 
 "There are examples, like if you look at the Oncosite test. It is a genetic 
panel test, right. In genetic panel tests are increasingly going in that same 
direction, imaging should be no different except that I think imaging has a 
higher challenge." 
 "Imaging has the entire business of radiopharmaceuticals and its maturity 
in the clinics. Right, if something that is in my view more relevant in terms 
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of therapeutic diagnostics. So something which is established, like a 
perfusion scan with technetium, those I can still see as clinical criteria for 
treatment and maybe reference criteria, but I don´t think there is any 
example outside of oncology that is using it as a CD." 
 "In oncology, imaging has a different burden, imaging is more like a clinical 
workup scenario… You do use imaging a lot, readout and protocol 
itself….they are not really a stratification or something in diagnostic use." 
 “The other side, one of the lessons I learned working on the IHC 
diagnostics... Firstly I see it is much more of an issue in Europe, where there 
is a lot more cost consciousness. There are hospitals given a certain 
amount of resources to take care of the patients, and that’s it. In the US 
there is no control, the only control is that the label says you cannot 
administer this if you don´t have the test. So you get the test done, the 
same thing can happen in Germany. The German government was tough 
for us and with our organisation, they are going to say "yeah ok, so you 
need to have that test done, but 125 Dollars is too much. We don´t have 
the money in our system to pay 125 Dollars for this test. So, we need to get 
that test for 45 Dollars." 
 “And so tumour mutations has been a very productive area for cancer 
research, and in that area, you have to accept that imaging has a very 
difficult battle to fight. Because in many cases you can see these mutations 
in circulating free DNA. Ham… if the mutation is there, you can begin to 
prescribe the drug.” 
 “But really for tumour mutations (imaging) has a very hard struggle. It is 
also the truth, the case that the imaging tools we have are not as precise as 
the free circulating DNA tools. In the MICAD [Molecular Imaging and 
Contrast Agent Database] database there are hundreds of eGFR tracers, 
but remember there are many many mutations, such as mutations which 
yet are discovered. And ideally, you would need to profile every molecular 
imaging tracers against all mutations, known and unknown. Which is 
almost an impossible thing to do.” 
 “And they won't be clean; different tracers will have different binding to 
different mutations. Whereas you just look on the free circulating DNA, you 
have the mutations status straight away.” 
 “So I think, what I am going to say is far from strong. But you could argue 
that academics are wasting their time with yet another eGFR tracer. I think, 
what I would say to the academic community is that cancer research moves 
on. We will come to an end... We will get good drugs for all of the tumour 
mutations or the important ones. The good drugs will go generic, they 
already are. We will develop drugs for 2nd and 3rd mutations, minor 
mutations, but eventually, we will come to that stage where that space is 
well covered.” 
 “In order to get the regulatory dossier for registration, you need to have 
your patient’s segmentation done right from the beginning of phase II or 
even phase I in oncology. And that is actually quite easy to do if you have a 
blood test. But it is very very difficult to do it with an imaging test. To get 
an imaging test logged in before you have seen any patient. That is the 
challenge." 
 “When the drug company is developing the drug it's developing it for a 
global market. So when [company name] is developing they're not just 
thinking of, certainly they think if you can sell it in the United States and 
EU, but they are also thinking about China, Philippines, Brazil, Indonesia. 
These are important markets! Places like China and the BRIC have a 
growing middle-class, they have western diseases and certainly want to 
have access to western medicines, and they can't afford it. If you going to 
have Diagnostic in your label you want to make sure it is available in every 
hospital in China, Philippines, Brazil otherwise you would not sell this 
drug.” 
 
Pros: 
 “There are some companies convinced. I don´t know if you know 
[Diagnostic RP Company]. [Diagnostic RP Company] developed a CD for 
patient selection for ovarian cancer. That got the attention of [Big pharma 
company], and I worked with [Diagnostic RP Company] during having 
clinical studies in Europe. And [Big Pharma Company] acquired the license 
for 800 million, which was a big deal a couple of years ago." 
 "There are huge opportunities still in cardiology, I tend to think that 
cardiology and neurology are better." 
 "Pharma has recognised that biomarkers and imaging are critical in the 
disease development… Today they recognised the use of biomarkers in the 
drug development, using imaging biomarker as inclusion criteria. Pharma 
companies are clearly coming to us with the intention of appropriate 
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patient selection. They are very interested in researching biomarkers, in 
the development point of view." 
 
Cons: 
 “…I think the problem that pharma companies always had with PET is the 
availability of the product. And so if you were to compare testing the 
Cerebrospinal fluid, with PET then effectively anyone, who can do a lumbar 
puncture, can get cerebrospinal fluid… If you used CFS testing then maybe 
you therapy get access in 90% of the available patients, if you got a PET/CT 
scan in front of it then you go to reduce the access of your therapy to 
patients." 
 "So pharma has got to that point …I don´t think that they are looking at 
nuclear medicine and RPs as an actual choice. And I think that ties into that 
availability, I think that they are worried that they could predict gate in 
front of their therapy. That meant it would slow the adoption of the 
therapy in the long run." 
 “…And not everyone thinks that amyloid imaging is that relevant, there are 
some people who do, but generally, the regulators don´t believe it.” 
 
Pros: 
  “In oncology, with secondary diseases such as metastases, the 
involvement of lymph nodes, and so forth, you can see that imaging can 
provide more information than a PSA test ... Hopefully, imaging can deliver 
much more information such as localisation or spreading of the disease. 
You really have to find the sweet spot of molecular imaging. Show that the 
test as such also makes sense and provides the information that 
contributes to the management of the patients.” 
 
Neutral: 
 "Well, I would say, one thing we have not discussed so much yet, which is 
very important to me. What are the disrupters, what is threatening 
molecular imaging? ... As you can see on the amyloid side, there is already 
the CSF test, and there is intensive research on blood-based tests.  And the 
disruptive innovation for molecular imaging is if a test exists which is much 
simpler and has the same amount of information. In the end, the question 
arises: "Why do I have to image?" 
 “Basically, it's not about living on the island of imaging, but you have to see 
what's happening around you and what other tests are being developed." 
 
Cons: 
 "Well, in oncology, where imaging is really needed to plan the intervention, 
the surgeries, you need the imaging information. So in oncology, you can 
see that imaging has its value. But I'm not so sure about amyloid plaques or 
Tau ...” 
 “However, if the CSF test, and the future blood tests, can provide 
information that is equivalent to the information of the imaging test, then I 
can well imagine that at least the use of imaging will decrease and you will 
first perform a cheap blood test. And for those who need an additional 
imaging test, for whatever reason, the imaging test will be performed in 
certain groups." 
 “Now one of the challenges is: should we calculate patient-specific 
dosimetry in each case? That could be very complex; this is what I 
mentioned at the beginning of the call where pharma companies did not 
want to have a potentially complicated step like a PET image before using 
their drug!  I think there is some disincentive to do patient-specific 
dosimetry for all these new emerging RPs because it adds complexity and 
more procedure steps.” 
 “Because unlike a blood test driven tissue test they (pharmaceutical 
industry) still looking at MI (Molecular Imaging) as a complex, expensive, 
hard to find the thing that would limit their market for their drugs.” 
 “The added value of imaging must be established in comparison to the 
blood test, the CSF test. Otherwise, it's just an even more expensive test. 
And we also asked ourselves how to differentiate the PET imaging test from 
the CSF test. And imaging allows us to do staging by region. A one-value 
test per patient may not work as well as an imaging test.” 
 
Pros: 
 "Previously, we wondered if we have local recurrence or distant 
metastases. We assumed it's more likely to have a local recurrence if the 
PSA rises slowly or just rises after 2, 3 years. If the value increases faster, it 
is a systemic recurrence. It was not very well-grounded. In individual cases, 
that helped little. People have always been irradiated, and still, the PSA 
221 
 
vivo imaging 
biomarkers vs in-
vitro assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
value has continued to increase. Then they got a systemic therapy. This was 
not a targeted treatment, but shooting into the forest with a lot (“Mit viel 
in den Wald schießen”). " 
 “The diagnosis of high-risk prostate cancer has improved because a much 
more accurate clinical diagnosis of the spread can be made. So if someone 
has diagnosed a highly aggressive prostate cancer by punch biopsy, then 
we now perform a PSMA PET / CT.” 
 “We have a much better chance of diagnosing lymph node metastases. This 
means that the field of lymphonodectomy at surgery, or the field of lymph 
node irradiation during initial radiotherapy, can be modified individually.” 
 “Imaging has created diagnostic added value! To what extent this affects 
the survival of the patient is too early to say, there is no data available yet." 
 “But we're already fishing out more patients with a low PSA score, who 
show either local recurrence or lymph node recurrence or distant 
metastasis. This is particularly important because it has been shown that at 
a lower PSA level, the secondary irradiation works better. The clinical 
advantage for the patient is a more targeted therapy than in the past.” 
 
Neutral: 
 “And I do not think that one will replace the other. I believe the added 
value in the reasonable combination of both.” 
 What we are currently doing with lymph node biopsies is to define the 
targeted molecular fingerprint of a tumour before initiating therapy. And 
then to make the best possible prediction about the further clinical course. 
We use LB (liquid biopsy) to better understand therapeutic response and 
functional evolution because a tumour is a dynamic tissue. But especially in 
this area, imaging plays an important role. Especially in the case of 
Hodgkin, not so much in molecular lymphoma. But in other aggressive 
lymphoma entities, the American guidelines request a PET. So one thing 
does not exclude the other ... Functional imaging is actually used to detect 
the clinical course at an early stage. " 
 "No, whether that's liquid biopsy or something else, actually, I do not really 
care. Because we've been looking for a better marker than the PSA value 
for years. PSA is not a good marker in primary diagnosis, but it's the best 
that we have, and one we have learned to deal with." 
 “And I think there will be a combination. I do not think that one will replace 
the other. But a combination of both will be able to represent the best 
possible status of the patient." 
 
Cons: 
 “The PSMA PET / CT test was primarily praised, many studies have been 
done with insane sensitivities and specificities. That very well may be, but 
we have checked surgically if the cells illuminating are really a tumour. And 
thus the sensitivity of the PSMA scan drops under 60%... " 
 “The big cue of the future is Liquid Biopsy. That one gets the molecular 
information about a tumour by markers in the blood, be it circulating 
tumour cells, exosomes or something similar. You get a prognostic or 
predictive marker.” 
 
xi. Statements regarding the topic “Mandatory Prescription of Biomarkers by Regulatory Authorities” 
(Chapter 4.3.4, Should Biomarkers Be Mandatory Prescribed by Regulatory Authorities? page 149) 
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 "I think that would be ... so it would be very good, it would be desirable. 
But if they manage to include the appropriate regulations in the licensing 
mechanisms? I do not think that will happen fast." 
 "Let's put it this way, in order to first initiate such a mechanism politically, 
there are very very expensive therapies needed, which lead to such great 
costs that they can no longer be controlled. And let's face it, then the 
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regulatory authorities need to see the reason that better diagnostic tests 
could reduce costs accordingly. " 
 "... the way we really have to go! Whether it's easy to walk, I vaguely doubt 
it. But that's the only true way." 
 "Yes, they will be demanded, definitely. It's just the question which tests 
required.  Of course, the pressure and commitment of the industry will be 
crucial in terms of which detection methods and biomarkers are required. 
But that will come as surely as that Amen in the church! It is already 
happening now. " 
 "I do not know if it will be prescribed, but it will all be a matter of cost. 
Saving money should be more a reason to convince the authorities. Rather 
than the pharmaceutical companies, which would want the drugs to be 
used broadly." 
 "We might even have allies in health care if they would understand this. 
But one does not always have the impression…” 
 "Yes, I think everything else makes no sense in my view. Whether the 
authorities think wisely is another matter. (Laughs)” 
 “So, you would have to do a precise cost analysis. We know the cost 
analysis. For example, when you look at bronchial carcinoma in PET, you 
just know that PET does not save lives, but it saves money. Because 
between 15-20% of patients receive an upstaging to stage N3, which 
prevents them from having surgery. One would have to do an additional 
PET in 10 patients, but in 2 or 1.5 patients you spare surgery! And a neat 
cost analysis would show that these 10 PETs are actually well-used money." 
 "I think there should be CDs; I think there should be biomarkers to select 
patients appropriately. Yeah absolutely, because there are two ways in 
oncology. There is one way that you try something and treat, and you got 
six cycles of chemotherapy, and in the end, you may know if it worked or 
not. To me that’s unethical, especially after one or two cycles you could do 
a simple FDG glucose metabolic imaging and see if the treatment works or 
doesn´t… that would be my first biomarker requirement. Is your glucose 
metabolism going down? If not, stop the treatment. But we have not 
reached that point." 
 “Yes, I think that will happen more and more. Because our health care 
system is already groaning enormously under the current costs. And in the 
future, the new therapeutics will certainly not be cheaper but rather more 
expensive. If you compare the costs of new therapies such as KART cells, 
ranging from € 200,000 to € 300,000 or more per treatment cycle, and 
costs of therapeutic agents such as 5-fluorazil, which have been developed 
in the '90s and' 80s and have total lifetime costs of less than 100 D-Mark or 
Euro per patient have, than you just see the gigantic difference.” 
 “And all new substances, whether they are antibodies or kinase inhibitors 
or whatever, are all very expensive. The compulsion to select just the right 
patient clientele, which also really benefits from the therapy, the coercion 
will increase extremely. In the future, you will not be able to afford to treat 
patients, do a CT scan or MRI after three months, and then say, "Well that 
did not work". But what we really need is this theranostic approach, which 
means that we perform an in-vivo imaging scan just before the therapy and 
prove "the antigen, our target structure that we want to achieve via 
therapy, is available". And thus the patient is a suitable candidate for the 
relatively expensive therapy. So the necessity will definitely increase.” 
 
 "I don´t think it going to be mandatory for every drug; it’s going to depend 
from drug to drug, indication by indication." 
 "What benefit does the diagnostic have? …If you can show in all common 
population, right, without a diagnostic that the benefit to the patients is 
substantially more, without the diagnostic, the existing therapy, right, so if 
you can improve the outcome significantly, they will approve the drug. 
Certainly, outside the US, they approve the drug, but the payers are not 
going to pay for it. So I think the way the diagnostics come in, the primary 
driver for that is there are two drugs. The one is "do you need to select that 
population to show a significant benefit", right, that´s the one. And the 
second one is "if you don´t have the diagnostic to show a significant 
benefit, is that given the costs of the drug, is that significant benefit enough 
to not have to use a diagnostic".” 
 "And I think outside of the US; generally if there is a diagnostic that can 
help to make that decision, the payers are going to be pushed to use it." 
 "Er, I think personally think over time.. the need to really find out which 
patient gets the right drug will become more and more important. Right. So 
whether it is the nuclear authority who asks for it or the spheres, the 
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insurance companies ask for it. It is still an open question in my view. … if it 
is available, some people can set that up. It is probably useful.” 
 "Interviewer: Will they (regulatory authorities) demand a CD maybe an 
imaging CD for like very expensive therapeutic drugs?: 
Interviewee: So yeah, very short: it could become important, it does not say 
it is right now, but it could become important either by the regulatory 
agency or by the sphere (e.g. insurance companies). And the sphere could 
be a big driver/ player here.  
 "Well, the regulators are not concerned about the cost of the drug. That is a 
different question for the healthcare systems.”  
 “So I think regulatory authorities are very interested in stratifying patients 
so you identify as many as possible who benefit and as few as possible who 
will have harm. … You could stratify patients with purely clinical 
observation, stratify them on the basis of standardised biomarkers you 
have in any lab: PSA, lung functional. Or you could stratify them on the 
basis of brand newly developed biomarker which is approved at the same 
time, in other words, a Companion diagnostic. But don't think the 
regulatory authorities care how you do it, all they care about it is whether 
you maximise the number of patients who benefit and minimize the 
number who have harm.  
 “The payers have a similar view because they want to maximise the cost-
benefit in terms of patients who benefit and minimize the cost of harm." 
 "No (MI as a CD), as far as the costs are concerned of molecular imaging 
tracers in cancer research. The 3 things you need to look at 1st, the assay 
needs to be locked down before you start and that is extremely difficult; 
2nd, if you are competing with a 50$ blood test that could be done in a lab it 
is hopeless, and 3rd, drug companies develop drugs for global markets, and 
so the imaging also needs to be available in that global market. And that 
are really difficult problems, the academics often miss." 
 
 "But I personally think we are always talking about investing a lot of money. 
In Germany you have huge difficulties getting PET reimbursed, that's a 
nuisance. Our sequencing analyses are not cheap right now, but they are 
vanishing compared to the cost of experimental therapy. I am firmly 
convinced that if you show the clinical benefits ... that these measures are 
required by the authorities. As it is already the case with acute leukaemia, 
where a detailed molecular diagnosis is carried out. This is also required 
according to the WHO classification, and there is no reason that this should 
be different in my area of research. This will almost certainly happen with 
lymphoma." 
 "So it's not going to happen that fast in Germany.  Or there's not even such 
a thing in Germany that something is required for any kind of treatment. 
But there will be guidelines and possibly it will find an entry into clinical 
practice via guidelines. It assumes, of course, that the method is widely 
available and that is not the case with the Ga-PSMA." 
 "If there were biomarkers that would be fine. I can imagine that it will be 
required." 
 "That's a good question. I can imagine, I can just imagine it. Right now, of 
course, it's fictional, because there's no marker that's so good that it could 
justify that. But I could imagine that the health insurances say: “yes only 
this and this patient we will cover costs”. It also depends a little bit on the 
fact that biomarkers driven clinical trials need to be performed… And that 
something is prescribed by law is absolutely conceivable! The question is, of 
course, this is contrary to the interests of the pharmaceutical industry. That 
will be interesting to see. Of course, they want everyone to get it." 
 “Interviewer: Right, it reduces the market a little bit in this area. 
Interviewee: Exactly, exactly and because they have to conduct the 
studies.... So that's interesting. But if there are any ground-breaking results, 
then I could imagine that (it will be required). Not in the foreseeable future, 
but in principle." 
 
 Well, I mean such would not be the right concept. But if a CD would be 
required to identify a patient population that benefits from the drug in 
some way, yes. Because if you need a test to identify the right patient 
population for your drug, I think in an indirect way you could, you know 
someone would use the word mandatory, but you know the company 
would need to show the evidence and that is sort of in an indirect way. 
They would need to have the evidence to support that.”  
 “…the likely scenario is that they will be mentioning the biomarker, or 
whatever marker that the test or a test a CD is supposed to identify, and 
then there will be a description of what test has been used. Rather 
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 performance characteristics of the test it has been used for example in the 
clinical trial." 
 "No, no under no circumstances, under any circumstances ... If the 
company says they would need it in combination, we will look at it. And if 
the company says they will go without it, then we will also look at it." 
 “Yes, I think that's very real. This is a situation where a positive study shows 
that a drug helps in marker-positive patients. And the approval would say 
that it can be used in these marker-positive patients. Now the Joint Federal 
Committee (GBA) is facing the decision, what to do? So you have to join this 
dichotomy in marker -positive and marker negative. The alternative either 
would be that you do not reimburse the drug, which would be a disaster! 
Because the drug also has a benefit. And vice versa, the other alternative 
would be that the GBA releases the drug for all patients, regardless of 
marker status. This would also be a disaster because that is a charter for 
non- complying use of approved drugs. So that does not work either, so 
there is no way around it…” 
 
xii. Statements regarding the topic “Benefits and Purpose of PPPs” (Chapter 4.3.4, Should Biomarkers 
Be Mandatory Prescribed by Regulatory Authorities?, page 149) 
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 “In principle, I think that makes very much sense. In Germany, this has 
often failed due to the extremely strict regulatory framework. It is not 
simply a PPP to the mutual benefit; it should be a win-win situation for 
both. From my experience, putting this on a solid legal basis so it can be a 
success is the biggest problem. Because there is so much bureaucracy 
associated with it, it also looks daunting. I think that needs to be greatly 
simplified to be successful. " 
 "The industry partner wins because he gets better diagnostic tests, or tests 
in general, for his therapy and the area of application. And on the other 
side, the academic partner wins because he has a better sense of where, in 
the future, the things he or she is dealing with scientifically, could have a 
clinical relevance on a broader spectrum." 
 "So the value is tremendously high, PPP is basically what drives the bulk of 
the research. The otherwise publicly funded research, so by DFG or EWIF, 
consists of 90% mechanistic research, which is also important, but has 
nothing to do with the whole issue of implementation… PPP research is 
exactly what drives the field, which we are extremely interested in." 
 "In the RP field, we are fortunate enough to find medium-sized companies 
that are very active, increasingly active. Because big pharma jumps in and 
buys up such companies. So I expect a lot from this financing branch for 
the future. Also associated with the hope that one is able to set up 
multicentre trials or something to generate evidence.” 
 “I heard about it, but I cannot rate you because I do not know the details. 
(Interviewer explained PPPs on the basis of the IMI initiative, and maybe 
the interviewee thought to comment on this specific project)" 
 "I think government agencies are not well suited to invest. The reason is 
that then the whole story starts, what is the payback? That is something 
even the NIH never tried. Because the NIHs provides grants for all kind of 
stuff, so then you could get IP which was in part funded by taxpayers. So, 
therefore, money should go back to the NIH also to the FED. That has never 
been done, because then it gets so complicated. That you cannot ask the 
Americans to do that. The American philosophy is more we support you, 
you make money and then taxpayer revenue comes in anyway. " 
 "Maybe something that works in Europe, it would be strongly politically by 
most, at least by the current crazy administration. But I think it would not 
score very well on either Democrats or Republicans, because you can 
knock the American way doing business.  
 "Yes, I think they are extremely useful. Er, there are many more 
approaches possible, not so much in Germany. In the United States more 
often, where they are trying to create a PPP between industry and certain 
university research institutions or even public research institutions. So I 
think that makes extraordinary sense.” 
 “Yes, in principle, this is definitely an instrument that does no harm. Er, but 
like everything in life, there are some advantages and disadvantages. 
Basically, there are certain divergent interests between the industry and 
the public sector. The researcher wants to publish, of course, he wants to 
become rich, while the industry wants to get rich, or at least does not want 
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to become poor. But yes, it can work, and it is safe (pause; take a 
breather), it is certainly a path leading to the goal, but not the only one.” 
 “There are other examples, where this was purely driven by academic, and 
only at the very end someone has put it on a commercial track... The IMI is 
something special, which always had the constraint ... an instrument where 
the industry forces the others what to do… The EU has initiatives where it 
promotes cooperation with companies, where companies can join, but the 
academic side is stronger. These is normally areas where the industry is not 
interested. There are federal instruments that provide incentives to 
participate. For example, we participate there.” 
 
 “No! That would be a PPP; we do not have that. What we do is we 
collaborate in research collaborations with other departments that 
develop therapeutics and then have them patented. And there we are 
trying to test the effectiveness of these substances at a preclinical level, 
just as early as possible. The diagnostic tests do not always have to be new, 
that could also be an established test which just needs to be brought 
together with the new therapy to show that it can help to predict the 
effectiveness of this therapy, or even to judge later when you perform it." 
 “The bulk of our third-party funding is exactly that. We also have large 
institutes, such as the Ludwig-Boltzmann Institute where there is [amount] 
for four years and so on. Those are all PPP or so FFG, K1 projects or 
something, or Christian Doppler laboratory, these are all extremely well-
sponsored projects in Austria… I also have a lot of board work, and for us, 
the political component is extremely important to gain the interest of the 
industry in doing such things." 
 “Yes, we do that ... we were once part of a study where a companion 
diagnostic was evaluated, but then, unfortunately, it failed (“ging in die 
Hose”). That was not necessarily a success story.” 
 “So there are companies who tried to do that... I don´t see this, maybe 
there is something, like contracting manufacturing. I find it; I hate it 
because it is so complicated and it takes so long. And if you think about it, 
for every drug you have to come up with an imaging biomarker, the drug is 
already there, and then you have to come up with a biomarker. You will 
never catch up. That’s why I think; the mechanism is different. It comes 
from a clinical need and then it can be a probe that happens and then by 
coincidence the probe also potentially gets your insight about the drug 
target. And you start with a drug that would make sense to me. So the 
other way round." 
 “I cannot think of anything.” 
 
 "It varies from company to company, but I could not say that everything is 
good or bad ... It depends a lot on the companies because we have 
partners from the technology industry who do not have that much money. 
That's a whole different order of magnitude, so you cannot expect Siemens 
Healthcare to be able to fund big clinical trials. They do not have budgets 
for those things. They are trying to support us, but not in a huge way. Also 
because we in Germany are no longer the largest market.” 
 "As far as the pharmaceutical companies are concerned, we have the 
problem, in some cases that the pharmaceutical companies do not realize 
that they need to talk to the nuclear medicine doctors.  
 “Yes, of course. Yes, there are quite a number of companies interested in, 
for example, labelling their cold products in order to achieve better patient 
selection for the therapy. Or also, what I already said at the beginning, 
therapy response, therapy control. How to dose the substance, so many 
questions of pharmacokinetics, pharmacodynamics, et cetera.” 
 
 "All do, all the companies can do that, and all the companies do that. I 
think the biggest benefit of PPP or any partnerships is that putting the 
resources together and focusing on issues that are ... that no company can 
solve. " 
 "No matter what the context, the main value of that is, it allows us to 
address issues that are important for the field as a whole, but none of us 
has the resources to do ourselves. Of each of us is trying to do it ourselves, 
it is completely inefficient. And there no competitive advantage to doing 
that. So that is the biggest value: bringing all these people together, 
focusing on issues of common problems that cross the border to move the 
field forward to give us the tools we need to." 
 "[Company name] labs has about 10.000 to 14.000 people, something like 
that….Most of that in clinical development and regulatory, and all that sort 
of stuff. …most of that expertise you are pointing out is the critical piece 
we need for drug development, drug discovery and drug development. And 
226 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
we are never going to have the expertise of the academic world. So 
absolutely to be able to tap into the cutting edge expertise which is out 
there in the academic world is extremely valuable in the PPP. " 
 "We don´t have all the expertise internally, so we need to be able to 
partner as a company... Partnerships are absolutely critical. You cannot do 
anything without them. That is not something which is unique to PPP. You 
don´t need PPP for that, that is my point. 
 "The kind of things that can be much more difficult is, the (break) they can 
work out, and there are examples where they do work out, both in the US 
and Europe. But when there are large groups of companies and academics 
working together in these PPP (IMI in Europe, FNIH in the US). Those things 
can work out really well, and those works can also work out that you don´t 
get much out of it at all. And I think in the end what determines how well it 
works, how well the academic and private partners their vision is aligned in 
the important things that have to be done. So it is kind of the same things 
with the smaller ones, but the more cooks you have, the more complex 
things get." 
 "So I would say we value this very highly. We are very very open to this 
particular concept of open innovation. We have certainly worked with a 
number of PP consortia, with IMI in Europe other consortia in the USA as 
well. And it caused very pharmaceutical areas like liver, brain, number of 
things we are actually sponsoring. Our time, our resources to really get into 
the consortia and work with them extensively. "" 
 "But there are many many examples Novartis is working with PCs (public 
consortia) particularly in neuro. So we don´t think we have all the answers 
and we are working with all the external partners to integrate science as 
best as we can really. And not just the academics in those consortia, of 
course, other pharmaceutical colleagues of us from other industries, from 
other companies. Short answer: We rate this very highly." 
 "I co-lead two IMI projects… so this is an area I'm very interested in, and I 
think there are a lot of misconceptions, mistakes in this area even from 
people who know a lot better.” 
 "But now coming on to PPP. The first thing I should say, that IMI is an 
experiment. It is a 5 billion Euro experiment; it is not guaranteed to work. 
Historically the drug industry has been very bad a PPP. If you look at other 
industries: defence, transportation, agriculture. A lot of the R&D risk is 
shared by the public and private sector. When even in the USA, the 
Pentagon carries a lot of R&D risk for the defence. In the EU we are very 
used to the idea that agriculture works in PPP. For historical reasons, the 
drug industry is very happy to carry the entire risk of R&D on its own. And 
then get the entire benefit to exclusivity…in comparison to other industries 
that is a very unusual model. So the idea of IMI is partially based on that 
the exclusive model that the pharmaceutical industry historically has had 
might not work forever…So the idea is to try to find a way for the public 
and private sector to work together. This is an experiment, as you know 
there are a 100 different projects running under IMI. And to be honest, 
some will be more successful than others.  
 “There are huge cultural challenges in working together between industry 
and academia. But the idea is to produce tools that everybody can use. So 
it might be the example that there is a role for generic predictive 
biomarkers, which could support a number of different drugs. The project I 
just started, TRISTAN, is developing imaging tools, which be used to predict 
not drug efficacy, but drug harm. And those, as you can imagine, are many 
different classes of drugs can cause the same type of harm. We are 
focusing on a number of different areas of harm. One of which is drug-
induced lung disease. Now there are over 300 drugs which cause that 
harmful effect, so potential imaging biomarkers could sweep a wide range 
of drug programs. And there will be difficult to protect IP on, so the 
imaging companies won´t develop them. Drug companies’ won´t develop 
them, just for one drug. So this seems to be an ideal place for PPP." 
 "So what we are currently thinking is, that we should develop the tools and 
then we would expect small business to be commercial it on a non-
exclusive basis as services." 
 "Different IMI projects there are different reasons for companies to be 
involved… In other areas companies are working on patient stratification, 
so they have a better sub setting of patients, and that will support all of 
their drug development. Sometimes they are developing better clinical 
assessment tools, again for more precise clinical trials. In other cases, they 
are developing better assays for toxicology…There are many reasons, why 
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drug companies are engaged in IMI, which has nothing to do with imaging 
at all. " 
 
 "It really comes down to the common interest. We are partnering with 
academics who are focused on questions and developing things which are 
relevant to the things we need to do. And we are able to come up with an 
agreement, this is a specific thing that needs to be done, and there is the 
focused on it. People actually deliver what is needed, that works out pretty 
well." 
 "There are things we appreciate we cannot do alone. Large Datasets… tools 
and devices we are not going to invent, but maybe someone else is going 
to invent, and we have to use them. That are those things that work well. 
What doesn´t work: Maybe the ability to build consensus. What we want 
to do exactly, across a number of different layers. It is often a difficult thing 
to achieve. By design, because we all are doing somehow different things… 
Being clearer about the valuables, and a consensus agreed faster. Because 
some of these taking four, five, six years.” 
 "The kind of things that can be much more difficult is, the (break) they can 
work out, and there are examples where they do work out, both in the US 
and Europe. But when there are large groups of companies and academics 
working together in these PPP (IMI in Europe, FNIH in the US). Those things 
can work out really well, and those works can also work out that you don´t 
get much out of it at all. And I think in the end what determines how well it 
works, how well the academic and private partners their vision is aligned in 
the important things that have to be done. So it is kind of the same things 
with the smaller ones, but the more cooks you have, the more complex 
things get." 
 "My experience with [company name]: we put a lot of investment into 
academia, to develop new tools for us… We funded a number of academic 
translational projects. A few postdocs here, a few postdocs there. Clinical, 
methodological trial there and that was useful to us, and it helped us in the 
development of compounds like [product]. But when I look back at that, I 
realize that all of our competitors like [company name] and [company 
name] where funding similar methodological projects with all the 
academics. And it would have been much better, rather than... say if 
[company name] spend 1 million dollars on some technology development 
and [company name] was, and [company name] was, the IMI approach 
would have been much better. If 10 companies put in 1 million dollars and 
then IMI matches that with another... 10 million dollars, rather than having 
a 1 million dollar project you have a 20 million project which would really 
give you much more robust assays… And the big advantage for the drug 
companies in there is, that the drug companies are in the driving seat and 
they can say very strongly “we want you to develop a tool that looks like 
this because if you develop something like this, it would be very useful to 
us”. And not just a tool, which makes a nice paper in Nature or something 
like that. The literature is full of tools that have been developed, published, 
and then the academics move on, and they never cross that translational 
gaps. So coming back to the Roadmap paper: the job of the drug 
companies in the IMI project is to kick that academic work across the 
translational gaps. That does make sense." 
 
 "For me the important thing of academic research or PPP, the important 
thing is that they are doing clinical trials in a manner that is recognised by 
regulatory bodies. If this means that they do their studies in a manner that 
is more likely to get data you can use for regulatory approval, then it would 
be a good thing." 
 "Hm, that is difficult. I felt that I don´t have enough experience to answer 
that, unfortunately. I haven´t been involved. My answer would be that 
they have not been particularly successful. But I wouldn´t high trust on that 
answer because I have not been close enough involved. But I don´t believe 
there weren´t any big successes." 
 "I think there is a very strong role for academia. I feel that there is, and 
there will always be a very strong load for academia. And because 
especially the RP companies rely very heavily on people in the university. 
They have the expertise, and I think that will continue without a doubt. 
Obviously, big pharma companies have a large in-house, and they have 
large organisations, but there will always be a mixture of a private 
company working with large academic in Europe.” 
 "I am not that familiar with them. I am not aware they do it in the PET 
business. Maybe in therapy and drugs, but not in the PET business. The 
FDA is not involved. The last time the FDA got involved was with the Mayo 
clinic filed for an application for approval for Choline for biochemically 
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recurrent prostate cancer and the FDA sort of helped them with their 
filling, but that was a unique situation that the Mayo Clinic gave up the 
right to make the Choline." 
 
 "Er, I guess the probably needs to be a better understanding in the 
academic community of the difference between having a technology that 
shows interesting data from non-prospective studies (laughs). So when, for 
a lot of these agents that look interesting and therapies that look 
interesting, getting approval for it you need to get back to the drawing 
board to do a proper dosimetry study.” 
 “I think either the academic community works in a more followed clinical 
trials process…or that it got an understanding that even you got interesting 
data in people, you will, actually for the regulators, still have to go through 
this proper regulatory process. So effectively those initial data what they 
have done is they de-risked the chance that the therapy works, but they 
haven´t decreased the total investment you have got to make the product 
into ah, something the regulator will approve.” 
 "It [Academic institutions] is a fantastic resource for us, actually with the 
community. And we got loads of collaborations across the globe with 
different academic communities looking at technologies. So the ideas are 
fantastic (laughs), and the innovation and ideas are fantastic." 
 "I think the speed at which the academics work can be a problem. It can be 
at a slower pace, and also I think that most academic institutions are really 
in publishing and that can be a tension between the requirement to 
publish and the requirement to translate. And therefore both sides in a 
PPP have a different goal, which is not always resolved. If it is a proper risk 
sharing development of an innovative product that may be different, but I 
have not been involved in some of those." 
 "Well, I think fundamentally they have different goals, and you always have 
to deal with that. The academic institutions are not, in general speaking, 
not results driven, and not scheduled driven. They are knowledge driven. 
The businesses, of course, are somebody is giving them money, either they 
borrow it from themselves or somebody gave them a bunch of money, and 
they have a timescale, they need to go on the market, and so they are very 
sensitive to results. They are very focused. They want this result. The 
academics would be happy with almost any results, right? (Laughs)  
 “But there is this fundamental alignment issue, not that you cannot work… 
So once you understand that those have fundamentally different 
motivations, there can be issues about who owns the co-development. Like 
a product or a feature or something that is innovative and new which 
comes out of the working together. Obviously the business wants to have 
the right to do it and the institution, a lot of institutions especially in the 
US, have business offices that try to monetarize their research. And they 
want to get a piece of that deal. So that there is this IP relation, and 
funding, always funding." 
 
Value: 
 "Well, on the one hand, of course, it's attractive because it's a consortium 
approach, you do not have to pay for everything. It's just a partnership.” 
 
Concerns: 
 “Concerns are that it is sometimes difficult to get consensus among all 
partners. We are also involved in a few IMI projects, and you see that the 
academic side thinks academically, and the industrial partners come with 
the industrial mind-set into the project. The agreement is not so easy, in 
the sense that it works for everyone.  
 “In the IMI projects, we have seen that it is difficult to design the study 
design to be as rigorous as one would expect from commercial 
development of an imaging test.” 
 “Closing the gap, yes in a sense, but you should not screw the expectations 
of the industrial side too high. Well, such an IMI project may be a good way 
to do some research, but it's not the panacea for developing imaging tests 
in a different way." 
 "Well, I can cite the Amypad Consortium as an example ... many academics 
are interested in researching things that are commercially negligible. Of 
course, from the point of view of the neuroscience community, they are 
academically valuable and would lead to good publications ... we're more 
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interested in really showing utility, mainstream and influence 
reimbursement decisions.” 
 
Benefits: 
 “I'm extremely open-minded ... I actually get a not inconsiderable share of 
research funds from the pharmaceutical industry.” 
 "Earlier, in the last 5-10 years, we have had IITs, we continue to try, but 
now it is no longer possible without support from the pharmaceutical 
industry.” 
 "Yes, if that helps, then that's good. But I always say that when the public 
sector joins the talk, it often gets complicated… I think the industry is able 
to see if there is a need or not, and there is an enormous need for prostate 
cancer in particular." 
 “Very little, one has heard little that it exists at all.” 
 “I think that is an absolutely important part. And there's nothing wrong 
with that because, on the one hand, the industry has some interest in 
monetizing it, but we also have an interest in getting a biomarker, or a 
diagnostic tool, that supports us and is good… So we both have the same 
interest. " 
 "So that's just a normal course of things, the initial invention comes from 
any academic institution and then the industry is brought on board." 
 "On the other hand, as with urine markers, it is just as often that 
something is invented in the laboratories of the industry and they simply 
need a clinical sparring partner to help them with the clinical evaluation. So 
it's both ways, and that's absolutely normal." 
 
Disadvantages: 
 “The pharmaceutical industry has the legitimate interest to make a profit, 
but they slightly tried to dominate the study design and the rationale of 
the study. And I see that as a problem. The particular shortcoming that 
different companies are difficult to bring together and to work together. "  
 "It succeeds in many cases, but in some cases, it does not work, and that's 
a pity." 
 “…you have to be very critically. Because I have said it before, the sponsors 
determine what we do. And ... the (research) question you would like to 
have answered for yourself are actually not funded, but they tell us what 
we have to do… But you have to question it very critically; you have to say 
that very clearly.” 
 “We've worked a lot with the pharmaceutical industry because it's actually 
the only ones that can fund larger studies. Say third-party funds. But more 
and more the industry tells us what we have to do. This has nothing to do 
with university research anymore...” 
 
 "Now in this sense you are going into subpopulations, small, rare cancers 
et cetera that is normally the area where collaborations between industry 
and academia are stronger because really industry then needs the 
academic, needs centres of references, networks and all of this stuff. And 
perhaps those could be right, right frameworks for some of these PPP.  
 “IMI is good at non-competitive stuff, so basic methodology, technology et 
cetera Now in this phase of the CD I wasn´t thinking immediately on 
something like IMI, because I thought the companies would be very 
interested in the certain type of biomarker, a certain type of drug. How can 
that be non-competitive? But I am thinking of this for the first time, so 
maybe the answer is a bit superficial." 
 “I have to pass on that one… But how these initiatives work, I have no idea, 
too little idea.” 
 
xiii. Statements regarding the topic “Research Focus Molecular Imaging” (Chapter 4.5, The Focus in 
Research and Development and the Future Role of Molecular Imaging, page 162) 
Item Manifestation Example of literal expressions 
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 "... we actually see ourselves as a companion diagnostic, which means we 
can assign patients to the right therapy based on their biological 
characterisation of the individual disease." 
 "So in clinical routine, the focus is still on standard procedures such as 
glucose metabolism rather than specific (targets) ... so FDG PET is also 
specific for Gluttransporter and Hexokinase, but ... of course less specific to 
specific tumours. In case of theranostic, we also have Companion Use with 
PSMA or DOTA compounds, Somatostatin Receptor Compounds." 
 "And of course, research is now increasingly moving in the direction of 
visualizing and quantifying very specific, drug-relevant targets. Including 
modern developments such as immune checkpoint inhibitors or things like 
PDL-1, PD-1. There are already compounds available for CXC4 or 
chemokine receptors. But this is the path taken in research, relatively little 
is translated into the clinic." 
 "It is quite possible that FDG PET will continue to be a very important pillar 
... but the next area where PET prevails or will solve a lot is neurology, but 
it also the cardio area ... "" 
 "Alzheimer's will cost mankind a lot of money ... And I think you'll have to 
use a CD. And that's why the topic of neurological dementia ... is an 
important field of research." 
 “So for neuroendocrine tumours, there is still room for research and 
optimization right now, but I would say 90% of all initiatives are currently 
focused on prostate cancer. And the success of PSMA, both in imaging and 
therapy, that's just, you cannot choose any other word for it, as "fabulous" 
... And there is of course still research on even better ligands, on 
combinations with different therapy nuclides be it Lutetium or Actinier ... I 
think that will be one of the priorities in the next five years. Henry Wagner 
... the forefather of nuclear medicine once said: "FDG is the molecule of 
the century" and I would say "PSMA is the molecule of this decade", at 
least for nuclear medicine ... And in the forefront of the success of 
Theranostics and the therapy, of course, enormous efforts are now made 
to establish further target structures, which are suitable for the theranostic 
approach. For me, this currently covers three areas: breast cancer, ... lung 
cancer, third is colon carcinoma and fourth ... pancreatic adenocarcinoma.” 
 “So there is a lot going on, of course, very difficult to say at this stage who 
will be ahead and what will be the next successful target structure. But 
there are already a few candidates who are really hot, yes.” 
 There are several tendencies: ... for a while, there were doubters who 
thought the therapeutic application in the NUK has no future. Which 
cannot be said any more today... PSMA is a very promising therapy ... But 
there are also a lot of other companies ... that initiated controlled studies. 
The PSMA found its way out of academia, but there are some radioactively 
labelled antibodies, or some alpha-therapies, where small, but also large 
players in the pharmaceutical sector, invest a lot of money.” 
 “The diagnosis is... (pause) Er, one hears very different opinions. I have 
recently heard the opinion of radiologists who thought that you no longer 
need FDG anyway and thus PET. Certainly, FDG has taken its place and it 
will be expanded here or there, and perhaps there are alternatives which 
will limit its use.” 
 
 "I see it in PET. Simply because you're more flexible with the labelling 
capabilities, and I think it's easier to attach a positron emitter to a 
biomolecule. SPECT emitters are just such big atoms that it's not that easy 
to (radio-) chemically attach the imaging signal so close to the target 
mechanism of treatment." 
 "And the problem with the PET radioisotopes, which are relatively short 
compared to the SPECT, I consider no problem. I believe that the 
availability of PET is not really a problem, at least in Germany. Not even in 
the US, I do not think that's a problem in any industrialized nation.” 
 "If you had asked me 2 years ago, then I would have propagated SPECT 
even more, but my euphoria slowed down a little bit. Because ultimately it 
is crucial how sensitive the procedures are. Thinking about Companion Use 
and the preparation for radionuclide therapy, then I could imagine that it is 
sufficient to use SPECT to detect the target. But if you think about in-vivo 
tumour characterisation, the characterisation of the tumour biology or 
applied systems biology or something like that, then you do not get very 
far with SPECT." 
 "So the question is, how the technologies will evolve from the point of 
reimbursement ... that is difficult to predict because there is a political and 
supply component. But generally speaking of the technology and the 
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upcoming development, I am also pretty sure that it will increasingly be 
PET-based." 
 "To the question of the availability, where possibly the PET, in comparison 
to the SPECT, has a disadvantage. I see a political and supply component.... 
Insofar SPECT is naturally also on the table since there are no 
reimbursement issues and also has advantages in availability. And that 
stands or falls with the industry commitment ... And, of course, some 
companies will probably focus more on SPECT, others more on PET when 
thinking about companion use. It will depend a bit on what technology will 
be implemented. Also, SPECT technology is improving, moving towards 
Cadmium–zinc–telluride digital detectors, maybe also ring detectors. Let's 
see what else is coming, but of course, PET is already much more 
accurate." 
 "Clearly in PET. SPECT, that's nonsense you have to be clear. Of course, it's 
easier and more accessible, but it's anachronistic! You have to move to 
PET, that's just the rethinking. You cannot work with a “Volksempfänger” if 
you could have a flat screen. That's of course nonsense. If you look at it 
short-sighted, to get it expanded quickly, you can think about SPECT. But if 
you want to go to a high level, you have to push PET and not SPECT.” 
 "No, no, you can forget about SPECT. In this case, I'm brutal. But that's very 
striking." 
 “Interviewer: Interview partners from the pharmaceutical industry believe 
that PET is not interesting for them because it's simply globally not 
available. SPECT already! 
Interviewee: Yes, but the pharmaceutical industry does not understand 
imaging. If you would build me a SPECT scanner, which first is as 
quantitative as the PET, secondly has the same spatial resolution and 
thirdly produces tracers with equal good properties as the PET Tracer, then 
I am ok. But the worldwide availability of PET scanners is already on the 
rise. I understand that the argument of these pharmaceutical people is 
correct, but I do not see that practically." 
 SPECT will remain important for cardiac imaging and some other clinical 
indication. The future is PET!” 
 “If so, perhaps SPECT-CT will have a certain chance, again in the wake of 
substances that have already been successful in PET/CT. An example is, e.g. 
So-called technetium-labelled somatostatin analogous ... It is also called 
the PET/CT of the poor man, yes. (Laughing). The advantage is that these 
SPECT tracers can be billed in the outpatient area because there is an 
existing billing structure. The colleagues in the outpatient area can thus 
use the substances. The same is true for technetium PSMA... But I think a 
big success will continue to be PET/CT.” 
 “Of course, when one looks beyond the borders of Germany, to the 
developing countries or to countries with less economic wealth, such as 
India or even China ... Of course, PET-CT will take a long time to get 
established, whereas SPECT or SPECT-CT is already routine in many nuclear 
medicine institutes. And thus, of course, there is a potential for 
technetium-labelled markers. But a real future, especially with regard to 
research and new development, I simply see PET/CT on top.” 
 "SPECT will definitely play a role  ... still purely because of capacity. If you 
look at it globally, SPECT has probably 10 times more capacity than PET ... 
Of course, PET has technological advantages, such as sensitivity and 
resolution for certain applications. For PSMA, PET has clear advantages, 
because the resolution creates a benefit. But there are applications where 
resolution is not what matters most.” 
 
 " When the drug company is developing the drug it's developing it for a 
global market.  So when [company name] is developing they're not just 
thinking of, certainly they think if you can sell it in the United States and 
EU, they are also thinking about China, Philippines, Brazil, Indonesia. These 
are important markets! If you going to have Diagnostic in your label you 
want to make sure it is available in every hospital in China, Philippines, 
Brazil otherwise you would not sell this drug. From that point of view you 
have PET agents... at least..., carbon is out of the question, fluorine can be 
challenging because of the half-life. Technetium is much more attractive. 
Gallium obviously with PET is more attractive, because you can use a 
generator and a nuclear medicine department can make it locally. And if I 
were looking developing a personalised healthcare compound, I would be 
very cautious about the fluorine agent.” 
 "I will give you some figures, they may not be that accurate, and there is a 
general truth behind them. I heard it said, that for every PET scan that is 
performed in the world ten SPECT or scintigraphy scans are performed, 
and for every SPECT or scintigraphy paper there are ten PET papers. Those 
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numbers may not be exactly right, but there is a truth behind it. That 
scintigraphy and SPECT are not sexy, whereas PET is incredibly sexy. PET is 
also expensive and so if you are an academic and you do have a PET facility 
you need to turn out a lot of papers. And if you are a young academics, like 
yourself, probably you think it's sexier to be in PET rather than SPECT." 
 
 "...develop imaging agents for cancer. And so far we have been successful 
with one of those products. So we have been going through clinical trials to 
develop a product for prostate cancer, called [product name]. And we had 
that product approved in the US and Europe. And we think that agent has 
potential applications in other types of cancer too." 
 "Okay, so I would say that the mission of [company name] is to develop 
theranostic platforms so drugs which have both a diagnostic and 
therapeutic component, which is shared. Not necessarily identical 
compounds, but they are shared. So that the personalised medicine is 
essential, that patients who benefit from a therapeutic agent are identified 
by the diagnostic component." 
 
 “Yes, that is a good question. Actually, because SPECT I think there will be 
research in SPECT and there is a whole lot of, you know there is a much 
wider uptake in SPECT than there is PET. If the real value of SPECT is going 
to be realized when SPECT/CT is available. I kind of think that SPECT/CT 
would be better than SPECT and most of the operators around SPECT and 
not SPECT/CT, because SPECT/CT explosion hasn´t happened yet, has it? If 
you factoring the costs of delivering the scan and the availability, SPECT/CT 
seems promising. But it suffers from access more than PET/CT, where 
SPECT there is no real access issue with SPECT, is there. But maybe that 
does not deliver the actual promise of SPECT as technology. And we only 
get the real promise of SPECT as a technology, but we have SPECT/CT 
everywhere." 
 "I think SPECT is definitely still an option. So the difference between SPECT 
and PET is based around the resolution, the spatial resolution of the 
imaging device. Not necessarily based on around basic physical properties. 
So if the SPECT cameras become more sophisticated as it appears they are, 
then I think SPECT and PET will have a role to play. And ultimately spatial 
resolution for a given price will determine how much SPECT and PET, not 
necessarily one or the other but rather how cheap the camera is for a given 
spatial resolution." 
 "Both are adequate, and given the cost circumstances both will remain, but 
PET will grow in the future. The opportunity to modify small molecules 
without significant influence on biodistribution is a clear advantage. With 
Fluorine the supply chain is already there." 
 
 "Well, I would say current mission and objective is the development of 
(pause) it is actually more (break) I would say the safety and efficacy is now 
self - evident, but the mission actually goes further in the utility of 
diagnostic tests. Because it is clear that safety and efficacy are not enough 
to bring diagnostic products on the market, get reimbursement and 
integrate them into the appropriate patient management. So currently the 
objective is to perform much more advanced phase III studies. We have to 
think about utility and of course health economics in the development of 
such products. " 
 "... since then, we have focused more on Life Cycle Management and push 
projects in the R&D pipeline, which are already more advanced in the 
development stage, so in Phase II or III. And in terms of personalised 
medicine, we initiated a study with an “old-fashioned” product ... to see if 
[product name] can predict that a patient needs a defibrillator (ICD) or 
not." 
 "Unlike as in CT and MRI, in MI when you want to expand the clinical 
indications it´s is generally tracer driven and probably requires a new 
specific tracer for that clinical area you want to go pursue... So and those 
new tracers might or might not drive something on the technology side… 
One example we had to do in the brain with the Alzheimer´s tracers …all 
the vendors came up with software to make that job easier, on linking the 
grey matter uptake of the amyloid tracers for Alzheimer disease relative to 
your reference region. So there was another case where the medical case, 
in this case, the software and to adapt to the tracer." 
 "Yeah, we do little investments… we do quite a bit of clinical trials for 
others, but we don´t charge them for the costs of things. It is sort of a small 
side business for us with the hope to get some more tracers on the market. 
And then we make investments in like; we gave support to the SNMs 
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clinical trials network on getting the Gallium PSMA project moving. So we 
do funding of others we think are worth…” 
 
 "So I would say that still ... we see the future in both areas... PET is a tough 
market but has a future because certain PET tracers will rather be 
produced than SPECT tracers. Purely from the technical view. On the other 
hand, PET is problematic ... because you either need your own 
infrastructure ... or you work with local partners ... There are also certain 
countries where SPECT has, aside from the big cities, advantageous 
logistics compared to PET. And because of the CZT solid-state detectors, 
the resolution in SPECT approaches the resolution of PET." 
 "And I think PET will continue to grow, but I think even SPECT… We 
traditionally still have more tracers in SPECT so, PET we just had one or two 
you know in the beginning and SPECT had ten or fifteen, depending on 
where you are. So that there was less need to expand the tracers for 
SPECT. But even in SPECT, there is a new prostate imaging agent coming, 
so SPECT will see some growth in prostate imaging. But most of the growth 
in our field will happen in PET in the future." 
 
 "I think the next best step is risk stratification and I'm totally open for 
whatever tools we're going to use. Then the next step must be to treat 
biologically adaptive, big keyword: personalised therapy. That are the two 
big steps which have to come into our area [lymphoma] and will come 
because there are too many people working on it." 
 "So in prostate cancer, if imaging gets even better, focal treatment for 
prostate cancer may play a significant role. Such as brachytherapy, local 
photodynamic therapy, HIFU (High intensity focused ultrasound), or such 
treatments. I don´t see drugs in local therapy; there will always be physical 
energy applied, which irradiates the tumour locally.... Otherwise, at an 
advanced stage, the individualized target therapy will play a role.” 
 “Ultimately, in 40-50 years, probably the entire treatment of cancer can 
only be handled with some supportive additional artificial intelligence. 
There will be so many markers, genetic markers, protein markers, the devil 
knows what will play a role, and from the whole hodgepodge of thousands 
of information and combination options, you have to find out the best 
therapy. And also the definition of what is the best therapy will not be 
feasible with clinical studies anymore ... maybe some kind of artificial 
intelligence has to do this task." 
 "I cannot say which way it is going. At the moment it looks like it's going 
into immunotherapy with the checkpoint inhibitors." 
 "What is also generally en vogue is the immunotherapy ... So the keyword 
is PDL-1 inhibitors, et cetera. This is a brand new drug class that is just very 
in vogue. But I think the big keyword of the future is the topic of liquid 
biopsy ... but also in general, to come back to the subject of nuclear 
medicine, the keyword theranostic is already big in the trend, high in the 
class." 
 "... for me, a 2-month gain in life is not the total breakthrough. For 
oncologists it is, and they are trying everything ... Probably the future will 
be in combination therapy. But I'm honest; we don´t know yet. And it's 
true that it's mostly triggered by industry. What annoys me... What keeps 
me so excited about these things is that ... We're investing millions and 
billions into metastatic patients, instead of putting a few million into 
prevention and early diagnosis and cure those patients with surgery or 
something else. Nothing happens here anymore. " 
 
 "Absolutely yes." 
 "My assessment is that functional imaging is evolving just as well ... but 
what I've seen so far is fascinating ... secondly, I think MI will continue to 
evolve as much as we do (IVCD). Many people are probably not yet aware 
that we even save costs. If we can use functional imaging, and / or other 
methods, to save patients from unnecessary therapies, or stop 
meaningless and start more meaningful therapies, that certainly also 
makes economic sense.” 
 "So for prostate cancer, if imaging gets even better, focal treatment for 
prostate cancer may play a significant role." 
 "Yes, a very big one, the imaging is getting better and better and better 
and better ... That will go on, I'm sure." 
 "It depends on the topic of treatment and if you have a biomarker that is 
good enough that the concentration of the biomarker tells us" ok, does the 
patient have a response or not? ". … then you could do without the 
imaging diagnostics. If, however, the patient has any consequence because 
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of the localisation of the tumour … imaging with corresponding sensitivity 
and specificity is still indispensable.” 
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